CN109206417B - Opioid receptor agonists and uses thereof - Google Patents

Opioid receptor agonists and uses thereof Download PDF

Info

Publication number
CN109206417B
CN109206417B CN201810702595.3A CN201810702595A CN109206417B CN 109206417 B CN109206417 B CN 109206417B CN 201810702595 A CN201810702595 A CN 201810702595A CN 109206417 B CN109206417 B CN 109206417B
Authority
CN
China
Prior art keywords
oxaspiro
decan
methyl
pyridin
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810702595.3A
Other languages
Chinese (zh)
Other versions
CN109206417A (en
Inventor
范江
朱凤飞
陈清平
汪成涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tibet Haisike Pharmaceutical Co ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Priority to CN202210889662.3A priority Critical patent/CN115124520A/en
Publication of CN109206417A publication Critical patent/CN109206417A/en
Application granted granted Critical
Publication of CN109206417B publication Critical patent/CN109206417B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems

Abstract

Compounds and salts thereof that may be used as opioid receptor ligands, as well as methods of making and compositions containing the compounds, and their use as mu opioid receptor agonists for the treatment of mu opioid receptor-mediated related disorders, such as pain and pain-related disorders, are described.

Description

Opioid receptor agonists and uses thereof
Technical Field
The present invention relates to compounds useful as opioid receptor ligands, or tautomers, mesomers, racemates, enantiomers, diastereomers or mixtures thereof, or pharmaceutically acceptable salts or compositions thereof, and to the use of the compounds of the invention for the treatment of pain.
Background
The opioid receptor is a G Protein Coupled Receptor (GPCR) and is a target for combining endogenous opioid peptide and opioid drugs. Various opioid receptors are present in the human body and are widely distributed in peripheral tissues such as the central nervous system, heart, digestive tract, blood vessels, kidney, etc. The opioid receptors mainly include three types, i.e., mu Opioid Receptor (MOR), delta Opioid Receptor (DOR), and Kappa Opioid Receptor (KOR). Endogenous Nociceptin is the 4 th member of the opioid receptor family, found relatively late, and is called the opioid receptor like 1 (ORL 1). The mu receptor has two subtypes of mu 1 and mu 2, the delta receptor has two subtypes of delta 1 and delta 2, and the kappa receptor has three subtypes of kappa 1, kappa 2 and kappa 3. The research shows that the Mu Opioid Receptor (MOR) has the strongest binding capacity with the morphpeptide, and the mu receptor is also the receptor protein site of main effect of analgesics such as morphine, fentanyl and the like. In recent years, studies show that the mu receptors of hypothalamus, frontal cortex, hippocampus and striatum show different degrees of down regulation after morphine addiction of rats, and simultaneously, the gene expression of the mu receptors is reduced.
Several studies on MOR agonists have been reported in the literature.
(1) CN106588899 discloses compounds of the following structure as MOR agonists,
Figure BDA0001714822470000011
wherein the content of the first and second substances,
R 1 selected from alkyl, heterocyclyl, alkoxy and alkenyl. The specific description in this patent is not considered to be part of the present invention.
(2) CN 103702561 discloses compounds of the following structure as MOR agonists,
Figure BDA0001714822470000021
R 21 and R 22 Independently is H or CH 3 ,A 4 Is of the formula C (CH) 2 ) n Wherein n =2-5; b 3 Is H or optionally substituted alkyl, B 4 Is C 1 -C 6 Alkyl radical, D 1 Is optionally substituted aryl, B 5 Is an optionally substituted aryl group. The specific description in this patent is not considered to be part of the present invention.
(3) WO2017063509 discloses compounds of the structure as MOR agonists,
Figure BDA0001714822470000022
wherein ring A is selected from cycloalkyl or heterocyclyl, R is selected from aryl and heteroaryl, R is 1 The same or different, and each is independently selected from hydrogen atom, alkyl group, alkoxy group, haloalkyl group, halogen, amino group, nitro group, hydroxy group, cyano group, cycloalkyl group, heterocyclic group, aryl group, heteroaryl group, and the like. The specific description in this patent is not considered to be part of the present invention.
In clinical analgesic treatment, opioids are mainly used to treat severe acute pain and cancer pain. Because opioid drugs have a plurality of adverse reactions such as nausea, vomiting, constipation, pruritus and the like, tolerance can be generated after long-term use, and side effects such as respiratory depression, constipation, addiction and the like are generated, so that the development of a novel small-molecule selective MOR agonist which has small side effect or no side effect, better activity and smaller dosage is urgently needed for effectively treating pain.
Disclosure of Invention
The invention aims to provide a small-molecule selective MOR agonist with higher activity, smaller dosage and small side effect.
The invention relates to a compound shown in a general formula (I) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereoisomer or a mixture form thereof, or pharmaceutically acceptable salt thereof,
Figure BDA0001714822470000023
wherein
A is selected from
Figure BDA0001714822470000031
And further substituted by 0 to 5R 4 Substitution;
b is phenyl, pyridyl, alkynyl or benzyl optionally further substituted with 0 to 5R 2 Substitution;
C 1 and C 2 Form a ring together with the carbon atom to which it is attached, said ring being selected from
Figure BDA0001714822470000032
R 1 Selected from H, halogen or C 1-6 An alkyl group;
R 2 selected from F, cl, -CF 3 、-CHF 2 、-CH 2 F. Hydroxy, cyano or C 1-6 An alkyl group;
R 3 selected from H, C 1-6 Alkyl or C 3-6 A cycloalkyl group;
R 4 selected from halogen, hydroxy, cyano, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl radical, C 1-6 Alkoxy, alkenyl, alkynyl, - (CH) 2 ) q R a 、-OR b 、-NR c R d 、-C(=O)NR e R f 、-C(=O)OR g 、C 3-6 Cycloalkyl, 3-to 6-membered heterocycloalkyl, 5-to 10-membered aryl, 5-to 10-membered heteroaryl, -O- (3-to 6-membered heterocycloalkyl), -O- (5-to 10-membered aryl), -O- (5-to 10-membered heteroaryl), -CH 2 ) q -S-C 1-6 Alkyl or-S (= O) 2 -C 1-6 An alkyl group;
R a selected from hydroxy, C 1-6 Alkoxy, acetoxy, acetamido, -O-C 3-6 A cycloalkyl group;
R b is selected from- (CH) 2 ) p C 3-6 Cycloalkyl, halogen substituted C 1-6 An alkyl group;
R c and R d Each independently selected from H or
Figure BDA0001714822470000033
R d1 Selected from H, C 1-6 An alkyl group;
R e and R f Each independently selected from H or C 1-6 An alkyl group;
R g is selected from H or C 1-6 An alkyl group;
alternatively, R 4 、R 1 Together with ring a, form a heterocycle;
q is selected from 1 or 2;
p is selected from 0, 1, 2 or 3;
m is selected from 0, 1, 2, 3 or 4;
n is selected from 1 or 2;
with the proviso that the following compounds are excluded:
Figure BDA0001714822470000041
in some embodiments, the compound of formula (I) or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
A is selected from
Figure BDA0001714822470000042
Is preferably selected from
Figure BDA0001714822470000043
Further preferred is from
Figure BDA0001714822470000044
Even further preferred from
Figure BDA0001714822470000045
R 21 Is selected from C 1-6 Alkoxy, alkynyl, - (CH) 2 ) q R a 、-OR b or-NR c R d Preferably selected from methoxy, ethynyl, cyclopropyloxy, ethynyl, n-propyloxy cyclobutyloxy, methoxymethyl, hydroxymethyl,
Figure BDA0001714822470000046
More preferably from ethynyl, cyclopropyloxy, cyclobutyloxy,
Figure BDA0001714822470000047
R 22 、R 23 、R 24 、R 25 、R 26 And R 27 Each independently selected from halogen, hydroxy, cyano, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl radical, C 1-6 Alkoxy, alkenyl, alkynyl, - (CH) 2 ) q R a 、-OR b 、-NR c R d 、-C(=O)NR e R f 、-C(=O)OR g 、C 3-6 Cycloalkyl, 3-to 6-membered heterocycloalkyl5-to 10-membered aryl, 5-to 10-membered heteroaryl, -O- (3-to 6-membered heterocycloalkyl), -O- (5-to 10-membered aryl), -O- (5-to 10-membered heteroaryl), -CH 2 ) q -S-C 1-6 Alkyl or-S (= O) 2 -C 1-6 Alkyl, preferably C 1-6 An alkoxy group;
R 28 is selected from-O-C 3-6 Cycloalkyl, preferably cyclopropyloxy;
R a selected from hydroxy, C 1-6 Alkoxy, acetoxy, acetamido, -O-C 3-6 A cycloalkyl group;
R b is selected from- (CH) 2 ) p C 3-6 Cycloalkyl, halogen substituted C 1-6 An alkyl group;
R c and R d Each independently selected from H or
Figure BDA0001714822470000051
R d1 Selected from H, C 1-6 An alkyl group;
R e and R f Each independently selected from H or C 1-6 An alkyl group;
R g is selected from H or C 1-6 An alkyl group;
alternatively, R 21 、R 1 And A ring form
Figure BDA0001714822470000052
q is selected from 1 or 2;
p is selected from 0, 1, 2 or 3;
m is selected from 0, 1, 2, 3 or 4;
with the proviso that the following compounds are excluded:
Figure BDA0001714822470000053
in some embodiments, the compound of formula (I) or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
A is selected from
Figure BDA0001714822470000054
In some embodiments, the compound of formula (I) or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
B is
Figure BDA0001714822470000055
1-propynyl or substituted by 0 to 5R 2 Substituted benzyl, preferably
Figure BDA0001714822470000056
4-fluorobenzyl or 1-propynyl, and more preferably
Figure BDA0001714822470000061
In some embodiments, a compound of formula (I) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, is included, wherein C 1 And C 2 Form a ring together with the carbon atom to which it is attached, said ring being selected from
Figure BDA0001714822470000062
R 3 Selected from H, C 1-6 Alkyl or C 3-6 A cycloalkyl group.
In some embodiments, the compound of formula (I) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, has the structure of formula (II)
Figure BDA0001714822470000063
Wherein
A is selected from
Figure BDA0001714822470000064
Preference is given to
Figure BDA0001714822470000065
Further preferred is from
Figure BDA0001714822470000066
Even further preferred from
Figure BDA0001714822470000067
R 21 Is selected from C 1-6 Alkoxy, alkynyl, - (CH) 2 ) q R a 、-OR b or-NR c R d Preferably selected from methoxy, ethynyl, cyclopropyloxy, cyclobutyloxy, methoxymethyl, hydroxymethyl,
Figure BDA0001714822470000068
More preferably from ethynyl, cyclopropyloxy, cyclobutyloxy,
Figure BDA0001714822470000071
R 22 、R 23 、R 24 、R 25 、R 26 And R 27 Each independently selected from halogen, hydroxy, cyano, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl radical, C 1-6 Alkoxy, alkenyl, alkynyl, - (CH) 2 ) q R a 、-OR b 、-NR c R d 、-C(=O)NR e R f 、-C(=O)OR g 、C 3-6 Cycloalkyl, 3-to 6-membered heterocycloalkyl, 5-to 10-membered aryl, 5-to 10-membered heteroaryl, -O- (3-to 6-membered heterocycloalkyl), -O- (5-to 10-membered aryl), -O- (5-to 10-membered heteroaryl), -CH 2 ) q -S-C 1-6 Alkyl or-S (= O) 2 -C 1-6 Alkyl, preferably C 1-6 An alkoxy group;
R 28 is selected from-O-C 3-6 Cycloalkyl, preferably cyclopropyloxy;
R a selected from hydroxy, C 1-6 Alkoxy, acetoxy, acetamido, -O-C 3-6 A cycloalkyl group; hydroxy, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, acetoxy, acetylamino, -O-cyclopropyl, -O-cyclobutyl, -O-cyclopentyl or-O-cyclohexyl;
R b is selected from- (CH) 2 ) p C 3-6 Cycloalkyl, halogen substituted C 1-6 Alkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CH 2 -cyclopropyl, -CH 2 -cyclobutyl, -CH 2 -cyclopentyl, -CH 2 -cyclohexyl, -CF 3 、-CHF 2 or-CH 2 F 1 Further preferred are cyclopropyl, cyclobutyl and-CH 2 -cyclopropyl, -CH 2 -cyclobutyl or-CHF 2
R c And R d Each independently selected from H or
Figure BDA0001714822470000072
R d1 Selected from H, C 1-6 Alkyl, preferably methyl or ethyl;
R e and R f Each independently selected from H or C 1-6 Alkyl, preferably H or methyl;
R g is selected from H or C 1-6 Alkyl, preferably H or methyl;
alternatively, R 21 、R 1 And A ring form
Figure BDA0001714822470000073
q is selected from 1 or 2, preferably 1;
p is selected from 0, 1, 2 or 3, preferably 0 or 1;
m is selected from 0, 1, 2, 3 or 4, preferably 0, 1 or 2;
with the proviso that the following compounds are excluded:
Figure BDA0001714822470000081
in some embodiments, the compound of structural formula (II) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof,
Wherein
A is selected from
Figure BDA0001714822470000082
Preference is given to
Figure BDA0001714822470000083
B is
Figure BDA0001714822470000084
1-propynyl or substituted by 0 to 5R 3 Substituted benzyl, preferably
Figure BDA0001714822470000085
4-fluorobenzyl or 1-propynyl, and more preferably
Figure BDA0001714822470000086
R 1 Selected from H or methyl;
R 21 selected from methoxy, ethynyl, cyclopropyloxy, cyclobutyloxy, methoxymethyl, hydroxymethyl,
Figure BDA0001714822470000087
R 22 、R 23 、R 24 、R 25 、R 26 And R 27 Each independently selected from F, cl, hydroxy, methyl, methoxy, ethynyl, hydroxymethyl, methoxymethyl, cyclopropyloxy, cyclobutyloxy,
Figure BDA0001714822470000088
Substituted with the substituent(s);
alternatively, R 21 、R 1 And A ring form
Figure BDA0001714822470000089
R 28 Selected from cyclopropoxy;
R 3 selected from F or Cl;
n is selected from 1 or 2;
with the proviso that the following compounds are excluded:
Figure BDA0001714822470000091
in some embodiments, the compound of structural formula (II) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
A is
Figure BDA0001714822470000092
Preference is given to
Figure BDA0001714822470000093
Further preferred is
Figure BDA0001714822470000094
Still further preferred
Figure BDA0001714822470000095
B is
Figure BDA0001714822470000096
4-fluorobenzyl or 1-propynyl, preferably
Figure BDA0001714822470000097
R 1 Is selected from H orMethyl, preferably H;
n is selected from 2;
with the proviso that the following compounds are excluded:
Figure BDA0001714822470000101
the invention relates to a compound shown in a general formula (II) or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, or pharmaceutically acceptable salt thereof,
Figure BDA0001714822470000102
Wherein
A is selected from
Figure BDA0001714822470000103
B is phenyl, pyridyl, alkynyl or benzyl optionally further substituted with 0 to 5R 2 Substitution;
R 1 selected from H, halogen or C 1-6 An alkyl group;
R 21 is selected from C 1-6 Alkoxy, alkynyl, - (CH) 2 ) q R a 、-OR b or-NR c R d
R 22 、R 23 、R 24 、R 25 、R 26 And R 27 Each independently selected from halogen, hydroxy, cyano, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl radical, C 1-6 Alkoxy, alkenyl, alkynyl, - (CH) 2 ) q R a 、-OR b 、-NR c R d 、-C(=O)NR e R f 、-C(=O)OR g 、C 3-6 Cycloalkyl, 3-to 6-membered heterocycloalkyl, 5-to 10-membered aryl, 5-to 10-membered heteroaryl, -O- (3-to 6-membered heterocycloalkyl), -O-, (5-to 10-membered aryl), -O- (5-to 10-membered heteroaryl), -CH 2 ) q -S-C 1-6 Alkyl or-S (= O) 2 -C 1-6 An alkyl group;
R 28 is selected from-O-C 3-6 Cycloalkyl, halogen or C 1-6 An alkyl group;
R a selected from hydroxy, C 1-6 Alkoxy, acetoxy, acetamido, -O-C 3-6 A cycloalkyl group;
R b is selected from- (CH) 2 ) p C 3-6 Cycloalkyl, halogen substituted C 1-6 An alkyl group;
R c and R d Each independently selected from H or
Figure BDA0001714822470000104
R d1 Selected from H, C 1-6 An alkyl group;
R e and R f Each independently selected from H or C 1-6 An alkyl group;
R g is selected from H or C 1-6 An alkyl group;
alternatively, R 21 、R 1 And A ring form
Figure BDA0001714822470000111
q is selected from 1 or 2;
p is selected from 0, 1, 2 or 3;
n is selected from 1 or 2;
m is selected from 0, 1, 2, 3 or 4;
with the proviso that,
when A is selected from
Figure BDA0001714822470000112
B is selected from pyridyl or phenyl, when n is selected from 2, m is not 0 and R is 21 Is other than C 1-6 An alkoxy group;
When A is selected from
Figure BDA0001714822470000113
B is selected from benzene ring or pyridineWhen it is basic, R 28 Is selected from-O-C 3-6 A cycloalkyl group; and does not include the following compounds:
Figure BDA0001714822470000114
in some embodiments, a is selected from
Figure BDA0001714822470000115
B is
Figure BDA0001714822470000116
1-propynyl or substituted by 0 to 5R 3 A substituted benzyl group;
R 1 selected from H or methyl;
R 21 selected from methoxy, ethynyl, cyclopropyloxy, cyclobutyloxy, methoxymethyl, hydroxymethyl,
Figure BDA0001714822470000117
R 22 、R 23 、R 24 、R 25 、R 26 And R 27 Each independently selected from F, cl, hydroxy, methyl, methoxy, ethynyl, hydroxymethyl, methoxymethyl, cyclopropyloxy, cyclobutyloxy,
Figure BDA0001714822470000118
Substituted with the substituent(s);
alternatively, R 21 、R 1 And A ring form
Figure BDA0001714822470000121
R 28 Selected from cyclopropoxy;
R 3 selected from F or Cl;
n is selected from 1 or 2;
with the proviso that,
when A is selected from
Figure BDA0001714822470000122
B is selected from pyridyl, when n is selected from 2, m is not 0 and R 21 Is not methoxy or
Figure BDA0001714822470000123
And does not include the following compounds:
Figure BDA0001714822470000124
in some embodiments, a is
Figure BDA0001714822470000125
B is
Figure BDA0001714822470000126
4-fluorobenzyl or 1-propynyl;
R 1 selected from H or methyl;
n is selected from 2;
provided that when B is selected from
Figure BDA0001714822470000127
When A is not
Figure BDA0001714822470000128
And does not include the following compounds:
Figure BDA0001714822470000131
in some embodiments, a compound of structural formula (I) or a tautomer, mesomer, racemate, enantiomer, or diastereomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:
Figure BDA0001714822470000132
Figure BDA0001714822470000141
In some embodiments, the compound of formula (I) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, has the structure of formula (III)
Figure BDA0001714822470000142
In some embodiments, a compound according to the structure of formula (III) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
A is selected from
Figure BDA0001714822470000143
And further substituted by 0 to 5R 4 Substitution; preference is given to
Figure BDA0001714822470000144
Further preferred is
Figure BDA0001714822470000145
It is still further preferred
Figure BDA0001714822470000146
Further preferred is
Figure BDA0001714822470000147
More preferably
Figure BDA0001714822470000148
B is pyridyl;
R 1 is selected from H or C 1-6 Alkyl, preferably H or methyl, further preferably H;
R 4 selected from halogen, hydroxy, cyano, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl radical, C 1-6 Alkoxy, alkenyl, alkynyl, - (CH) 2 ) q R a 、-OR b 、-NR c R d 、-C(=O)NR e R f 、-C(=O)OR g 、C 3-6 Cycloalkyl, 3-to 6-membered heterocycloalkyl, 5-to 10-membered aryl, 5-to 10-membered heteroaryl, -O- (3-to 6-membered heterocycloalkyl), -O- (5-to 10-membered aryl), -O- (5-to 10-membered heteroaryl), -CH 2 ) q -S-C 1-6 Alkyl or-S (= O) 2 -C 1-6 Alkyl, preferably halogen, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl radical, C 1-6 Alkoxy, - (CH) 2 ) q R a 、-OR b -O- (3-to 6-membered heterocycloalkyl), -O- (5-to 10-membered aryl) or-O- (5-to 10-membered heteroaryl), further preferably halogen, C 1-6 Alkoxy, -OR b -O- (3-to 6-membered heterocycloalkyl), -O- (5-to 10-membered aryl) or-O- (5-to 10-membered heteroaryl), more preferably halogen or C 1-6 An alkoxy group;
R a selected from hydroxy, C 1-6 Alkoxy, acetoxy, acetamido, -O-C 3-6 Cycloalkyl, preferably hydroxy or C 1-6 An alkoxy group;
R b is selected from- (CH) 2 ) p C 3-6 Cycloalkyl or halogen substituted C 1-6 Alkyl, preferably- (CH) 2 ) p C 3-6 A cycloalkyl group;
R c and R d Each independently selected from H or
Figure BDA0001714822470000151
Preferably H;
R d1 selected from H, C 1-6 Alkyl, preferably H or methyl;
R e and R f Each independently selected from H or C 1-6 Alkyl, preferably H or methyl;
R g is selected from H or C 1-6 Alkyl, preferably methyl or ethyl;
q is selected from 1 or 2, preferably 1;
p is selected from 0, 1, 2 or 3, preferably 0 or 1;
n is selected from 2.
In some embodiments, a compound according to the structure of formula (III) or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
A is selected from
Figure BDA0001714822470000152
And further substituted by 0 to 5R 4 Substitution;
R 4 selected from halogen, hydroxy, cyano, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl radical, C 1-6 Alkoxy, alkenyl, alkynyl, - (CH) 2 ) q R a 、-OR b 、-NR c R d 、-C(=O)NR e R f 、-C(=O)OR g 、C 3-6 Cycloalkyl, 3-to 6-membered heterocycloalkyl, 5-to 10-membered aryl, 5-to 10-membered heteroaryl, -O- (3-to 6-membered heterocycloalkyl), -O- (5-to 10-membered aryl), -O- (5-to 10-membered heteroaryl), -CH 2 ) q -S-C 1-6 Alkyl or-S (= O) 2 -C 1-6 An alkyl group;
R a selected from hydroxy, C 1-6 Alkoxy, acetoxy, acetamido, -O-C 3-6 A cycloalkyl group;
R b is selected from- (CH) 2 ) p C 3-6 Cycloalkyl, halogen substituted C 1-6 An alkyl group;
R c and R d Each independently selected from H or
Figure BDA0001714822470000153
R d1 Selected from H, C 1-6 An alkyl group;
R e and R f Each independently selected from H or C 1-6 An alkyl group;
R g is selected from H orC 1-6 An alkyl group;
q is selected from 1 or 2;
p is selected from 0, 1, 2 or 3.
In some embodiments, a compound according to the structure of formula (III) or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
A is selected from
Figure BDA0001714822470000161
And further substituted by 0 to 5R 4 Substitution;
R 4 selected from halogen or C 1-6 An alkoxy group.
In some embodiments, a compound according to the structure of formula (III) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from one of the following structures:
Figure BDA0001714822470000162
in some embodiments, a compound having the structure of formula (I), or a tautomer, mesomer, racemate, enantiomer, or diastereomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, has the structure of formula (IV)
Figure BDA0001714822470000163
A is selected from
Figure BDA0001714822470000164
And further substituted by 0 to 5R 4 Substituted, preferably
Figure BDA0001714822470000165
Further preferred is
Figure BDA0001714822470000166
Further preferred is
Figure BDA0001714822470000167
C 1 And C 2 Together with the carbon atom to which they are attached form a ring selected from
Figure BDA0001714822470000171
R 3 Selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl, preferably methyl, ethyl, propyl, isopropyl, 3-pentyl, cyclopentyl, cyclopropyl, cyclobutyl or cyclohexyl;
R 4 selected from halogen, hydroxy, cyano, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl radical, C 1-6 Alkoxy, alkenyl, alkynyl, - (CH) 2 ) q R a 、-OR b 、-NR c R d 、-C(=O)NR e R f 、-C(=O)OR g 、C 3-6 Cycloalkyl, 3-to 6-membered heterocycloalkyl, 5-to 10-membered aryl, 5-to 10-membered heteroaryl, -O- (3-to 6-membered heterocycloalkyl), -O- (5-to 10-membered aryl), -O- (5-to 10-membered heteroaryl), -CH 2 ) q -S-C 1-6 Alkyl or-S (= O) 2 -C 1-6 Alkyl, preferably halogen, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl radical, C 1-6 Alkoxy, - (CH) 2 ) q R a 、-OR b -O- (3-to 6-membered heterocycloalkyl), -O- (5-to 10-membered aryl) or-O- (5-to 10-membered heteroaryl), further preferably halogen, C 1-6 Alkoxy, -OR b -O- (3-to 6-membered heterocycloalkyl), -O- (5-to 10-membered aryl) or-O- (5-to 10-membered heteroaryl), more preferably halogen or C 1-6 An alkoxy group;
R a selected from hydroxy, C 1-6 Alkoxy, acetoxy, acetamido, -O-C 3-6 Cycloalkyl, preferably hydroxy or C 1-6 An alkoxy group;
R b is selected from- (CH) 2 ) p C 3-6 Cycloalkyl or halogen substituted C 1-6 Alkyl, preferably- (CH) 2 ) p C 3-6 A cycloalkyl group;
R c and R d Each independently selected from H or
Figure BDA0001714822470000172
Preferably H;
R d1 is selected from H or C 1-6 Alkyl, preferably H or methyl;
R e and R f Each independently selected from H or C 1-6 Alkyl, preferably H or methyl;
R g is selected from H or C 1-6 Alkyl, preferably methyl or ethyl;
q is selected from 1 or 2, preferably 1;
p is selected from 0, 1, 2 or 3, preferably 0 or 1;
n is selected from 2.
In some embodiments, a compound according to the structure of formula (IV) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
A is selected from
Figure BDA0001714822470000173
And further substituted by 0 to 5R 4 Substitution;
R 4 selected from halogen or C 1-6 An alkoxy group.
In a preferred embodiment of the present invention, the compound having the structure of formula (IV) or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
A is selected from
Figure BDA0001714822470000181
And further substituted by 0 to 5R 4 Substitution;
C 1 and C 2 To be connected withThe carbon atoms together forming a ring selected from
Figure BDA0001714822470000182
R 3 Selected from H, methyl, ethyl, isopropyl, 3-pentyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
R 4 selected from F, cl, methoxy or ethoxy;
n is selected from 2.
In some embodiments, a compound according to the structure of formula (IV) or a tautomer, mesomer, racemate, enantiomer, or diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, is selected from one of the following structures:
Figure BDA0001714822470000183
Figure BDA0001714822470000191
the present invention also relates to a compound of formula (V) or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, or a pharmaceutically acceptable salt thereof,
Figure BDA0001714822470000192
wherein
Figure BDA0001714822470000193
Is a single bond or a double bond;
R 11 selected from H, phenyl or pyridyl, said phenyl or pyridyl being optionally further substituted by 0 to 3 substituents selected from F, cl, br, I, -CF 3 、-CHF 2 、-CH 2 F、C 1-4 Alkyl or C 1-4 Alkoxy radicalSubstituted with a substituent of the group;
R 12 each independently selected from H or
Figure BDA0001714822470000194
R 13 Each independently selected from H,
Figure BDA0001714822470000195
R 14 Selected from H, phenyl or C 1-6 Alkyl, said phenyl, alkyl being optionally further substituted by 0 to 2 substituents selected from F, cl, br, I, -CF 3 、-CHF 2 、-CH 2 F or C 1-4 Substituted by a substituent of an alkyl group;
R 1 is selected from H or C 1-4 An alkyl group;
a is selected from
Figure BDA0001714822470000196
R 21 Selected from methoxy, ethynyl, cyclopropyloxy, cyclobutyloxy, methoxymethyl, hydroxymethyl,
Figure BDA0001714822470000201
R 22 、R 23 、R 24 、R 25 、R 26 And R 27 Each independently selected from F, cl, hydroxy, methyl, methoxy, ethynyl, hydroxymethyl, methoxymethyl, cyclopropyloxy, cyclobutyloxy,
Figure BDA0001714822470000202
Substituted with a substituent of (1);
R 28 selected from F, cl or C 1-6 An alkyl group;
m is selected from 0, 1 or 2;
provided that R is 11 、R 12 And R 13 Cannot be both H and R 12 And R 13 And only one is H.
In some embodiments, the compound of formula (V) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
R 11 Selected from H, phenyl or pyridyl, said phenyl or pyridyl being optionally further substituted with 0 to 3 substituents selected from F, cl or methoxy;
R 12 each independently selected from H or
Figure BDA0001714822470000203
R 13 Each independently selected from H,
Figure BDA0001714822470000204
R 14 Selected from H or phenyl, said phenyl optionally further substituted with 0 to 1 substituents selected from F, cl or methyl;
R 1 is selected from H;
a is selected from
Figure BDA0001714822470000205
R 21 Selected from methoxy;
R 28 selected from Cl or methyl;
m is selected from 0 or 1;
provided that R is 11 、R 12 And R 13 Cannot be both H and R 12 And R 13 And only one is H.
In some embodiments, a compound of formula (V) or a tautomer, mesomer, racemate, enantiomer, or diastereomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, is selected from one of the following structures:
Figure BDA0001714822470000211
In another aspect of the invention, a compound according to the following structure or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof,
Figure BDA0001714822470000212
Figure BDA0001714822470000221
Figure BDA0001714822470000231
Figure BDA0001714822470000241
another aspect of the invention relates to the compound or its tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the salt comprises hydrochloride, sulfate, phosphate, acetate, trifluoroacetate, fumarate, hemi-fumarate, maleate, malate, citrate, succinate, benzenesulfonate or p-toluenesulfonate salt.
The invention also relates to a pharmaceutical composition comprising: an effective dose of the compound, or a tautomer, mesomer, racemate, enantiomer, or diastereomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, or further comprising one or more additional therapeutic agents and a pharmaceutically acceptable carrier or excipient. The composition may further comprise at least one additional analgesic, anti-faecal agent.
The invention also relates to the application of the compound or the tautomer, the mesomer, the racemate, the enantiomer, the diastereomer or the mixture form thereof, or the pharmaceutically acceptable salt thereof or the composition in preparing a medicament for preventing or treating pain, wherein the pain can be postoperative pain, cancer-caused pain, neuropathic pain, traumatic pain, inflammation-caused pain and the like.
The present invention also relates to a method for preventing or treating pain, which comprises administering to a subject an effective amount of said compound or its tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, or a pharmaceutically acceptable salt thereof, or said composition.
The mu opioid receptor-mediated related disorder of the present invention is selected from pain, immune dysfunction, inflammation, esophageal reflux, neurological and psychiatric disorders, urological and reproductive disorders, cardiovascular disorders, and respiratory disorders.
The terms used in the specification and claims have the following meanings.
Carbon, hydrogen, oxygen, sulfur, nitrogen or F, cl, br, I referred to in the groups and compounds of the invention include isotopes thereof, and carbon, hydrogen, oxygen, sulfur or nitrogen referred to in the groups and compounds of the invention are optionally further replaced by one or more of their corresponding isotopes, wherein isotopes of carbon include 12 C、 13 C and 14 c, isotopes of hydrogen including protium (H), deuterium (D, also called deuterium), tritium (T, also called deuterium), isotopes of oxygen including 16 O、 17 O and 18 isotopes of O, sulfur including 32 S、 33 S、 34 S and 36 isotopes of S, nitrogen including 14 N and 15 isotopes of N, fluorine include 17 F and 19 isotopes of F, chlorine including 35 Cl and 37 cl, isotopes of bromine including 79 Br and 81 Br。
"alkyl" means a straight or branched chain saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably an alkyl group of 1 to 8 carbon atoms, more preferably an alkyl group of 1 to 6 carbon atoms, and further preferably an alkyl group of 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and various branched isomers thereof. Alkyl groups may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment.
"alkoxy" means-O-alkyl. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, cyclopropoxy, and cyclobutoxy.
"acetoxy" refers to-O- (C = O) -CH 3 Wherein methyl may be further substituted;
"acetylamino" means-NR' - (C = O) -CH 3 Wherein methyl may be further substituted and R' may be H or alkyl;
"amino" means-NH 2
By "cyano" is meant
Figure BDA0001714822470000251
"Nitro" means-NO 2
"hydroxy" means-OH.
"carboxyl" means-COOH.
"carbonyl" means- (C = O) -.
"carboxylate" refers to the group-COOR 19a Wherein R is 19a Is C 1-6 An alkyl group.
"amido" means a-CONR 20a R 21a Wherein R is 20a And R 21a Each independently selected from H, alkyl or carbocyclyl, said alkyl or carbocyclyl may be further substituted.
"hydroxyalkyl" is an alkyl group substituted with 1,2 or 3 hydroxyl groups, preferably C 1-4 An alkyl group. Non-limiting examples include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1, 2-dihydroxypropyl, 1, 3-dihydroxypropyl and 2, 3-dihydroxypropyl.
"cycloalkyl" means a saturated or unsaturated monocyclic cycloalkyl group, which may be substituted or unsubstituted, and the ring carbon atoms include 3 to 20 carbon atoms, preferably 3 to 10 carbon atoms, further preferably 3 to 8 carbon atoms, non-limiting examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1, 5-cyclooctadienyl, 1, 4-cyclohexadienyl, cycloheptatrienyl and the like.
"Heterocycloalkyl" means a substituted or unsubstituted saturated or unsaturated compound containing at least 1 to 5 substituents selected from N, O, S (= O) or S (= O) 2 A non-aromatic ring system of heteroatoms or groups, the non-aromatic ring system comprising 3 to 20 ring atoms, preferably 3 to 10 ring atoms, more preferably 3 to 8 ring atoms. Optionally substituted N, S in the heterocyclyl ring may be oxidized to various oxidation states. Non-limiting examples include oxacyclopropane, oxetanyl, oxocyclopentyl, oxocyclohexyl, oxooctyl, aziridinyl, azetidinyl, azacyclohexyl, azacyclopropenyl, 1, 3-dioxolanyl, 1, 4-dioxolanyl, 1, 3-dioxacyclohexyl, 1, 3-dithiocyclohexyl, azepinyl, morpholinyl, piperazinyl, pyridyl, furyl, thienyl, pyrrolyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, thiomorpholinyl, dihydropyranyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyrazolyl, 1, 4-dioxadienyl, 2H-1, 2-oxazinyl, 2, 5-dihydrothienyl,
Figure BDA0001714822470000261
And the like.
"aryl" refers to substituted or unsubstituted 6 to 14 membered cyclic aromatic groups, including monocyclic aromatic groups and fused ring aromatic groups. Preferably 6 to 14-membered aromatic ring, further preferably 6 to 10-membered aromatic ring, non-limiting examples of which include phenyl, naphthyl, anthryl, phenanthryl and the like. The aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is an aryl ring, non-limiting examples of which include:
Figure BDA0001714822470000262
"heteroaryl" refers to a substituted or unsubstituted 5 to 14 membered aromatic ring containing 1 to 5 substituents selected from N, O or S (= O) n A hetero atom or group, preferably a 5-to 10-membered heteroaromatic ring, further preferably 5-to 6-membered. Non-limiting examples of heteroaryl groups include, but are not limited to, pyridyl, furyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholine, thiomorpholine, 1, 3-dithiane, benzimidazole, perindopyl, benzimidazole, benzopyridine, pyrrolopyridine, and the like. The heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring joined together to the parent structure is a heteroaryl ring, non-limiting examples of which include
Figure BDA0001714822470000263
"alkenyl" means a straight or branched chain unsaturated aliphatic hydrocarbon group consisting of 2 to 20 carbon atoms, preferably an alkenyl group of 2 to 12 carbon atoms, more preferably an alkenyl group of 2 to 8 carbon atoms, containing a carbon-carbon double bond. Non-limiting examples include vinyl, propen-2-yl, buten-2-yl, penten-4-yl, hexen-2-yl, hexen-3-yl, hepten-2-yl, hepten-3-yl, hepten-4-yl, octen-3-yl, nonen-3-yl, decen-4-yl and undecen-3-yl.
"alkynyl" means a straight or branched chain unsaturated aliphatic hydrocarbon group containing carbon-carbon triple bonds and consisting of 2 to 20 carbon atoms, preferably alkynyl of 2 to 12 carbon atoms, more preferably alkynyl of 2 to 8 carbon atoms. Non-limiting examples include ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl, butyn-2-yl, butyn-3-yl, 3-dimethylbutyn-2-yl, pentyn-1-yl, pentyn-2-yl, hexyn-1-yl, 1-heptyn-1-yl, heptyn-3-yl, heptyn-4-yl, octyn-3-yl, nonyn-3-yl, decyn-4-yl, undec-3-yl, dodecyn-4-yl.
"benzyl" means-CH 2 -phenyl, said phenyl being substituted or unsubstituted, non-limiting examples of which include-CH 2 -phenyl, -CH 2 P-methylphenyl, and the like.
"pharmaceutically acceptable salt" or "pharmaceutically acceptable salt thereof" refers to a salt of a compound of the present invention that retains the biological effectiveness and properties of the free acid or free base obtained by reaction with a non-toxic inorganic or organic base, or a non-toxic inorganic or organic acid. Non-limiting examples of the inorganic base include Al, ca, li, mg, K, na, and Zn; non-limiting examples of the organic base include ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, tetramethylamine, diethanolamine, ethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, caffeine, procaine, choline, betaine, benzaminum, ethylenediamine, glucosamine, N-methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, and polyamine resins; non-limiting examples of the inorganic and organic acids include sulfuric acid, phosphoric acid, nitric acid, hydrobromic acid, hydrochloric acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, benzenesulfonic acid, benzoic acid, phenylacetic acid, salicylic acid, alginic acid, anthranilic acid, camphoric acid, citric acid, vinylsulfonic acid, formic acid, fumaric acid, furoic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, mucic acid, pamoic acid, pantothenic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, malonic acid, 2-hydroxypropionic acid, oxalic acid, glycolic acid, glucuronic acid, galacturonic acid, citric acid, lysine, arginine, aspartic acid, cinnamic acid, methanesulfonic acid, ethanesulfonic acid, and trifluoromethanesulfonic acid.
"pharmaceutical composition" refers to a mixture of one or more compounds of the present invention, pharmaceutically acceptable salts or prodrugs thereof, and other chemical components, wherein "other chemical components" refers to pharmaceutically acceptable carriers, excipients, and/or one or more other therapeutic agents.
By "carrier" is meant a material that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
"excipient" refers to an inert substance added to a pharmaceutical composition to facilitate administration of a compound. Non-limiting examples include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives (including microcrystalline cellulose), gelatin, vegetable oils, polyethylene glycols, diluents, granulating agents, lubricants, binders, and disintegrating agents.
"optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs or does not. Such as: "alkyl optionally substituted with F" means that the alkyl group may, but need not, be substituted with F, and the description includes the case where the alkyl group is substituted with F and the case where the alkyl group is not substituted with F.
Detailed Description
The following detailed description is provided for the purpose of illustrating the embodiments and the advantageous effects thereof, and is not intended to limit the scope of the present disclosure.
The structure of the compounds is determined by Nuclear Magnetic Resonance (NMR) and/or Mass Spectrometry (MS), and Supercritical Fluid Chromatography (SFC) resolves the chiral structure.
NMR shift (. Delta.) of 10 -6 The units in (ppm) are given.
NMR was measured using (Bruker ADVANCE III 400) nuclear magnetic instrument in deuterated dimethyl sulfoxide (DMSO-d) 6 ) Deuterated chloroform (CDCl) 3 ) Deuterated methanol (CD) 3 OD), internal standard Tetramethylsilane (TMS), 1HNMR information is tabulated in the following format: chemical shift (multiplet (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), number of protons).
MS was measured (Agilent 6120B (ESI)).
HPLC was carried out using an Agilent 1260DAD high pressure liquid chromatograph (Zorba x SB-C18 100x 4.6 mm).
The thin layer chromatography silica gel plate adopts HSGF254 of tobacco yellow sea or GF254 of Qingdao, the specification of the silica gel plate used by Thin Layer Chromatography (TLC) is 0.15 mm-0.20 mm, and the specification of the thin layer chromatography separation and purification product is 0.4 mm-0.5 mm.
The column chromatography generally uses 200-300 mesh silica gel of the Tibet Huanghai silica gel as a carrier.
The known starting materials of the present invention can be synthesized by methods known in the art or purchased from Chengdu Kelong chemical industry, chengdu Xiong chemical industry, chengdu chemical industry, aister (Chengdu) pharmaceutical technology GmbH, shaoshan far chemical technology (Shanghai) GmbH, pharmaceutical industry GmbH of the national medicine group, bailinghi Technology GmbH, etc.
The nitrogen atmosphere means that the reaction flask is connected with a nitrogen balloon with a volume of about 1L.
The hydrogen atmosphere refers to a reaction flask connected with a hydrogen balloon with a volume of about 2L.
The hydrogenation reaction is usually carried out by vacuum pumping, hydrogen filling and repeated operation for 3 times.
In the examples, the solution means an aqueous solution unless otherwise specified.
In the examples, the reaction temperature is, unless otherwise specified, room temperature, which is 20 ℃ to 30 ℃.
Brief description:
THF: tetrahydrofuran;
DMF is N, N-dimethylformamide;
me: a methyl group;
PE is petroleum ether;
EA ethyl acetate
THP 2-tetrahydropyran.
Intermediate 1: (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1)
(R)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000291
The first step is as follows: 6-oxaspiro [4.5] decan-9-ol (1 b)
6-oxaspiro[4.5]decan-9-ol
Figure BDA0001714822470000292
3-buten-1-ol (8.39g, 116.5mmol) and cyclopentanone (1 a) (14.6g, 174.0 mmol) were added to the reaction flask and the temperature was reduced to 0 ℃. 75% concentrated sulfuric acid (33.1g, 337mmol) was added dropwise to the reaction mixture, the temperature of which did not exceed 5 ℃. Naturally raising the temperature to room temperature after the addition is finished, and reacting for 12 hours. At 0 ℃, water (100 mL) was added to the reaction solution, the pH was adjusted to about 8 with sodium hydroxide solution, the product was extracted with ethyl acetate (100 mL × 4), and the combined organic phases were washed with saturated brine (50 mL × 2). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. After sample stirring, purification by column chromatography using (ethyl acetate: petroleum ether =1 = 20-1) gave 6-oxaspiro [4.5] decan-9-ol (1 b) as an oily liquid (7.2 g, yield: 40%).
Ms m/z(ESI):139.3[M-OH];
1 H NMR(400MHz,CDCl 3 )δ4.13-4.11(m,2H),3.56-3.50(m,1H),1.86-1.71(m,4H),1.64-1.56(m,2H),1.46-1.36(m,6H).
The second step: 6-oxaspiro [4.5] decan-9-one (1 c)
6-oxaspiro[4.5]decan-9-one
Figure BDA0001714822470000301
6-oxaspiro [4.5] decan-9-ol (1 b) (5.5g, 35.25mmol) and dichloromethane (120 mL) were added to the reaction flask and the temperature was reduced to 0 ℃. Desmatin oxidant (30g, 70.5 mmol) was added to the reaction mixture in portions at 0 ℃ at a temperature not exceeding 5 ℃. After the addition, the reaction was allowed to naturally warm to room temperature for 12 hours. Sodium bicarbonate solution (80 mL) was added dropwise to the reaction solution to adjust PH =8, filtered, the filter cake was washed with dichloromethane (40 mL × 2), the filtrates were combined, the product was extracted with dichloromethane (50 mL × 2), and the organic phases were combined and washed with saturated brine (50 mL × 2). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. After sample stirring, column purification was performed using (ethyl acetate: petroleum ether =1: 30-1).
Ms m/z(ESI):155.3[M+H];
1 H NMR(400MHz,CDCl 3 )δ3.97-3.94(m,2H),2.47-2.42(m,4H),1.85-1.76(m,2H),1.65-1.61(m,2H),1.60-1.53(m,4H).
The third step: 2-cyano-2- [ 6-oxaspiro [4.5] decan-9-ylidene ] acetic acid methyl ester (E/Z) (1 d)
(E/Z)methyl 2-cyano-2-(6-oxaspiro[4.5]decan-9-ylidene)acetate
Figure BDA0001714822470000302
6-oxaspiro [4.5] decan-9-one (1 c) (25.0g, 0.162mol), methyl cyanoacetate (19.3g, 0.194mol), ammonium acetate (3.75g, 48.64mmol) and acetic acid (1.95g, 32.43mmol) were successively added to toluene (70 mL) at room temperature, heated under reflux to dehydrate and react for 6 hours. After completion of the reaction, water (120 mL) was added to extract the product with ethyl acetate (50 mL. Times.2), the combined organic phases were washed with saturated brine (30 mL. Times.2), and the organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. After sample stirring, purification by column chromatography using (ethyl acetate: petroleum ether =1 = 80-1) gave methyl 2-cyano-2- [ 6-oxaspiro [4.5] decan-9-ylidene ] acetate (E/Z) (1 d) as an oily liquid (30.0 g, yield: 78.65%).
Ms m/z(ESI):258.2[M+Na];
1 H NMR(400MHz,CDCl 3 )δ3.88-3.86(m,1H),3.84(s,3H),3.81-3.78(m,1H),3.16-3.12(m,2H),2.76-2.72(m,2H),1.82-1.76(m,4H),1.68-1.53(m,4H).
The fourth step: methyl 2-cyano-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) carboxylate (1 e)
methyl 2-cyano-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetate
Figure BDA0001714822470000311
A solution of 2-bromopyridine (48.0 g,0.3 mol) in THF (150 mL) was added dropwise to a solution of isopropyl magnesium chloride (150 mL, 2M in tetrahydrofuran) at 0 ℃ under nitrogen at 0 ℃ and then stirred at room temperature for 3 hours, ketone iodide (3.5 g) was added and stirred at room temperature for 0.5 hours, and then a mixture of E and Z isomers of methyl 2-cyano-2- [ 6-oxaspiro [4.5] decan-9-ylidene ] acetate (1 d) (47g, 0.2 mol) in tetrahydrofuran (200 mL) was added dropwise to the reaction solution. After the addition, the reaction mixture was heated to 55 ℃ and stirred for 8 hours. The reaction mixture was poured into a mixture of 200g ice/1N HCl (200 mL). The product was extracted with ethyl acetate (500 mL. Times.4), and the combined organic phases were washed with saturated brine (200 mL. Times.1), dried over anhydrous sodium sulfate and concentrated. After sample stirring, purification by column chromatography using (EA: PET =1 = 80-1) gave methyl 2-cyano-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) carboxylate (1 e) (44.0 g, yield: 70.1%) as an oily liquid.
Ms m/z(ESI):315.1[M+H];
1 H NMR(400MHz,CDCl 3 )δ8.62-8.59(m,1H),7.74-7.70(m,1H),7.70-7.68(m,1H),7.21-7.19(m,1H),4.15-4.11(m,3H),3.81-3.66(d,3H),2.67-2.60(m,2H),2.11-2.04(m,1H),1.61-1.28(m,9H).
The fifth step: 2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (1 f)
2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetonitrile
Figure BDA0001714822470000321
Ethylene glycol (20 mL) was added to methyl 2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetate (1 e) (1.57g, 4.99mmol) followed by potassium hydroxide (0.56g, 9.99mmol), and after the addition the reaction was heated to 120 ℃ for 5 hours, the reaction mixture was cooled to room temperature and water (60 mL) was added, the product was extracted with ethyl acetate (50 mL. Times.4), the combined organic phases were washed with saturated brine (40 mL. Times.1), dried over anhydrous sodium sulfate and concentrated. After sample stirring, column purification was performed using (EA: PET =1 = 80-1 50) to give 2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (1 f) (0.8 g, yield: 60%) as an oily liquid.
Ms m/z(ESI):257.3[M+H];
And a sixth step: (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (1 g-1)
(R)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetonitrile
(S) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (1 g-2)
(S)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetonitrile
Figure BDA0001714822470000322
Resolution of the compound 2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile
2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (30 g) was taken for resolution to obtain, after separation, two optical isomer compounds (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (1 g-1) (4.04min, 10.79g, white solid, ee% = 99.7%) and compound (S) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (1 g-2) (retention time: 2.00min,11.17g, white solid, ee% = 99.6%).
Splitting conditions are as follows: apparatus, thar 350 preparatory SFC (SFC-9); column Chiralpak AD,300 × 50mm I.D.,10 μm; mobile phase A: CO2, B: methanol; gradient B45%; the flow rate is 200mL/min; back pressure is 100bar; the column temperature is 38 ℃; the wavelength is 220nm; the period is 7min; compound (1F) was dissolved in methanol to give 60mg/ml; injection, 15 ml/needle.
The seventh step: (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1)
(R)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000331
Lithium aluminum hydride (0.56g, 15.0 mmol) was dissolved in tetrahydrofuran (30 mL), and the temperature was reduced to 0 ℃ to add (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (1 g-1) (1.0 g,3.9 mmol) in tetrahydrofuran (30 mL) to complete the reaction at room temperature overnight. The reaction was cooled to 0 ℃, quenched with water (0.6 mL), sodium hydroxide solution (10%, 1.2 mL) and water (1.2 mL), dried with anhydrous sodium sulfate, stirred for 20 minutes, the solid filtered and washed with tetrahydrofuran (20 mL × 3). The combined organic phases were concentrated to give (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (1.0 g, yield: 98%).
Ms m/z(ESI):261.2[M+H + ];
Example 1
2- (6-Fluorospiro [ chroman-2, 1' -cyclopentanyl ] -4-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (Compound 1)
2-(6-fluorospiro[chroman-2,1'-cyclopentan]-4-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine hydrochloride
Figure BDA0001714822470000332
The first step is as follows: 6-Fluorospiro [ chroman-2, 1' -cyclopentylalkyl ] compounds]-4-one (1B)
6-fluorospiro[chroman-2,1'-cyclopentan]-4-one
Figure BDA0001714822470000341
1- (5-fluoro-2-hydroxyphenyl) ethanone 1A (10g, 65mmol) was dissolved in toluene (110 mL), and cyclopentanone (6.6g, 78mol) and pyrrole (14.1g, 198mol) were added to the solution, and the mixture was heated under reflux for 20 hours, cooled to room temperature, added with water (100 mL), extracted with ether (100 mL. Times.2), washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and subjected to column chromatography (petroleum ether/ethyl acetate = 20) to give 6-fluoropirocyclo [ chroman-2, 1' -cyclopentanyl ] -4-one 1B (12.1 g, yield 92%) as a pale yellow oily product
The second step is that: (Z) -2- (6-Fluorospiro [ benzofuran-2, 1' -cyclopentyl ] -4-methylene) acetonitrile (1C)
(Z)-2-(6-fluorospiro[chroman-2,1'-cyclopentan]-4-ylidene)acetonitrile
Figure BDA0001714822470000342
Sodium hydride (1.14g, 47.7mmol) was dissolved in tetrahydrofuran (70 mL), and cyanomethyl ethyl phosphate (6.75g, 38.15mmol) was added to the system at zero degrees to conduct a reaction for 60min. The reaction system was cooled to 0 ℃ and 6-fluorospiro [ chroman-2, 1' -cyclopentanyl ] -4-one 1B (7 g, 31.8mmol) was added thereto, and after reacting for 15min, the temperature was raised to room temperature overnight. Water (20 mL) was added to the reaction, and the aqueous phase was extracted with ether (30 mL × 2), washed with a saturated saline solution (50 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 50).
Ms m/z(ESI):266.1[M+Na + ]。
The third step: 2- (6-Fluorospiro [ benzofuran-2, 1' -cyclopentyl ] -4-yl) ethylamine (1D)
2-(6-fluorospiro[chroman-2,1'-cyclopentan]-4-yl)ethanamine
Figure BDA0001714822470000343
(Z) -2- (6-Fluorospiro [ benzofuran-2, 1' -cyclopentyl ] -4-methylene) acetonitrile 1C (2g, 8.22mmol) was dissolved in methanol (40 mL) and sodium borohydride (3.1g, 82.2mmol) was added in portions. Cobalt dichloride (2.14g, 6.4mmol) was then added slowly and the reaction was carried out for 12h at room temperature. The solvent methanol was removed under reduced pressure, extracted with dichloromethane (15 mL × 2), washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and subjected to column chromatography (dichloromethane/methanol (v/v) = 20) to give 2- (6-fluoropyclospiro [ benzofuran-2, 1' -cyclopentyl ] -4-yl) ethylamine 1D (0.4 g, yield: 80%) as a light yellow oil.
Ms m/z(ESI):250.2[M+H + ]。
The fourth step: 2- (6-Fluorospiro [ benzofuran-2, 1' -cyclopentyl ] -4-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (1E)
2-(6-fluorospiro[chroman-2,1'-cyclopentan]-4-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine
Figure BDA0001714822470000351
2- (6-Fluorospiro [ benzofuran-2, 1' -cyclopentyl ] -4-yl) ethylamine 1D (0.3g, 1mmol) was dissolved in dichloromethane (10 mL) at room temperature, and 3-methoxythiophene-2-aldehyde (0.2g, 1mmol) and sodium sulfate (1g, 10mmol) were added in this order and stirred at room temperature overnight. Methanol (3 mL) was added, sodium borohydride (0.05g, 1mmol) was added, reaction was carried out for 2h, water (20 mL) was added to the system, extraction was carried out with dichloromethane (30 mL × 3), organic phases were combined, washed with a saturated saline solution (50 mL × 1), dried over anhydrous sodium sulfate, the filtrate was concentrated, and column chromatography purification (dichloromethane/methanol (v/v) = 1) was carried out to obtain a yellow liquid product, 2- (6-fluoropirocyclo [ benzofuran-2, 1' -cyclopentyl ] -4-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine 1E (0.4 g, yield 75%).
Ms m/z(ESI):376.1[M+H + ]。
Resolution of Compound 1E
2- (6-Fluorospiro [ benzofuran-2, 1' -cyclopentyl ] -4-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine 1E (728 mg) was taken for resolution, and after separation, two optical isomers, compound 1E-1 (retention time: 5.36s,336.25mg, light yellow oil,% ee = 100%), compound 1E-2 (retention time: 5.76s,274.37mg, light yellow oil,% ee = 98.9%) were obtained.
Splitting conditions are as follows: apparatus, thar analytical SFC (SFC-A); a column, chiralPak AD,150 × 4.6mm I.D.,3 μm; mobile phase A: carbon dioxide, B: isopropyl alcohol; gradient B25%; the flow rate is 200mL/min; back pressure is 100bar; the column temperature is 38 ℃; wavelength is 220nm; the period is 12min; sample preparation Compound 1E was dissolved in methanol to 18mg/ml; injection, 6ml per needle.
The fifth step: 2- (6-Fluorospiro [ benzofuran-2, 1' -cyclopentyl ] -4-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (Compound 1)
2-(6-fluorospiro[chroman-2,1'-cyclopentan]-4-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine hydrochloride
2- (6-Fluorospiro [ benzofuran-2, 1 '-cyclopentyl ] -4-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine 1E (0.28g, 0.75mmol) was dissolved in ethyl acetate (8 mL), a solution of hydrogen chloride in ethyl acetate (2mL, 4N) was added, reacted for 0.5h, and the solvent was removed under reduced pressure to give the product 2- (6-Fluorospiro [ benzofuran-2, 1' -cyclopentyl ] -4-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride compound 1 (0.31 g, 100% yield) as a pale yellow oil.
Ms m/z(ESI):376.1[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ7.42(d,1H),6.96(d,1H),6.89(t,1H),6.70(m,1H),6.61-6.59(m,1H),4.22(s,2H),3.82(s,3H),3.00-2.95(m,3H),2.21-2.17(m,1H),1.83-1.81(m,4H),1.67-1.60(m,7H).
Compound 1E-1 and compound 1E-2 salt formation methods according to compound 1 gave (R) -2- (6-fluorospiro [ benzofuran-2, 1 '-cyclopentyl ] -4-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (compound 1-1) and (S) -2- (6-fluorospiro [ benzofuran-2, 1' -cyclopentyl ] -4-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (compound 1-2), respectively.
Example 2
(S) -N- ((3-Methoxythien-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (Compound 2)
(S)-N-((3-methoxythiophen-2-yl)methyl)-N-methyl-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000361
Figure BDA0001714822470000371
The first step is as follows: (S) -N- ((3-Methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (2A) (S) -N- ((3-methoxythiopen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxapiro [4.5]
Figure BDA0001714822470000372
(S) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (1.0 g, 3.62mmol) was dissolved in dichloromethane (15 mL), and sodium sulfate (2.57g, 18.1 mmol) and 3-methoxythiophene-2-carboxaldehyde (0.64g, 4.52mmol) were added to the reaction, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.17g, 4.52mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and after the crude product was subjected to column chromatography (dichloromethane/methanol (v/v) =50
Ms m/z(ESI):387.2[M+H + ];
The second step is that: (S) -N- ((3-methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (2B)
(S)-N-((3-methoxythiophen-2-yl)methyl)-N-methyl-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000381
(S) -N- ((3-Methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (2A) (0.216g, 0.51mmol) and formaldehyde (0.06g, 2.04mmol) were added to 1, 2-dichloroethane (20 mL) at room temperature. After the addition, the reaction was carried out at room temperature for 3 hours. Sodium triacetoxyborohydride (0.16g, 0.77mmol) was added to the reaction mixture, and the reaction was carried out at room temperature for 16 hours. The reaction solution was poured into a saturated sodium bicarbonate solution (15 mL), the aqueous phase was extracted with ethyl acetate (25 mL. Times.2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give (S) -N- ((3-methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (2B) (0.18 g, yield: 88.2%) as an oily liquid.
Ms m/z(ESI):401.2[M+H + ];
The third step: (S) -N- ((3-Methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 2) (S) -N- ((3-methoxythiopen-2-yl) methyl) -N-methyl-2- (9- (pyridine-2-yl) -6-oxapiro [4.5] ]dec-9-yl) ethylamine hydrochloride
Figure BDA0001714822470000382
(S) -N- ((3-methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (2B) (0.18g, 0.39mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction was directly spin dried to give (S) -N- ((3-methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 2) as a yellow solid (0.16 g, 98% yield).
Ms m/z(ESI):401.2[M+H + ];
1 H NMR(400MHz,CD 3 OD)δ8.73-8.71(d,1H),8.56-8.52(m,1H),8.09-7.92(d,1H),7.90-7.89(m,1H),7.87(d,1H),7.31-7.29(m,1H),7.02-7.01(d,1H),6.90-6.88(m,1H),4.48(m,1H),4.29(m,1H),4.28(s,1H),3.87(s,3H),3.05(m,1H),2.91(m,1H),2.63-2.59(m,1H),1.30-1.17(d,6H).
Example 3
(R) -N- ((3-Methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 3)
(R)-N-((3-methoxythiophen-2-yl)methyl)-N-methyl-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000391
The first step is as follows: (R) -N- ((3-methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (3B)
(R)-N-((3-methoxythiophen-2-yl)methyl)-N-methyl-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000392
(R) -N- ((3-Methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (3A, synthesized according to patent CN201280021050.7, example 15) (0.216g, 0.51mmol) and formaldehyde (0.06g, 2.04mmol) were added to 1, 2-dichloroethane (20 mL) at room temperature. After the addition, the reaction was carried out at room temperature for 3 hours. Sodium triacetoxyborohydride (0.16g, 0.77mmol) was added to the reaction solution, and after the addition, the reaction was carried out at room temperature for 16 hours. The reaction solution was poured into a saturated sodium bicarbonate solution (15 mL), the aqueous phase was extracted with ethyl acetate (25 mL. Times.2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give (R) -N- ((3-methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (3B) (0.18 g, yield: 88.2%) as an oily liquid.
Ms m/z(ESI):401.2[M+H + ];
The second step is that: (R) -N- ((3-Methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 3) (R) -N- ((3-methoxythiopen-2-yl) methyl) -N-methyl-2- (9- (pyridine-2-yl) -6-oxapiro [4.5] ]dec-9-yl) ethylamine hydrochloride
Figure BDA0001714822470000401
(R) -N- ((3-methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (3B) (0.18g, 0.39mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction was directly spin dried to give (R) -N- ((3-methoxythiophen-2-yl) methyl) -N-methyl-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 3) (0.16 g, 98% yield) as a yellow solid.
Ms m/z(ESI):401.2[M+H + ];
1 H NMR(400MHz,CD 3 OD)δ8.73-8.71(d,1H),8.56-8.52(m,1H),8.09-7.92(d,1H),7.90-7.89(m,1H),7.87(d,1H),7.31-7.29(m,1H),7.02-7.01(d,1H),6.90-6.88(m,1H),4.48(m,1H),4.29(m,1H),4.28(s,1H),3.87(s,3H),3.05(m,1H),2.91(m,1H),2.63-2.59(m,1H),1.30-1.17(d,6H).
Example 4
(R) -N- ((3- (cyclopropylmethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 4)
(R)-N-((3-(cyclopropylmethoxy)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000411
The first step is as follows: 3-methoxythiophene-2-carboxaldehyde (4B)
3-methoxythiophene-2-carbaldehyde
Figure BDA0001714822470000412
Under the protection of nitrogen, 3-methoxythiophene (4A) (5g, 43.8mmol) was dissolved in tetrahydrofuran (30 mL), the temperature was reduced to-78 ℃, N-butyllithium (19.3mL, 48.2mmol) was added dropwise to the reaction, the reaction was warmed to room temperature for 1 hour, N-dimethylformamide (4.8g, 65.7mmol) was added dropwise to the reaction, and the reaction was continued at room temperature for 1.5 hours. The reaction solution was quenched with saturated ammonium chloride (30 mL), water (30 mL) was added, the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with saturated sodium chloride (50 mL), dried over anhydrous sodium sulfate, filtered, and after concentrating the filtrate, the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 20.
1 H NMR(400MHz,CDCl 3 )δ9.99(d,1H),7.64(dd,1H),6.87(d,1H),3.99(s,3H).
The second step is that: 3-Hydroxythiophene-2-carbaldehyde (4C)
3-hydroxythiophene-2-carbaldehyde
Figure BDA0001714822470000413
3-methoxythiophene-2-carboxaldehyde (4B) (3.5g, 25mmol) is dissolved in trichloromethane (40 mL), the temperature is reduced to-10 ℃, then trichloromethane (20 mL) solution of boron tribromide (7.4g, 30mmol) is dripped into the reaction, and the reaction is carried out for 1 hour at 50 ℃ after the addition. Cooling, quenching the reaction with water (50 mL) and 2M hydrochloric acid (20 mL), extraction of the aqueous phase of the separated liquid with dichloromethane (30 mL × 2), combining the organic phases, washing with saturated sodium chloride solution (50 mL), drying over anhydrous sodium sulfate, filtration, concentration of the filtrate, and column chromatography of the crude product (petroleum ether/ethyl acetate (v/v) = 3) gave 3-hydroxythiophene-2-carbaldehyde (4C) as a yellow solid (1.5 g, yield: 48%).
1 H NMR(400MHz,CDCl 3 )δ10.71(s,1H),9.64(d,1H),7.59(d,1H),6.77(dd,1H).
The third step: 3- (cyclopropylmethoxy) thiophene-2-carbaldehyde (4D) 3- (cyclopropropylmethoxy) thiophene-2-carbaldehyde
Figure BDA0001714822470000421
3-Hydroxythiophene-2-carbaldehyde (4C) (1.4g, 11mmol) was dissolved in N, N-dimethylformamide (20 mL), and potassium carbonate (1.8g, 13mmol) and bromocyclopropane (1.75g, 13mmol) were added thereto, followed by completion of the reaction at 100 ℃ for 2 hours. Water (80 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (30 mL × 2), the combined organic phases were washed with a saturated sodium chloride solution (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 5) to obtain 3- (cyclopropylmethoxy) thiophene-2-carbaldehyde (4D) as an oily liquid (1.8 g, yield: 90%).
1 H NMR(400MHz,CDCl 3 )δ10.21-9.85(m,1H),7.73-7.47(m,1H),6.82(d,1H),3.99(d,2H),1.47-1.16(m,1H),0.85-0.55(m,2H),0.38(q,2H).
The fourth step: (R) -N- ((3- (cyclopropylmethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (4E)
(R)-N-((3-(cyclopropylmethoxy)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000422
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.3g, 1.1 mmol) was dissolved in dichloromethane (10 mL), and sodium sulfate (0.8g, 5.5 mmol) and 3- (cyclopropylmethoxy) thiophene-2-carbaldehyde (4D) (0.3g, 1.7 mmol) were added to the reaction, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.07g, 1.7mmol) was added to the reaction and stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (20 mL), the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give a crude product which was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):427.2[M+H + ];
The fifth step: (R) -N- ((3- (cyclopropylmethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 4)
(R)-N-((3-(cyclopropylmethoxy)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000431
(R) -N- ((3- (cyclopropylmethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (4E) (0.18g, 0.42mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -N- ((3- (cyclopropylmethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 4) as a yellow solid (0.2 g, yield: 100%).
Ms m/z(ESI):427.3[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.89(d,1H),8.63(d,1H),8.24-7.95(m,2H),7.48(d,1H),6.99(d,1H),4.26(s,2H),3.94(d,2H),3.90-3.80(m,1H),3.79-3.67(m,1H),3.02(dd,1H),2.62-2.44(m,3H),2.27(ddd,3H),2.01-1.82(m,2H),1.72-1.47(m,5H),1.25-1.17(m,2H),0.85(d,1H),0.70-0.57(m,2H),0.46-0.30(m,2H).
Example 6
N- ((3-Methylthion-2-yl) methyl) -2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 6-1)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-2,6-dioxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000441
The first step is as follows: 2, 6-dioxaspiro [4.5] decan-9-ol (6B)
2,6-dioxaspiro[4.5]decan-9-ol
Figure BDA0001714822470000442
To a mixture of 3-buten-1-ol (6A) (5g, 69.3mmol) and tetrahydrofuran-3-one (7.6g, 90.1mmol) was added dropwise a 75% sulfuric acid solution (20.4 g,208.0 mmol) at 0 ℃. After the addition was completed, the reaction was allowed to warm to room temperature for 5 hours. At low temperature, water (50 mL) was added to the reaction solution, PH ≈ 8 was adjusted with sodium hydroxide solid, the aqueous phase was extracted with ethyl acetate (50 mL × 5), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and after the filtrate was concentrated, the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 10) to obtain 2, 6-dioxaspiro [4.5] decan-9-ol (6B) as an oily liquid (4.2 g, yield: 38%).
Ms m/z(ESI):159.2[M+H + ];
The second step: 2, 6-dioxaspiro [4.5] decan-9-one (6C)
2,6-dioxaspiro[4.5]decan-9-one
Figure BDA0001714822470000451
2, 6-dioxaspiro [4.5] decan-9-ol (6B) (4.2g, 27mmol) was dissolved in dichloromethane (50 mL), cooled to 0 ℃ and pyridinium chlorochromate (8.7 g,40.5 mmol) was added to the reaction, and the reaction was completed at room temperature overnight. To the reaction solution was added methyl tert-butyl ether (80 mL), and filtered with celite, the filtrate was directly spun dry, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =20: 1. About.2) to give 2, 6-dioxaspiro [4.5] decan-9-one (6C) (4 g, yield: 94%) as a yellow oily liquid.
The third step: 2-cyano-2- (2, 6-dioxaspiro [4.5] decan-9-ylidene) acetic acid methyl ester (6D)
methyl 2-cyano-2-(2,6-dioxaspiro[4.5]decan-9-ylidene)acetate
Figure BDA0001714822470000452
2, 6-dioxaspiro [4.5] decan-9-one (6C) (4 g,25.6 mmol), methyl cyanoacetate (3g, 30.7 mmol), ammonium acetate (0.72g, 7.7 mmol), acetic acid (0.3g, 5.1 mmol) and toluene (50 mL) were charged into a reaction flask and heated to reflux for 4 hours. After cooling, a sodium hydrogencarbonate solution (50 mL) was added to the reaction solution, and aqueous ethyl acetate (30 mL × 3) was extracted, the organic phases were combined, washed with a saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =1 to 2).
Ms m/z(ESI):238.2[M+H + ];
The fourth step: 2-cyano-2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) acetic acid methyl ester (6E)
methyl 2-cyano-2-(9-(pyridin-2-yl)-2,6-dioxaspiro[4.5]decan-9-yl)acetate
Figure BDA0001714822470000461
Isopropyl magnesium chloride (15.6 mL,31.6 mmol) was charged into a reaction flask, the temperature was lowered to 0 ℃ and a solution of 2-bromopyridine (5g, 31.6 mmol) in tetrahydrofuran (20 mL) was added dropwise to the reaction, after reaction at room temperature for 3 hours, cuprous iodide (0.4 g,2.1 mmol) was added to the reaction, the reaction was stirred for 0.5 hours, and a solution of methyl 2-cyano-2- (2, 6-dioxaspiro [4.5] decan-9-ylidene) acetate (6D) (5g, 21mmol) in tetrahydrofuran (10 mL) was added dropwise to the reaction and allowed to react at room temperature for 18 hours. The reaction was quenched by adding ice water (30 mL) and 1N hydrochloric acid (30 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated saline solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =10: 1-1) to give methyl 2-cyano-2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) acetate (6E) (4 g, yield: 60%) as an oily liquid.
Ms m/z(ESI):317.1[M+H + ];
The fifth step: 2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) acetonitrile (6F)
2-(9-(pyridin-2-yl)-2,6-dioxaspiro[4.5]decan-9-yl)acetonitrile
Figure BDA0001714822470000462
Ethylene glycol (40 mL) was added to methyl 2-cyano-2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) acetate (6E) (4.2g, 13mmol), potassium hydroxide (1.5g, 26mmol) was added thereto, and the mixture was heated to 120 ℃ to react for 3 hours. The reaction solution was cooled, water (80 mL) was added, the aqueous phase was extracted with ethyl acetate (50 mL × 4), the organic phases were combined, washed with a saturated sodium chloride solution (30 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =4: 1-1) to give 2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) acetonitrile (6F) as a yellow oily liquid (2.8 g, yield: 82%).
Ms m/z(ESI):259.1[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.63(ddd,1H),7.78-7.64(m,1H),7.41(dd-1H),7.26-7.14(m,1H),3.97-3.64(m,4H),3.56(d,0.5H),3.21(d,0.5H),2.90-2.46(m,4H),2.16-1.81(m,4H),1.41(ddd,0.5H),1.13(dt,0.5H).
And a sixth step: 2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) ethylamine (6G)
2-(9-(pyridin-2-yl)-2,6-dioxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000471
Lithium aluminum hydride (0.58g, 15.4 mmol) was dissolved in tetrahydrofuran (20 mL), cooled to 0 ℃ and 2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) acetonitrile (6F) (2g, 7.7 mmol) in tetrahydrofuran (10 mL) was added dropwise to the reaction, and the reaction was allowed to proceed overnight at room temperature. The reaction was quenched with water (0.6 mL), sodium hydroxide solution (10%, 1.2 mL) and water (0.8 mL) in that order, dried by addition of anhydrous sodium sulfate, stirred for 20 min, the solid filtered and washed with tetrahydrofuran (20 mL. Times.3). The combined organic phases were concentrated to give 2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) ethylamine (6G) (1.6G, yield: 79%).
Ms m/z(ESI):263.1[M+H + ];
The seventh step: n- ((3-Methylthion-2-yl) methyl) -2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) ethylamine (6H)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-2,6-dioxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000472
2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) ethylamine (6G) (1.6G, 6.1mmol) was dissolved in methylene chloride (15 mL), and sodium sulfate (4.3G, 30.5 mmol) and 3-methoxythiophene-2-carboxaldehyde (1.3G, 9.1mmol) were added to the reaction, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.35g, 9.1mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give crude product which was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):389.2[M+H + ];
The compound N- ((3-methylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) ethylamine (6H) (1.3 g) was isolated by two SFC preparations to obtain four optical isomers, compound 6H-1 (retention time: 5.41min,0.28g, oily liquid, ee% = 98.2%), compound 6H-2 (retention time: 6.99min,0.38g, oily liquid, ee% = 99.4%), compound 6H-3 (retention time: 7.78min,0.31g, oily liquid, ee% = 99.5%), compound 6H-4 (retention time: 11.15min,0.24g, oily liquid, ee% = 99.0%).
First SFC preparation conditions:
MG II preparatory SFC (SFC-1);
column, cellulose-2, 250X 30mm I.D.,5 μm;
mobile phase A: carbon dioxide, B: methanol (0.1% ammonia);
gradient B40%;
the flow rate is 60mL/min;
back pressure is 100bar;
the column temperature is 38 ℃;
the wavelength is 220nm;
the period is 16min;
sample preparation, compound is dissolved in methanol to make 26mg/ml; injection 1 ml/needle. Pure compound 6-1,6-4 and mixtures 6-2 and 6-3 were obtained.
Second SFC preparation conditions:
MG II preparatory SFC (SFC-14);
a column, chiralPak AD,250 × 30mm i.d.,5 μm;
mobile phase A: carbon dioxide, B: ethanol;
Gradient B40%;
the flow rate is 50mL/min;
back pressure is 100bar;
the column temperature is 38 ℃;
wavelength is 220nm;
the period is 4.5min;
eighth step: n- ((3-Methylthion-2-yl) methyl) -2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) ethanamine (Compound 6)
N-((3-methoxythiophen-2-yl)methyl)-2-9-(pyridin-2-yl)-2,6-dioxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000491
Compound 6H (0.18g, 0.39mmol) was dissolved in ethyl acetate (5 mL), to which a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added, and the reaction was stirred at room temperature for 0.5 hour. The reaction was directly spin-dried to give N- ((3-methylthiophen-2-yl) methyl) -2- ((5R, 9R) -9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 6) as a white solid (0.16 g, 98% yield).
The compound 6H-1, the compound 6H-2, the compound 6H-3 and the compound 6H-4 are salified according to the steps to obtain the compound 6-1, the compound 6-2, the compound 6-3 and the compound 6-4:
compound 6-1:
Ms m/z(ESI):389.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.86(d,1H),8.58(d,1H),8.11(t,1H),8.00(d,1H),7.46(d,1H),7.00(d,1H),4.19(s,2H),3.97-3.67(m,7H),3.44-3.32(m,1H),3.13-2.86(m,2H),2.60-2.15(m,7H),2.12-1.87(m,2H).
compound 6-2:
Ms m/z(ESI):389.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.85(t,1H),8.64-8.44(m,1H),8.22-7.80(m,2H),7.47(d,1H),7.00(d,1H),4.19(s,2H),4.02-3.66(m,8H),3.59(d,1H),3.08-2.89(m,1H),2.66-2.43(m,3H),2.34-2.07(m,3H),2.00(d,1H),1.60-1.47(m,1H),1.30(dt,1H).
compound 6-3:
Ms m/z(ESI):389.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.93-8.82(m,1H),8.58(dd,1H),8.16(t,1H),7.99(dd,1H),7.49(d,1H),7.03(d,1H),4.21(s,2H),3.99-3.66(m,8H),3.61(d,1H),3.00(td,1H),2.62-2.45(m,3H),2.38-2.10(m,3H),2.00(ddd,1H),1.56(dd,1H),1.32(dt,1H).
compounds 6-4:
Ms m/z(ESI):389.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.74(dd,1H),8.45(dt,1H),8.04-7.78(m,2H),7.37(d,1H),6.90(d,1H),4.10(s,2H),3.90-3.61(m,7H),3.27-3.22(m,1H),2.98-2.78(m,2H),2.49-2.02(m,7H),2.01-1.78(m,2H).
example 9
N- ((3-Methylthioen-2-yl) methyl) -2- (9- (prop-1-yn-1-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine hydrochloride (Compound 9)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(prop-1-yn-1-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000501
The first step is as follows: 2-cyano-2- (9- (prop-1-yn-1-yl) -6-oxaspiro [4.5] decan-9-yl) acetic acid methyl ester (9B)
methyl 2-cyano-2-(9-(prop-1-yn-1-yl)-6-oxaspiro[4.5]decan-9-yl)acetate
Figure BDA0001714822470000511
Under the protection of nitrogen, propynyl magnesium bromide (102mL, 51mmol) was charged into a reaction flask, the temperature was reduced to 0 ℃ and cuprous iodide (0.32g, 1.7 mmol) was added to the reaction, and the reaction was stirred for 0.5 hour, and then a solution of methyl 2-cyano-2- (6-oxaspiro [4.5] decan-9-ylidene) acetate (1 d) (4g, 17mmol) in tetrahydrofuran (20 mL) was added dropwise to the reaction and allowed to react at 50 ℃ for 4 hours. The reaction was quenched by adding 1N hydrochloric acid (40 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated saline solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 5).
Ms m/z(ESI):276.1[M+H + ];
The second step is that: 2- (9- (Prop-1-yn-1-yl) -6-dioxaspiro [4.5] decan-9-yl) acetonitrile (9C)
2-(9-(prop-1-yn-1-yl)-6-oxaspiro[4.5]decan-9-yl)acetonitrile
Figure BDA0001714822470000512
Ethylene glycol (20 mL) was added to methyl 2-cyano-2- (9- (prop-1-yn-1-yl) -6-oxaspiro [4.5] decan-9-yl) acetate (9B) (2g, 7.2mmol), potassium hydroxide (0.81g, 14.4 mmol) was further added thereto, and the mixture was heated to 120 ℃ to react for 3 hours. The reaction solution was cooled, water (80 mL) was added, the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 5) to give 2- (9- (prop-1-yn-1-yl) -6-dioxaspiro [4.5] decan-9-yl) acetonitrile (9C) as a yellow oily liquid (1.2 g, yield: 76%).
Ms m/z(ESI):218.1[M+H + ];
The third step: 2- (9- (prop-1-yn-1-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (9D)
2-(9-(prop-1-yn-1-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000521
Lithium aluminum hydride (0.42g, 11mmol) was dissolved in tetrahydrofuran (15 mL), the temperature was lowered to 0 ℃ and 2- (9- (prop-1-yn-1-yl) -6-dioxaspiro [4.5] decan-9-yl) acetonitrile (9C) (1.2g, 5.5 mmol) in tetrahydrofuran (5 mL) was added dropwise to the reaction, and the reaction was allowed to proceed overnight at room temperature. The reaction was cooled to 0 deg.C, quenched with water (0.4 mL), sodium hydroxide solution (10%, 0.8 mL) and water (1.2 mL) in that order, dried by addition of anhydrous sodium sulfate, stirred for 20 minutes, filtered, and the solid washed with tetrahydrofuran (20 mL. Times.3). The organic phase was concentrated to give 2- (9- (prop-1-yn-1-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (9D) (0.8 g, yield: 70%) as a yellow oily liquid.
Ms m/z(ESI):222.1[M+H + ];
The fourth step: n- ((3-Methylthioen-2-yl) methyl) -2- (9- (prop-1-yn-1-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (9E)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(prop-1-yn-1-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000522
2- (9- (prop-1-yn-1-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (9D) (0.6 g,2.7 mmol) was dissolved in dichloromethane (15 mL), and sodium sulfate (1.9g, 13.5mmol) and 3-methoxythiophene-2-carboxaldehyde (0.57g, 4 mmol) were added to the reaction, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.15g, 4 mmol) was added to the reaction mixture, and the reaction mixture was stirred for 20 minutes, followed by addition of methanol (15 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give crude N- ((3-methylthiophen-2-yl) methyl) -2- (9- (prop-1-yn-1-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (9E) (0.4 g, yield: 40%) as a yellow oily liquid by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):348.2[M+H + ];
The fifth step: n- ((3-Methylthioen-2-yl) methyl) -2- (9- (prop-1-yn-1-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine hydrochloride (Compound 9)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(prop-1-yn-1-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000531
N- ((3-Methylthioen-2-yl) methyl) -2- (9- (prop-1-yn-1-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (9E) (0.4g, 1.1mmol) was dissolved in ethyl acetate (8 mL), a solution of hydrogen chloride in ethyl acetate (2mL, 2.0M) was added, and the reaction was stirred at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give N- ((3-methylthiophen-2-yl) methyl) -2- (9- (prop-1-yn-1-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (compound 9) (0.44 g, yield: 100%) as a white solid.
Ms m/z(ESI):348.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ7.51(d,1H),7.06(d,1H),4.31(s,2H),3.98-3.83(m,4H),3.66-3.62(m,1H),3.22(dd,2H),2.34-2.21(m,1H),1.80-1.43(m,16H).
Example 10
N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (3-methoxythiophen-2-yl) methylamine hydrochloride (Compound 10)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)methyl)-1-(3-methoxythiophen-2-yl)methanamine hydrochloride
Figure BDA0001714822470000532
Figure BDA0001714822470000541
The first step is as follows: 9-hydroxy-6-oxaspiro [4.5] dec-8-ene-8-carboxylic acid methyl ester (10B)
methyl 9-hydroxy-6-oxaspiro[4.5]dec-8-ene-8-carboxylate
Figure BDA0001714822470000542
The compound sodium hydride (12.45g, 0.311mol) was charged into a 2000mL three-substance reaction flask, washed with n-hexane (30 mL. Times.3) under nitrogen, tetrahydrofuran (600 mL) was added to the reaction flask, and 6-oxaspiro [4.5] decan-9-one (40g, 0.259mol) (1 c) in tetrahydrofuran (60 mL) was added dropwise with stirring overnight, and after the addition, the mixture was stirred at room temperature for 0.5 hour, and then a solution of dimethyl carbonate (98g, 1.090mol) was added dropwise and stirred at 80 ℃ under reflux for 4 hours. The reaction solution was cooled to room temperature, poured into 600 g of an ice-water mixture under stirring, acidified to pH1-2 with 5% hydrochloric acid, extracted with dichloromethane (150 mL × 3), the organic phases were combined and washed with saturated brine (100 mL × 1), dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography (petroleum ether/ethyl acetate (V/V) = 10/1) to give methyl 9-hydroxy-6-oxaspiro [4.5] dec-8-ene-8-carboxylate (10B) as a yellow oily compound (51 g, yield: 92.64%).
Ms m/z(ESI):213.1[M+H + ];
1 HNMR(400MHz,CDCl 3 )δ11.72(s,1H),4.26(t,2H),3.76(s,3H),2.35-2.34(t,2H),1.88-1.85(m,2H),1.80-1.73(m,2H),1.69-1.60(m,2H),1.53-1.45(m,2H).
The second step is that: 9- (((trifluoromethyl) sulfonyl) oxy) -6-oxaspiro [4.5] dec-8-ene-carboxylic acid methyl ester (10C)
methyl 9-(((trifluoromethyl)sulfonyl)oxy)-6-oxaspiro[4.5]dec-8-ene-8-carboxylate
Figure BDA0001714822470000551
Methyl 9-hydroxy-6-oxaspiro [4.5] dec-8-ene-8-carboxylate (10B) (51g, 0.243mol) was dissolved in methylene chloride (500 mL), stirred and cooled to-78 ℃, diisopropylethylamine (34.1g, 0.264mol) was added and trifluoromethanesulfonic anhydride (101.680g, 0.360mol) was added dropwise, and stirring was completed at room temperature for 3 hours. The reaction mixture was poured into 500mL of a saturated sodium bicarbonate solution, subjected to liquid separation, the aqueous phase was extracted with dichloromethane (200 mL × 3), the organic phases were combined, washed with saturated brine (200 mL × 1), dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to give 82g of a crude brown oil, and silica gel column chromatography using petroleum ether/ethyl acetate (V/V) =30/1 gave a brown oil of 9- (((trifluoromethyl) sulfonyl) oxy) -6-oxaspiro [4.5] dec-8-ene-carboxylic acid methyl ester (10C) (51 g, yield: 61.47%).
Ms m/z(ESI):367.0[M+Na + ]。
The third step: 9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-ene-8-carboxylic acid methyl ester (10D)
methyl 9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-ene-8-carboxylate
Figure BDA0001714822470000552
Compound 9- (((trifluoromethyl) sulfonyl) oxy) -6-oxaspiro [4.5] dec-8-ene-carboxylic acid methyl ester (10C) (32.8g, 95.266mmol) was dissolved in toluene (328 mL), p-fluorobenzeneboronic acid (17.34g, 127.54mmol), tetratriphenylphosphine palladium (6.083g, 5.264mmol), sodium carbonate (22.24g, 209.8mmol), ethanol (82 mL), water (82 mL) were added, the reaction solution was bubbled with nitrogen for 10 minutes and replaced with nitrogen 3 times, and stirring and refluxing were carried out at 120 ℃ for 4 hours, the reaction solution was cooled to room temperature, water 500mL was added, extraction was carried out with diethyl ether (200 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated to dryness, silica gel 200-300 mesh (petroleum ether/ethyl acetate (V/V) = 25/1) to give 9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-ene-carboxylic acid methyl ester (4.5: 52 g, yield: 52.52%).
Ms m/z(ESI):313.3[M+Na + ];
1 H NMR(400MHz,CDCl 3 )δ7.12-7.07(m,2H),7.05-6.99(m,2H),4.46-4.45(t,2H),3.51(s,3H),2.45-2.43(t,3H),1.96-1.90(m,2H),1.84-1.76(m,2H),1.69-1.63(m,2H),1.58-1.45(m,2H).
The fourth step: (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methanol (10E)
(9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)methanol
Figure BDA0001714822470000561
The compound lithium aluminum tetrahydroborate (2.6g, 41.05mmol) and tetrahydrofuran (70 mL) were sequentially charged into a three-necked reaction flask, and a solution of methyl 9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-ene-8-carboxylate (10D) (7.00g, 24.111mmol) in tetrahydrofuran (10 mL) was added dropwise with stirring at room temperature, followed by reaction at room temperature for 2 hours. The reaction solution was cooled to 0 ℃ or lower with an ice salt bath, and water (2.6 mL), a 20% sodium hydroxide solution (5.2 mL), water (2.6 mL), and celite were added to the reaction solution in this order while stirring, and the cake was washed with tetrahydrofuran (10 mL. Times.3) and filtered, and the filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness, and then petroleum ether/ethyl acetate (V/V) =10/1-3/1 was purified by silica gel 200-300 mesh column chromatography to give a colorless oily product (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methanol (10E) (5.83 g, yield: 92.27%).
Ms m/z(ESI):285.1[M+Na + ];
1 HNMR(400MHz,CD 3 OD)δ7.25-7.20(m,2H),7.10-7.04(m,2H),4.34-4.33(t,2H),3.94(s,2H),2.37-2.36(t,2H),1.95-1.89(m,2H),1.84-1.75(m,2H),1.72-1.63(m,2H),1.61-1.53(m,2H).
The fifth step: 8- (chloromethyl) -9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-ene (10F)
8-(chloromethyl)-9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-ene
Figure BDA0001714822470000562
The compound (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methanol (10E) (2.000g, 7.625 mmol) was dissolved in methylene chloride (20 mL), triethylamine (1.54g, 15.26mmol) was added thereto, the mixture was stirred and cooled to 0 ℃ and a solution of methanesulfonyl chloride (0.962g, 8.40mmol) was added dropwise thereto, and the reaction was completed at room temperature for 4 hours. To the reaction solution was added a saturated ammonium chloride solution (50 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined and washed with a saturated ammonium chloride solution (50 mL × 1), and the organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to give 8- (chloromethyl) -9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-ene (10F) (2.14 g, yield: 99.86%) as a yellow oily product.
Ms.m/z(ESI):303.1[M+Na + ];
1 HNMR(400MHz,CD 3 OD)δ7.26-7.20(m,2H),7.09-7.00(m,2H),4.34-4.33(t,2H),3.93(s,2H),2.40-2.39(t,2H),1.96-1.90(m,2H),1.85-1.76(m,2H),1.71-1.62(m,2H),1.57-1.48(m,2H).
And a sixth step: 8- (Azidomethyl) -9- (4-tetrafluorophenyl) -6-oxaspiro [4.5] dec-8-ene (10G)
8-(azidomethyl)-9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-ene
Figure BDA0001714822470000571
The compound 8- (chloromethyl) -9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-ene (10F) (2.000g, 7.12mmol) was dissolved in DMF (20 mL), and sodium azide (0.92g, 14.25mmol) was added and stirred at 80 ℃ for 4 hours. The reaction solution was cooled to room temperature, and 100 mL of saturated brine was added, extraction was performed with ethyl acetate (50 mL × 3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and silica gel column chromatography was performed using petroleum ether/ethyl acetate (V/V) =20/1 to give 8- (azidomethyl) -9- (4-tetrafluorophenyl) -6-oxaspiro [4.5] dec-8-ene (10G) (1.4G, yield: 68.63%) as a colorless oily product.
1 HNMR(400MHz,CD 3 OD)δ7.14-7.09(m,2H),7.08-7.01(m,2H),4.28-4.27(t,2H),3.68(s,2H),2.40(s,2H),1.97-1.91(m,2H),1.87-1.77(m,2H),1.71-1.61(m,2H),1.57-1.50(m,2H).
The seventh step: (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methylamine (10H)
(9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)methanamine
Figure BDA0001714822470000572
The compound 8- (azidomethyl) -9- (4-tetrafluorophenyl) -6-oxaspiro [4.5] dec-8-ene (10G) (0.320g, 1.11mmol) was dissolved in tetrahydrofuran (3 mL), water (0.3 mL) was added, triphenylphosphine (0.436G, 1.66mmol) was added with stirring, and the mixture was stirred at room temperature overnight. To the reaction solution, 20mL of 1N hydrochloric acid was added and extracted with diethyl ether (10 mL. Times.3), the aqueous phase was adjusted to pH8 with a saturated sodium bicarbonate solution and extracted with ethyl acetate (10 mL. Times.3), and the ethyl acetate was combined, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to give the product (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methylamine (10H) (270 mg, yield: 92.8%) as a colorless oily product.
1 H NMR(400MHz,DMSO-d 6 )δ7.30-7.25(m,2H),7.18-7.12(m,2H),4.21(s,2H),2.97(s,2H),2.26(s,2H),1.82-1.74(m,2H),1.71-1.55(m,4H),1.51-1.44(m,4H).
Eighth step: n- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (3-methoxythien-2-yl) methylamine (10I)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)methyl)-1-(3-methoxythiophen-2-yl)methanamine
Figure BDA0001714822470000581
The compound (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methylamine (10H) (0.250g, 0.957mmol), 3-methoxythiophene-2-carbaldehyde (0.204g, 1.430mmol) was dissolved in dichloromethane (10 mL), and anhydrous sodium sulfate (0.679g, 4.780mmol) was added thereto, followed by stirring at room temperature overnight. Sodium borohydride (0.060g, 1.600mmol) was added and stirred at room temperature for 1 hour, and 3 ml of anhydrous methanol was added and stirred for 2 hours. Water (20 mL) was added to the reaction solution, extraction was performed with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL × 1), the organic phase was dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, EA/PE =2/1-3/1 to give N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (3-methoxythiophen-2-yl) methylamine (10I) (220 mg, yield: 59.3%) as a yellow oily product.
Ms.m/z(ESI):388.1[M+H + ];
The ninth step: n- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (3-methoxythien-2-yl) methanamine hydrochloride (Compound 10)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)methyl)-1-(3-methoxythiophen-2-yl)methanamine hydrochloride
Figure BDA0001714822470000582
The compound N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (3-methoxythien-2-yl) methylamine (10I) (0.200g, 0.516 mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.135mL, 0.540 mmol) was added and stirred at room temperature for 2 hours. Filtration afforded the product N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (3-methoxythiophen-2-yl) methylamine hydrochloride (compound 10) as a yellow solid (210 mg, yield: 96%).
Ms.m/z(ESI):388.2[M+H + -HCl];
1 HNMR(400MHz,CD 3 OD)δ7.47-7.46(d,1H),7.15-7.04(m,4H),6.96-6.94(d,1H),4.28(s,2H),4.12(s,2H),3.81(s,3H),3.56(s,2H),2.42(s,2H),1.97-1.91(m,2H),1.85-1.76(m,2H),1.74-1.66(m,2H),1.61-1.53(m,2H).
Example 11
N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methyl-1- (3-methoxythiophen-2-yl) methylamine hydrochloride (Compound 11)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)methyl)-1-(3-methoxythiophen-2-yl)methanamine hydrochloride
Figure BDA0001714822470000591
The first step is as follows: (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methylamine (11B)
(9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)methanamine
Figure BDA0001714822470000592
The compound 8- (azidomethyl) -9- (4-tetrafluorophenyl) -6-oxaspiro [4.5] dec-8-ene (10G) (0.500g, 1.74mmol) was dissolved in methanol (10 mL), palladium carbon (0.2g, 10%, water content 50%) was added, and the mixture was replaced with hydrogen gas 3 times, stirred at room temperature overnight (normal pressure), filtered with celite, the filter cake was washed with anhydrous methanol (10 mL. Times.2), and the filtrate was evaporated to dryness to obtain colorless oily product (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-yl) methylamine (11B) (300 mg, yield: 61.7%).
Ms.m/z(ESI):264.2[M+H + ]。
The second step is that: n- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methyl-1- (3-methoxythiophen-2-yl) methylamine (11C)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)methyl)-1-(3-methoxythiophen-2-yl)methanamine
Figure BDA0001714822470000601
The compound (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-yl) methylamine (11B) (0.400g, 1.83mmol) and 3-methoxythiophene-2-carbaldehyde (0.389g, 2.74mmol) were dissolved in methylene chloride (10 mL), and anhydrous sodium sulfate (1.295g, 9.12mmol) was added thereto, followed by stirring at room temperature overnight. Sodium borohydride (0.104g, 2.740 mmol) was added thereto, and the mixture was stirred at room temperature for 1 hour, and then 3 ml of anhydrous methanol was added thereto, and the mixture was stirred for 2 hours. To the reaction solution was added 20mL of water, extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL × 1), the organic phase was dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, EA/PE =2/1-3/1 to give N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-yl) methyl-1- (3-methoxythiophen-2-yl) methylamine (11C) (270 mg, yield: 38%) as a yellow oily product.
Ms.m/z(ESI):390.2[M+H + ]。
The third step: n- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methyl-1- (3-methoxythiophen-2-yl) methylamine hydrochloride (Compound 11)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)methyl)-1-(3-methoxythiophen-2-yl)methanamine hydrochloride
Figure BDA0001714822470000602
The compound N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methyl-1- (3-methoxythiophen-2-yl) methylamine (11C) (0.200g, 0.513mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.135mL, 0.54mmol) was added and stirred at room temperature for 2 hours, and filtration gave N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methyl-1- (3-methoxythiophen-2-yl) methylamine hydrochloride (compound 11) (207 mg, yield: 94.6%) as a white solid.
Ms.m/z(ESI):390.2[M+H + -HCl];
1 HNMR(400MHz,CD 3 OD)δ7.44-7.43(d,1H),7.25-7.22(dd,2H),7.09-7.04(m,2H),6.96-6.95(d,1H),4.13-4.12(d,2H),3.95-3.92(d,1H),3.84(s,3H),3.83-3.80(d,1H),3.39-3.27(m,2H),2.53-2.50(d,1H),2.15-2.00(m,3H),1.86-1.52(m,8H).
Example 12
(R) -N- ((3- (difluoromethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 12)
(R)-N-((3-(difluoromethoxy)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000611
The first step is as follows: 3- (Difluoromethoxy) thiophene-2-carbaldehyde (12A)
3-(difluoromethoxy)thiophene-2-carbaldehyde
Figure BDA0001714822470000612
3-Hydroxythiophene-2-carbaldehyde (4C) (0.35g, 2.7 mmol) and potassium hydroxide (3.1g, 55mmol) were dissolved in acetonitrile (10 mL) and water (10 mL) at room temperature, the temperature was reduced to 0 deg.C, diethyl bromofluoromethylphosphonate (1.5g, 5.5 mmol) was added dropwise to the reaction, and the reaction was allowed to warm to room temperature and stirred for 1 hour. The reaction solution was extracted with ethyl acetate (20 mL × 3), the combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was evaporated to dryness, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =20: 1-10) to give 3- (difluoromethoxy) thiophene-2-carbaldehyde (12A) (0.4 g, yield 80%) as an oily liquid product.
Ms m/z(ESI):178.9[M+H + ];
The second step is that: (R) -N- ((3- (difluoromethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (12B) (R) -N- ((3- (difluoromethoxy) thiophen-2-yl) methyl) -2- (9- (pyridine-2-yl) -6-oxapiro [4.5]
Figure BDA0001714822470000621
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (0.3g, 1.1 mmol) was dissolved in methylene chloride (10 mL), and sodium sulfate (0.8g, 5.5 mmol) and 3- (difluoromethoxy) thiophene-2-carbaldehyde (12A) (0.3g, 1.7 mmol) were added to the reaction mixture, and the reaction was allowed to proceed at room temperature overnight. Sodium borohydride (0.07g, 1.7 mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (30 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):423.2[M+H + ];
The third step: (R) -N- ((3- (difluoromethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 12)
(R)-N-((3-(difluoromethoxy)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000622
(R) -N- ((3- (difluoromethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (12B) (0.3 g, 0.71mmol) was dissolved in ethyl acetate (8 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -N- ((3- (difluoromethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 12) as a yellow solid (0.32 g, yield: 100%).
Ms m/z(ESI):423.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.63(dd,1H),8.00(t,1H),7.67(d,1H),7.59(d,1H),7.47-7.44(m,1H),7.03(t,1H),6.77(d,1H),4.25(s,2H),3.77-3.74(m,2H),2.99-2.96(m,1H),2.51-2.42(m,3H),2.22-2.10(m,1H),1.98-1.90(m,2H),1.82-1.71(m,2H),1.66-1.40(m,5H),1.17-1.02(m,1H),0.75-0.72(m,1H).
Example 14
N- ((3-Methoxythien-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) ethylamine hydrochloride (Compound 14)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000631
Figure BDA0001714822470000641
The first step is as follows: ethyl 9-oxo-6-oxaspiro [4.6] decane-10-carboxylate (14B-1)
ethyl 9-oxo-6-oxaspiro[4.6]undecane-10-carboxylate
Ethyl 10-oxo-6-oxaspiro [4.6] decane-9-carboxylate (14B-2)
ethyl 10-oxo-6-oxaspiro[4.6]undecane-9-carboxylate
Figure BDA0001714822470000642
6-oxaspiro [4.6] decan-9-one (14A) (15.4 g, 0.1mol) was dissolved in methylene chloride (100 mL), cooled to-40 ℃ and then a boron trifluoride diethyl etherate solution (17.0 g, 0.12mol) and ethyl diazoacetate (14.8g, 0.13mol) were added dropwise to the reaction mixture, followed by reaction at-40 ℃ for 2 hours. The reaction solution was quenched with sodium bicarbonate solution (20 mL), the aqueous phase was extracted with dichloromethane (100 mL × 3), the organic phases were combined, washed with saturated sodium chloride (80 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 30).
Ms m/z(ESI):263.1[M+Na + ];
1 H NMR(400MHz,CDCl 3 )δ8.58-8.57(d,1H),7.65-7.63(td,1H),7.29-7.27(d,1H),7.10-7.09(dd,1H),3.74-3.70(m,1H),3.56-3.54(m,1H),2.52-2.50(m,2H),2.49-2.46(m,2H),1.93-1.18(m,14H).
The second step is that: 6-oxaspiro [4.6] decan-9-one (14C-1)
6-oxaspiro[4.6]undecan-9-one
6-oxaspiro [4.6] decan-10-one (14C-2)
6-oxaspiro[4.6]undecan-10-one
Figure BDA0001714822470000651
Ethyl 9-oxo-6-oxaspiro [4.6] decane-10-carboxylate ethyl (14B-1) and 9-oxo-6-oxaspiro [4.6] decane-10-carboxylate (14B-2) (24.0 g,0.1 mol) were dissolved in water (200 mL), and potassium carbonate (70.2 g,0.5 mol) was added to the reaction mixture, after which the mixture was heated to 100 ℃ to react for 5 hours. The aqueous phase was extracted with dichloromethane (100 mL. Times.3), the organic phases were combined, washed with saturated sodium chloride (80 mL. Times.1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =100
Ms m/z(ESI):169.1[M+H + ];
The third step: (Z/E) -methyl 2-cyano-2- (6-oxaspiro [4.6] decan-9-ylidene) carboxylate (14D-1)
(Z/E)-methyl 2-cyano-2-(6-oxaspiro[4.6]undecan-9-ylidene)acetate
(Z/E) -methyl 2-cyano-2- (6-oxaspiro [4.6] decan-10-ylidene) carboxylate (14D-2)
(Z/E)-methyl 2-cyano-2-(6-oxaspiro[4.6]undecan-10-ylidene)acetate
Figure BDA0001714822470000652
A mixture (10.0g, 0.162mol) of 6-oxaspiro [4.6] decan-9-one (14C-1) and 6-oxaspiro [4.6] decan-10-one (14C-1), methyl cyanoacetate (7.0g, 0.194mol), ammonium acetate (1.4g, 48.64mmol) and acetic acid (0.7g, 32.43mmol) were successively added to toluene (50 mL) at room temperature. After completion of the reaction, water (120 mL) was added to extract the product with ethyl acetate (40 mL. Times.2), and the combined organic phases were washed with saturated brine (30 mL. Times.2). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. Column purification with EA: PET =1 80-1 to give oily liquids (Z/E) -methyl 2-cyano-2- (6-oxaspiro [4.6] decan-9-ylidene) carboxylate (14D-1) and (Z) -methyl 2-cyano-2- (6-oxaspiro [4.6] decan-10-ylidene) carboxylate (14D-2) (30.0 g, yield: 78.65%).
Ms m/z(ESI):272.1[M+Na + ];
1 H NMR(400MHz,CDCl 3 )δ3.88-3.86(m,1H),3.84(s,3H),3.81-3.78(m,1H),3.16-3.12(m,2H),2.76-2.72(m,2H),1.82-1.76(m,4H),1.68-1.53(m,4H).
The fourth step: methyl 2-cyano-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) carboxylate (14E-1)
methyl 2-cyano-2-(9-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-9-yl)acetate
Methyl 2-cyano-2- (10- (pyridin-2-yl) -6-oxaspiro [4.5] decan-10-yl) carboxylate (14E-2)
methyl 2-cyano-2-(10-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-10-yl)acetate
Figure BDA0001714822470000661
A solution of 2-bromopyridine (3.2 g,20.0 mmol) in THF (15 mL) was added dropwise to a solution of isopropylmagnesium chloride (10 mL, 2M in THF) at 0 ℃ under nitrogen at room temperature, followed by stirring for 3 hours, ketone iodide (0.34g, 1.8 mmol) was added thereto and stirring at room temperature for 0.5 hour, and then a mixture of E and Z isomers of methyl 2-cyano-2- [ 6-oxaspiro [4.5] decan-9-ylidene ] acetate (4.7 g,20.0 mmol) in THF (20 mL) was added dropwise to the reaction mixture. After the addition, the reaction mixture was heated to 55 ℃ and stirred for 8 hours. The reaction mixture was poured into a mixture of 200g ice/1N HCl (100 mL). The product was extracted with ethyl acetate (50 mL. Times.4), and the combined organic phases were washed with saturated brine (40 mL. Times.1), dried over anhydrous sodium sulfate and concentrated. Purification by column chromatography with EA: PET =1 80-1 to give methyl 2-cyano-2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) carboxylate (14E-1) and methyl 2-cyano-2- (10- (pyridin-2-yl) -6-oxaspiro [4.5] decan-10-yl) carboxylate (14E-2) as oily liquids (2.0 g, yield: 32.0%).
Ms m/z(ESI):329.1[M+H + ];
The fifth step: 2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] undecan-9-yl) acetonitrile (14F)
2-(9-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-9-yl)acetonitrile
2- (10- (pyridin-2-yl) -6-oxaspiro [4.5] undecan-10-yl) acetonitrile (33A)
2-(10-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-10-yl)acetonitrile
Figure BDA0001714822470000671
Ethylene glycol (50 mL) was added to methyl 2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetate (14E-1) and methyl 2-cyano-2- (10- (pyridin-2-yl) -6-oxaspiro [4.5] decan-10-yl) carboxylate (14E-2) (5.0 g, 15.24mmol), then potassium hydroxide (1.7g, 30.4 mmol) was added, after which the reaction liquid was heated to 120 ℃ for 5 hours, the reaction mixture was cooled to room temperature and water (100 mL) was added, the product was extracted with ethyl acetate (50 mL. Times.4), the combined organic phases were washed with saturated brine (40 mL. Times.1), dried over anhydrous sodium sulfate and concentrated. Purification on a column with EA: PET =1 80-1 to give 2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (14F) and 2- (10- (pyridin-2-yl) -6-oxaspiro [4.5] undecan-10-yl) acetonitrile (33A) as oily liquids (0.8 g, yield: 19.4%). And 2- (10- (pyridin-2-yl) -6-oxaspiro [4.5] undecan-10-yl) acetonitrile (1.08 g, yield: 26.2%).
Ms m/z(ESI):271.1[M+H + ];
Compound (14F) 1 H NMR(400MHz,CDCl 3 )δ8.63-8.62(d,1H),7.72-7.70(m,1H),7.39-7.37(d,1H),7.21-7.19(m,1H),3.83-3.68(m,1H),3.59-3.57(m,1H),2.77-2.69(m,2H),2.65-2.61(m,1H),2.43-2.37(m,1H),1.96-1.94(m,4H),1.92-1.48(m,8H).
Compound (33A) 1 H NMR(400MHz,CDCl 3 )δ8.63-8.61(d,1H),7.72-7.70(m,1H),7.42-7.39(d,1H),7.21-7.19(m,1H),3.71-3.68(m,1H),3.57-3.53(m,1H),2.77-2.65(m,2H),2.62-2.61(m,1H),2.54-2.43(m,1H),1.90-1.48(m,12H).
And a sixth step: 2- (9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) ethylamine (14G)
2-(9-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-9-yl)ethanamine
Figure BDA0001714822470000672
Lithium aluminum hydride (0.56g, 15.0 mmol) was dissolved in tetrahydrofuran (30 mL), and the temperature was reduced to 0 ℃ to add 9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) acetonitrile (14F) (0.9g, 3.0 mmol) in tetrahydrofuran (10 mL) to complete the reaction at room temperature overnight. The reaction was cooled to 0 ℃, quenched with water (0.6 mL), sodium hydroxide solution (10%, 1.2 mL) and water (1.2 mL), dried with anhydrous sodium sulfate, stirred for 20 minutes, the solid filtered and washed with tetrahydrofuran (20 mL × 3). The combined organic phases were concentrated to give 9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) ethylamine (14G) (0.5G, yield: 50%).
Ms m/z(ESI):275.2[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.58-8.57(d,1H),7.65-7.63(td,1H),7.29-7.27(d,1H),7.10-7.09(dd,1H),3.74-3.70(m,1H),3.56-3.54(m,1H),2.52-2.50(m,2H),2.49-2.46(m,2H),1.93-1.18(m,14H).
The seventh step: n- ((3-Methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) ethylamine (14H)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-9-yl)ethanamine
Figure BDA0001714822470000681
9- (pyridin-2-yl) -6-oxaspiro [4.6] undec-9-yl) ethylamine (14G) (0.5g, 2.0mmol) was dissolved in methylene chloride (15 mL), and sodium sulfate (1.3g, 7.5mmol) and 3-methoxythiophene-2-carboxaldehyde (0.28g, 3.0mmol) were added to the reaction, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.09g, 2.0 mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) =50
Ms m/z(ESI):401.2[M+H + ];
The eighth step: n- ((3-Methoxythien-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) ethylamine hydrochloride (Compound 14)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000691
N- ((3-Methoxythien-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) ethylamine (14G) (0.2g, 0.42mmol) was dissolved in ethyl acetate (3 mL), a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added, and the reaction was stirred at room temperature for 0.5 hour. The reaction was directly spun dry to give N- ((3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) ethylamine hydrochloride (compound 14) (0.185 g, 85.7% yield) as an off-white solid.
Ms m/z(ESI):401.2[M+H + ];
1 H NMR(400MHz,DMSO-d 6 )δ8.63-8.62(d,1H),7.95(s,1H),7.57-7.56(d,1H),7.44-7.43(d,1H),7.29-7.28(s,1H),7.05-7.04(d,1H),4.06-4.04(m,2H),3.80(s,3H),3.58-3.56(m,2H),2.67-2.66(m,2H),2.20-1.99(m,2H),1.98-1.36(m,12H).
Resolution of the compound N- ((3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) ethylamine hydrochloride (Compound 14)
(compound 14) (170 mg) was taken for resolution to obtain, after separation, two optical isomers of the free base compound, compound 14H-1 (retention time: 4.12min,49.26mg, oily liquid, ee% = 99.6%), compound 14H-2 (retention time: 5.29min,43.63mg, oily liquid, ee% = 99.0%).
Splitting conditions are as follows: MG II preparatory SFC (SFC-13); column P Cellulose-2,250 × 30mm i.d.,5 μm. Mobile phase a: carbon dioxide, B: methanol (0.1% ammonia); gradient B60%; the flow rate is 60mL/min; back pressure is 100bar; the column temperature is 38 ℃; wavelength is 220nm; the period is 5.5min; sample preparation Compound 14 was dissolved in methanol to 8mg/ml; injection 2 ml/needle.
Compound 14H-1 and compound 14H-2 Compound 14-1 and compound 14-2 can be obtained by a salt-forming method of Compound 14:
compound 14-1:
Ms m/z(ESI):401.2[M+H + ];
1 H NMR(400MHz,DMSO-d 6 )δ8.58-8.57(d,1H),7.83(s,1H),7.56-7.55(d,1H),7.44-7.43(d,1H),7.29-7.28(s,1H),7.05-7.04(d,1H),4.06-4.04(m,2H),3.80(s,3H),3.58-3.57(m,1H),3.41-3.39(m,1H),2.67-2.66(m,2H),2.20-1.99(m,2H),1.98-1.36(m,12H).
compound 14-2:
Ms m/z(ESI):401.2[M+H + ];
1 H NMR(400MHz,DMSO-d 6 )δ8.59-8.58(d,1H),7.86(s,1H),7.56-7.48(d,1H),7.46-7.43(d,1H),7.32-7.28(s,1H),7.05-7.04(d,1H),4.07-4.04(m,2H),3.79(s,3H),3.58-3.56(m,2H),2.67-2.66(m,2H),2.27-2.20(m,2H),1.99-1.36(m,12H).
example 15
2- (9- (4-Fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (Compound 15)
2-(9-(4-fluorobenzyl)-6-oxaspiro[4.5]decan-9-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine hydrochloride
Figure BDA0001714822470000701
The first step is as follows: 2-cyano-2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) acetic acid methyl ester (15B)
methyl 2-cyano-2-(9-(4-fluorobenzyl)-6-oxaspiro[4.5]decan-9-yl)acetate
Figure BDA0001714822470000702
The compound magnesium powder (0.450g, 18.80mmol) and diethyl ether (10 mL) were charged into a three-necked reaction flask, 4-fluorobenzyl chloride (1.200g, 8.300mmol) in diethyl ether (10 mL) was added dropwise under nitrogen protection, and the mixture was stirred at room temperature for 1 hour, and further cuprous iodide (0.400g, 2.090mmol) was added into the reaction flask under ice bath and stirred for 10 minutes, and a solution of methyl 2-cyano-2- (6-oxaspiro [4.5] decan-9-ylidene) acetate (1 d) (1.500g, 6.37mmol) in diethyl ether (20 mL) was added dropwise and stirred at room temperature overnight. The reaction mixture was added to 100mL of a stirred ice-water mixture, 6N hydrochloric acid was added to dissolve it, extraction was performed with ethyl acetate (30 mL. Times.3), the organic phases were combined and washed with saturated brine (50 mL. Times.1), the organic phase was dried over anhydrous sodium sulfate, filtration was performed, evaporation was performed, silica gel column chromatography was performed, and petroleum ether/ethyl acetate (V/V) =10/1 to obtain methyl 2-cyano-2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) acetate (15B) (1.7 g, yield: 73.4%) as a colorless oil
Ms m/z(ESI):346.2[M+H + ];
1 HNMR(400MHz,DMSO-d 6 )δ7.24-7.07(m,4H),4.34-4.15(d,1H),3.70-3.52(m,4H),3.3(s,1H),2.95-2.85(m,1H),2.76-2.63(dd,1H),1.95-1.33(m,10H).
The second step is that: 2- (9- (4-Fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (15C)
2-(9-(4-fluorobenzyl)-6-oxaspiro[4.5]decan-9-yl)acetonitrile
Figure BDA0001714822470000711
Methyl 2-cyano-2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) acetate (15B) (1.7g, 4.925 mmol) was dissolved in ethylene glycol (25 mL), potassium hydroxide (0.553 g, 9.86mmol) was added, the mixture was stirred at 120 ℃ for 4 hours, the reaction mixture was cooled to room temperature, 50mL of water was added, ethereal oil (50 mL × 3) was extracted, the organic phases were combined and washed with saturated brine (50 mL × 3), the organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to dryness, and petroleum ether/ethyl acetate (V/V) =10/1 by silica gel column chromatography gave 2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (15C) as a colorless oily compound (0.963 g, yield: 68.1%).
Ms m/z(ESI):310.1[M+Na + ];
1 H NMR(400MHz,CDCl 3 ):δ7.22-7.12(m,2H),7.04-6.98(m,2H),3.77-3.71(dt,1H),3.60-3.54(ddd,1H),2.81-2.71(q,2H),2.38-2.21(dd,2H),1.99-1.93(ddd,1H),1.89-1.85(m,1H),1.79-1.50(m,8H),1.43-1.34(m,2H).
The third step: 2- (9- (4-Fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (15D)
2-(9-(4-fluorobenzyl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000721
The compound 2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) acetonitrile (15C) (0.54g, 1.88mmol) was dissolved in tetrahydrofuran (10 mL), and lithium aluminum hydride (0.143g, 3.76mmol) was added with stirring and stirred at room temperature overnight. Water (0.4 mL), a 20% NaOH solution (0.8 mL), and water (0.4 mL) were sequentially added dropwise to the reaction solution in a salt bath with ice, stirred for 1 hour, filtered, and the organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The product, 2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (15D) (0.45 g, yield: 82.2%) was obtained as a colorless oil.
Ms m/z(ESI):292.2[M+H + ]。
The fourth step: 2- (9- (4-Fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (15E)
2-(9-(4-fluorobenzyl)-6-oxaspiro[4.5]decan-9-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine
Figure BDA0001714822470000722
The compound 2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (15D) (0.800g, 2.75mmol), 3-methoxythiophene-2-carbaldehyde (0.600g, 4.22mmol) was dissolved in dichloromethane (10 mL), and anhydrous sodium sulfate (2.000g, 14.080mmol) was added and stirred at room temperature overnight. Sodium borohydride (0.170g, 4.470mmol) was added thereto, and the mixture was stirred at room temperature for 1 hour, and then 3 ml of anhydrous methanol was added thereto, and the mixture was stirred for 2 hours. To the reaction solution was added 20mL of water, extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL × 1), the organic phase was dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1-3).
Ms.m/z(ESI):418.2[M+H + ]。
The fifth step: 2- (9- (4-Fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (Compound 15)
2-(9-(4-fluorobenzyl)-6-oxaspiro[4.5]decan-9-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine hydrochloride
Figure BDA0001714822470000731
The compound 2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (15E) (0.472g, 1.130mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.330mL, 1.320mmol) was added and stirred at room temperature for 2 hours. Filtration gave the product 2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (compound 15) as a white solid (500 mg, yield: 97.6%).
Ms.m/z(ESI):418.2[M+H + -HCl];
1 H NMR(400MHz,CD 3 OD):δ7.30-7.29(d,1H),7.09-7.06(m,2H),6.99-6.95(m,3H),3.91(s,2H),3.87(s,3H),3.69-3.63(m,2H),2.81-2.68(dtd,2H),2.66-2.62(d,1H),2.55-2.51(d,1H),1.82-1.41(m,14H).
Example 16
2- (9- (4-Fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl-N- (3-methylbenzyl) ethylamine hydrochloride (Compound 16)
2-(9-(4-fluorobenzyl)-6-oxaspiro[4.5]decan-9-yl)-N-(3-methylbenzyl)ethanamine hydrochloride
Figure BDA0001714822470000732
The first step is as follows: 2- (9- (4-Fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl-N- (3-methylbenzyl) ethylamine (16B)
2-(9-(4-fluorobenzyl)-6-oxaspiro[4.5]decan-9-yl)-N-(3-methylbenzyl)ethanamine
Figure BDA0001714822470000741
The compound 2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (15D) (0.250g, 0.858mmol), 3-methylbenzaldehyde (0.155g, 1.29mmol) was dissolved in methylene chloride (10 mL), and anhydrous sodium sulfate (0.610g, 4.30mmol) was added to stir at room temperature overnight. Sodium borohydride (0.049 g, 1.30mmol) was added thereto, and the mixture was stirred at room temperature for 1 hour, and then 3 ml of anhydrous methanol was added thereto, and the mixture was stirred for 2 hours. To the reaction solution was added 20mL of water, extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL × 1), the organic phase was dried over colorless sodium sulfate, filtered and evaporated to dryness, and subjected to silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1-3).
Ms.m/z(ESI):396.3[M+H + ]。
The second step is that: 2- (9- (4-Fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl-N- (3-methylbenzyl) ethylamine hydrochloride (Compound 16)
2-(9-(4-fluorobenzyl)-6-oxaspiro[4.5]decan-9-yl)-N-(3-methylbenzyl)ethanamine hydrochloride
Figure BDA0001714822470000742
Compound 2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl-N- (3-methylbenzyl) ethylamine (16B) (0.062g, 0.160mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.090mL, 0.180mmol) was added and stirred at room temperature for 2 hours, filtration gave 2- (9- (4-fluorobenzyl) -6-oxaspiro [4.5] decan-9-yl-N- (3-methylbenzyl) ethylamine hydrochloride (compound 16) (62 mg, yield: 92%) as a white solid.
Ms.m/z(ESI):396.3[M+H + -HCl];
1 HNMR(400MHz,CD 3 OD):δ7.39-7.29(m,4H),7.16-7.12(dd,2H),7.02-6.97(t,2H),4.19(s,2H),3.73-3.65(m,2H),3.21-3.07(m,2H),2.77-2.70(t,1H),2.59-2.55(d,2H),2.03-1.98(m,1H),1.85-1.45(m,13H).
Example 17
N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (m-methylbenzene) methylamine hydrochloride (Compound 17)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)methyl)-1-(m-tolyl)methanaminehydrochloride
Figure BDA0001714822470000751
The first step is as follows: n- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (m-methyltolyl) methylamine (17B)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)methyl)-1-(m-tolyl)methanamine
Figure BDA0001714822470000752
The compound (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methylamine (17A) (0.630g, 2.395mmol), 3-methylbenzaldehyde (0.432g, 3.593mmol) was dissolved in methylene chloride (10 mL), and anhydrous sodium sulfate (1.700g, 11.975mmol) was added to stir at room temperature overnight. Sodium borohydride (0.136g, 3.593 mmol) was added and stirred at room temperature for 1 hour, and 3 ml of anhydrous methanol was added and stirred for 2 hours. To the reaction solution was added 20mL of water, extracted with ethyl acetate (10 mL × 3), and the organic phases were combined and washed with saturated brine (30 mL × 1), dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, EA/PE =2/1-3/1 to give N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (m-methyltolyl) methylamine (17B) (500 mg, yield: 56.7%) as a yellow oily product.
Ms.m/z(ESI):366.2[M+H + ];
The second step is that: n- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (m-methyltolyl) methylamine hydrochloride (Compound 17)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)methyl)-1-(m-tolyl)methanaminehydrochloride
Figure BDA0001714822470000761
The compound N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (m-methylbenzene) methylamine (17B) (0.500g, 1.37mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.700mL, 1.4 mmol) was added and stirred at room temperature for 2 hours. Filtration gave the product, N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (m-methylbenzene) methylamine hydrochloride (compound 17) as a white solid (520 mg, yield: 94.7%).
Ms.m/z(ESI):366.2[M+H + -HCl];
1 HNMR(400MHz,CD 3 OD)δ7.27-7.21(m,2H),7.10-7.06(m,4H),7.03-6.99(m,2H),4.30(s,2H),3.99(s,2H),3.55(s,2H),2.40(s,2H),2.32(s,3H),1.96-1.90(m,2H),1.84-1.78(m,2H),1.75-1.65(m,2H),1.60-1.54(m,2H).
Example 18
N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine amine hydrochloride (Compound 18)
2-(9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine hydrochloride
Figure BDA0001714822470000762
The first step is as follows: 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) acetonitrile (18B)
2-(9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)acetonitrile
Figure BDA0001714822470000771
The compound 8- (chloromethyl) -9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-ene (18A) (2.000g, 7.12mmol) was dissolved in DMF (20 mL), and potassium cyanide (2.40g, 36.86mmol) was added thereto, followed by stirring at 80 ℃ for 4 hours. The reaction mixture was cooled to room temperature, water (200 mL), ethyl acetate (100 mL) were added and stirred, liquid separation was performed, the aqueous phase was extracted with ethyl acetate (100 mL × 3), the organic phases were combined and washed with saturated brine (200 mL × 3), the aqueous phase was treated with sodium hypochlorite and poured into a waste tank, the organic phase was dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, (petroleum ether/ethyl acetate (V/V)) =30/1-10/1 to give 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) acetonitrile (18B) (1.0 g, yield: 25.88%) as a white solid.
Ms.m/z(ESI):294.1[M+Na + ]。
The second step is that: 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) ethylamine (18C)
2-(9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)ethanamine
Figure BDA0001714822470000772
The compound 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) acetonitrile (18B) (0.500g, 1.84mmol) was dissolved in THF (10 mL), and lithium aluminum hydride (0.140g, 3.68mmol) was added with stirring, and after completion of the addition, the mixture was stirred at room temperature overnight (12 hours). Water (0.5 mL), a 20% NaOH solution (1 mL) and water (0.5 mL) were added dropwise to the reaction mixture in this order under a ice salt bath, stirred for 1 hour, filtered, and the organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to dryness to give 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) ethylamine (18C) (0.5 g, yield: 98.5%) as a yellow oily product.
Ms.m/z(ESI):276.1[M+H + ]。
The third step: 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) -N- ((3-methoxythien-2-yl) methyl) ethylamine (18D)
2-(9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine
Figure BDA0001714822470000781
The compound 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) ethylamine (18C) (0.400g, 1.45mmol), 3-methoxythiophene-2-carbaldehyde (0.310g, 2.180mmol) was dissolved in dichloromethane (10 mL), and anhydrous sodium sulfate (1.03g, 7.254mmol) was added, followed by stirring at room temperature overnight. Sodium borohydride (0.083g, 2.200mmol) was added thereto and stirred at room temperature for 1 hour, and 3 ml of anhydrous methanol was added thereto and stirred for 2 hours. To the reaction solution was added 20mL of water, followed by extraction with ethyl acetate (10 mL × 3), and the organic phases were combined and washed with saturated brine (30 mL × 1), and the organic phase was dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, EA/PE =2/1-3/1 to give 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (18D) (66 mg, yield: 11%) as a yellow oily product.
Ms.m/z(ESI):402.1[M+H + ]。
The fourth step: 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) -N- ((3-methoxythien-2-yl) methyl) ethylamine hydrochloride (Compound 18)
2-(9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine hydrochloride
Figure BDA0001714822470000782
The compound 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (18D) (0.066 g, 0.16mmol) was dissolved in ethyl acetate (5 mL), and an ethyl acetate solution of hydrogen chloride (0.100mL, 0.2mmol) was added and stirred at room temperature for 2 hours. Filtration afforded the product 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (compound 18) (70 mg, yield: 97%) as a white solid.
Ms.m/z(ESI):402.1[M+H + -HCl];
1 HNMR(400MHz,CD 3 OD)δ7.49-7.48(d,1H),7.18-7.07(m,4H),7.04-7.02(d,1H),4.16(s,4H),3.89(s,3H),2.91-2.87(m,2H),2.33-2.27(dd,4H),1.93-1.87(m,2H),1.80-1.77(m,2H),1.72-1.64(m,2H),1.59-1.52(m,2H).
Example 19
2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) -N- (3-methylbenzyl) ethylamine hydrochloride (Compound 19)
2-(9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)-N-(3-methylbenzyl)ethanaminehydrochloride
Figure BDA0001714822470000791
The first step is as follows: 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) -N- (3-methylbenzyl) ethylamine (19B) 2- (9- (4-fluorophenyl) -6-oxapiro [4.5] dec-8-en-8-yl) -N- (3-methyllbenzyl) ethanamine
Figure BDA0001714822470000792
The compound 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) ethylamine (18C) (0.415g, 1.51mmol), 3-methylbenzaldehyde (0.2.72g, 2.26mmol) was dissolved in dichloromethane (10 mL), and anhydrous sodium sulfate (1.070g, 7.542mmol) was added, followed by stirring at room temperature overnight. Sodium borohydride (0.086g, 2.300mmol) was added thereto and stirred at room temperature for 1 hour, and 3 ml of anhydrous methanol was added thereto and stirred for 2 hours. To the reaction solution was added 20mL of water, extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL × 1), the organic phase was dried over colorless sodium sulfate, filtered and evaporated to dryness, and subjected to silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1-3).
Ms.m/z(ESI):380.2[M+H + ];
The second step is that: 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) -N- (3-methylbenzyl) ethylamine hydrochloride (Compound 19)
2-(9-(4-fluorophenyl)-6-oxaspiro[4.5]dec-8-en-8-yl)-N-(3-methylbenzyl)ethanaminehydrochloride
Figure BDA0001714822470000801
The compound N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methyl) -1- (m-methyltolyl) methylamine (19B) (0.044g, 0.12mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.075mL, 0.15mmol) was added and stirred at room temperature for 2 hours. Filtration gave the product 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) -N- (3-methylbenzyl) ethylamine hydrochloride (compound 19) as a white solid (46 mg, yield: 95%).
Ms.m/z(ESI):380.2[M+H + -HCl];
1 HNMR(400MHz,CD 3 OD)δ7.33-7.07(m,8H),4.17(m,2H),4.03(s,2H),2.95-2.90(m,2H),2.36(s,3H),2.33-2.29(m,4H),1.93-1.87(m,2H),1.83-1.77(m,2H),1.74-1.64(m,2H),1.59-1.52(m,2H).
Example 20
N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methyl) -1- (m-methyltolyl) methylamine hydrochloride (Compound 20)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)methyl)-1-(m-tolyl)methanaminehydrochloride
Figure BDA0001714822470000802
The first step is as follows: n- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methyl) -1- (m-methyltolyl) methylamine (20B)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)methyl)-1-(m-tolyl)methanamine
Figure BDA0001714822470000811
Compound (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-yl) methylamine (20A) (0.400g, 1.52mmol), 3-methylbenzaldehyde (0.274g, 2.28mmol) were dissolved in methylene chloride (10 mL), and anhydrous sodium sulfate (1.080g, 7.59mmol) was added, followed by stirring at room temperature overnight. Sodium borohydride (0.087g, 2.28mmol) was added thereto and stirred at room temperature for 1 hour, and 3 ml of anhydrous methanol was added thereto and stirred for 2 hours. To the reaction solution, 20mL of water was added, extraction was performed with ethyl acetate (10 mL × 3), organic phases were combined and washed with saturated brine (30 mL × 1), and the organic phase was dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1-3) to obtain N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-yl) methyl) -1- (m-methyltolyl) methylamine (20B) (230 mg, yield: 41.2%) as a colorless oily product.
Ms.m/z(ESI):368.2[M+H + ]。
The second step is that: n- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-yl) methyl) -1- (m-methyltolyl) methylamine hydrochloride (Compound 20)
N-((9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)methyl)-1-(m-tolyl)methanaminehydrochloride
Figure BDA0001714822470000812
The compound N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methyl) -1- (m-methyltolyl) methylamine (0.230g, 0.626 mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.400mL, 0.800mmol) was added, followed by stirring at room temperature for 2 hours. Filtration gave the product N- ((9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methyl) -1- (m-methyltolyl) methylamine hydrochloride (compound 20) as a white solid (230 mg, yield: 91%).
Ms.m/z(ESI):368.2[M+H + -HCl]
1 HNMR(400MHz,CD 3 OD):δ7.26-7.20(m,4H),7.11-7.02(m,4H),4.04-3.84(m,4H),3.39-3.30(m,2H),2.50-2.47(d,1H),2.32(s,3H),2.16-2.01(m,3H),1.87-1.52(m,8H).
Example 21
(R) -5- (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) -4,5,6, 7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride (Compound 21)
(R)-5-(2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride
Figure BDA0001714822470000821
The first step is as follows: (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetaldehyde (21B)
(R)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetaldehyde
Figure BDA0001714822470000822
2- [ (9R) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl ] acetonitrile (1 g) (1.28g, 5.0 mmol) was dissolved in dry toluene (20 mL), and diisobutylaluminum hydride (11.0 mmol) was added dropwise to the reaction mixture at-70 ℃ when the temperature of the dry ice acetone bath was lowered to-70 ℃ and the temperature T < -70 ℃ was reached, followed by reaction at-70 ℃ for 3 hours. Ammonium chloride solution (10 mL) was added at-70 ℃ and extracted with ethyl acetate (40 mL. Times.3). The organic phases were combined and washed with saturated saline solution (25 mL. Times.1). Dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) =100: 1-50).
Ms m/z(ESI):260.1[M+H + ];
The second step: (R) -5- (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) -4,5,6, 7-tetrahydrothiophene [3,2-C ] pyridine (21C)
(R)-5-(2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
Figure BDA0001714822470000831
(R) -2- (9- (pyridin-2-yl) -6-oxa [4.5] decan-9-yl) acetaldehyde (21B) (0.519g, 2.0mmol) was dissolved in methylene chloride (36 mL), and sodium sulfate (1.42g, 5.0mmol) and 4,5,6, 7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride (0.44g, 2.5mmol) were added to the reaction, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.095g, 2.50mmol) was added to the reaction mixture, and the mixture was stirred for 30 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give crude product which was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):383.2[M+H + ];
The third step: (R) -5- (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) -4,5,6, 7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride (Compound 21)
(R)-5-(2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride
Figure BDA0001714822470000832
(R) -5- (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) -4,5,6, 7-tetrahydrothiophene [3,2-C ] pyridine (21C) (0.10 g, 0.26mmol) was dissolved in ethyl acetate (5 mL), a solution of hydrogen chloride in ethyl acetate (1 mL, 2.0M) was added, and the reaction was stirred at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -5- (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) -4,5,6, 7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride (Compound 21) as a white solid (0.09 g, 82% yield).
Ms m/z(ESI):383.2[M+H + ];
1 H NMR(400MHz,DMSO-d 6 )δ8.63(s,1H),7.93(s,1H),7.63(s,1H),7.46-7.45(m,2H),6.86-6.85(m,1H),3.63-3.57(m,4H),3.17-3.06(m,3H),3.11-3.08(m,1H),2.50-2.42(m,2H),2.27(m,1H),2.01(m,1H),1.72(m,1H),1.50-1.04(m,7H).
Example 22
(R) -5- (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) -4,5,6, 7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride (Compound 22)
(R)-6-(2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine hydrochloride
Figure BDA0001714822470000841
The first step is as follows: (R) -5- (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) -4,5,6, 7-tetrahydroisothiophene [3,2-c ] pyridine (22A)
(R)-6-(2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine
Figure BDA0001714822470000842
(R) -2- (9- (pyridin-2-yl) -6-oxa [4.5] decan-9-yl) acetaldehyde (21B) (0.259g, 1.0mmol) was dissolved in methylene chloride (36 mL), and sodium sulfate (1.42g, 5.0mmol) and 4,5,6, 7-tetrahydroisothiophene [3,2-c ] pyridine hydrochloride (0.22g, 1.25mmol) were added to the reaction, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.048 g, 1.25mmol) was added to the reaction, and the reaction was stirred for 30 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give crude product which was purified by column chromatography (dichloromethane/methanol (v/v) = 40.
Ms m/z(ESI):383.2[M+H + ];
The third step: (R) -5- (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) -4,5,6, 7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride (Compound 22)
(R)-6-(2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine hydrochloride
Figure BDA0001714822470000851
((R) -5- (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) -4,5,6,7 tetrahydroisothiophene [3,2-c ] pyridine (22A) (0.050g, 0.13mmol) was dissolved in ethyl acetate (5 mL), a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added, the reaction was stirred at room temperature for 0.5 hour, and the reaction mixture was directly spin-dried to give (R) -5- (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) -4,5,6,7 tetrahydroisothiophene [3,2-c ] pyridine hydrochloride (Compound 22) (0.05 g, 92% yield) as a white solid.
Ms m/z(ESI):383.2[M+H + ];
1 H NMR(400MHz,DMSO-d 6 )δ8.61-8.60(s,1H),7.87(s,1H),7.43(s,2H),7.33(m,1H),6.92-6.90(m,1H),4.03-4.01(m,3H),3.61-3.58(m,2H),3.18-3.10(m,2H),2.44(m,3H),2.23(m,1H),1.99(m,1H),1.68-155(m,1H),2.01(m,1H),,1.72(m,1H),1.55-1.16(m,9H).
Example 23
(R) -N- ((3-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 23)
(R)-N-((3-ethynylthiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000861
The first step is as follows: 3- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (23B)
3-((trimethylsilyl)ethynyl)thiophene-2-carbaldehyde
Figure BDA0001714822470000862
3-bromothiophene-2-carbaldehyde (23A) (2g, 10.47mmol) and trimethylsilyne (1.54g, 15.70mmol) were dissolved in tetrahydrofuran (15 mL) and triethylamine (15 mL), and trans-bis (triphenylphosphine) palladium (II) dichloride (0.367 mg, 0.52mmol) and cuprous iodide (0.199mg, 1.05mmol) were added to the reaction under nitrogen, and the reaction was allowed to warm to 60 ℃ for 2 hours. The reaction solution was filtered, concentrated, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 50) to give 3- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (23B) (2 g, yield: 91%) as an oily liquid.
1 H NMR(400MHz,CDCl 3 )δ10.13(d,1H),7.64(dd,1H),7.17(d,1H),0.28(m,9H).
The second step is that: 3-ethynylthiophene-2-carbaldehyde (23C)
3-ethynylthiophene-2-carbaldehyde
Figure BDA0001714822470000863
3- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (23B) (2g, 9.6 mmol) was dissolved in methanol (20 mL), and potassium carbonate (2g, 14mmol) was added to the reaction, after which the reaction was carried out at room temperature for 1 hour. The reaction solution was quenched with water (50 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 2), the organic phases were combined, washed with a saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 20) to obtain 3-ethynylthiophene-2-carbaldehyde (23C) as a yellow solid (1.2 g, yield: 92%).
1 H NMR(400MHz,CDCl 3 )δ10.15(d,1H),7.67(dd,1H),7.22(d,1H),3.46(s,1H).
The third step: (R) -N- ((3-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5]
Decan-9-yl) ethylamine (23D)
(R)-N-((3-ethynylthiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470000871
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.3 g, 1.15mmol) was dissolved in dichloromethane (10 mL), and sodium sulfate (0.818g, 5.76mmol) and 3-ethynylthiophene-2-carbaldehyde (23C) (0.235g, 1.73mmol) were added to the reaction and reacted at room temperature overnight. Sodium borohydride (0.07g, 1.73mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (30 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):381.2[M+H + ];
The fourth step: (R) -N- ((3-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 23)
(R)-N-((3-ethynylthiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470000881
(R) -N- ((3-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (23D) (0.03g, 0.078mmol) was dissolved in ethyl acetate (2 mL), and a solution of hydrogen chloride in ethyl acetate (0.5mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -N- ((3-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 23) as a yellow solid (0.03 g, yield: 91%).
Ms m/z(ESI):381.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.82(dd,1H),8.49(t,1H),8.07(d,1H),7.92-7.89(m,1H),7.58(d,1H),7.13(d,1H),4.42(s,2H),3.92(s,1H),3.84-3.67(m,2H),3.05(td,1H),2.59-2.45(m,3H),2.29(td,1H),2.20-2.10(m,2H),1.94-1.78(m,2H),1.69-1.50(m,5H),1.22-1.15(m,1H),0.85-0.77(m,1H).
Example 24
2- ((3-chlorobenzyl) amino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide hydrochloride (Compound 24)
2-((3-chlorobenzyl)amino)-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)acetamide hydrochloride
Figure BDA0001714822470000882
Figure BDA0001714822470000891
The first step is as follows: para methylaniline (24B)
p-toluidine
Figure BDA0001714822470000892
P-methylnitrobenzene (24B) (13.7g, 100mmol) was dissolved in ethanol (100 mL), palladium on carbon (1.37g, wt = 10%) was added, the reaction system was evacuated, hydrogen was introduced to replace three times, and the reaction was carried out under a hydrogen balloon at room temperature for 12 hours. The pad was filtered with suction and filtered, the filter cake was washed with ethanol (20 mL. Times.2), and the filtrate was concentrated to give p-methylaniline (24B) as a yellow solid (10 g, 93.4% yield).
1 H NMR(400MHz,CDCl 3 )δ6.95(d,2H),6.67-6.46(m,2H),3.40(s,2H),2.23(s,3H).
The second step is that: n- (p-tolyl) -6-dioxaspiro [4.5] decan-9-amine (24C)
N-(p-tolyl)-6-oxaspiro[4.5]decan-9-amine
Figure BDA0001714822470000893
P-methylaniline (24B) (2g, 18.7 mmol) was dissolved in methanol (20 mL), 6-dioxaspiro [4.5] decan-9-one (3.45g, 22.4 mmol) and acetic acid (1.5 g, 25mmol) were added to the reaction, and reacted at room temperature for 1 hour, and sodium cyanoborohydride (0.449g, 28mmol) was added to the reaction, and reacted at room temperature overnight. The reaction solution was quenched with saturated sodium bicarbonate solution (50 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 2), the organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 50.
1 H NMR(400MHz,CDCl 3 )δ6.98(d,2H),6.54(d,2H),3.87-3.76(m,1H),3.64(td,1H),3.50(tt,1H),2.23(s,3H),2.06-1.92(m,3H),1.81-1.69(m,3H),1.67-1.43(m,5H),1.44-1.30(m,2H).
Third step 2-chloro-N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24D)
2-chloro-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)acetamide
Figure BDA0001714822470000901
N- (p-tolyl) -6-dioxaspiro [4.5] decan-9-amine (24C) (2g, 8.15mmol) and triethylamine (1.23g, 12.22mmol) were dissolved in methylene chloride (40 mL), cooled to 0 ℃ and chloroacetyl chloride (1.1g, 9.78mmol) was added dropwise to the reaction and reacted at room temperature for 1 hour. The reaction solution was quenched with a saturated sodium bicarbonate solution (30 mL), the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with a saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 10) to obtain 2-chloro-N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24D) as an oily liquid (2 g, yield: 76.3%).
1 H NMR(400MHz,CDCl 3 )δ7.23(d,2H),6.99(d,2H),4.89(ddd,1H),3.82-3.57(m,4H),2.40(s,3H),2.09-1.93(m,1H),1.74-1.31(m,11H).
The fourth step 2-azido-N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24E)
2-azido-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)acetamide
Figure BDA0001714822470000902
2-chloro-N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24D) (2g, 6.22mmol) was dissolved in N, N-dimethylformamide (20 mL), and sodium azide (0.81g, 12.44mmol) was added to the reaction, after which the reaction was allowed to react at room temperature for 3 hours. The reaction solution was quenched with water (30 mL), the aqueous phase was extracted with methyl t-butyl ether (30 mL. Times.3), the organic phases were combined, washed with a saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 2-azido-N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24E) (2 g, yield: 98%) as an oily liquid.
The fifth step 2-amino-N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24F)
2-amino-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)acetamide
Figure BDA0001714822470000911
2-azido-N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24E) (2g, 6.09mmol) was dissolved in tetrahydrofuran (20 mL) and water (5 mL), and triphenylphosphine (3.19g, 12.2mmol) was added to the reaction, after which the reaction was carried out at room temperature for 3 hours. 1M hydrochloric acid solution (20 mL) was added to the reaction, the aqueous phase was extracted with ethyl acetate (20 mL. Times.3), the organic phase was removed, the aqueous phase was adjusted to pH ≈ 9 with 1M sodium hydroxide solution, the aqueous phase was extracted with ethyl acetate (20 mL. Times.3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain 2-amino-N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24F) (1.5 g, yield: 81%) as an oily liquid.
Ms m/z(ESI):303.2[M+H + ];
And a sixth step: 2- ((3-chlorobenzyl) amino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24G) 2- ((3-chlorobenzinyl) amino) -N- (6-oxapiro [4.5] ]can-9-yl) -N- (p-tolyl) acetamide
Figure BDA0001714822470000912
2-amino-N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24F) (0.3 g, 0.99mmol) was dissolved in methylene chloride (10 mL), and sodium sulfate (0.7 g,5.0 mmol) and 3-chlorobenzaldehyde (0.21g, 1.5mmol) were added thereto and reacted at room temperature overnight. Sodium borohydride (0.057g, 1.5mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and reaction with stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give crude product which was purified by column chromatography (dichloromethane/methanol (v/v) = 50).
Ms m/z(ESI):427.2[M+H + ];
The seventh step: 2- ((3-chlorobenzyl) amino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide hydrochloride (Compound 24)
2-((3-chlorobenzyl)amino)-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)acetamide hydrochloride
Figure BDA0001714822470000921
2- ((3-chlorobenzyl) amino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24G) (0.15g, 0.351mmol) was dissolved in ethyl acetate (5 mL), a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added, and the reaction was stirred at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give 2- ((3-chlorobenzyl) amino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide hydrochloride (Compound 24) as a white solid (0.16 g, yield: 98%).
Ms m/z(ESI):427.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ7.57-7.39(m,3H),7.35(t,3H),7.08(d,2H),4.82-4.77(m,1H),4.15(s,2H),3.75-3.64(m,2H),3.49(s,2H),2.41(s,3H),2.12-1.98(m,1H),1.77-1.44(m,9H),1.38-1.27(m,2H).
Example 25
2- (((3-Methylthion-2-yl) methyl) amine) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide hydrochloride (Compound 25)
2-(((3-methoxythiophen-2-yl)methyl)amino)-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)acetamide hydrochloride
Figure BDA0001714822470000922
Figure BDA0001714822470000931
The first step is as follows: 2- (((3-methylthiophen-2-yl) methyl) amine) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (25A)
2-(((3-methoxythiophen-2-yl)methyl)amino)-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)acetamide
Figure BDA0001714822470000932
2-amino-N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (24F) (0.3g, 0.99mmol) was dissolved in methylene chloride (10 mL), and sodium sulfate (0.7g, 5.0mmol) and 3-methoxythiophene-2-carbaldehyde (0.21g, 1.5 mmol) were added to the reaction, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.057g, 1.5mmol) was added to the reaction, and the reaction mixture was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give crude 2- (((3-methylthiophen-2-yl) methyl) amine) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (25A) (0.15 g, yield: 35%) as a yellow oily liquid by column chromatography (dichloromethane/methanol (v/v) = 50).
Ms m/z(ESI):429.2[M+H + ];
The second step is that: 2- (((3-Methylthioen-2-yl) methyl) amine) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide hydrochloride (Compound 25)
2-(((3-methoxythiophen-2-yl)methyl)amino)-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)acetamide hydrochloride
Figure BDA0001714822470000933
2- (((3-Methylthion-2-yl) methyl) amine) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide (25A) (0.15g, 0.351mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give 2- (((3-methylthiophen-2-yl) methyl) amine) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acetamide hydrochloride (Compound 25) as a white solid (0.16 g, yield: 98%).
Ms m/z(ESI):429.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ7.48(d,1H),7.34(d,2H),7.07(d,2H),6.98(d,1H),4.81-4.78(m,1H),4.23(s,2H),3.75(s,3H),3.72-3.66(m,2H),3.39(s,2H),2.41(s,3H),2.10-2.00(m,1H),1.78-1.47(m,9H),1.35-1.26(m,2H).
Example 26
2- (2- (6-Oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- (3-chlorophenyl) ethylamine hydrochloride (Compound 26)
2-(2-(6-oxaspiro[4.5]decan-9-yl)pyridin-3-yl)-N-(3-chlorobenzyl)ethanamine hydrochloride
Figure BDA0001714822470000941
Figure BDA0001714822470000951
The first step is as follows: 6-oxaspiro [4.5] dec-8-en-9-yl trifluoromethanesulfonate (26B)
6-oxaspiro[4.5]dec-8-en-9-yl trifluoromethanesulfonate
Figure BDA0001714822470000952
6-oxaspiro [4.5] decan-9-one (26A) (10.0g, 64.8mmol) was dissolved in a three-necked flask with tetrahydrofuran (120 mL), the temperature was lowered to-78 ℃, lithium diisopropylamide (38.9mL, 77.8mmol) was added dropwise to the reaction mixture, the temperature was maintained at-65 ℃ or lower, stirring was carried out for 20 minutes after the addition was completed, N-phenylbis (trifluoromethanesulfonyl) imide (25.5g, 71.3mmol) was dissolved in tetrahydrofuran (30 mL), and then the mixture was added dropwise to the reaction mixture, and the mixture was allowed to warm to room temperature for reaction for 3 hours. After the reaction was completed, the reaction mixture was quenched by addition of saturated aqueous sodium bicarbonate solution, extracted with methyl t-butyl ether (100 mL. Times.2), the organic phases were combined, washed with 10% aqueous sodium hydroxide (100 mL. Times.2), water (100 mL. Times.1), saturated brine (100 mL. Times.1), filtered and dried, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/100-1/20), and concentrated to dryness to give 6-oxaspiro [4.5] dec-8-en-9-yl trifluoromethanesulfonate (26B) (10.2 g, yield 54.9%) as a yellow oily product.
1 H NMR(400MHz,CDCl 3 )δ5.79-5.69(m,1H),4.26-4.24(t,1H),3.85-3.82(q,1H),2.42-2.40(m,1H),1.88-1.78(m,4H),1.68-1.51(m,4H).
The second step is that: 4, 5-tetramethyl-2- (6-oxaspiro [4.5] dec-8-en-9-yl) -1,3, 2-dioxaborane (26C)
4,4,5,5-tetramethyl-2-(6-oxaspiro[4.5]dec-8-en-9-yl)-1,3,2-dioxaborolane
Figure BDA0001714822470000961
6-oxaspiro [4.5] dec-8-en-9-yl trifluoromethanesulfonate (26B) (7.9g, 28mmol) was dissolved in a single-neck flask with dioxane (80 mL), pinacol diborate (14g, 55mmol), potassium acetate (5.4g, 55mmol) were added, vacuum was applied and nitrogen was replaced 3 times, 1' -bis (diphenylphosphino) ferrocene ] dichloropalladium (II) (1.0g, 1.4mmol) was added, vacuum was applied and nitrogen was replaced 3 times, and the mixture was heated to 80 ℃ under nitrogen for 7 hours. Methyl tert-butyl ether (100 mL) was added, filtered through celite, rinsed with methyl tert-butyl ether (50 mL. Times.2), the organic phases were combined, concentrated to dryness, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/100-1/30) and concentrated to dryness to give 4,4,5,5-tetramethyl-2- (6-oxaspiro [4.5] dec-8-en-9-yl) -1,3, 2-dioxaborane (26C) as a colorless oil (7 g, 96% yield).
1 H NMR(400MHz,CDCl 3 )δ6.52-6.38(dt,1H),4.22-4.20(q,1H),3.71-3.69(t,1H),2.22-2.13(m,2H),1.80-1.63(m,8H),1.27-1.26(d,12H).
The third step: 2- (6-oxaspiro [4.5] dec-8-en-9-yl) nicotinaldehyde (26D)
2-(6-oxaspiro[4.5]dec-8-en-9-yl)nicotinaldehyde
Figure BDA0001714822470000962
4, 5-tetramethyl-2- (6-oxaspiro [4.5] dec-8-en-9-yl) -1,3, 2-dioxaborane (26C) (12.6 g, 47.7mmol), 2-bromo-3-pyridinecarbaldehyde (11.5 g,62.0 mmol), tetrakis (triphenylphosphine) palladium (3.3 g, 2.9mmol), sodium carbonate (11.1g, 105mmol) were dissolved in toluene (80 mL), ethanol (20 mL), water (20 mL), and the mixture was heated to 90 ℃ for 5 hours. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (100 mL. Times.2), and the organic phases were combined, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 0/100-1/20) by column flushing and concentrated to dryness to give 2- (6-oxaspiro [4.5] dec-8-en-9-yl) nicotinaldehyde (26D) as a yellow oil (4.5 g, yield 39%).
1 H NMR(400MHz,CDCl 3 )δ10.20-10.18(q,1H),8.79-8.77(dt,1H),8.22-8.20(q,1H),7.37-7.28(m,1H),5.80-5.69(dt,1H),4.42-3.94(m,2H),2.76-2.72(m,2H),1.96-1.69(m,8H).
The fourth step: (2- (6-oxaspiro [4.5] dec-8-en-9-yl) pyridin-3-yl) methanol (26E)
(2-(6-oxaspiro[4.5]dec-8-en-9-yl)pyridin-3-yl)methanol
Figure BDA0001714822470000971
2- (6-oxaspiro [4.5] dec-8-en-9-yl) nicotinaldehyde (26D) (2.5 g, 10mmol) was dissolved in a single-neck flask with tetrahydrofuran (20 mL), the temperature was lowered to 0 ℃, sodium borohydride (0.51g, 13mmol) was added to the reaction mixture in three portions, and after completion of the addition, the reaction was carried out at room temperature for 4 hours. The reaction was quenched by dropwise addition of saturated ammonium chloride, water (50 mL) was added, extraction was performed with ethyl acetate (30 mL × 4), the organic phases were combined, dried by addition of anhydrous sodium sulfate, filtered and concentrated, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 0/100-1/20) by column chromatography, and concentrated to dryness to give (2- (6-oxaspiro [4.5] dec-8-en-9-yl) pyridin-3-yl) methanol (26E) (1.7 g, yield 67%) as a colorless oil.
The fifth step: (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) methanol (26F)
(2-(6-oxaspiro[4.5]decan-9-yl)pyridin-3-yl)methanol
Figure BDA0001714822470000972
(2- (6-oxaspiro [4.5] dec-8-en-9-yl) pyridin-3-yl) methanol (26E) (2.0 g, 8.2mmol) was dissolved in methanol (20 mL), palladium on carbon (0.4 g, 20%) was added, and the air in the reaction flask was replaced with hydrogen three times and reacted under hydrogen for 3 hours. The palladium-carbon contained in the reaction mixture was filtered off with Celite, rinsed with ethyl acetate (20 mL. Times.2), and the filtrate was concentrated to dryness to give (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) methanol (26F) (2.0 g, 99% yield) as a colorless oil.
LCMS m/z=248.1[M+1];
And a sixth step: (2- (7-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) methyl methanesulfonate (26G)
(2-(7-oxaspiro[4.5]decan-9-yl)pyridin-3-yl)methyl methanesulfonate
Figure BDA0001714822470000981
(2- (6-Oxaspiro [4.5] decan-9-yl) pyridin-3-yl) methanol (26F) (2.3, 9.3 mmol) was dissolved in methylene chloride (20 mL), triethylamine (1.41g, 14.0 mmol) was added thereto, the temperature was lowered to 0 ℃ and methanesulfonyl chloride (1.38g, 12.1 mmol) was added dropwise to the reaction mixture, and the mixture was allowed to warm to room temperature for 3 hours. Water (50 mL) was added to the reaction mixture, followed by liquid separation, extraction of the aqueous phase with dichloromethane (20 mL), combination of the organic phases, drying with anhydrous sodium sulfate, filtration and concentration, and purification of the crude product by column chromatography (ethyl acetate: petroleum ether (v/v) = 0/100-1/30) column chromatography, and concentration to dryness gave (2- (7-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) methylmethanesulfonate (26G) as a yellow oil (2.1G, 69% yield).
The seventh step: 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) acetonitrile (26H)
2-(2-(6-oxaspiro[4.5]decan-9-yl)pyridin-3-yl)acetonitrile
Figure BDA0001714822470000982
(2- (7-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) methylmethanesulfonate (26G) (2.1g, 6.5 mmol), potassium cyanide (1.3g, 19mmol) were dissolved in N, N-dimethylformamide (20 mL) in a single vial and heated to 85 ℃ for 5 hours. Water (50 mL) was added to the reaction solution, extraction was performed with ethyl acetate (50 mL. Times.3), the organic phases were combined and washed with water (50 mL. Times.3), the organic phase was dried, filtered and concentrated, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/100-1/30) using a column punch and concentrated to dryness to give 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) acetonitrile (26H) (1.3 g, yield 79%) as a yellow oil.
1 H NMR(400MHz,CDCl 3 )δ8.59-8.57(q,1H),7.67-7.65(dd,1H),7.19-7.16(dd,1H),3.93-3.88(m,1H),3.78-3.71(m,3H),3.14-3.08(m,1H),2.16-2.09(m,4H),1.82-1.57(m,8H).
Eighth step: 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) ethylamine (26I)
2-(2-(6-oxaspiro[4.5]decan-9-yl)pyridin-3-yl)ethanamine
Figure BDA0001714822470000991
Aluminum lithium hydride (0.96g, 25mmol) was dissolved in tetrahydrofuran (10 mL), the temperature was reduced to 0 ℃ or lower, 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) acetonitrile (26H) (1.3 g,5 mmol) was dissolved in tetrahydrofuran (5 mL), and the mixture was added dropwise to the reaction mixture, followed by reaction at 0 ℃ for 2 hours. Water (1 mL), 15% aqueous sodium hydroxide (1 mL), water (3 mL) was slowly added dropwise to the reaction, stirred for half an hour and filtered, rinsed with ethyl acetate (10 mL), and the filtrate was dried and concentrated to afford 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) ethylamine (26I) (0.4 g, 30% yield) as a yellow oil.
LCMS m/z=261.2[M+H + ];
The ninth step: 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- (3-chlorophenyl) ethanamine (26J)
2-(2-(6-oxaspiro[4.5]decan-9-yl)pyridin-3-yl)-N-(3-chlorobenzyl)ethanamine
Figure BDA0001714822470000992
2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) ethylamine (26I) (0.20g, 0.77mmol), 3-chlorobenzaldehyde (0.16g, 1.15mmol) were dissolved in methylene chloride (10 mL), magnesium sulfate (0.46g, 3.84mmol) was added, the mixture was stirred at room temperature overnight, sodium borohydride (0.05g, 1.15mmol) was added, the mixture was stirred at room temperature for 1 hour, and anhydrous methanol (3 mL) was added and the mixture was stirred for 2 hours. Water (20 mL) was added to the reaction solution, extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL), the organic phase was dried over colorless sodium sulfate, filtered to dryness, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/10-1/1) cartridge, concentrated to dryness to give 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- (3-chlorophenyl) ethylamine (26J) (0.22 g, 74% yield) as a pale yellow oil.
LCMS m/z=385.2[M+H + ];
The tenth step: 2- (2- (6-Oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- (3-chlorophenyl) ethylamine hydrochloride (Compound 30)
2-(2-(6-oxaspiro[4.5]decan-9-yl)pyridin-3-yl)-N-(3-chlorobenzyl)ethanamine hydrochloride
Figure BDA0001714822470001001
2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- (3-chlorophenyl) ethanamine (26J) (0.22g, 0.57mmol) was dissolved in ethyl acetate (10 mL), an ethyl acetate solution of hydrochloric acid (1mL, 4mol/L) was added dropwise, a white solid precipitated, stirred for half an hour, and concentrated to dryness to give 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- (3-chlorophenyl) ethanamine hydrochloride (Compound 26) (0.23 g, 95% yield).
LCMS m/z=385.2[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.67-8.66(q,1H),8.51(d,1H),7.95-7.92(dd,1H),7.66(s,1H),7.53-7.48(m,1H),4.33-4.32(d,2H),4.11-4.09(t,1H),3.90-3.88(dd,2H),3.65(m,1H),3.39(s,3H),2.07-1.57(m,13H).
Example 27
2- (2- (6-Oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (Compound 27)
2-(2-(6-oxaspiro[4.5]decan-9-yl)pyridin-3-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine hydrochloride
Figure BDA0001714822470001002
The first step is as follows: 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (27A)
2-(2-(6-oxaspiro[4.5]decan-9-yl)pyridin-3-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine
Figure BDA0001714822470001011
2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) ethylamine (26I) (0.20g, 0.77mmol), 3-methoxythiophene-2-carbaldehyde (0.16g, 1.2mmol) were dissolved in methylene chloride (10 mL), magnesium sulfate (0.46g, 3.84mmol) was added, stirring was continued overnight at room temperature, sodium borohydride (44mg, 1.15mmol) was added, stirring was continued at room temperature for 1 hour, and anhydrous methanol (3 mL) was added and stirring was continued for 2 hours. Water (20 mL) was added to the reaction solution, extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL), the organic phase was dried over colorless sodium sulfate, filtered to dryness, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/10-1/1) cartridge, concentrated to dryness to give 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (27A) (0.22 g, 74% yield) as a pale yellow oil.
LCMS m/z=387.2[M+H + ];
The second step: 2- (2- (6-Oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (Compound 27)
2-(2-(6-oxaspiro[4.5]decan-9-yl)pyridin-3-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine hydrochloride
Figure BDA0001714822470001012
2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (27A) (0.10 g, 0.26mmol) was dissolved in ethyl acetate (10 mL), and a solution of hydrochloric acid in ethyl acetate (1mL, 4mol/L) was added dropwise with solid precipitation, stirred for half an hour and concentrated to dryness to give 2- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -N- (3-chlorophenyl) ethylamine hydrochloride (Compound 27) (0.08 g, 70% yield) as an orange solid.
LC-MS m/z=387.2[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.68-8.67(d,1H),8.53-8.51(d,1H),7.96-7.92(t,1H),7.54-7.53(d,1H),7.08-7.06(d,1H),4.41(s,2H),3.94(s,3H),3.89-3.87(d,2H),3.60-3.57(q,1H),3.37-3.30(m,4H),2.05-1.62(m,13H).
Example 28
(R) -N- ((3- (methoxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 28)
(R)-N-((3-(methoxymethyl)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decn-9-yl)ethanamine hydrochloride
Figure BDA0001714822470001021
The first step is as follows: 3- (methoxymethyl) thiophene (28B)
3-(methoxymethyl)thiophene
Figure BDA0001714822470001022
Sodium hydrogen (3.15g, 131.3mmol) was dissolved in tetrahydrofuran (40 mL) at zero degrees, and then thiophene 3-ylmethanol (28A) (5g, 43.7mmol) was added to the solution, and after addition, iodomethane (9.32g, 65.69mmol) was added dropwise, and after addition, 60 degrees reaction was performed for 2h, cooling was performed, water (30 mL) was added, ethyl acetate extraction (50 mL × 3), water washing (50 mL × 1), the organic phases were combined, washed with a saturated saline solution (50 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and subjected to column chromatography separation and purification (n-hexane/ethyl acetate = 10) to obtain a yellow liquid product, 3- (methoxymethyl) thiophene (28B) (5.6 g, yield 100%).
1 H NMR(400MHz,CDCl 3 ):δ7.31–7.26(m,1H),7.21(m,H),7.08-7.06(m,1H),4.46(s,2H),3.37(s,3H)。
The second step is that: 3- (methoxymethyl) thiophene-2-carbaldehyde (28C)
3-(methoxymethyl)thiophene-2-carbaldehyde
Figure BDA0001714822470001031
3- (methoxymethyl) thiophene (28B) (2g, 12.8mmol) was dissolved in tetrahydrofuran (10 mL), and then the reaction system was cooled to-78 ℃ and n-butyllithium (6.88mL, 17.2mmol) was added thereto, after which the reaction was completed for 0.5h, and dimethylformamide (1.4g, 20mmol) was added thereto up to zero and the reaction was continued for 2h. Ammonium chloride water (20 mL) was added, extracted with EA (20 mL × 3), and the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and subjected to column chromatography separation and purification (n-hexane/ethyl acetate = 5.
The third step: (R) -N- ((3- (methoxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (28D)
(R)-N-((3-(methoxymethyl)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470001032
3- (methoxymethyl) thiophene-2-aldehyde (28C) (0.2g, 1.27mmol) was dissolved in dichloromethane (10 ml), and (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1), anhydrous sodium sulfate (1.31 g) was added thereto in this order. The reaction was allowed to react overnight at room temperature, sodium borohydride (0.065g, 1.73mmol) was added, stirring was continued for 2h, water (20 mL) was added, extraction was performed with ethyl acetate (20 mL × 3), the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography purification (dichloromethane/methanol =20 1) was performed to obtain N- ((3- (methoxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine (28D) (0.3g, 70%) as a yellow liquid.
Ms m/z(ESI):401.1[M+H + ];
The fourth step: (R) -N- ((3- (methoxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 28)
(R)-N-((3-(methoxymethyl)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decn-9-yl)ethanamine hydrochloride
Figure BDA0001714822470001041
(R) -N- ((3- (methoxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine (28D) (0.3g, 0.7 mmol) was dissolved in EA (5 mL) and the solution of ethyl hydrogen chloride acetate (2mL, 4N) was added at 0 ℃ and the reaction was continued for 0.5h, after which the solvent was removed under reduced pressure to give (R) -N- ((3- (methoxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine hydrochloride (Compound 28) (0.31g, 100%) as a white solid.
Ms m/z(ESI):401.1[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.83(m,1H),8.83(m,1H),8.52(t,1H),8.10(d,1H),7.95(m,1H),7.49(d,1H),7.04(d,1H),4.53(s,2H),4.36(s,2H),3.77(m,2H),3.40(s,3H),3.04(td,1H),2.52(m,3H),2.30(td,1H),2.15(m,2H),1.91(m,2H),1.59(m,5H),1.34-1.32(m,3H)。
Example 29
(R) -N- (3-Cyclopropylbenzyl) -2- (9- (pyridin-2-yl) -6-oxa [4.5] decan-9-yl) ethylamine hydrochloride (Compound 29)
(R)-N-(3-cyclopropoxybenzyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470001042
Figure BDA0001714822470001051
The first step is as follows: methyl 3- (2-bromoethoxy) benzoate (29B)
methyl 3-(2-bromoethoxy)benzoate
Figure BDA0001714822470001052
Methyl 3-phenolic hydroxybenzoate (29A) (7g, 46mmol) was dissolved in DMF (40 mL), potassium carbonate (12.7g, 92mmol), 1, 2-dibromoethane (26g, 184mmol) were added to the solution in this order, reaction was carried out for 24h, cooling, water (150 mL) was added, dichloromethane was extracted (50 mL × 4), washing was carried out with a saturated aqueous salt solution (150 mL × 3), anhydrous sodium sulfate was dried, filtration was carried out, the filtrate was concentrated, and column chromatography separation purification (n-hexane/ethyl acetate = 10) was carried out to obtain methyl 3- (2-bromoethoxy) benzoate (29B) (5 g, yield 50%) as a pale yellow oily product,
1 H NMR(400MHz,CDCl 3 ):δ7.68–7.66(m,1H),7.57–7.56(m,1H),7.36-7.26(m,H),7.14-7.11(m,1H),4.36-4.33(t,2H),3.92(s,3H),4.67-4.64(t,2H)。
The second step is that: methyl 3- (vinyl) benzoate (29C)
methyl 3-(vinyloxy)benzoate
Figure BDA0001714822470001053
3- (2-Bromoethoxy) benzoate (29B) (3g, 11.57mmol) was dissolved in THF (20 mL), potassium tert-butoxide solution (23mL, 23mmol) was added, and the reaction was continued for 5h. Water (100 mL) was added, extraction was performed with ethyl acetate (20 mL. Times.3), the organic phases were combined, washed with a saturated saline solution (30 mL. Times.1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give methyl 3- (vinyl) benzoate 29C as a pale yellow oil product (2.2 g, yield 60%).
Ms m/z(ESI):215.1[M+H + ]
The third step: methyl 3-cyclopropylbenzoate (29D)
methyl 3-cyclopropoxybenzoate
Figure BDA0001714822470001061
Methyl 3- (vinyl) benzoate (29C) (2.2g, 12mmol) was dissolved in methylene chloride (40 mL), diiodomethane (13g, 49mmol) was added thereto, followed by cooling to 0 ℃ and diethyl zinc (3.1g, 21mmol) was slowly added dropwise. After 5h reaction at room temperature, 1N aqueous hydrochloric acid (20 mL) was added to clear the solution, extracted with dichloromethane (20 mL. Times.3), the organic phases were combined, washed with saturated aqueous saline solution (30 mL. Times.1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give methyl 3-cyclopropylbenzoate (29D) (1.9g, 60%) as a crude pale yellow liquid, which was directly used in the next step.
Ms m/z(ESI):215.1[M+H + ]。
The fourth step: (3-Cyclopropylphenyl) methanol (29E)
(3-cyclopropoxyphenyl)methanol
Figure BDA0001714822470001062
Methyl 3-cyclopropylbenzoate (29D) (1.9g, 9.9mmol) was dissolved in tetrahydrofuran (15 mL) at room temperature, lithium aluminum hydride (0.75, 20mmol) was added at 0 ℃ and the reaction was continued for 2 hours, then water (0.75 mL), 10% aqueous sodium hydroxide (0.75 mL), water (0.75 mL), anhydrous sodium sulfate (2 g) was added to the reaction mixture, the mixture was stirred for 10 minutes, and the mixture was filtered, and the filtrate was concentrated under reduced pressure to remove the solvent, to obtain (3-cyclopropylphenyl) methanol (29E) (1.3g, 80%) as a colorless oily product.
Ms m/z(ESI):187.1[M+H + ]。
The fifth step: 3-Cyclopropylbenzaldehyde (29F)
3-cyclopropoxybenzaldehyde
Figure BDA0001714822470001063
At room temperature, (3-cyclopropylphenyl) methanol (29E) (1.3 g,7.9 mmol) was dissolved in dichloromethane (15 mL), dess-min reagent (5g, 12mmol) was added at 0 ℃, after the addition, the reaction was continued for 0.5h, and extraction was performed with dichloromethane (20 mL × 3), and the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (n-hexane/ethyl acetate = 20) was performed to isolate and purify 3-cyclopropylbenzaldehyde (29F) (0.08g, 10%) as a pale yellow liquid product
Ms m/z(ESI):163.1[M+H + ]。
And a sixth step: (R) -N- (3-cyclopropylbenzyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (29G)
(R)-N-(3-cyclopropoxybenzyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470001071
3-Cyclopropylbenzaldehyde (29F) (0.08g, 0.5 mmol) was dissolved in methylene chloride (10 mL), and (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine (0.2g, 0.6 mmol) and anhydrous sodium sulfate (0.6 g) were added thereto in this order. After reacting overnight at room temperature, sodium borohydride (0.02g, 0.6 mmol) was added, stirring was continued for 2h, water (20 mL) was added, extraction was performed with dichloromethane (20 mL × 3), the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (dichloromethane/methanol =20 = 1) was performed to isolate and purify the product N- (3-cyclopropylbenzyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (29G) as a yellow oily product (0.09g, 60%).
Ms m/z(ESI):407.1[M+H + ]。
The seventh step: (R) -N- (3-Cyclopropylbenzyl) -2- (9- (pyridin-2-yl) -6-oxa [4.5] decan-9-yl) ethylamine hydrochloride (Compound 29)
(R)-N-(3-cyclopropoxybenzyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanaminehydrochloride
Figure BDA0001714822470001072
Dissolving N- (3-cyclopropylbenzyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine (29G) (0.09g, 0.2mmol) in ethyl acetate (5 mL) at room temperature, adding hydrogen chloride in ethyl acetate (2 mL, 4N) at 0 deg.C, continuing the reaction for 0.5h, and removing the solvent under reduced pressure to obtain (R) -N- ((3- (methoxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine hydrochloride (Compound 29) (0.09g, 96%)
Ms m/z(ESI):407.1[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.81(d,1H),8.47(t,1H),8.06(d,1H),7.90(m,1H),7.33(m,1H),7.12(dd,1H),6.99(d,1H),4.06(s,2H),3.78(m,2H),3.03(td,1H),2.51(ddd,2H),2.30(td,1H),2.14(m,2H),1.88(m,2H),1.57(m,5H),0.81(m,2H),0.67(dd,2H)。
Example 30
(R) -N- ((3-Cyclopropoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 30)
(R)-N-((3-cyclopropoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470001081
The first step is as follows: 3- (2-Bromoethoxy) thiophene-2-carboxylic acid methyl ester (30B)
methyl 3-(2-bromoethoxy)thiophene-2-carboxylate
Figure BDA0001714822470001091
Methyl 3-hydroxythiophene-2-carboxylate (30A) (10g, 63.2mmol) was dissolved in N, N-dimethylformamide (50 mL) at room temperature, and potassium carbonate (34.9g, 252.8mmol) and dibromoethane (95g, 505.7mmol) were added, and the reaction was completed at 80 ℃ for 2 hours. To the reaction solution was added water (200 mL), the aqueous phase was extracted with methyl tert-butyl ether (50 mL × 3), the combined organic phases were washed with a saturated sodium chloride solution (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 20).
1 H NMR(400MHz,CDCl 3 )δ7.41(d,1H),6.84(d,1H),4.43(t,2H),3.85(s,3H),3.65(t,2H).
The second step is that: 3- (ethyleneoxy) thiophene-2-carboxylic acid methyl ester (30C)
methyl 3-(vinyloxy)thiophene-2-carboxylate
Figure BDA0001714822470001092
3- (2-Bromoethoxy) thiophene-2-carboxylic acid methyl ester (30B) (14g, 52.8mmol) was dissolved in tetrahydrofuran (100 mL), cooled to 0 ℃ and a solution of sodium bis (trimethylsilyl) amide (39.5 mL, 79mmol) was added dropwise to the reaction and reacted at 0 ℃ for 1 hour. The reaction solution was quenched with a saturated ammonium chloride solution (100 mL), the liquids were separated, the aqueous phase was extracted with ethyl acetate (50 mL × 2), the organic phases were combined, washed with a saturated sodium chloride solution (80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 10) to obtain methyl 3- (ethyleneoxy) thiophene-2-carboxylate (30C) as a yellow solid (5.5 g, yield: 57%).
1 H NMR(400MHz,CDCl 3 )δ7.42(d,1H),6.87(d,1H),6.67(dd,1H),4.82(dd,1H),4.49(dd,1H),3.86(s,3H).
The third step: 3- (Cyclopropoxy) thiophene-2-carboxylic acid methyl ester (30D)
methyl 3-cyclopropoxythiophene-2-carboxylate
Figure BDA0001714822470001093
Methyl 3- (vinyloxy) thiophene-2-carboxylate (30C) (5.5g, 29.9 mmol) and diiodomethane (40g, 149mmol) were dissolved in dichloromethane (80 mL) under nitrogen, cooled to 0 deg.C, and diethylzinc (59.5mL, 119mmol) was added dropwise to the reaction, after which the reaction was allowed to proceed overnight at room temperature. The reaction was quenched by adding a saturated ammonium chloride solution (80 mL) to the reaction solution, separating the layers, extracting the aqueous phase with dichloromethane (50 mL × 2), combining the organic phases, washing with a saturated sodium chloride solution (80 mL), drying over anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and then purifying the crude product by column chromatography (petroleum ether/ethyl acetate (v/v) = 1-10) to obtain methyl 3- (cyclopropoxy) thiophene-2-carboxylate (30D) as an oily liquid (3 g, yield: 50.7%).
1 H NMR(400MHz,CDCl 3 )δ7.40(d,1H),7.12(d,1H),3.99-3.89(m,1H),3.82(s,3H),1.00-0.87(m,2H),0.84-0.73(m,2H).
The fourth step: (3-Cyclopropoxythiophen-2-yl) methanol (30E)
(3-cyclopropoxythiophen-2-yl)methanol
Figure BDA0001714822470001101
Lithium aluminum hydride (1.2 g, 30mmol) was dissolved in tetrahydrofuran (40 mL), cooled to 0 deg.C, and then a solution of methyl 3- (cyclopropoxy) thiophene-2-carboxylate (30D) (3 g, 15mmol) in tetrahydrofuran (10 mL) was added dropwise to the reaction, and the reaction was carried out at room temperature for 2 hours. The reaction was cooled to 0 ℃, and quenched with water (1.2 mL), sodium hydroxide solution (10%, 1.2 mL) and water (3.6 mL) in that order, dried by adding anhydrous sodium sulfate, the solid was filtered and washed with tetrahydrofuran (20 mL × 2), and the combined organic phases were concentrated to give an oily liquid (3-cyclopropoxythiophene-2-yl) methanol (30E) (2.5 g, yield: 97%).
The fifth step: 3-Cyclopropoxythiophene-2-carbaldehyde (30F)
3-cyclopropoxythiophene-2-carbaldehyde
Figure BDA0001714822470001102
(3-Cyclopropoxythiophen-2-yl) methanol (30E) (1.5g, 8.81mmol) was dissolved in dichloromethane (50 mL), cooled to 0 ℃ and manganese dioxide (7.66g, 88.1mmol) was added to the reaction, and the reaction was carried out at room temperature for 12 hours. The reaction solution was filtered of a solid and washed with dichloromethane (20 mL. Times.2), and the combined organic phases were concentrated to give 3-cyclopropoxythiophene-2-carbaldehyde (30F) (1.4 g, yield: 94%) as an oily liquid.
1 H NMR(400MHz,CDCl 3 )δ9.93(d,1H),7.63(dd,1H),7.10(d,1H),3.97(td,1H),0.95-0.81(m,4H).
And a sixth step: (R) -N- ((3-Cyclopropoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (30G)
(R)-N-((3-cyclopropoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470001111
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.50g, 1.92mmol) was dissolved in dichloromethane (20 mL), and sodium sulfate (1.36g, 9.60mmol) and 3-cyclopropyloxythiophene-2-carbaldehyde (30F) (0.388g, 2.3mmol) were added to the reaction and reacted overnight at room temperature. Sodium borohydride (0.11g, 2.88mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (30 mL. Times.3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated and the crude product was purified by preparative HPLC (method: acetonitrile/0.1% aqueous ammonia-25% _60% _15 min) to give (R) -N- ((3-cyclopropoxythien-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (30G) (0.5G, yield: 63%) as an oily liquid.
Ms m/z(ESI):413.2[M+H + ]。
The seventh step: (R) -N- ((3-Cyclopropoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 30)
(R)-N-((3-cyclopropoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470001112
(R) -N- ((3-Cyclopropoxythen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (30G) (0.50g, 1.21mmol) was dissolved in ethyl acetate (10 mL), and a solution of hydrogen chloride in ethyl acetate (1 mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -N- ((3-cyclopropoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (compound 30) as a white solid (0.54 g, yield: 99%).
Ms m/z(ESI):413.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.89(d,1H),8.67(d,1H),8.22(d,1H),8.08(t,1H),7.47(d,1H),7.18(d,1H),4.15(s,2H),3.98-3.91(m,1H),3.89-3.80(m,1H),3.75-3.69(m,1H),3.04-2.91(m,1H),2.54-2.45(m,3H),2.39-2.26(m,1H),2.20(t,2H),2.01-1.80(m,2H),1.75-1.41(m,5H),1.24-1.18(m,1H),0.90-0.68(m,5H).
Example 31
3- (benzylamino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) propanamide hydrochloride (Compound 31)
3-(benzylamino)-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)propanamide hydrochloride
Figure BDA0001714822470001121
First step N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acrylamide (31A)
N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)acrylamide
Figure BDA0001714822470001122
N- (p-tolyl) -6-dioxaspiro [4.5] decan-9-amine (24C) (1.5g, 6.1mmol) and triethylamine (0.93g, 9.2mmol) were dissolved in methylene chloride (20 mL), cooled to 0 ℃ and chloropropionyl chloride (0.93g, 7.3mmol) was added dropwise to the reaction, after which the reaction was carried out at room temperature for 2 hours. The reaction solution was quenched with a saturated sodium bicarbonate solution (30 mL), the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with a saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 10) to give N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acrylamide (31A) as an oily liquid (1.5 g, yield: 82%).
1 H NMR(400MHz,CDCl 3 )δ7.21(t,2H),6.94(d,2H),6.32(dd,1H),5.83(dd,1H),5.44(dd,1H),5.07-4.90(m,1H),3.77-3.59(m,2H),2.43-2.31(m,3H),2.09-1.95(m,1H),1.81-1.30(m,11H).
Second step 3- (benzylamino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) propanamide (31B) 3-
(benzylamino)-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)propanamide
Figure BDA0001714822470001131
N- (6-dioxaspiro [4.5] decan-9-yl) -N- (p-tolyl) acrylamide (31A) (0.30g, 1.0 mmol) was dissolved in tetrahydrofuran (10 mL), and benzylamine (0.215g, 2.0 mmol) and 1, 8-diazabicycloundec-7-ene (0.305g, 2.0 mmol) were added to the reaction, which was heated to reflux for 12 hours. The reaction solution was quenched with water (30 mL), the aqueous phase was extracted with ethyl acetate (20 mL. Times.3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated and the crude product was purified by preparative HPLC (method: acetonitrile/0.1% aqueous ammonia-45% _75% _15 min) to give 3- (benzylamino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) propionamide (31B) (0.2 g, yield: 50%).
Ms m/z(ESI):407.3[M+H + ]。
The third step: 3- (benzylamino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) propanamide hydrochloride (Compound 31)
3-(benzylamino)-N-(6-oxaspiro[4.5]decan-9-yl)-N-(p-tolyl)propanamide hydrochloride
Figure BDA0001714822470001132
3- (benzylamino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) propanamide (31B) (0.2g, 0.492mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give 3- (benzylamino) -N- (6-oxaspiro [4.5] decan-9-yl) -N- (p-tolyl) propanamide hydrochloride (compound 31) as a white solid (0.21 g, yield: 96%).
Ms m/z(ESI):407.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ7.59-7.38(m,5H),7.31(d,2H),7.07(d,2H),4.93-4.82(m,1H),4.19(s,2H),3.74-3.61(m,2H),3.18(t,2H),2.46-2.27(m,5H),2.03(d,1H),1.72-1.54(m,9H),1.40-1.28(m,2H).
Example 32
(R) -N- ((4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 32)
(R)-N-((4-ethynylthiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470001141
The first step is as follows: 4- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (32B)
4-((trimethylsilyl)ethynyl)thiophene-2-carbaldehyde
Figure BDA0001714822470001151
4-bromothiophene-2-carbaldehyde (32A) (2g, 10.47mmol) and trimethylsilyne (1.54g, 15.70mmol) were dissolved in tetrahydrofuran (15 mL) and triethylamine (15 mL), and trans-bis (triphenylphosphine) palladium (II) dichloride (0.367 mg, 0.52mmol) and cuprous iodide (0.199mg, 1.05mmol) were added to the reaction under nitrogen, and the temperature was raised to 60 ℃ for 2 hours. The reaction solution was filtered, and the organic phase was concentrated, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 50) to give 4- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (32B) (2 g, yield: 91.7%) as an oily liquid.
1 H NMR(400MHz,CDCl 3 )δ9.88(d,1H),7.85-7.68(m,2H),0.25(m,9H).
The second step is that: 4-ethynylthiophene-2-carbaldehyde (32C)
4-ethynylthiophene-2-carbaldehyde
Figure BDA0001714822470001152
4- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (32B) (2g, 9.6 mmol) was dissolved in methanol (20 mL), and potassium carbonate (2g, 14mmol) was added to the reaction, and the reaction was allowed to proceed at room temperature for 1 hour after the addition. The reaction solution was quenched with water (50 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 2), the organic phases were combined, washed with a saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 20) to obtain 4-ethynylthiophene-2-carbaldehyde (32C) as a yellow solid (1.2 g, yield: 92%).
1 H NMR(400MHz,CDCl 3 )δ9.90(d,1H),7.99-7.62(m,2H),3.10(s,1H).
The third step: (R) -N- ((4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (32D)
(R)-N-((4-ethynylthiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470001161
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.3g, 1.15mmol) was dissolved in dichloromethane (10 mL), and sodium sulfate (0.818g, 5.76mmol) and 4-ethynylthiophene-2-carbaldehyde (32C) (0.235g, 1.73mmol) were added to the reaction and reacted at room temperature overnight. Sodium borohydride (0.07g, 1.73mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (30 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) =50:1 to 20) to give (R) -N- ((4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (32D) as a yellow oily liquid (0.31 g, yield: 70%).
Ms m/z(ESI):381.2[M+H + ];
The fourth step: (R) -N- ((4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 32)
(R)-N-((4-ethynylthiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470001162
(R) -N- ((4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (32D) (0.3 g, 0.788mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -N- ((4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 32) as a white solid (0.32 g, yield: 97%).
Ms m/z(ESI):381.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.87(d,1H),8.64(t,1H),8.19(t,1H),8.11-7.97(m,1H),7.69(s,1H),7.29(s,1H),4.31(s,2H),3.89-3.80(m,1H),3.72(ddd,1H),3.50(s,1H),3.05(td,1H),2.64-2.43(m,3H),2.41-2.28(m,1H),2.28-2.12(m,2H),2.02-1.83(m,2H),1.70-1.51(m,5H),1.27-1.17(m,1H),0.90-0.81(m,1H).
Example 33
N- ((3-Methoxythien-2-yl) methyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine hydrochloride (Compound 33)
N-((3-methoxythiophen-2-yl)methyl)-2-(10-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-10-yl)ethanamine hydrochloride
Figure BDA0001714822470001171
The first step is as follows: 2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine (33B)
2-(10-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-10-yl)ethanamine
Figure BDA0001714822470001172
Lithium aluminum hydride (0.56g, 15.0 mmol) was dissolved in tetrahydrofuran (30 mL), and the temperature was reduced to 0 ℃ to add 2- (10- (pyridin-2-yl) -6-oxaspiro [4.5] undecan-10-yl) acetonitrile (33A) (1.08g, 4.0 mmol) in tetrahydrofuran (10 mL) to the reaction, followed by reaction at room temperature overnight. The reaction was cooled to 0 ℃, quenched with water (0.6 mL), sodium hydroxide solution (10%, 1.2 mL) and water (1.2 mL), dried with anhydrous sodium sulfate, stirred for 20 minutes, the solid filtered and washed with tetrahydrofuran (20 mL × 3). The combined organic phases were concentrated to give 2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine (33B) (0.8 g, yield: 72.5%).
Ms m/z(ESI):275.2[M+H + ];
The second step is that: n- ((3-Methoxythiophen-2-yl) methyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine (33C)
N-((3-methoxythiophen-2-yl)methyl)-2-(10-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-10-yl)ethanamine
Figure BDA0001714822470001181
2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine (33B) (0.5g, 1.82mmol) was dissolved in methylene chloride (15 mL), and sodium sulfate (1.3g, 7.5mmol) and 3-methoxythiophene-2-carboxaldehyde (0.35g, 2.46mmol) were added to the reaction, followed by reaction at room temperature overnight. Sodium borohydride (0.14g, 3.64mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and after the crude product was subjected to column chromatography (dichloromethane/methanol (v/v) =50
Ms m/z(ESI):401.2[M+H + ];
The third step: n- ((3-Methoxythien-2-yl) methyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine hydrochloride (Compound 33)
N-((3-methoxythiophen-2-yl)methyl)-2-(10-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-10-yl)ethanamine hydrochloride
Figure BDA0001714822470001182
N- ((3-Methoxythien-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) ethylamine (33B) (0.5g, 1.25mmol) was dissolved in ethyl acetate (3 mL), a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added, and the reaction was stirred at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give N- ((3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-9-yl) ethylamine hydrochloride (Compound 33) (0.5 g, 91.6% yield) as an off-white solid.
Ms m/z(ESI):401.2[M+H + ];
1 H NMR(400MHz,DMSO-d 6 )δ8.80(s,1H),8.59-8.58(d,1H),7.89(s,1H),7.57-7.56(d,1H),7.35(s,1H),7.05-7.04(d,1H),3.78(s,3H),3.64-3.61(m,2H),2.67(m,2H),2.28-2.27(m,4H),1.91-1.83(m,3H),1.77-1.47(m,12H).
Example 34
N- (3-chlorophenyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine hydrochloride (Compound 34)
N-(3-chlorobenzyl)-2-(10-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-10-yl)ethanaminehydrochloride
Figure BDA0001714822470001191
The first step is as follows: n- (3-chlorophenyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine (34A)
N-(3-chlorobenzyl)-2-(10-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-10-yl)ethanamine
Figure BDA0001714822470001192
2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine (33B) (0.3 g, 1.09mmol) was dissolved in methylene chloride (15 mL), and sodium sulfate (1.3 g,7.5 mmol) and 3-methoxythiophene-2-carboxaldehyde (0.23g, 1.64mmol) were added to the reaction and reacted overnight at room temperature. Sodium borohydride (0.083g, 2.18mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and after the crude product was subjected to column chromatography (dichloromethane/methanol (v/v) =50
Ms m/z(ESI):399.2[M+H + ];
The second step is that: n- (3-chlorophenyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine hydrochloride (Compound 34)
N-(3-chlorobenzyl)-2-(10-(pyridin-2-yl)-6-oxaspiro[4.6]undecan-10-yl)ethanaminehydrochloride
Figure BDA0001714822470001201
N- (3-chlorophenyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine (34A) (0.23g, 0.57mmol) was dissolved in ethyl acetate (3 mL), a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added, and the reaction was stirred at room temperature for 0.5 hour. The reaction was directly spun dry to give N- (3-chlorophenyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine hydrochloride (compound 34) (0.225 g, 97.8% yield) as an off-white solid.
Ms m/z(ESI):399.2[M+H + ];
1 H NMR(400MHz,DMSO-d 6 )δ8.79-8.77(d,1H),8.45-8.44(m,1H),8.11-8.09(d,1H),7.86(s,1H),7.54(s,1H),7.44-7.40(m,3H),3.78(s,3H),3.73-3.66(m,1H),3.63-3.61(m,1H),3.03-3.01(m,1H),2.61-2.56(m,4H),2.24-2.23(m,2H),1.99-1.93(m,2H),1.92-1.91(m,3H)1.60-1.45(m,6H).
Resolution of the Compound N- (3-chlorophenyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine hydrochloride (Compound 34)
(compound 34) (220 mg) was taken for resolution, and after separation, two optical isomers, compound (R) -N- (3-chlorophenyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine (compound 34A-1) (retention time: 5.36min,59.68mg, oily liquid, ee% = 100%), compound (S) -N- (3-chlorophenyl) -2- (10- (pyridin-2-yl) -6-oxaspiro [4.6] undecan-10-yl) ethylamine (compound 34A-2) (retention time: 6.01min,70.27mg, oily liquid, ee% = 100%), were obtained.
Splitting conditions are as follows:
MG II preparatory SFC (SFC-15); column ChiralPak AD,250 × 30mm i.d.,5 μm. Mobile phase a: carbon dioxide, B: methanol (0.1% ammonia); gradient B30%; the flow rate is 50mL/min; back pressure is 100bar; the column temperature is 38 ℃; the wavelength is 220nm; the period is 3min; sample preparation, compound is dissolved in methanol to make 7mg/ml; injection 2 ml/needle.
Compound 34A-1 and compound 34A-2 can be obtained by a salt-forming method of compound 34 to obtain compound 34-1 and compound 34-2:
compound 34-1:
Ms m/z(ESI):399.2[M+H + ];
1 H NMR(400MHz,DMSO-d 6 )δ8.79-8.77(d,1H),8.45-8.44(m,1H),8.11-8.09(d,1H),7.86(s,1H),7.54(s,1H),7.44-7.40(m,3H),3.78(s,3H),3.73-3.66(m,1H),3.63-3.61(m,1H),3.03-3.01(m,1H),2.61-2.56(m,4H),2.24-2.23(m,2H),1.99-1.93(m,2H),1.92-1.91(m,3H)1.60-1.45(m,6H).
compound 34-2:
Ms m/z(ESI):399.2[M+H + ];
1 H NMR(400MHz,DMSO-d 6 )δ8.78-8.76(d,1H),8.43-8.41(m,1H),8.09-8.07(d,1H),7.84(s,1H),7.54(s,1H),7.45-7.40(m,3H),4.12(s,3H),3.73-3.66(m,1H),3.64-3.60(m,1H),3.03-3.01(m,1H),2.61-2.56(m,4H),2.24-2.23(m,2H),2.10–2.05(m,2H),1.97-1.92(m,3H),1.59-1.45(m,6H).
example 35
(R) -N- (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amine) methyl) thiophen-3-yl) acetamide hydrochloride (Compound 35)
(R)-N-(2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)acetamide hydrochloride
Figure BDA0001714822470001211
The first step is as follows: 3-Acetylaminothiophene-2-carboxylic acid methyl ester (35B)
methyl 3-acetamidothiophene-2-carboxylate
Figure BDA0001714822470001221
Methyl 3-aminothiophene-2-carboxylate (35A) (10g, 63.617mmol) was dissolved in methylene chloride (100 mL), and pyridine (10.06g, 127.23mmol) and acetic anhydride (7.794g, 76.341mmol) were added successively with stirring, and after completion of the addition, the mixture was stirred at room temperature overnight. The reaction mixture was added with a saturated ammonium chloride solution (100 mL) and separated, the aqueous phase was extracted with dichloromethane (20 mL. Times.2), the organic phases were combined and washed with 1N hydrochloric acid and a saturated saline solution (20 mL. Times.2) in this order, the organic phase was dried over anhydrous sodium sulfate, and the mixture was filtered and evaporated to dryness to give methyl 3-acetamidothiophene 2-carboxylate (35B) (12 g, yield: 94.68%) as a yellow solid product.
Ms.m/z(ESI):200.1[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ10.14(s,1H),8.12(d,1H),7.46-7.45(d,1H),3.89(s,3H),2.23(s,3H).
The second step is that: n- (2- (hydroxymethyl) thiophen-3-yl) acetamide (35C)
N-(2-(hydroxymethyl)thiophen-3-yl)acetamide
Figure BDA0001714822470001222
The compound lithium aluminum hydride (0.382g, 10.04mmol) and tetrahydrofuran (25 mL) were sequentially charged into a 100mL three-necked reaction flask, and a solution of methyl 3-acetamidothiophene 2-carboxylate (35B) (1.0 g, 5.019mmol) in tetrahydrofuran (5 mL) was added dropwise with stirring at room temperature, and the reaction was allowed to proceed overnight at room temperature. The reaction solution was cooled to 0 ℃ or lower with an ice salt bath, and water (0.6 mL), a 20% sodium hydroxide solution (1.2 mL), water (0.6 mL) and celite were added to the reaction solution in this order while stirring, and the resulting mixture was washed with tetrahydrofuran (10 mL. Times.3) and filtered, and the filtrate was dried over anhydrous sodium sulfate, filtered and concentrated to dryness to give N- (2- (hydroxymethyl) thiophen-3-yl) acetamide (35C) (0.8 g, yield: 90%) as a yellow oily product.
Ms m/z(ESI):194.0[M+Na + ];
1 H NMR(400MHz,DMSO-d 6 )δ9.47(s,1H),7.31-7.29(d,1H),7.17(d,1H),5.30(t,1H),4.54-4.52(d,2H),2.01(s,3H).
The third step: n- (2-Methoxymethylenethiophene-3-yl) acetamide (35D)
N-(2-formylthiophen-3-yl)acetamide
Figure BDA0001714822470001231
The compound N- (2- (hydroxymethyl) thiophen-3-yl) acetamide (35C) (0.58g, 3.39mmol) was dissolved in dichloromethane (20 mL), stirred and cooled to 0 deg.C, and a solution of dess-martin oxidant (0.772g, 1.82mmol) was added, after which the reaction was completed at room temperature for 4 hours. To the reaction solution was added a saturated thiosulfate solution (50 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined and washed with a saturated carbonic acid inner solution (50 mL × 1), the organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to give a yellow solid product, N- (2-formol thiophen-3-yl) acetamide (35D) (0.40 g, yield: 69.8%).
The fourth step: (R) -N- (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amine) methyl) thiophen-3-yl) acetamide (35E)
(R)-N-(2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)acetamide
Figure BDA0001714822470001232
The compound N- (2-Methoxymethylthien-3-yl) acetamide (35D) (0.422g, 2.50mmol), (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.50g, 1.92mmol) was dissolved in dichloromethane (20 mL), and anhydrous sodium sulfate (1.36g, 9.60mmol) was added and stirred at room temperature overnight. Sodium borohydride (0.109g, 2.88mmol) was added thereto and stirred at room temperature for 1 hour, and 3 ml of anhydrous methanol was added thereto and stirred for 2 hours. Water (20 mL) was added to the reaction solution, extraction was performed with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL × 1), the organic phase was dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, EA/PE =2/1-3/1 to give (R) -N- (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amine) methyl) thiophen-3-yl) acetamide (35E) (400 mg, yield: 50.4%) as a colorless oily product.
Ms.m/z(ESI):414.2[M+H + ];
The fifth step: (R) -N- (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amine) methyl) thiophen-3-yl) acetamide hydrochloride (Compound 35)
(R)-N-(2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)acetamide hydrochloride
Figure BDA0001714822470001241
The compound (R) -N- (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amine) methyl) thiophen-3-yl) acetamide (35E) (0.400g, 0.968mmol) was dissolved in ethyl acetate (5 mL), and an ethyl acetate solution of hydrogen chloride (0.968mL, 0.968mmol) was added and the mixture was stirred at room temperature for 2 hours. The reaction solution was evaporated to dryness to give (R) -N- (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amine) methyl) thiophen-3-yl) acetamide hydrochloride (compound 35) as a yellow solid (420 mg, yield: 96.5%).
Ms.m/z(ESI):414.2[M+H + -HCl];
1 H NMR(400MHz,CD 3 OD)δ8.89(dd,1H),8.67(td,1H),8.23(d,1H),8.12–8.05(m,1H),7.52(d,1H),6.99–6.94(m,1H),4.24–4.13(m,2H),3.87(dt,1H),3.73(ddd,1H),3.05(td,1H),2.59(td,1H),2.53–2.42(m,2H),2.40–2.24(m,2H),2.21(d,1H),2.15(s,3H),2.05–1.96(m,2H),1.93–1.44(m,7H).
Example 36
5- (2- ((3-chlorobenzyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 36)
5-(2-((3-chlorobenzyl)amino)ethyl)-1-methyl-5-(pyridin-2-yl)piperidin-2-one hydrochloride
Figure BDA0001714822470001242
Figure BDA0001714822470001251
The first step is as follows: 3- (1, 3-dioxo-2-yl) -2- (pyridin-2-yl) propionitrile (36B)
3-(1,3-dioxolan-2-yl)-2-(pyridin-2-yl)propanenitrile
Figure BDA0001714822470001252
2- (pyridin-2-yl) acetonitrile (36A) (2.26g, 19.1mmol) was dissolved in tetrahydrofuran (30 ml), and sodium hydride (0.5g, 23mmol) was added to the solution, and after 2 hours of reaction, 2- (bromomethyl) -1, 3-dioxolane (3.51g, 21mmol) was reacted at room temperature for 24 hours. Cooling, addition of water (150 mL), extraction with ethyl acetate (50 mL × 4), washing with a saturated saline solution (150 mL × 3), drying over anhydrous sodium sulfate, filtration, concentration of the filtrate, and purification by column chromatography (n-hexane/ethyl acetate = 10) gave the product 3- (1, 3-dioxo-2-yl) -2- (pyridin-2-yl) propionitrile (36B) (1 g, yield 30%) as a yellow oily substance,
Ms m/z(ESI):205.1[M+H + ]。
The second step is that: methyl 4-cyano-5- (1, 3-dioxolan-2-yl) -4- (pyridin-2-yl) pentanoate (36C)
methyl 4-cyano-5-(1,3-dioxolan-2-yl)-4-(pyridin-2-yl)pentanoate
Figure BDA0001714822470001261
3- (1, 3-dioxo-2-yl) -2- (pyridin-2-yl) propionitrile (36B) (0.5g, 2mmol) was dissolved in dichloromethane (20 mL), 1, 5-diazabicyclo [5.4.0] undec-5-ene (0.6 g, 4mmol) and methyl acrylate (0.4g, 4mmol) were added, and the reaction was continued for 15h after completion of the addition. The reaction was concentrated and purified by column chromatography (petroleum ether/ethyl acetate =5: 1) to give methyl 4-cyano-5- (1, 3-dioxolan-2-yl) -4- (pyridin-2-yl) pentanoate (36C) as a yellow oily product (0.7 g, 86% yield).
Ms m/z(ESI):291.1[M+H + ];
The third step: 5- ((1, 3-Dioxolan-2-yl) methyl) -5- (pyridin-2-yl) piperidin-2-one (36D)
5-((1,3-dioxolan-2-yl)methyl)-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470001262
4-cyano-5- (1, 3-dioxolan-2-yl) -4- (pyridin-2-yl) pentanoate (36C) (0.23g, 0.8mmol) was dissolved in methanol (10 ml), raney nickel (0.047 g, 0.08mmol) was added and reacted at 60 ℃ for 10h under a hydrogen balloon atmosphere. 15mL of dichloromethane was added to clear the reaction solution, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated and column chromatographed (dichloromethane/methanol =30: 1) to isolate and purify 5- ((1, 3-dioxolan-2-yl) methyl) -5- (pyridin-2-yl) piperidin-2-one (36D) (0.19g, 60%) as a yellow oily product.
Ms m/z(ESI):263.1[M+H + ]。
The fourth step: 5- ((1, 3-Dioxolan-2-yl) methyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one (36E)
5-((1,3-dioxolan-2-yl)methyl)-1-methyl-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470001263
At room temperature, 5- ((1, 3-dioxolan-2-yl) methyl) -5- (pyridin-2-yl) piperidin-2-one (36D) (0.3 g, 1mmol) was dissolved in tetrahydrofuran (15 mL), and at 0 ℃, sodium hydride (0.04g, 2mmol), methyl iodide (0.2g, 2mmol) were added, after the addition was completed, the reaction was continued for 2h, 2mL of water was added to the reaction solution, anhydrous sodium sulfate was added and dried, the filtrate was filtered, the solvent was removed by concentration under reduced pressure, and column chromatography (dichloromethane/methanol =30
Ms m/z(ESI):277.2[M+H + ]。
The fifth step: 2- (1-methyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde (36F)
2-(1-methyl-6-oxo-3-(pyridin-2-yl)piperidin-3-yl)acetaldehyde
Figure BDA0001714822470001271
5- ((1, 3-Dioxolan-2-yl) methyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one (36E) (0.3g, 1.1mmol) was dissolved in tetrahydrofuran (5 mL) and concentrated hydrochloric acid (8 mL) at room temperature, stirred overnight at room temperature, and the reaction mixture was concentrated to give 2- (1-methyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde (36F) (0.26g, 100%) as a black oily product, which was directly charged into the next step.
Ms m/z(ESI):233.1[M+H + ]。
And a sixth step: 5- (2- ((3-chlorobenzyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one (36J)
5-(2-((3-chlorobenzyl)amino)ethyl)-1-methyl-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470001272
2- (1-methyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde (36F) (0.14g, 0.6 mmol) was dissolved in methylene chloride (10 ml), and m-chlorobenzylamine (0.11g, 0.78mmol), anhydrous sodium sulfate (0.6 g) were added thereto in this order. After reaction at room temperature overnight, sodium borohydride (0.036g, 0.9mmol) was added, stirring was continued for 2h, water (20 mL) was added, extraction was performed with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated brine solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (dichloromethane/methanol =30: 1) was performed to isolate and purify the product 5- (2- ((3-chlorobenzyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one (36J) (0.03g, 10%) as a pale yellow oil.
Ms m/z(ESI):358.2[M+H + ]。
The seventh step: 5- (2- ((3-chlorobenzyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 36)
5-(2-((3-chlorobenzyl)amino)ethyl)-1-methyl-5-(pyridin-2-yl)piperidin-2-one hydrochloride
Figure BDA0001714822470001281
5- (2- ((3-chlorobenzyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one 36J (0.03g, 0.2mmol) was dissolved in EA (5 mL) at room temperature, ethyl hydrogen chloride solution (2mL, 4N) was added at 0 deg.C, the reaction was continued for 0.5h, and the solvent was removed under reduced pressure to give 5- (2- ((3-chlorobenzyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 36) as a white solid (0.03g, 96%).
Ms m/z(ESI):358.2[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.93(d,1H),8.64(t,1H),8.08(dd,2H),7.57(s,1H),7.43(m,3H),3.85(d,1H),3.31(s,2H),3.05(d,2H),3.01(m,1H),2.85(td,1H),2.65(m,1H),2.52(m,2H),2.36(ddd,2H),2.12(m,1H),2.00(d,3H)。
Example 37
(2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methanolic acid hydrochloride (Compound 37)
(2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)methanolhydrochloride
Figure BDA0001714822470001282
Figure BDA0001714822470001291
The first step is as follows: 2- (Thien-3-ylmethoxy) tetrahydro-2H-pyran (37B)
2-(thiophen-3-ylmethoxy)tetrahydro-2H-pyran
Figure BDA0001714822470001292
Thiophen-3-ylmethanol (28A) (5g, 60mmol) was dissolved in tetrahydrofuran (40 mL), and dihydropyran (5g, 60mmol) and a hydrochloric acid solution (0.5ml, 3n) were sequentially added, reacted for 3H, cooled, added with water (50 mL), extracted with dichloromethane (50 mL × 4), washed with a saturated saline solution (150 mL × 3), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and subjected to column chromatography separation and purification (n-hexane/ethyl acetate =10 1) to obtain 2- (thiophen-3-ylmethoxy) tetrahydro-2H-pyran (37B) (11 g, yield 90%) as a pale yellow liquid product.
1 H NMR(400MHz,CDCl 3 ):δ7.30–7.26(m,2H),7.23–7.11(m,1H),7.10–7.08(m,1H),4.75(t,2H),4.68(d,2H),4.56(d,2H),3.91–3.88(m,1H),3.57-3.51(m,1H),1.72–1.43(m,8H).
The second step is that: 3- (((tetrahydro-2H-pyran-2-yl) oxy) methyl) thiophene-2-aldehyde (37C)
3-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)thiophene-2-carbaldehyde
Figure BDA0001714822470001293
2- (thien-3-ylmethoxy) tetrahydro-2H-pyran 37B (1g, 5 mmol) was dissolved in tetrahydrofuran (10 mL), the reaction was cooled to-78 deg.C, n-butyllithium (0.354g, 5.54mmol) was added, the reaction was raised to zero degrees for 0.5H after completion of the addition, dimethylformamide (0.55g, 7.58mmol) was added and the reaction was continued for 2H. Ammonium chloride solution (20 mL) was added, extraction was performed with ethyl acetate (20 mL × 3), the organic phases were combined, washed with saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and subjected to column chromatography separation and purification (n-hexane/ethyl acetate =5: 1) to obtain a pale yellow liquid product, 3- (((tetrahydro-2H-pyran-2-yl) oxy) methyl) thiophene-2-aldehyde (37C) (0.4 g, yield 40%).
1 H NMR(400MHz,CDCl 3 ):δ10.15(d,1H),7.68–7.66(m,1H),7.21(d,1H),5.08-4.85(m,1H),4.74(t,1H),4.72(s,1H),3.87-3.84(m,1H),3.57-3.53(m,1H),1.73-1.52(m,9H)。
The third step: (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) -N- ((3- (((tetrahydro-2H-pyran-2-yl) oxy) methyl) thiophen-2-yl) methyl) ethanamine (37D)
(R)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)-N-((3-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)thiophen-2-yl)methyl)ethanamine
Figure BDA0001714822470001301
3- (((tetrahydro-2H-pyran-2-yl) oxy) methyl) thiophene-2-aldehyde 37C (0.33g, 1.5 mmol) was dissolved in dichloromethane (10 ml), to which was added in turn (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.38g, 1.5 mmol), anhydrous sodium sulfate (1.7 g). After an overnight reaction at room temperature, sodium borohydride (0.083g, 2.2mmol) was added, stirring was continued for 2H, water (20 mL) was added, extraction was performed with dichloromethane (20 mL × 3), the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (dichloromethane/methanol = 30).
Ms m/z(ESI):471.3[M+H + ].
The fourth step: (R) - (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methanol (37E)
(R)-(2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)methanol
Figure BDA0001714822470001302
(R) -raw material 2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) -N- ((3- (((tetrahydro-2H-pyran-2-yl) oxy) methyl) thiophen-2-yl) methyl) ethylamine (37D) (0.3g, 0.6 mmol) was added to methanol (10 mL), hydrochloric acid (1ml, 5n) was added, reacted at room temperature for 1H, water (20 mL) was added, extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and (dichloromethane/methanol = 30) to obtain (R) - (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) amino) methyl) thiophen-3-yl) methanol (37E) (019g, 80%) as a yellow liquid.
Ms m/z(ESI):387.2[M+H + ].
The fifth step: (R) - (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methanolic hydrochloride (Compound 37)
(R)-(2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)methanolhydrochloride
Figure BDA0001714822470001311
(R) - (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) amino) methyl) thiophen-3-yl) methanol (37E) (0.19g, 0.49mmol) was dissolved in ethyl acetate (5 mL) and the solution was then ethyl hydrogen chloride (1mL, 4N) at 0 deg.C, followed by reaction for 0.5h and removal of the solvent under reduced pressure to give (R) - (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) amino) methyl) thiophen-3-yl) methanolate (Compound 37) (0.19g, 96%) as a white solid at room temperature.
Ms m/z(ESI):387.2[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.87(dd,1H)8.63(td,1H),8.19(d,1H),8.04(m,1H),7.46(d,1H),7.04(d,1H),4.68(s,2H),4.38(s,2H),3.77(m,2H),3.31(s,3H),3.05(td,1H),2.54(m,3H),2.34(td,1H),2.21(m,2H),1.93(m,2H),1.61(m,4H)。
Example 38
2- ((3-chlorophenyl) amine) -N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide hydrochloride (Compound 38)
2-((3-chlorobenzyl)amino)-N-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetamidehydrochloride
Figure BDA0001714822470001321
The first step is as follows: 6-oxaspiro [4.5] decane-9-cyano (38B)
6-oxaspiro[4.5]decane-9-carbonitrile
Figure BDA0001714822470001322
6-oxaspiro [4.5] decan-9-one (38A) (15.7g, 102mmol) was dissolved in dimethyl glycol ether (500 mL) in a three-necked flask, p-toluenesulfonylmethylisonitrile (45.7g, 234mmol) was added, the temperature was reduced to 0 ℃ or below, ethanol (10.8g, 234mmol) was added dropwise to the reaction mixture, potassium tert-butoxide (40.0g, 356mmol) was added to the reaction mixture in portions, the exotherm was vigorous, and after the addition, the temperature was raised to 60 ℃ for 5 hours. The reaction was poured into a mixture of 100g of ice (100 mL of water). The product was extracted with methyl tert-butyl ether (100 mL. Times.3), washed with brine (100 mL), dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/40-1/20) by column flushing and concentrated to dryness to give 6-oxaspiro [4.5] decane-9-cyano (38B) (10 g, yield 59.4%) as a pale yellow oil.
LCMS m/z=166.1[M+H + ].
The second step: 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-cyano (38C)
9-(pyridin-2-yl)-6-oxaspiro[4.5]decane-9-carbonitrile
Figure BDA0001714822470001331
6-Oxaspiro [4.5] decane-9-cyano (38B) (6.0g, 36mmol) was dissolved in a single-neck flask with tetrahydrofuran (60 mL), 2-fluoropyridine (3.5g, 36mmol) was added, the temperature was reduced to-70 ℃ or lower, sodium bis (trimethylsilyl) amide (25.4mL, 50.8mmol) was slowly added dropwise to the reaction mixture, and after completion of the addition, the mixture was stirred for 10 minutes, and the mixture was allowed to warm to room temperature for reaction for 3 hours. After cooling to about 0 ℃, saturated aqueous ammonium chloride solution was added dropwise, water (200 mL) was added, the mixture was extracted with ethyl acetate (100 mL × 2), the organic phases were combined, the organic phase was washed with water (200 mL), saturated sodium chloride solution (200 mL), dried, filtered and concentrated to give 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-cyano (38C) as a yellow oil (7.18 g, yield 81.6%).
LCMS m/z=243.1[M+H + ].
The third step: 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-carboxamide (38D)
9-(pyridin-2-yl)-6-oxaspiro[4.5]decane-9-carboxamide
Figure BDA0001714822470001332
9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-cyano (38C) (0.50g, 2.06mmol), potassium carbonate (0.86g, 6.19mmol) were dissolved in dimethyl sulfoxide (10 mL) in a single-neck flask, the temperature was reduced to 0 ℃, hydrogen peroxide (1.17g, 10.32mmol) was added dropwise to the reaction mixture, and the mixture was naturally warmed to room temperature and stirred for 1 hour after completion of addition. Water (20 mL) was added, extraction was performed with ethyl acetate (20 mL. Times.3), the organic phases were combined, dried over anhydrous sodium sulfate was added, filtered and concentrated, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/40-1/10) using a plug column, and concentrated to dryness to give 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-carboxamide (38D) (0.54 g, yield 100%) as a pale yellow oil.
LCMS m/z=261.1[M+H + ].
The fourth step: methyl (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) carbamate (38E)
methyl(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)carbamate
Figure BDA0001714822470001341
9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-carboxamide (38D) (0.536 g, 2.06mmol) was dissolved in methanol (10 mL), potassium hydroxide (0.231g, 4.12mmol) was added thereto and stirred well, and iodobenzene acetate (0.995g, 3.09mmol) was added to the reaction mixture and reacted at room temperature for half an hour. Water (50 mL) was added, extracted with ethyl acetate (50 mL. Times.3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and concentrated to dryness to give methyl (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) carbamate (38E) as a yellow oil (0.6 g, 100% yield).
LCMS m/z=291.1[M+H + ].
The fifth step: 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-amino (38F)
9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-amine
Figure BDA0001714822470001342
Methyl (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) carbamate (38E) (7.76g, 26.7 mmol), 3N aqueous sodium hydroxide (28.5mL, 85.5mmol), and ethanol (70 mL) were added to a microwave tube and reacted at 150 ℃ for half an hour in a microwave reactor. The solvent was dried by rotation, purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/40-1/5), and concentrated to dryness to give 9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-amino (38F) as a yellow oil (3.91 g, 63% yield).
LCMS m/z=233.1[M+H + ].
And a sixth step: 2-chloro-N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38G)
2-chloro-N-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetamide
Figure BDA0001714822470001343
9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-amino (38F) (1.0g, 4.3mmol) was dissolved in methylene chloride (10 mL), triethylamine (1.3g, 12.9mmol) was added thereto, the mixture was cooled to 0 ℃ and chloroacetyl chloride (0.58g, 5.2mmol) was added dropwise to the reaction mixture, and the reaction was completed for 3 hours. The solvent was dried by rotation, purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/40-1/5), and concentrated to dryness to give 2-chloro-N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38G) (0.8G, yield 60%) as a yellow solid.
1 H NMR(400MHz,CDCl 3 )δ8.57-8.56(d,1H),7.71-7.67(dt,1H),7.44-7.42(d,1H),7.19-7.16(t,1H),7.06(s,1H),3.98(s,2H),3.85-3.82(m,2H),2.35-2.28(m,4H),1.83-1.39(m,8H).
The seventh step: 2-Azide-N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38H)
2-azido-N-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetamide
Figure BDA0001714822470001351
2-chloro-N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38G) (0.8g, 2.6 mmol) was dissolved in N, N-dimethylformamide (10 mL), and sodium azide (0.5g, 7.8mmol) was added to the solution to react at room temperature for 2 hours. Water (20 mL) was added, extraction was performed with methyl t-butyl ether (20 mL. Times.3), the organic phases were combined, washed with saturated brine (30 mL. Times.1), and the solvent was dried by spinning to give 2-azido-N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38H) (0.62 g, 76% yield) as an orange solid.
Eighth step: 2-amino-N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38I)
2-amino-N-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetamide
Figure BDA0001714822470001352
After 2-azido-N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38H) (0.62g, 2.0 mmol) was dissolved in tetrahydrofuran (10 mL), triphenylphosphine (0.77g, 2.9 mmol) was added thereto, and the reaction mixture was allowed to exotherm and cooled naturally to room temperature for 2 hours. The solvent was dried by rotation, purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/20-1/2), and concentrated to dryness to give 2-amino-N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38I) (0.54 g, yield 95%) as a pale yellow oil.
LCMS m/z=290.2[M+H + ].
The ninth step: 2- ((3-chlorophenyl) amino) -N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38J)
2-((3-chlorobenzyl)amino)-N-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetamide
Figure BDA0001714822470001353
2-amino-N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38I) (0.30g, 1.04mmol), 3-chlorobenzaldehyde (0.22g, 1.55mmol) were dissolved in dichloromethane (10 mL), magnesium sulfate (0.62g, 5.18mmol) was added, stirring was continued overnight at room temperature, sodium borohydride (59mg, 1.55mmol) was added, stirring was continued at room temperature for 1 hour, and anhydrous methanol (3 mL) was added and stirring was continued for 2 hours. To the reaction solution was added water (20 mL), extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL), the organic phase was dried over colorless sodium sulfate, filtered and evaporated to dryness, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/10-1/1) punch column and concentrated to dryness to give 2- ((3-chlorophenyl) amino) -N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38J) (0.3 g, yield 70%) as a pale yellow oil.
LCMS m/z=414.2[M+H + ].
The tenth step: 2- ((3-chlorophenyl) amino) -N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide hydrochloride (Compound 38)
2-((3-chlorobenzyl)amino)-N-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetamidehydrochloride
Figure BDA0001714822470001361
N- (2- (6-oxaspiro [4.5] decan-9-yl) pyridin-3-yl) -2- ((3-chlorophenyl) amino) acetamide (38J) (0.26g, 0.63mmol) was dissolved in ethyl acetate (10 mL) in a one-neck flask, a solution of hydrogen chloride in ethyl acetate (1 mL,1.7 mol/L) was added dropwise, a solid precipitated, and the reaction was stirred for 30 minutes. The solvent was dried by evaporation to give 2- ((3-chlorophenyl) amino) -N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide hydrochloride (compound 38) as a white solid (0.27 g, 95% yield).
LCMS m/z=414.2[M+H + ].
1 H NMR(400MHz,CD 3 OD)δ8.74-8.73(dd,1H),8.55(dt,1H),8.17-8.15(d,1H),7.94-7.43(t,1H),7.53(s,1H),7.49-7.40(m,3H),4.23-4.22(d,2H),4.08-4.04(d,1H),4.01-3.99(m,1H),3.93-3.89(d,1H),3.82-3.78(m,1H),2.68-2.47(dd,2H),2.25-2.10(m,3H),176-1.57(m,7H).
Example 39
2- (((3-Methylthion-2-yl) methyl) amino) -N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide hydrochloride (Compound 39)
2-(((3-methoxythiophen-2-yl)methyl)amino)-N-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetamide hydrochloride
Figure BDA0001714822470001371
The first step is as follows: 2- (((3-methylthiophen-2-yl) methyl) amino) -N- (9- (pyridin-2-yl) -6-oxaspiro [ 4.5)]Decan-9-yl) acetamide (39A)
2-(((3-methoxythiophen-2-yl)methyl)amino)-N-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetamide
Figure BDA0001714822470001372
2-amino-N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (38I) (0.30g, 1.04mmol), 3-methoxythiophene-2-carbaldehyde (0.22g, 1.55mmol) were dissolved in dichloromethane (10 mL), magnesium sulfate (0.62g, 5.18mmol) was added thereto, the mixture was stirred at room temperature overnight, sodium borohydride (59mg, 1.55mmol) was added thereto, the mixture was stirred at room temperature for 1 hour, and anhydrous methanol (3 mL) was added thereto and the mixture was stirred for 2 hours. Water (20 mL) was added to the reaction solution, extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL), the organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to dryness, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/10-1/1) cartridge and concentrated to dryness to give 2- (((3-methylthiophen-2-yl) methyl) amino) -N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (39A) as a pale yellow oil (0.20 g, 50% yield).
LCMS m/z=416.3[M+H + ].
The second step is that: 2- (((3-Methylthion-2-yl) methyl) amino) -N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide hydrochloride (Compound 39)
2-(((3-methoxythiophen-2-yl)methyl)amino)-N-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)acetamide hydrochloride
Figure BDA0001714822470001381
2- (((3-Methylthioen-2-yl) methyl) amino) -N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide (39A) (0.20g, 0.26mmol) was dissolved in ethyl acetate (10 mL), a solution of hydrochloric acid in ethyl acetate (1 mL, 1.7mol/L) was added dropwise, a solid precipitated, stirred for half an hour, and concentrated to dryness to give 2- (((3-Methylthioen-2-yl) methyl) amino) -N- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) acetamide hydrochloride (Compound 39) (0.2 g, 92% yield) as a light brown solid.
LCMS m/z=416.3[M+H + ].
1 H NMR(400MHz,CD 3 OD)δ8.77-8.76(d,1H),8.63(dt,1H),8.25-8.23(d,1H),8.02-7.99(t,1H),7.51-7.50(d,1H),7.05-7.04(d,1H),4.31-4.30(d,2H),4.06-4.02(m,2H),3.92(s,3H),3.88-3.84(m,2H),2.69-2.46(dd,2H),2.15-2.11(m,3H),1.76-1.59(m,6H),1.36-1.29(m,1H).
Example 40
1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -N-methyl-3- (thiophen-2-yl) propyl-2-amine hydrochloride (Compound 40)
1-(9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl)-N-methyl-3-(thiophen-2-yl)propan-2-amine hydrochloride
Figure BDA0001714822470001382
Figure BDA0001714822470001391
The first step is as follows: 9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-ol (40B)
9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-ol
Figure BDA0001714822470001392
2, 6-dioxaspiro [4.5] decan-9-one (1 c) (9.24g, 60.0 mmol) was dissolved in tetrahydrofuran (20 mL) at 0 ℃ under nitrogen. Phenylmagnesium bromide (1.0M, 78.0 mL) was added dropwise to the reaction mixture. After the addition, the reaction was carried out at 0 ℃ for 4 hours. Ammonium chloride solution (40 mL) was added at 0 ℃, the product was extracted with ethyl acetate (40 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and after concentrating the filtrate, the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =10: 1-1) to give 9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-ol (40B) as an oily liquid (15.0 g, yield: 100%).
Ms m/z(ESI):273.1[M+Na + ];
1 H NMR(400MHz,CDCl 3 )δ7.48-7.45(m,2H),7.05-7.00(m,2H),4.04-3.96(m,1H),3.73-3.72(m,1H),2.46-2.33(m,2H),1.67-1.49(m,10H).
The second step is that: 9-allyl-9- (4-fluorophenyl) -6-oxaspiro [4.5] decane (40C)
9-allyl-9-(4-fluorophenyl)-6-oxaspiro[4.5]decane
Figure BDA0001714822470001393
9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-ol (0.5 g,2.0 mmol) was dissolved in methylene chloride (15 mL) and cooled to 0 ℃ and boron trifluoride ether solution (0.6 g,4.0 mmol) and allyltrimethylsilane (0.5 g,4.0 mmol) were added and reacted at 0 ℃ for 2 hours after completion of the addition. Ammonium chloride solution (20 mL) was added at 0 ℃, the product was extracted with dichloromethane (20 mL × 2), the combined organic phases were washed with saturated sodium bicarbonate solution (20 mL × 1), saturated brine solution (20 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, after which the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =80: 1-6) to give 9-allyl-9- (4-fluorophenyl) -6-oxaspiro [4.5] decane (40C) as a yellow oily liquid (0.3 g, yield: 100%).
Ms m/z(ESI):297.1[M+Na + ];
1 H NMR(400MHz,CDCl 3 )δ7.36-7.22(m,2H),7.02-6.98(m,2H),5.32-5.29(m,1H),5.28-5.26(t,2H),3.88-3.71(m,2H),2.07-2.06(m,1H),1.84-1.70(m,3H),1.66-1.26(m,10H).
The third step: 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) acetic acid (40D)
2-(9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl)acetic acid
Figure BDA0001714822470001401
9-allyl-9- (4-fluorophenyl) -6-oxaspiro [4.5] decane (40C) (6.0g, 21.87mmol), sodium periodate (18.71g, 87.46mmol), ruthenium (III) trichloride hydrate (0.1g, 0.5 mmol), acetonitrile (40 mL), chloroform (40 mL) and water (40 mL) were added to a reaction flask, and after completion of the addition, the reaction was vigorous exothermic at room temperature for 4 hours. The product was extracted with ethyl acetate (40 mL × 4), the combined organic phases were washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 30.
Ms m/z(ESI):291.1[M-H + ];
1 H NMR(400MHz,CDCl 3 )δ7.28-7.26(m,2H),7.02-6.96(m,2H),3.75-3.69(m,2H),2.60-2.44(q,2H),2.43-2.40(d,1H),2.11-2.06(m,2H),1.70(m,1H),1.66(m,1H),1.52(m,1H),1.47-1.41(m,1H),1.31-1.18(m,1H).
The fourth step: 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) acetyl chloride (40E)
2-(9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl)acetyl chloride
Figure BDA0001714822470001411
After 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) acetic acid (40D) (0.3g, 0.99mmol) was dissolved in methylene chloride (10 mL), the temperature was lowered to 0 ℃ and N, N-dimethylformamide (0.01 mL) and oxalyl chloride (0.2g, 1.5 mmol) were added to the solution, after which the reaction was completed at 0 ℃ for 3 hours. The reaction solution was concentrated to dryness to give 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) acetyl chloride (40E) (0.3 g, yield: 100%) as a yellow oily liquid.
The fifth step: ethyl 2- (thiophen-2-yl) ethyl ester (40G)
ethyl 2-(thiophen-2-yl)acetate
Figure BDA0001714822470001412
After 2-thienylacetic acid (40F) (5.68g, 39.9 mmol) was dissolved in N, N-dimethylformamide (15 mL) under nitrogen, potassium carbonate (8.28g, 59.9 mmol) and iodoethane (7.48g, 47.9 mmol) were added to the reaction solution in this order, and after reaction at room temperature for 3 hours, ice water (60 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (30 mL. Times.3), the organic phases were combined, washed with a saturated saline solution (30 mL. Times.1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain ethyl 2- (thien-2-yl) ethyl ester (40G) (3.6G, yield: 53%) as a brown oily liquid.
Ms m/z(ESI):171.1[M+H + ];
And a sixth step: ethyl 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3-oxa-4- (thiophen-2-yl) butanoate (40H)
ethyl2-(9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl)-3-oxo-4-(thiophen-2-yl)butanoate
Figure BDA0001714822470001413
Ethyl 2- (thien-2-yl) ethyl ester (40G) (0.17g, 1.0mmol) was dissolved in tetrahydrofuran (20 mL), and the temperature was lowered to-70 ℃ to add sodium hexamethyldisilazide (1.0M, 1.3mmol) dropwise to the reaction mixture, and the reaction was carried out at-70 ℃ for 0.5 hour. After 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) acetyl chloride (40E) (0.32g, 1.0mmol) was dissolved in tetrahydrofuran (5 mL), the solution was added dropwise to the reaction mixture, and after completion of the reaction at-70 ℃ for 0.5 hour, the temperature was naturally raised to room temperature for 2 hours. The reaction solution was added with an ammonium chloride solution (10 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 6).
Ms m/z(ESI):467.1[M+Na + ];
The seventh step: 1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thiophen-2-yl) propyl-2-one (40I)
1-(9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl)-3-(thiophen-2-yl)propan-2-one
Figure BDA0001714822470001421
Ethyl 2- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3-oxa-4- (thiophen-2-yl) butyrate (40H) (0.44g, 0.99mmol) was dissolved in dimethyl sulfoxide (10 mL), and sodium chloride (0.3 g) and water (0.5 mL) were added to the reaction solution, followed by heating to 130 ℃ for 4 hours. The reaction solution was cooled to room temperature, quenched with water (30 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with saturated sodium chloride (30 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was subjected to column chromatography (petroleum ether/ethyl acetate (v/v) =40: 1-6) to give 1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thiophen-2-yl) propyl-2-one (40I) (0.2 g, yield: 50%) as a yellow oily liquid.
Ms m/z(ESI):395.1[M+Na + ];
1 H NMR(400MHz,CDCl 3 )δ7.30-7.27(m,2H),7.16-7.14(m,1H),7.02-6.90(m,2H),6.89-6.88(m,1H),6.57-6.56(m,1H),3.73-3.70(m,2H),3.26(s,2H),2.90-2.86(d,1H),2.56-2.55(d,1H),2.34-2.33(d,1H),2.14-2.13(q,2H),1.90-1.88(m,1H),1.67-1.66(m,1H),1.51-1.50(m,1H),1.34-1.26(m,6H).
Eighth step: 1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thiophen-2-yl) propyl-2-amine (40J)
1-(9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl)-3-(thiophen-2-yl)propan-2-amine
Figure BDA0001714822470001431
1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thiophen-2-yl) propyl-2-one (40I) (0.374g, 1.0 mmol) was dissolved in anhydrous methanol (10 mL), and ammonium acetate (1.116g, 15.1mmol) and sodium cyanoborohydride (0.189g, 3.01mmol) were added in this order, and the reaction was stirred at room temperature for 48 hours. The reaction solution was poured into ice water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL. Times.3), the organic phases were combined, washed with saturated sodium chloride (20 mL. Times.1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thiophen-2-yl) propyl-2-amine (40J) (0.2 g, yield: 50%) as a yellow oily liquid.
Ms m/z(ESI):374.2[M+H + ];
The ninth step: tert-butyl (1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thiophen-2-yl) propyl-2-yl) carboxylate (40K)
tert-butyl(1-(9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl)-3-(thiophen-2-yl)propan-2-yl)carbamate
Figure BDA0001714822470001432
1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thien-2-yl) propyl-2-amine (40J) (0.374g, 1.0mmol) was added to methylene chloride (20 mL), and triethylamine (0.142g, 1.4mmol) and di-tert-butyl dicarbonate (0.284g, 1.3mmol) were further added, and the reaction was completed at 25 ℃ for 12 hours. The reaction solution was added to water (20 mL), the aqueous phase was extracted with dichloromethane (30 mL × 2), the organic phases were combined, washed with sodium chloride (20 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 20).
Ms m/z(ESI):496.2[M+Na + ];
The tenth step: tert-butyl (1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thiophen-2-yl) propyl-2-yl) (methyl) carboxylate (40L)
tert-butyl(1-(9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl)-3-(thiophen-2-yl)propan-2-yl)(methyl)carbamate
Figure BDA0001714822470001441
Tert-butyl (1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thiophen-2-yl) propyl-2-yl) carboxylate (40K) (0.15g, 0.32mmol) was added to N, N-dimethylformamide (30 mL) and the temperature was reduced to 0 ℃. Sodium hydride (10.0 mg, 0.44mmol) was added thereto, and the reaction was carried out at 0 ℃ for 0.5 hour. Methyl iodide (63.0 mg, 0.44mmol) was added dropwise to the reaction solution, and reacted at 0 ℃ for 4 hours. The reaction solution was added to water (20 mL), the aqueous phase was extracted with dichloromethane (30 mL × 2), the organic phases were combined, washed with sodium chloride (20 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and then the crude product was subjected to column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 20) to give t-butyl (1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thiophen-2-yl) propyl-2-yl) (methyl) carboxylate (40L) (0.15 g, yield: 97%) as a yellow oily liquid.
Ms m/z(ESI):388.2[M-100];
The eleventh step: 1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -N-methyl-3- (thiophen-2-yl) propyl-2-amine (40N)
1-(9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl)-N-methyl-3-(thiophen-2-yl)propan-2-amine
Figure BDA0001714822470001442
Tert-butyl (1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -3- (thiophen-2-yl) propyl-2-yl) (methyl) carboxylate (40L) (0.15g, 0.30mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 2 hours. The reaction solution was directly spin-dried to give 1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -N-methyl-3- (thiophen-2-yl) propyl-2-amine hydrochloride (40N) as a white solid (0.12 g, 98% yield).
Ms m/z(ESI):388.2[M+H + ];
Resolution of the compound 1- (9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -N-methyl-3- (thiophen-2-yl) propyl-2-amine hydrochloride (40N):
the compound (40N) (0.15 g) was taken for resolution and after separation, four optical isomer compounds (R) -1- ((S) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -N-methyl-3- (thien-2-yl) propyl-2-amine (compound 40M-1) (11.36 mg, oily liquid,% ee = 100%), (R) -1- ((R) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -N-methyl-3- (thien-2-yl) propyl-2-amine hydrochloride ((compound 40M-2) (14.66 g, oily liquid,% ee = 98.9%), (S) -1- ((R) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-9-yl) -N-methyl-3- (thien-2-yl) propyl-2-amine hydrochloride compound 40M-3) (4.0 g, oily liquid,% ee = 4.5] decan-3-methyl-3- (thien-2-yl) propyl-2-amine hydrochloride compound 40M-3) (4M-3) (4.0 g, 6-oxaspiro [4.5] decan% Yl) propyl-2-amine hydrochloride ((compound 40M-4) (5.1 g, oily liquid, ee% = 96.4%).
Splitting conditions are as follows: MG II preparatory SFC (SFC-15); column ChiralPak IC,250 × 30mm i.d.,5 μm. Mobile phase a: carbon dioxide, B: methanol; gradient B30%; the flow rate is 60mL/min; back pressure is 100bar; the column temperature is 38 ℃; the wavelength is 220nm; the period is 3min; sample preparation compound 40M was dissolved in methanol to 3mg/ml; injection, 0.8 ml/needle.
The salt formation procedure of example 39 was used to synthesize the salts of the four optical isomers:
compound 40-1:
Ms m/z(ESI):389.2[M+H + ];
1 H NMR(400MHz,CD 3 OD)δ8.86(d,1H),8.58(d,1H),8.11(t,1H),8.00(d,1H),7.46(d,1H),7.00(d,1H),4.19(s,2H),3.97-3.67(m,7H),3.44-3.32(m,1H),3.13-2.86(m,2H),2.60-2.15(m,7H),2.12-1.87(m,2H)。
compound 40-2:
Ms m/z(ESI):389.2[M+H + ];
1 H NMR(400MHz,CD 3 OD)δ8.86(d,1H),8.58(d,1H),8.11(t,1H),8.00(d,1H),7.46(d,1H),7.00(d,1H),4.19(s,2H),3.97-3.67(m,7H),3.44-3.32(m,1H),3.13-2.86(m,2H),2.60-2.15(m,7H),2.12-1.87(m,2H).
compound 40-3:
Ms m/z(ESI):389.2[M+H + ];
1 H NMR(400MHz,CD 3 OD)δ8.86(d,1H),8.58(d,1H),8.11(t,1H),8.00(d,1H),7.46(d,1H),7.00(d,1H),4.19(s,2H),3.97-3.67(m,7H),3.44-3.32(m,1H),3.13-2.86(m,2H),2.60-2.15(m,7H),2.12-1.87(m,2H).
compound 40-4:
Ms m/z(ESI):389.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.86(d,1H),8.58(d,1H),8.11(t,1H),8.00(d,1H),7.46(d,1H),7.00(d,1H),4.19(s,2H),3.97-3.67(m,7H),3.44-3.32(m,1H),3.13-2.86(m,2H),2.60-2.15(m,7H),2.12-1.87(m,2H).
example 42
(R) -N- ((3-Cyclobutoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 42)
(R)-N-((3-cyclobutoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470001461
The first step is as follows: cyclobutylmethanesulfonate (42B)
cyclobutyl methanesulfonate
Figure BDA0001714822470001462
Cyclobutanol (42A) (2g, 27.74mmol) and triethylamine (4.21g, 33.28mmol) were dissolved in dichloromethane (30 mL), cooled to 0 deg.C, methanesulfonyl chloride (3.81g, 27.2 mmol) was added dropwise to the reaction, and the reaction was allowed to warm to room temperature for 1 hour. The reaction solution was quenched with water (30 mL), the aqueous phase of the separated liquid was extracted with dichloromethane (20 mL. Times.2), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give cyclobutylmethanesulfonate (42B) (3.8 g, yield: 91%) as a yellow oily liquid.
The second step is that: 3- (Cyclobutoxy) thiophene-2-carbaldehyde (42C)
3-cyclobutoxythiophene-2-carbaldehyde
Figure BDA0001714822470001471
3-Hydroxythiophene-2-carbaldehyde (0.3g, 2.3mmol) was dissolved in N, N-dimethylformamide (10 mL) at room temperature, and potassium carbonate (0.48g, 3.5 mmol) and cyclobutylmethanesulfonate (42B) (0.53g, 3.5 mmol) were added thereto, followed by reaction at 80 ℃ for 6 hours. To the reaction solution was added water (50 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 2), the combined organic phases were washed with a saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 5) to obtain 3- (cyclobutoxy) thiophene-2-carbaldehyde (42C) as an oily liquid (0.15 g, yield: 35%).
Ms m/z(ESI):183.1[M+H + ];
The third step: (R) -N- ((3-Cyclobutoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (42D)
(R)-N-((3-cyclobutoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470001472
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.214g, 0.823mmol) was dissolved in methylene chloride (10 mL), and sodium sulfate (0.584g, 4.11mmol) and 3- (cyclobutoxy) thiophene-2-carbaldehyde (42C) (0.15g, 0.823mmol) were added to the reaction solution, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.047g, 1.23mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and reaction with stirring for 1 hour. The reaction was quenched with water (20 mL), the aqueous phase was extracted with dichloromethane (20 mL. Times.3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and the crude product was purified by preparative HPLC (method: acetonitrile/0.1% aqueous ammonia-58% _58% _15 min) to give (R) -N- ((3-cyclobutoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (42D) (0.1 g, 28.5% yield) as a yellow oily liquid.
Ms m/z(ESI):427.2[M+H + ]。
The fourth step: (R) -N- ((3-Cyclobutoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 42)
(R)-N-((3-cyclobutoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470001481
(R) -N- ((3-Cyclobutoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (42D) (0.1g, 0.234mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -N- ((3-cyclobutoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 42) as a white solid (0.11 g, yield: 100%).
Ms m/z(ESI):427.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.84(dd,1H),8.56(td,1H),8.12(d,1H),7.99-7.96(m,1H),7.44(d,1H),6.85(d,1H),4.75-4.65(m,1H),4.20(s,2H),3.87-3.66(m,2H),2.99(td,1H),2.61-2.32(m,5H),2.29(td,1H),2.22-2.01(m,4H),1.98-1.76(m,3H),1.76-1.36(m,6H),1.20-1.17(m,1H),0.85-0.77(m,1H).
Example 43
5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 43)
5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-1-methyl-5-(pyridin-2-yl)piperidin-2-onehydrochloride
Figure BDA0001714822470001491
The first step is as follows: 5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one (43A)
5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-1-methyl-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470001492
2- (1-methyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde (36F) (0.15g, 0.65mmol) was dissolved in methylene chloride (10 ml), and (3-methoxythiophen-2-yl) methylamine (0.11g, 0.77mmol), triethylamine (0.078g, 0.77mmol), and anhydrous sodium sulfate (0.6 g) were added thereto in this order. React overnight at room temperature, add sodium borohydride (0.039g, 0.97mmol), continue stirring for 2h, add water (20 mL), extract with dichloromethane (20 mL × 3), combine the organic phases, wash with saturated aqueous sodium chloride solution (30 mL × 1), dry over anhydrous sodium sulfate, filter, concentrate the filtrate, and column chromatographically (dichloromethane/methanol = 30).
Ms m/z(ESI):360.2[M+H + ]。
The second step is that: 5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 43)
5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-1-methyl-5-(pyridin-2-yl)piperidin-2-onehydrochloride
Figure BDA0001714822470001493
5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride 43A (0.13g, 0.36mmol) was dissolved in ethyl acetate (5 mL) and the solution of ethyl hydrogen chloride acetate (2mL, 4N) was added at 0 ℃ and the reaction was continued for 0.5h after completion of addition, and the solvent was removed under reduced pressure to give 5- (2- ((3-chlorobenzyl) amino) ethyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 43) as a white solid (0.13g, 95%).
Ms m/z(ESI):360.2[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.80(d,1H),8.34(d,1H),7.85(d,1H),7.78(m,1H),7.46(d,1H),7.40(d,1H),4.21(s,2H),4.07(dd,1H),3.88(s,3H),3.72(m,1H),3.03(s,3H),2.89(td,1H),2.74(td,1H),2.57(td,1H),2.35(m,4H),2.08(m,1H)。
Example 44
N- (3-Cyclopropylbenzyl) -2- (9- (pyridin-2-yl) -6-oxa [4.5] decan-9-yl) ethylamine hydrochloride (Compound 44)
N-(3-cyclopropoxybenzyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanaminehydrochloride
Figure BDA0001714822470001501
The first step is as follows: 5- ((1, 3-Dioxolan-2-yl) methyl) -1-isopropyl-5- (pyridin-2-yl) piperidin-2-one (44A) 5- ((1, 3-dioxolan-2-yl) methyl) -1-isoproyl-5- (pyridinyl-2-yl) piperidine-2-one
Figure BDA0001714822470001511
5- ((1, 3-Dioxolan-2-yl) methyl) -5- (pyridin-2-yl) piperidin-2-one (36D) (0.1g, 1mmol) was dissolved in ethylene glycol dimethyl ether (5 mL) at room temperature, potassium tert-butoxide (0.04g, 0.38mmol), isopropyl iodide (0.064g, 0.38mmol) were added at room temperature, the reaction was continued for 0.5h with warming to 60 ℃ after completion of the addition, isopropyl iodide (0.064g, 0.38mmol) and potassium tert-butoxide (0.04g, 0.38mmol) were added to the reaction solution every 1h, 8 times were repeatedly added, 20mL of water was added to the reaction solution, ethyl acetate extraction (20 mL. Times.2) was added with anhydrous sodium sulfate for drying, filtration was performed, the filtrate was concentrated under reduced pressure to remove the solvent, column chromatography (dichloromethane/methanol = 30) gave 5- ((1, 3-dioxolan-2-yl) methyl) -1-isopropyl-5- (pyridin-2-yl) piperidin-2-one (96A) (96A 96%
Ms m/z(ESI):305.2[M+H + ]。
The second step is that: 2- (1-isopropyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde (44B)
2-(1-isopropyl-6-oxo-3-(pyridin-2-yl)piperidin-3-yl)acetaldehyde
Figure BDA0001714822470001512
At room temperature, 5- ((1, 3-dioxolan-2-yl) methyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one 44A (0.3g, 1mmol) was dissolved in tetrahydrofuran (10 mL) and concentrated hydrochloric acid (2 mL), stirred at room temperature overnight, and the reaction was concentrated to give the product 2- (1-isopropyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde 44B (0.3g, 100% crude) as a black oil, which was directly used in the next step.
Ms m/z(ESI):261.2[M+H + ]。
The third step: 1-isopropyl-5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -5- (pyridin-2-yl) piperidin-2-one (44C)
isopropyl-5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470001513
2- (1-isopropyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde 44B (0.15g, 0.58mmol) was dissolved in methylene chloride (10 ml), and (3-methoxythiophen-2-yl) methylamine (0.099g, 0.69mmol), triethylamine (0.070g, 0.69mmol), and anhydrous sodium sulfate (0.56 g) were added thereto in this order. React at room temperature overnight, add sodium borohydride (0.035g, 0.86mmol), continue stirring for 2h, add water (20 mL), extract with dichloromethane (30 mL × 2), combine the organic phases, wash with saturated brine solution (30 mL × 1), dry over anhydrous sodium sulfate, filter, concentrate the filtrate, and column chromatographe (dichloromethane/methanol = 30.
Ms m/z(ESI):388.2[M+H + ]。
The fourth step: 1-isopropyl-5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 44)
isopropyl-5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-5-(pyridin-2-yl)piperidin-2-onehydrochloride
Figure BDA0001714822470001521
1-isopropyl-5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -5- (pyridin-2-yl) piperidin-2-one 44C (0.062g, 0.16mmol) was dissolved in ethyl acetate (5 mL) and the ethyl hydrogen chloride acetate solution (2mL, 4N) was added at 0 ℃ and reacted for 0.5h further, after which the solvent was removed under reduced pressure to give 1-isopropyl-5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 44) (0.071g, 95%) as a white solid at room temperature.
Ms m/z(ESI):358.2[M+H + ]。
1 H NMR(400MHz,CD 3 OD):δ8.79(d,1H),8.33(t,1H),7.89(d,1H),7.77(m,1H),7.47(d,1H),7.01(d,1H),4.21(s,2H),3.88(s,3H),3.62(d,2H),2.89(td,1H),2.73(td,1H),2.52(m,2H),2.31(m,3H),1.21(d,3H),1.10(d,3H).
Example 45
5- (2- ((3-chlorobenzyl) amino) ethyl) -1-isopropyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 45)
5-(2-((3-chlorobenzyl)amino)ethyl)-1-isopropyl-5-(pyridin-2-yl)piperidin-2-onehydrochloride
Figure BDA0001714822470001531
The first step is as follows: 5- (2- ((3-chlorobenzyl) amino) ethyl) -1-isopropyl-5- (pyridin-2-yl) piperidin-2-one (45A)
5-(2-((3-chlorobenzyl)amino)ethyl)-1-isopropyl-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470001532
2- (1-isopropyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde 44B (0.15g, 0.58mmol) was dissolved in methylene chloride (10 ml), and (3-chlorobenzyl) methylamine (0.098g, 0.69mmol), triethylamine (0.070g, 0.69mmol), and anhydrous sodium sulfate (0.56 g) were added thereto in this order. React overnight at room temperature, add sodium borohydride (0.035g, 0.86mmol), continue stirring for 2h, add water (20 mL), extract with dichloromethane (30 mL × 2), combine the organic phases, wash with saturated brine solution (30 mL × 1), dry over anhydrous sodium sulfate, filter, concentrate the filtrate, column chromatographe (dichloromethane/methanol = 30.
Ms m/z(ESI):386.2[M+H + ]。
The fourth step: 5- (2- ((3-chlorobenzyl) amino) ethyl) -1-isopropyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 45)
5-(2-((3-chlorobenzyl)amino)ethyl)-1-isopropyl-5-(pyridin-2-yl)piperidin-2-onehydrochloride
Figure BDA0001714822470001533
5- (2- ((3-chlorobenzyl) amino) ethyl) -1-isopropyl-5- (pyridin-2-yl) piperidin-2-one 45A (0.085 g, 0.22mmol) was dissolved in ethyl acetate (5 mL) at room temperature, and after completion of addition, a solution of ethyl hydrogen chloride acetate (2mL, 4N) was reacted for 0.5h, and the solvent was removed under reduced pressure to give 5- (2- ((3-chlorobenzyl) amino) ethyl) -1-isopropyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride compound 45 (0.09g, 95%) as a white solid.
Ms m/z(ESI):386.2[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.91(dd,1H),8.60(td,1H),8.12(s,1H),8.02(dd,1H),7.55(s,1H),7.43(dd,2H),4.13(s,2H),3.88(s,3H),3.91(d,1H),3.76(d,1H),3.01(td,1H),2.84(td,1H),2.60(tt,2H),2.40(m,3H),1.24(d,3H),1.12(d,3H).
Example 46
(R) - (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl acetate hydrochloride (Compound 46)
(R)-(2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)methyl acetate hydrochloride
Figure BDA0001714822470001541
The first step is as follows: 3- (hydroxymethyl) thiophene-2-aldehyde (46D)
3-(hydroxymethyl)thiophene-2-carbaldehyde
Figure BDA0001714822470001551
3- (((tetrahydro-2H-pyran-2-yl) oxy) methyl) thiophene-2-carbaldehyde (37C) (4.6 g, 22.63mmol) was dissolved in methanol (20 mL), and a hydrochloric acid solution (0.3mL, 3N) was added, and after completion of addition, the reaction was continued at room temperature for 5 hours. The reaction solution was concentrated, and column chromatography ((petroleum ether/ethyl acetate (V/V)) = 3) gave 3- (hydroxymethyl) thiophene-2-aldehyde 46D (2.3g, 90%) as a yellow oily liquid.
1 H NMR(400MHz,CDCl 3 ):δ9.97(s,1H),7.73(d,1H),7.21(d,1H),4.91(s,2H)
The second step is that: (R) - (2- (((2- (9-pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methanol (46E)
(R)-(2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-y)methanol
Figure BDA0001714822470001552
3- (hydroxymethyl) thiophene-2-aldehyde 46D (0.33g, 1mmol) was dissolved in dichloromethane (10 ml), to which was added in turn (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.66g, 2.6 mmol), anhydrous sodium sulfate (2.31 g). After reacting overnight at room temperature, sodium borohydride (0.14g, 3.5mmol) was added, stirring was continued for 2h, water (20 mL) was added, extraction was performed with ethyl acetate (20 mL × 3), the organic phases were combined, washed with a saturated saline aqueous solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography was performed to purify (dichloromethane/methanol =5 1) to obtain a yellow liquid (2- (((2- (9-pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) amino) methyl) thiophen-3-yl) methanol 46E (0.5g, 80%)
Ms m/z(ESI):387.3[M+H + ]。
The third step: tert-butyl ((3- (hydroxymethyl) thiophen-2-yl) methyl) (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) carboxylate (46F)
tert-butyl((3-(hydroxymethyl)thiophen-2-yl)methyl)(2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)carbamate
Figure BDA0001714822470001561
(R) - (2- (((2- (9-pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) amino) methyl) thiophen-3-yl) methanol 46E (1.1g, 2.8mmol) was dissolved in methylene chloride (20 mL), to which triethylamine (0.35g, 3.4mmol) and di-tert-butyl dicarbonate (0.68g, 3.1mmol) were added in this order, and the reaction was continued at room temperature for 5 hours. The reaction solution was concentrated and purified by column chromatography (dichloromethane/methanol =30: 1) to obtain (R) -tert-butyl ((3- (hydroxymethyl) thiophen-2-yl) methyl) (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) carboxylate 46F (1 g, yield 72%) as a yellow oily product.
Ms m/z(ESI):487.3[M+H + ]。
The fourth step: (R) - (2- ((tert-butyloxycarbonyl) (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl acetate (46G)
(R)-(2-(((tert-butoxycarbonyl)(2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)methyl acetate
Figure BDA0001714822470001562
(R) -tert-butyl ((3- (hydroxymethyl) thiophen-2-yl) methyl) (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) carboxylate 46F (0.6G, 1.28mmol) was dissolved in dichloromethane (20 mL) at room temperature, triethylamine (0.1lg, 1.6 mmol), acetyl chloride (0.126g, 1.6 mmol) were added in this order at 0 ℃, reaction was continued for 2h, water (20 mL) was added to the reaction solution, dichloromethane (20 mL. Times.3) was extracted, the organic phases were combined, washed with a saturated saline solution (30 mL. Times.1), dried over anhydrous sodium sulfate, the filtrate was concentrated, purified by column chromatography (dichloromethane/methanol = 30) to give (R) - (2- ((tert-butoxycarbonyl) (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) amino) methyl) thiophene-3-methyl) acetate (250.80G)
The fifth step: (R) - (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl acetate (46H)
(R)-(2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)methyl acetate
Figure BDA0001714822470001571
(2- ((tert-butoxycarbonyl) (2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl acetate 46G (0.25g, 0.37mmol) was dissolved in EA (5 mL) at room temperature, an ethyl hydrogen chloride solution (2mL, 4N) was added at 0 ℃ and the reaction was continued for 2H at room temperature, the solvent was removed under reduced pressure and column chromatography (CH 2CL2/MEOH = 30) gave a yellow oily product (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl acetate 46H (0.17g, 96%)
And a sixth step: (R) - (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl acetate hydrochloride (Compound 46)
(R)-(2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)methyl acetatehydrochloride
Figure BDA0001714822470001572
(R) - (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl acetate 46H (0.17g, 0.37mmol) was dissolved in EA (5 mL) and the solution of ethyl hydrogen chloride (2mL, 4N) was dissolved at 0 ℃ and reacted at room temperature for 0.5H, after completion of addition, the solvent was removed under reduced pressure to give (R) - (2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl acetate (compound 46) (0.17g, 94%).
Ms m/z(ESI):429.3[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.50(ddd,1H),7.74(m,1H),7.47(d,1H),7.21(m,2H),6.95(d,1H),5.00(s,2H),3.79(s,2H),3.73(m,2H),2.48(dt,2H),2.40(dd,1H),2.01(m,5H),1.89(d,1H),1.61(m,10H)。
Example 47
9- (2- (((3-Methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one hydrochloride (Compound 47)
9-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-9-(pyridin-2-yl)spiro[4.5]decan-6-onehydrochloride
Figure BDA0001714822470001581
The first step is as follows: dimethyl 6-oxaspiro [4.5] decane-7, 9-dicarboxylate (47B)
dimethyl 6-oxospiro[4.5]decane-7,9-dicarboxylate
Figure BDA0001714822470001591
Lithium diisopropylate tetrahydrofuran solution (22mL, 22mmol, 2M) was added to tetrahydrofuran (20 mL) at-70 ℃ under nitrogen. Methyl cyclopentanecarboxylate (47A) (2.56g, 20mmol) was dissolved in tetrahydrofuran (10 mL) at-70 ℃ and then added dropwise to the reaction mixture, and after the addition, the reaction was carried out at-70 ℃ for 1 hour, and methyl acrylate (3.8g, 44mmol) was dissolved in tetrahydrofuran (10 mL) and then added dropwise to the reaction mixture, and after the addition, the reaction was carried out at-70 ℃ for 4 hours. To the reaction solution was added ammonium chloride solution (20 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and then the crude product was subjected to column chromatography (petroleum ether/ethyl acetate (v/v) =100:1 to 60) to obtain dimethyl 6-oxaspiro [4.5] decane-7, 9-dicarboxylate (47B) as an oily liquid (4.2 g, yield: 41%).
Ms m/z(ESI):269.1[M+H + ];
The second step is that: methyl 10-oxaspiro [4.5] decane-7-carboxylic ester (47C)
methyl 10-oxospiro[4.5]decane-7-carboxylate
Figure BDA0001714822470001592
Dimethyl 6-oxaspiro [4.5] decane-7, 9-dicarboxylate (47B) (2.1g, 7.8mmol) was dissolved in dimethyl sulfoxide (20 mL), and water (1 mL) and sodium chloride (1.2g, 9.4mmol) were added thereto, followed by completion of the reaction at 150 ℃ for 16 hours. Water (50 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 100.
Ms m/z(ESI):211.3[M+H + ];
The third step: methyl 1, 4-dioxaspiro [4.0.4 ] 6 .4 5 ]Tetradecyl-12-carboxylate (47D)
methyl 1,4-dioxadispiro[4.0.4 6 .4 5 ]tetradecane-12-carboxylate
Figure BDA0001714822470001601
Reacting methyl 10-oxaspiro [4.5]]Decane-7-carboxylic acid ester (47C) (0.9g, 4.0 mmol), ethylene glycol (0.3g, 5.0 mmol), p-toluenesulfonic acid (0.08g, 0.4mmol) and toluene (20 mL) were added to the reaction flask, and the reaction was heated to reflux for 4 hours. After cooling, a sodium hydrogencarbonate solution (20 mL) was added to the reaction solution, and an aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated saline solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =1 to 1) to obtain methyl 1, 4-dioxaspiro [4.0.4 6 .4 5 ]Tetradecyl-12-carboxylate (47D) (0.9 g, yield: 80%).
Ms m/z(ESI):255.2[M+H + ];
The fourth step: methyl 12- (pyridinyl-2-yl) -1, 4-dioxaspiro [4.0.4 6 .4 5 ]Tetradecyl-12-carboxylate (47E)
methyl 12-(pyridin-2-yl)-1,4-dioxadispiro[4.0.4 6 .4 5 ]tetradecane-12-carboxylate
Figure BDA0001714822470001602
Under the protection of nitrogen, methyl 1, 4-dioxaspiro [4.0.4 ] is reacted at-70 DEG C 6 .4 5 ]Tetradecyl-12-carboxylate (47D) (0.85g, 3.3mmol) and 2-fluoropyridine (0.35g, 3.3mmol) were added to tetrahydrofuran (10 mL), and a solution of hexamethyldisilazane potassium amino tetrahydrofuran (4.0 m) was added at-70 deg.CL,4.0mmol, 1.0M) was added dropwise to the reaction mixture, and after completion of the addition, the reaction was carried out at-70 ℃ for 20 minutes, and then the temperature was naturally raised to room temperature for reaction for 3 hours. To the reaction solution at 0 ℃, ammonium chloride solution (20 mL) is added, the aqueous phase is extracted with ethyl acetate (30 mL × 3), the organic phases are combined, dried over anhydrous sodium sulfate, filtered, and after the filtrate is concentrated, the crude product is purified by column chromatography (petroleum ether/ethyl acetate (v/v) =80: 1-30) to give methyl 12- (pyridin-2-yl) -1, 4-dioxaspiro [4.0.4 6 .4 5 ]Tetradecyl-12-carboxylate (47E) (0.7 g, yield: 60%).
Ms m/z(ESI):332.2[M+H + ];
The fifth step: (12- (pyridinyl-2-yl) -1, 4-dioxaspiro [ 4.0.4) 6 .4 5 ]Tetradecyl-12-yl) methanol (47F)
(12-(pyridin-2-yl)-1,4-dioxadispiro[4.0.4 6 .4 5 ]tetradecan-12-yl)methanol
Figure BDA0001714822470001611
Lithium aluminum hydride (0.152g, 4.0 mmol) was dissolved in tetrahydrofuran (20 mL), cooled to 0 deg.C, and the methyl 12- (pyridin-2-yl) -1, 4-dioxaspiro [4.0.4 ] 6 .4 5 ]Tetradecyl-12-carboxylate (47D) (0.662g, 2.0 mmol) in tetrahydrofuran (10 mL) was added to the reaction mixture, and the reaction was allowed to proceed overnight at room temperature. The reaction was cooled to 0 ℃, quenched with water (0.2 mL), sodium hydroxide solution (10%, 0.3 mL) and water (0.3 mL), dried by addition of anhydrous sodium sulfate, stirred for 20 minutes, the solid filtered and washed with tetrahydrofuran (20 mL × 3). The combined organic phases were concentrated to give (12- (pyridin-2-yl) -1, 4-dioxaspiro [4.0.4 ] 6 .4 5 ]Tetradecyl-12-yl) methanol (47F) (0.55 g, yield: 91%).
Ms m/z(ESI):304.1[M+H + ];
And a sixth step: (12- (pyridinyl-2-yl) -1, 4-dioxaspiro [ 4.0.4) 6 .4 5 ]Tetradecyl-12-yl) methyl methanesulfonate (47G)
(12-(pyridin-2-yl)-1,4-dioxadispiro[4.0.4 6 .4 5 ]tetradecan-12-yl)methyl methanesulfonate
Figure BDA0001714822470001612
(12- (pyridyl-2-yl) -1, 4-dioxaspiro [4.0.4 ] spiro at 0 DEG C 6 .4 5 ]Tetradecyl-12-yl) methanol (47F) (0.5g, 2.0mmol) was dissolved in methylene chloride (20 mL), and the temperature was reduced to 0 ℃ to add triethylamine (0.282g, 2.8mmol), followed by stirring for 10 minutes after completion of the addition. Methanesulfonyl chloride (0.107g, 0.94mmol) was added dropwise to the reaction solution, and after the addition, the reaction was carried out at room temperature for 3 hours. Water (10 mL) was added, and the mixture was extracted with methylene chloride (20 mL. Times.4). The organic phases were combined and washed with saturated saline solution (50 mL. Times.1). Drying over anhydrous magnesium sulfate, filtering, and concentrating the filtrate under reduced pressure to give (12- (pyridyl-2-yl) -1, 4-dioxaspiro [4.0.4 ] 6 .4 5 ]Tetradecyl-12-yl) methyl methanesulfonate (47G) (0.35G, yield: 60%).
Ms m/z(ESI):382.3[M+H + ];
The seventh step: 2- (12- (pyridinyl-2-yl) -1, 4-dioxaspiro [ 4.0.4) 6 .4 5 ]Tetradecyl-12-yl) acetonitrile (47H)
2-(12-(pydin-2-yl)-1,4-dioxadispiro[4.0.4 6 .4 5 ]tetradecan-12-yl)acetonitrile
Figure BDA0001714822470001621
Reacting (12- (pyridyl-2-yl) -1, 4-dioxaspiro [4.0.4 ] 6 .4 5 ]Tetradecyl-12-yl) methyl methanesulfonate (47G) (0.3g, 0.8mmol) was dissolved in dimethyl sulfoxide (10 mL), and sodium cyanide (0.102g, 1.23mmol) and sodium iodide (13.8mg, 0.08mmol) were further added to complete the reaction at 150 ℃ for 8 hours. Water (50 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 60) to obtain 2- (12- (pyridin-2-yl) -1, 4-dioxaspiro [4.0.4 6 .4 5 ]Tetradecyl-12-Yl) acetonitrile (47H) (0.3 g, yield: 100%).
Ms m/z(ESI):313.1[M+H + ];
Eighth step: 2- (12- (pyridinyl-2-yl) -1, 4-dioxaspiro [4.0.4 6 .4 5 ]Tetradecyl-12-yl) ethyl-1-amine (47I)
2-(12-(pyridin-2-yl)-1,4-dioxadispiro[4.0.4 6 .4 5 ]tetradecan-12-yl)ethan-1-amine
Figure BDA0001714822470001622
Lithium aluminum hydride (0.114g, 3.0 mmol) was dissolved in tetrahydrofuran (30 mL), cooled to 0 deg.C, and 2- (12- (pyridin-2-yl) -1, 4-dioxaspiro [4.0.4 ] 6 .4 5 ]Tetradecyl-12-yl) acetonitrile (47H) (0.312g, 1.0 mmol) in tetrahydrofuran (10 mL) was added to the reaction, and the reaction was allowed to complete at room temperature overnight. The reaction was cooled to 0 ℃, quenched with water (0.2 mL), sodium hydroxide solution (10%, 0.3 mL) and water (0.3 mL), dried with anhydrous sodium sulfate, stirred for 20 minutes, the solid filtered and washed with tetrahydrofuran (20 mL × 3). The combined organic phases were concentrated to give 2- (12- (pyridin-2-yl) -1, 4-dioxaspiro [4.0.4 ] 6 .4 5 ]Tetradecyl-12-yl) ethyl-1-amine (47I) (0.316 g, yield: 100%).
Ms m/z(ESI):317.2[M+H + ];
The ninth step: n- ((3-Methoxythiophen-2-yl) methyl) -2- (12- (pyridinyl-2-yl) -1, 4-dioxaspiro [ 4.0.4) 6 .4 5 ]Tetradecyl-12-yl) ethyl-1-amine (47J)
(47B)N-((3-methoxythiophen-2-yl)methyl)-2-(12-(pyridin-2-yl)-1,4-dioxadispiro[4.0.46.45]tetradecan-12-yl)ethan-1-amine
Figure BDA0001714822470001631
Reacting 2- (12- (pyridyl-2-yl) -1, 4-dioxaspiro [4.0.4 ] 6 .4 5 ]Tetradecyl-12-yl) ethyl-1-amine (47I) (0.316g, 1.0mmol) was dissolved in methylene chloride (20 mL), and sodium sulfate (1.3 g,10.5 mmol) and 3-methoxythiophene-2-carboxaldehyde (0.142g, 1.0 mmol) were added to the reaction, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.049 g, 1.30mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and after the crude product was purified by column chromatography (dichloromethane/methanol (v/v) =50 6 .4 5 ]Tetradecyl-12-yl) ethyl-1-amine (47J) (0.15 g, 34% yield).
Ms m/z(ESI):443.2[M+H + ];
The tenth step: 9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one (47K)
9-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-9-(pyridin-2-yl)spiro[4.5]decan-6-one
Figure BDA0001714822470001632
Reacting N- ((3-methoxythiophen-2-yl) methyl) -2- (12- (pyridinyl-2-yl) -1, 4-dioxaspiro [4.0.4 6 .4 5 ]Tetradecyl-12-yl) ethyl-1-amine (47J) (50.0 mg, 0.11mmol) was dissolved in tetrahydrofuran (4 mL), cooled to 0 ℃ and hydrochloric acid (6M, 1mL) was added to the reaction solution, and the reaction was allowed to proceed overnight at room temperature. The reaction solution was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) =50]Decan-6-one (47K) (30 mg, yield: 66%).
Ms m/z(ESI):399.3[M+H + ];
The eleventh step: 9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one hydrochloride (Compound 47)
9-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-9-(pyridin-2-yl)spiro[4.5]decan-6-one hydrochloride
Figure BDA0001714822470001641
9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one (47K) (30mg, 0.075 mmol) was dissolved in ethyl acetate (4 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give 9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one hydrochloride (compound 47) as a white solid (30 mg, yield: 91.6%).
Ms m/z(ESI):399.3[M+H + ];
1 H NMR(400MHz,CD3OD)δ9.31-9.30(d,1H),8.66-8.64(m,1H),8.16-8.11(m,2H),7.56-7.51(d,1H),7.12-7.10(d,1H),4.44(s,2H),3.98(s,3H),2.61-2.60(m,2H),2.45-2.43(m,2H),2.15(m,2H),1.94(m,2H),1.79(m,2H),1.78-1.43(m,9H).
Resolution of Compound 47
9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one hydrochloride (compound 47) (100 mg) was taken for resolution to give, after separation, two optical isomers, compound 47-1 (retention time: 3.89min,20.53mg, white solid, ee% = 100%), compound 47-2 (retention time: 5.18min,20.47mg, white solid, ee% = 100%).
Splitting conditions are as follows: the instrument is Gilson GX-281Liquid Handler Prep HPLC BG; column Phenomenex Kinetex XB-C18 150mm 30mm,5 μm,100A, AX mobile phase A: H 2 O (0.05% TFA), B: ACN; gradient B0-25%; the flow rate is 25mL/min; the column temperature is 25 ℃; the wavelength is 220nm; the period is 4min; sample preparation, compound 47 is dissolved in acetonitrile to prepare 3.3mg/ml; injection 2.0 ml/needle.
The twelfth step: (R) -9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one hydrochloride (Compound 47-1)
(R)-9-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-9-(pyridin-2-yl)spiro[4.5]decan-6-one hydrochloride
Figure BDA0001714822470001651
(R) -9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one (compound 47) (22mg, 0.055mmol) was dissolved in ethyl acetate (4 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one hydrochloride (compound 47-1) as a white solid (25 mg, yield: 100%).
Ms m/z(ESI):399.3[M+H + ];
1 H NMR(400MHz,CD3OD)δ9.27-9.26(d,1H),8.62-8.60(m,1H),8.14-8.09(m,2H),7.35-7.33(d,1H),7.12-7.10(d,1H),4.41(s,2H),3.95(s,3H),2.61-2.60(m,2H),2.45-2.44(m,2H),2.17(m,2H),1.96(m,2H),1.77(m,2H),1.76-1.43(m,9H).
(S) -9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one hydrochloride (Compound 47-2)
(S)-9-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-9-(pyridin-2-yl)spiro[4.5]decan-6-one hydrochloride
Figure BDA0001714822470001652
(S) -9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one (Compound 47) (20mg, 0.054mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (S) -9- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -9- (pyridin-2-yl) oxa [4.5] decan-6-one hydrochloride (compound 47-2) as a white solid (20 mg, yield 100%).
Ms m/z(ESI):399.3[M+H + ];
1 H NMR(400MHz,CD3OD)δ9.31-9.30(d,1H),8.66-8.64(m,1H),8.16-8.11(m,2H),7.56-7.51(d,1H),7.12-7.10(d,1H),4.44(s,2H),4.14-3.98(s,3H),2.61-2.60(m,2H),2.45-2.43(m,2H),2.15(m,2H),1.94(m,2H),1.79(m,2H),1.78-1.43(m,9H).
Example 48
N- (3-chlorobenzyl) -1- ((8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-8-yl) methanamine hydrochloride (Compound 48)
N-(3-chlorobenzyl)-1-((8,9trans)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-8-yl)methanamine hydrochloride
Figure BDA0001714822470001661
The first step is as follows: 9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-8-ene-8-carboxylic acid methyl ester (48B)
methyl 9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-8-ene-8-carboxylate
Figure BDA0001714822470001662
Dissolving compound 9- (((trifluoromethyl) sulfonyl) oxy) -6-oxaspiro [4.5] dec-8-ene-carboxylic acid methyl ester (10C) (26.0g, 75.58mmol) in DMF (260 mL), adding pyridine-2-boronic acid (13.9g, 113.37mmol), 1 '-bisdiphenylphosphinoferrocene, 1' -bis (diphenylphosphino) ferrocene (4.213g, 7.558mmol), palladium acetate (0.848g, 3.77mmol), cesium carbonate (36.938g, 113.37mmol), cuprous chloride (7.482g, 75.78mmol) after addition, bubbling the reaction solution with nitrogen for 10 minutes and replacing with nitrogen 3 times, stirring and refluxing at 120 ℃ for 4 hours, cooling the reaction solution to room temperature, adding water 500 mL, extracting with ether (200 mL × 3), combining organic phases, drying with anhydrous sodium sulfate, filtering, concentrating, purifying with silica gel column chromatography (200-300 mesh), eluting with ethyl acetate (1.848-ene-carboxylic acid methyl ester) (1.9-8 g, colorless oil yield: 8- (9-8-5V): 32%).
Ms m/z(ESI):274.1[M+H + ];
1 HNMR(400MHz,CDCl 3 )δ8.61-8.59(ddd,1H),7.69-7.64(td,1H),7.22-7.18(m,2H),4.49-4.47(t,2H),2.93(s,3H),2.60-2.58(t,2H),1.98-1.55(m,8H).
The second step is that: (9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-8-carboxylic acid methyl ester (48C)
methyl 9-(pyridin-2-yl)-6-oxaspiro[4.5]decane-8-carboxylate
Figure BDA0001714822470001671
The compound, methyl 9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-8-ene-8-carboxylate (48B) (7.0 g, 25.64mmol), was dissolved in methanol (70 mL), and palladium on charcoal (3.0 g,10% by weight, water content 50%) was added, and the mixture was replaced with hydrogen 3 times, and stirred at room temperature under normal pressure hydrogenation overnight. Filtration was carried out, the filter cake was washed with methanol (10 mL. Times.3), and the filtrate was evaporated to dryness to give methyl 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-8-carboxylate (48C) (6.3 g, yield: 90%)
Ms m/z(ESI):276.2[M+H + ].
1 H NMR(400MHz,CD 3 OD)δ8.44-8.42(m,1H),7.77-7.73(td,1H),7.37-7.35(dd,1H),7.23-7.20(dd,1H),4.14-4.10(dd,1H),4.03-3.99(dd,1H),3.47(s,3H),3.40-3.35(dt,1H),3.18-3.17(dd,1H),2.12-2.07(m,1H),1.88-1.54(m,9H).
The third step: (8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-8-carboxylic acid methyl ester (48D)
(8,9trans)-methyl 9-(pyridin-2-yl)-6-oxaspiro[4.5]decane-8-carboxylate
Figure BDA0001714822470001672
Methyl 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-8-carboxylate (48C) (3.6 g, 13.09mmol) was dissolved in methanol (130 mL), nitrogen gas was replaced 3 times, and a methanol solution of sodium methoxide (2.91mL, 15.71mmol) was added and stirred under nitrogen for reflux for 12 hours. The reaction solution was evaporated to dryness, a saturated ammonium chloride solution (100 mL) was added and extracted with ethyl acetate (50 mL × 3), and the organic phases were combined and washed with a saturated saline solution (200 mL × 1), dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to a silica gel column chromatography (petroleum ether/ethyl acetate (V/V)) =10/1, yellow solid. Methyl (8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-8-carboxylate (48D) was obtained as a yellow solid (2.1 g, yield: 58%).
Ms m/z(ESI):276.2[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.55-8.54(d,1H),7.67(s,1H),7.22-7.18(d,2H),4.06-4.02(dd,1H),3.76-3.70(dd,1H),3.51(s,3H),3.41(s,1H),3.21-3.14(m,1H),2.10-1.56(m,10H).
The fourth step: ((8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-8-yl) methanol (48E)
((8,9trans)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-8-yl)methanol
Figure BDA0001714822470001681
The compound lithium aluminum hydride (0.58g, 15.27mmol) and tetrahydrofuran (25 mL) were sequentially charged into a 250mL three-necked reaction flask, and a solution of (8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-8-carboxylic acid methyl ester (48D) (2.10 g, 7.63mmol) in tetrahydrofuran (5 mL) was added dropwise with stirring at room temperature, and the reaction was completed at room temperature for 2 hours. The reaction solution was cooled to 0 ℃ or lower with an ice salt bath, water (0.6 mL), a 20% sodium hydroxide solution (1.2 mL), water (0.6 mL), and filtered with celite in this order with stirring, the cake was washed with tetrahydrofuran (10 mL × 3) and filtered, the filtrate was dried with anhydrous sodium sulfate, filtered, and concentrated to dryness, and the residue was subjected to column chromatography with silica gel 200-300 mesh (petroleum ether/ethyl acetate (V/V) =10 1-3) to give a colorless oily product ((8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-8-yl) methanol (48E) (1.8 g, yield: 95.49%).
Ms m/z(ESI):248.2[M+Na + ]。
The fifth step: (8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-8-carbaldehyde (48F)
(8,9trans)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decane-8-carbaldehyde
Figure BDA0001714822470001682
The compound ((8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-8-yl) methanol (48E) (0.224g, 0.91mmol) was dissolved in dichloromethane (20 mL), stirred and cooled to 0 ℃ and a solution of dess-martin oxidant (0.772g, 1.82mmol) was added and the reaction was completed at room temperature for 4 hours. To the reaction solution was added a saturated thiosulfate solution (50 mL), the aqueous phase was extracted with ethyl acetate (30 mL. Times.3), the organic phases were combined and washed with a saturated sodium bicarbonate solution (50 mL. Times.1), the organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to give a colorless oily product (8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-8-carbaldehyde (48F) (0.20 g, yield: 91.6%).
Ms.m/z(ESI):246.1[M+Na + ]。
And a sixth step: n- (3-chlorobenzyl) -1- ((8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-8-yl) methylamine (48G)
N-(3-chlorobenzyl)-1-((8,9trans)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-8-yl)methanamine
Figure BDA0001714822470001691
The compound (8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-8-carbaldehyde (48F) (0.20g, 0.815mmol), 3-chlorobenzylamine (0.150g, 1.06mmol) was dissolved in dichloromethane (10 mL), and anhydrous sodium sulfate (0.579g, 4.077mmol) was added, and the mixture was stirred at room temperature overnight. Sodium borohydride (0.046 g, 1.223mmol) was added and stirred at room temperature for 1 hour, and 3 ml of anhydrous methanol was added and stirred for 2 hours. Water (20 mL) was added to the reaction solution, extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL × 1), the organic phase was dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, EA/PE =2/1-3/1 to give N- (3-chlorobenzyl) -1- ((8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-8-yl) methylamine (48G) (229 mg, yield: 75.7%) as a yellow oily product.
Ms.m/z(ESI):371.1[M+H + ];
The ninth step: n- (3-chlorobenzyl) -1- ((8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-8-yl) methanamine hydrochloride (Compound 48)
N-(3-chlorobenzyl)-1-((8,9trans)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-8-yl)methanaminehydrochloride
Figure BDA0001714822470001692
The compound N- (3-chlorobenzyl) -1- ((8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-8-yl) methylamine (48G) (0.228g, 0.615mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.615mL, 1.23mmol) was added and stirred at room temperature for 2 hours. The reaction solution was evaporated to dryness to give the product N- (3-chlorobenzyl) -1- ((8, 9 trans) -9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-8-yl) methanamine hydrochloride (compound 48) (241 mg, yield: 97.3%) as a white solid.
Ms.m/z(ESI):371.1[M+H + -HCl];
1 H NMR(400MHz,CD 3 OD)δ8.81-8.79(d,1H),8.63-8.59(t,1H),8.19-8.17(d,1H),8.02-7.99(t,1H),7.57(s,1H),7.49-7.31(m,3H),4.18-4.09(q,3H),3.61-3.55(t,1H),3.41-3.35(t,Hz,1H),3.05-2.99(t,1H),2.76-2.72(d,1H),2.63(s,1H),2.14-2.01(m,2H),1.96-1.89(m,1H),1.85-1.55(m,7H).
Example 49
9-benzyl-1- (3-chlorobenzyl) -4-oxa-1, 9-diazaspiro [5.5] undecan-2-one hydrochloride (Compound 49)
9-benzyl-1-(3-chlorobenzyl)-4-oxa-1,9-diazaspiro[5.5]undecan-2-one hydrochloride
Figure BDA0001714822470001701
The first step is as follows: 8-benzyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (49B)
8-benzyl-1,3,8-triazaspiro[4.5]decane-2,4-dione
Figure BDA0001714822470001702
1-Benzylpiperidin-4-one (49A) (20.0 g, 105.68mmol) was dissolved in ethanol (140 mL), added to potassium cyanide (14.3 g,219.6 mmol) and water (140 mL) with stirring, and stirred at 85 ℃ under reflux for 36 hours. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with hot water (100 mL. Times.3) and dried to give 8-benzyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (49B) (24.3 g, yield: 88.68%) as a white solid.
Ms.m/z(ESI):260.1[M+H + ]。
The second step is that: 4-amino-1-benzylpiperidine-4-carboxylic acid (49C)
4-amino-1-benzylpiperidine-4-carboxylic acid
Figure BDA0001714822470001711
8-benzyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (49B) (24.0 g, 92.56mmol) and water (350 mL) were charged into a reaction flask, and lithium hydroxide monohydrate (19.42g, 462.8 mmol) was added under stirring, and the mixture was refluxed for 24 hours. A large amount of the precipitated white solid was removed by filtration, and the filtrate was cooled to 0 to 5 ℃ and pH-adjusted with 5N hydrochloric acid to precipitate a large amount of white solid, which was filtered, and the filter cake was washed with water (50 mL. Times.2) and dried to give 4-amino-1-benzylpiperidine-4-carboxylic acid (49C) (20 g, yield: 92.23%) as a white solid.
Ms.m/z(ESI):235.1[M+H + ]。
The third step: (4-amino-1-benzylpiperidin-4-yl) methanol (49D)
(4-amino-1-benzylpiperidin-4-yl)methanol
Figure BDA0001714822470001712
4-amino-1-benzylpiperidine-4-carboxylic acid (49C) (17.0 g, 72.56mmol) and tetrahydrofuran (500 mL) were charged into a reaction flask, and lithium aluminum hydride (11.03g, 290.2mmol) was added in small portions with stirring and stirred at room temperature overnight. Water (22 mL), a 20% NaOH solution (44L) and water (22 mL) were added dropwise to the reaction solution in this order under a salt bath with ice, the mixture was stirred for 1 hour, filtered, the filter cake was dried over anhydrous sodium sulfate with tetrahydrofuran (20 mL. Times.3) as an organic phase, filtered and evaporated to dryness to give a colorless oily product (4-amino-1-benzylpiperidin-4-yl) methanol (49D) (13 g, yield: 81.33%).
Ms.m/z(ESI):221.1[M+H + ]。
The fourth step: 9-benzyl-4-oxa-1, 9-diazaspiro [5.5] undecan-2-one (49E)
9-benzyl-4-oxa-1,9-diazaspiro[5.5]undecan-2-one
Figure BDA0001714822470001721
(4-amino-1-benzylpiperidin-4-yl) methanol (49D) (2.0g, 9.079mmol) was dissolved in dichloromethane (20 mL), triethylamine (1.011g, 9.986 mmol) was added with stirring, a solution of chloroacetyl chloride (0.923g, 8.171mmol) in dichloromethane (10 mL) was added dropwise at a temperature of 0 ℃ and the mixture was stirred at room temperature overnight. The mixture was concentrated to dryness, THF (10 mL) was added thereto, the mixture was stirred and cooled to 0 ℃ and a solution of potassium tert-butoxide in tetrahydrofuran (26mL, 26.33mmol) was added thereto, followed by reaction at room temperature overnight. The reaction was evaporated to dryness and silica gel column chromatography (DCM/MeOH = 20/1) afforded the product 9-benzyl-4-oxa-1, 9-diazaspiro [5.5] undecan-2-one (49E) (1.8 g, yield: 76%) as a white solid.
Ms.m/z(ESI):261.1[M+H + ]。
The fifth step: 9-benzyl-1- (3-chlorobenzyl) -4-oxa-1,9-diazaspiro [5.5] undecan-2-one (49F) 9-benzyl-1- (3-chlorobenzyl) -4-oxa-1,9-diazaspiro [5.5]
Figure BDA0001714822470001722
9-benzyl-1- (3-chlorobenzyl) -4-oxa-1,9-diazaspiro [5.5] undecan-2-one (49E) (1.0 g, 3.842mmol) was dissolved in tetrahydrofuran (30 mL), tetrabutylammonium iodide (1.703g, 4.610mmol) was added with stirring, sodium hydrogen (0.307g, 7.683mmol) was added at a temperature of 0 ℃, sodium hydrogen (0.307g, 7.683mmol) was added after stirring for 20 minutes, 3-chlorobenzyl bromide (0.947g, 4.610mmol) was added, and stirring was carried out at room temperature for 2.5 hours. The reaction solution was added to 40g of an ice water mixture, stirred to melt, extracted with ethyl acetate (20 mL × 3), the organic phases were combined and washed with saturated ammonium chloride (50 mL × 2), the organic phase was dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography with DCM/MeOH =50/1 to give the product 9-benzyl-1- (3-chlorobenzyl) -4-oxa-1,9-diazaspiro [5.5] undecan-2-one (49F) (1.2 g, yield: 81.15%) as a white solid.
Ms.m/z(ESI):385.1[M+H + ]。
And a sixth step: 9-benzyl-1- (3-chlorobenzyl) -4-oxa-1,9-diazaspiro [5.5] undecan-2-one hydrochloride (Compound 49)
9-benzyl-1-(3-chlorobenzyl)-4-oxa-1,9-diazaspiro[5.5]undecan-2-one hydrochloride
Figure BDA0001714822470001731
The compound 9-benzyl-1- (3-chlorobenzyl) -4-oxa-1,9-diazaspiro [5.5] undecan-2-one (49F) (0.200g, 0.520mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.520mL, 0.520mmol) was added and stirred at room temperature for 2 hours. The reaction solution was evaporated to dryness to give the product 9-benzyl-1- (3-chlorobenzyl) -4-oxa-1,9-diazaspiro [5.5] undecan-2-one hydrochloride (compound 49) as a white solid (210 mg, yield: 95.9%).
Ms.m/z(ESI):385.1[M+H + -HCl];
1 H NMR(400MHz,CD3OD)δ7.56-7.46(m,5H),7.31-7.17(m,4H),4.70(s,2H),4.34(s,2H),4.29(s,2H),4.10(s,2H),3.44-3.35(m,2H),3.22-3.12(m,2H),2.38(td,2H),1.95(d,2H).
Example 50
2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (Compound 50)
2-((8,9trans)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine hydrochloride
Figure BDA0001714822470001732
Figure BDA0001714822470001741
The first step is as follows: 9- (4-fluorophenyl) -6-oxaspiro [4.5] decane-8-carboxylic acid methyl ester (50B)
methyl 9-(4-fluorophenyl)-6-oxaspiro[4.5]decane-8-carboxylate
Figure BDA0001714822470001742
The compound methyl 9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-ene-8-carboxylate (10D) (22.6 g, 77.85mmol) was dissolved in methanol (100 mL) and added, palladium on charcoal (10 g,10% by weight, water content 50%) was added, and the mixture was replaced with hydrogen gas 3 times, and the mixture was hydrogenated under normal pressure and stirred at room temperature overnight. The filtrate was filtered, and the filter cake was washed with methanol (10 mL. Times.3), and the filtrate was evaporated to dryness to give methyl 9- (4-fluorophenyl) -6-oxaspiro [4.5] decane-8-carboxylate (50B) (21 g, yield: 92.3%) as a colorless oily compound.
Ms m/z(ESI):293.1[M+H + ];
The second step is that: (8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decane-8-carboxylic acid methyl ester (50C)
(8,9trans)-methyl 9-(4-fluorophenyl)-6-oxaspiro[4.5]decane-8-carboxylate
Figure BDA0001714822470001743
Methyl 9- (4-fluorophenyl) -6-oxaspiro [4.5] decane-8-carboxylate (50B) (9.2 g, 31.51mmol) was dissolved in methanol (300 mL), and the mixture was replaced with nitrogen 3 times, to which a methanol solution of sodium methoxide (7.0 mL, 37.81mmol) was added, and the mixture was stirred under nitrogen for 12 hours under reflux. The reaction solution was evaporated to dryness, a saturated ammonium chloride solution (100 mL) was added, extraction was performed with ethyl acetate (50 mL × 3), the organic phases were combined, and washed with a saturated saline solution (200 mL × 1), dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to silica gel column chromatography (petroleum ether/ethyl acetate (V/V)) =10/1 to obtain a yellow solid (8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decane-8-carboxylic acid methyl ester yellow solid compound (50C) (6.4 g, yield: 70%).
Ms m/z(ESI):315.3[M+Na + ];
1 HNMR(400MHz,CD 3 OD)δ7.25-7.20(m,2H),7.02-6.96(m,2H),3.92-3.88(d,1H),3.74-3.69(t,1H),3.43(s,3H),3.16-3.08(td,1H),2.85-2.79(td,1H),2.15-2.08(m,1H),1.85-1.56(m,9H).
The third step: ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methanol (50D)
((8,9trans)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)methanol
Figure BDA0001714822470001751
The compound lithium aluminum hydride (1.677g, 44.14mmol) and tetrahydrofuran (70 mL) were sequentially charged into a 250mL three-necked flask, and a solution of methyl (8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decane-8-carboxylate (50C) (6.400g, 22.07mmol) in tetrahydrofuran (10 mL) was added dropwise with stirring at room temperature, after which the reaction was completed at room temperature for 2 hours. The reaction solution was cooled to 0 ℃ or lower with an ice salt bath, water (2.6 mL), a 20% sodium hydroxide solution (5.2 mL), water (2.6 mL) and celite were added dropwise to the reaction solution in this order while stirring, the cake was washed with tetrahydrofuran (10 mL. Times.3) and filtered, the filtrate was dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and subjected to silica gel 200-300 mesh column chromatography using petroleum ether/ethyl acetate (V/V) =10/1-3/1 to give a colorless oily product ((8, 9-return) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) methanol (50D) (5.7 g, yield: 98.58%).
Ms m/z(ESI):287.1[M+Na + ];
The fourth step: (8, 9 trans) -8- (chloromethyl) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decane (50E)
(8,9trans)-8-(chloromethyl)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decane
Figure BDA0001714822470001752
The compound (9- (4-fluorophenyl) -6-oxaspiro [4.5] dec-8-en-8-yl) methanol (50D) (6.000g, 22.90mmol) was dissolved in methylene chloride (60 mL), triethylamine (4.626 g, 45.80mmol) was added thereto, the mixture was stirred and cooled to 0 ℃ to add dropwise a methanesulfonyl chloride (3.148g, 27.48mmol) solution, and the reaction was completed at room temperature for 4 hours. To the reaction solution was added a saturated ammonium chloride solution (50 mL), the aqueous phase was extracted with ethyl acetate (30 mL. Times.3), the organic phases were combined and washed with a saturated ammonium chloride solution (50 mL. Times.1), the organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to dryness to give a yellow oily product (8, 9 trans) -8- (chloromethyl) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decane (50E) (8.00 g, crude yield: over 100%).
Ms.m/z(ESI):305.1[M+Na + ]。
The fifth step: 2- ((8, 9 trans) -9- (4-fluorobenzene) -6-oxaspiro [4.5] decan-8-yl) acetonitrile (50F)
2-((8,9trans)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)acetonitrile
Figure BDA0001714822470001761
The compound (8, 9 trans) -8- (chloromethyl) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decane (50E) (7.800g, 21.76mmol) was dissolved in DMF (80 mL), and potassium cyanide (5.657g, 87.03mmol) was added and stirred at 80 ℃ for 4 hours. The reaction solution was cooled to room temperature, water (200 mL) was added, the aqueous phase was extracted with ethyl acetate (100 mL. Times.3), the organic phases were combined and washed with saturated brine (200 mL. Times.3), the aqueous phase was treated with sodium hypochlorite and poured into a waste vat, the organic phase was dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, petroleum ether/ethyl acetate (V/V) =30/1-10/1 to give 2- ((8, 9 trans) -9- (4-fluorobenzene) -6-oxaspiro [4.5] decan-8-yl) acetonitrile (50F) (5.73 g, yield: 91%) as a white solid product.
Ms.m/z(ESI):296.1[M+Na + ]。
And a sixth step: 2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) ethylamine (50G)
2-((8,9trans)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)ethanamine
Figure BDA0001714822470001762
The compound 2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) acetonitrile (50F) (2.73g, 9.913mmol) was dissolved in THF (65 mL), and lithium aluminum hydride (0.7534g, 19.83mmol) was added with stirring, after which stirring was carried out at room temperature overnight (12 hours). Water (0.8 mL), a 20% NaOH solution (1.6 mL), and water (0.8 mL) were added dropwise to the reaction mixture in this order under an ice salt bath, and the mixture was stirred for 1 hour, filtered, and the organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to give 2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) ethylamine (50G) (1.7G, yield: 61.4%) as a yellow oily product.
Ms.m/z(ESI):278.1[M+H + ]。
The seventh step: 2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (50H)
2-((8,9trans)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine
Figure BDA0001714822470001771
The compound 2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) ethylamine (50G) (0.500g, 1.704mmol), 3-methoxythiophene-2-carbaldehyde (0.315g, 2.215mmol) was dissolved in dichloromethane (20 mL), and anhydrous sodium sulfate (1.21g, 8.521mmol) was added and stirred at room temperature overnight. Sodium borohydride (0.097g, 2.556 mmol) was added thereto and stirred at room temperature for 1 hour, and 3ml of anhydrous methanol was added thereto and stirred for 2 hours. Water (20 mL) was added to the reaction solution, extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL × 1), the organic phase was dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, EA/PE =2/1-3/1 to give 2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (50H) as a yellow oily product (380 mg, yield: 55.2%).
Ms.m/z(ESI):404.1[M+H + ]。
Eighth step: 2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (Compound 50)
2-((8,9trans)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)-N-((3-methoxythiophen-2-yl)methyl)ethanamine hydrochloride
Figure BDA0001714822470001772
The compound 2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine (50H) (0.380g, 0.943mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.943mL, 0.943mmol) was added and stirred at room temperature for 2 hours. Filtration gave the product, 2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) -N- ((3-methoxythiophen-2-yl) methyl) ethylamine hydrochloride (Compound 50) as a white solid (390 mg, yield: 98.9%).
Ms.m/z(ESI):404.1[M+H + -HCl];
1 H NMR(400MHz,CD 3 OD)δ7.47-7.46(d,1H),7.27-7.22(m,2H),7.06-7.00(m,3H),4.11-4.08(m,2H),3.88(s,3H),3.80-3.75(dd,1H),3.44-3.38(t,1H),2.86-2.79(td,1H),2.64-2.56(m,2H),2.10-2.05(m,1H),1.89-1.37(m,12H).
Example 51
N- (3-chlorobenzyl) -2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) ethylamine hydrochloride (Compound 51)
N-(3-chlorobenzyl)-2-((8R,9S)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)ethanamine hydrochloride
Figure BDA0001714822470001781
The first step is as follows: n- (3-chlorobenzyl) -2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) ethanamine (51A)
N-(3-chlorobenzyl)-2-((8R,9S)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)ethanamine
Figure BDA0001714822470001782
Compound 2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) ethylamine (50G) (0.500g, 1.704mmol), m-chlorobenzaldehyde (0.3114g, 2.215mmol) was dissolved in methylene chloride (20 mL), and anhydrous sodium sulfate (1.21g, 8.521mmol) was added and stirred at room temperature overnight. Sodium borohydride (0.097g, 2.556 mmol) was added thereto and stirred at room temperature for 1 hour, and 3 ml of anhydrous methanol was added thereto and stirred for 2 hours. To the reaction solution was added 20mL of water, the aqueous phase was extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL × 1), the organic phase was dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, EA/PE =2/1-3/1 to give N- (3-chlorobenzyl) -2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) ethylamine (51A) (415 mg, yield: 60.6%) as a yellow oily product.
Ms.m/z(ESI):402.2[M+H + ]。
The second step is that: n- (3-chlorobenzyl) -2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) ethylamine hydrochloride (Compound 51)
N-(3-chlorobenzyl)-2-((8R,9S)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-8-yl)ethanamine
Figure BDA0001714822470001791
The compound N- (3-chlorobenzyl) -2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) ethanamine (51A) (0.380g, 0.943mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (0.943mL, 0.943mmol) was added and the mixture was stirred at room temperature for 2 hours. Filtration gave the product N- (3-chlorobenzyl) -2- ((8, 9 trans) -9- (4-fluorophenyl) -6-oxaspiro [4.5] decan-8-yl) ethylamine hydrochloride (Compound 51) as a white solid (410 mg, yield: 98.7%).
Ms.m/z(ESI):402.2[M+H + -HCl];
1 H NMR(400MHz,CD 3 OD)δ7.46-7.39(m,3H),7.29-7.23(m,3H),7.06-7.01(t,2H),4.08-4.00(m,2H),3.83-3.79(dd,1H),3.46-3.39(t,1H),2.95-2.87(td,1H),2.70-2.57(m,2H),2.08-2.05(d,1H),1.89-1.45(m,12H).
Example 52
N- (3-chlorophenyl) -1- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methylamine hydrochloride (Compound 52)
N-(3-chlorobenzyl)-1-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)methanamine hydrochloride
Figure BDA0001714822470001792
Figure BDA0001714822470001801
The first step is as follows: 6-oxaspiro [4.5] decane-9-carbaldehyde (52B)
6-oxaspiro[4.5]decane-9-carbaldehyde
Figure BDA0001714822470001802
After 6-oxaspiro [4.5] decan-9-one (1 c) (1.00g, 6.48mmol) was dissolved in tetrahydrofuran (20 mL), methoxymethyltriphenylphosphine chloride (5.56g, 16.21mmol) was added thereto, the temperature was reduced to 0 ℃ and a tetrahydrofuran solution of potassium tert-butoxide (1M, 16.2mL) was added dropwise to the reaction mixture, followed by stirring for 3 hours after the addition. Aqueous hydrochloric acid (2M, 8.1mL) was added and the mixture was stirred at room temperature overnight. Water (50 mL) was added, extraction was performed with ethyl acetate (30 mL. Times.3), the organic phases were combined, washed with saturated brine (50 mL. Times.2), dried over anhydrous sodium sulfate, filtered and evaporated to dryness, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/100-1/10) to give 6-oxaspiro [4.5] decane-9-carbaldehyde (52B) (0.95 g, yield 87%) as a yellow oil.
LCMS m/z=169.1[M+H + ]
The second step: 6-Oxaspiro [4.5] decane-9-carboxylic acid methyl ester (52C)
methyl 6-oxaspiro[4.5]decane-9-carboxylate
Figure BDA0001714822470001803
6-oxaspiro [4.5] decane-9-carbaldehyde (52B) (0.95g, 5.6 mmol), potassium hydroxide (0.82g, 15mmol) were dissolved in methanol (10 mL), the temperature was lowered to 0 ℃ and elemental iodine (1.9g, 7.3mmol) was dissolved in methanol (10 mL), and then the solution was added dropwise to the reaction mixture, and the reaction was carried out for half an hour after the addition. The reaction was quenched by dropwise addition of saturated aqueous sodium thiosulfate solution, water (20 mL) was added, extraction was performed with ethyl acetate (20 mL. Times.3), the organic phases were combined, washed with saturated brine (30 mL. Times.2), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/100-1/10) and concentrated to dryness to give methyl 6-oxaspiro [4.5] decane-9-carboxylate (52C) (1.1 g, yield 98%)
1 H NMR(400MHz,CDCl 3 )3.82-3.77(m,1H),3.68(s,3H),3.59-3.53(m,1H),2.63-2.57(m,1H),1.80-1.55(m,12H).
The third step: 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-carboxylic acid methyl ester (52D)
methyl 9-(pyridin-2-yl)-6-oxaspiro[4.5]decane-9-carboxylate
Figure BDA0001714822470001811
6-Oxaspiro [4.5] decane-9-carboxylic acid methyl ester (52C) (1.0 g,5.0 mmol) was dissolved in a single-neck flask with tetrahydrofuran (10 mL), 2-fluoropyridine (0.7 g,7.6 mmol) was added thereto, the temperature was lowered to-70 ℃ or below, bis (trimethylsilyl) sodium amide (5.0 mL,10.1 mmol) was slowly added dropwise to the reaction mixture, and after completion of the addition, stirring was carried out for 10 minutes, and the mixture was allowed to warm to room temperature and reacted for 3 hours. Cooling to about 0 ℃, dropwise adding saturated aqueous ammonium chloride, adding water (20 mL), extracting with ethyl acetate (20 mL × 2), combining the organic phases, washing the organic phases with water (20 mL) and saturated sodium chloride solution (20 mL), drying, filtering, concentrating, purifying the crude product by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/100-1/10) column flushing, concentrating to dryness to obtain yellow oily 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-carboxylic acid methyl ester (52D) (0.6 g, yield 40%).
LCMS m/z=276.2[M+H + ];
The fourth step: (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methanol (52E)
(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)methanol
Figure BDA0001714822470001812
Aluminum lithium hydride (0.25g, 0.65mmol) was stirred in a reaction flask with tetrahydrofuran (5 mL), cooled to 0 ℃ and methyl 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-carboxylate (52D) (0.6 g, 2.18mmol) was dissolved in tetrahydrofuran (5 mL) and added dropwise to the reaction mixture, and the reaction was completed for 2 hours. Water (0.25 g), 10% aqueous sodium hydroxide (0.5 g), and water (0.25 g) were added dropwise in this order, and after stirring for 10 minutes, the mixture was filtered, rinsed with ethyl acetate, and the organic phase was concentrated to dryness to give (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methanol (52E) (0.55 g, yield 100%) as a pale yellow oil.
LCMS m/z=248.1[M+H + ];
The fifth step: 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-carbaldehyde (52F)
9-(pyridin-2-yl)-6-oxaspiro[4.5]decane-9-carbaldehyde
Figure BDA0001714822470001821
(9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methanol (52E) (0.55g, 2.2mmol) was dissolved in methylene chloride (10 mL), cooled to 0 ℃ and dessimutan (2.2g, 5.1mmol) was added to the reaction mixture, and then allowed to spontaneously rise to room temperature for reaction for 3 hours. Water (20 mL) was added, extraction was performed with dichloromethane (20 mL × 2), the organic phases were combined, the organic phase was washed with water (20 mL), saturated sodium chloride solution (20 mL), dried, filtered and concentrated, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/100-1/10) cartridge, concentrated to dryness to give 9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-carbaldehyde (52F) (0.3 g, 50% yield) as a pale yellow oil.
1 H NMR(400MHz,CDCl 3 )9.71(s,1H),8.62-8.61(d,1H),7.72-7.68(dt,1H),7.29-7.26(d,1H),7.22-7.19(dd,1H),3.83-3.78(m,2H),2.52-2.30(m,3H),2.06-2.04(m,1H),1.88-1.41(m,8H).
And a sixth step: n- (3-chlorophenyl) -1- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methylamine (52G)
N-(3-chlorobenzyl)-1-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)methanamine
Figure BDA0001714822470001822
9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-carbaldehyde (52F) (0.14g, 0.57mmol), 3-chlorobenzylamine (0.12g, 0.86mmol) were dissolved in methylene chloride (10 mL), magnesium sulfate (0.34g, 2.9mmol) was added, and the mixture was stirred at room temperature overnight, sodium borohydride (33mg, 0.86mmol) was added and the mixture was stirred at room temperature for 1 hour, and anhydrous methanol (3 mL) was added and the mixture was stirred for 2 hours. Water (20 mL) was added to the reaction solution, extraction was performed with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL), the organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to dryness, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/10-1/1) and concentrated to dryness to give N- (3-chlorophenyl) -1- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methylamine (52G) (0.20G, 90% yield) as a pale yellow oil.
LCMS m/z=371.2[M+H + ];
The seventh step: n- (3-chlorophenyl) -1- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methanamine hydrochloride (Compound 52)
N-(3-chlorobenzyl)-1-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)methanamine hydrochloride
Figure BDA0001714822470001831
N- (3-chlorophenyl) -1- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methylamine (52G) (0.20g, 0.5 mmol) was dissolved in ethyl acetate (10 mL), an ethyl acetate solution of hydrochloric acid (1 mL, 1.7mol/L) was added dropwise to precipitate a solid, and the mixture was stirred for half an hour and concentrated to dryness to give N- (3-chlorophenyl) -1- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methylamine hydrochloride (Compound 52) (0.21G, yield 100%) as a white solid.
LCMS m/z=371.2[M+H + ];
1 H NMR(400MHz,CD 3 OD)8.77-8.75(dd,1H),8.29-8.26(d,1H),7.94-7.92(d,1H),7.78-7.75(t,1H),7.53(s,1H),7.44-7.40(m,3H),4.26-4.16(q,2H),3.78-3.76(m,2H),3.46-3.43(d,1H),2.50-2.43(m,2H),2.08-1.94(m,3H),1.76-1.22(m,10H).
Example 53
1- (3-Methoxythiophene-2-yl) -N- ((9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methyl) methanamine hydrochloride (Compound 53)
1-(3-methoxythiophen-2-yl)-N-((9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)methyl)methanamine hydrochloride
Figure BDA0001714822470001832
The first step is as follows: 1- (3-Methoxythiophene-2-yl) -N- ((9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methyl) methylamine (53A)
1-(3-methoxythiophen-2-yl)-N-((9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)methyl)methanamine
Figure BDA0001714822470001841
9- (pyridin-2-yl) -6-oxaspiro [4.5] decane-9-carbaldehyde (52F) (0.14g, 0.57mmol), 3-methoxythiophene-2-methylaminobenzenesulfonate (0.26g, 0.86mmol) were dissolved in dichloromethane (10 mL), triethylamine (87mg, 0.86mmol), magnesium sulfate (0.34g, 2.9mmol) were added, stirring was continued at room temperature overnight, sodium borohydride (33mg, 0.86mmol) was added, stirring was continued at room temperature for 1 hour, and anhydrous methanol (3 mL) was added and stirring was continued for 2 hours. Water (20 mL) was added to the reaction solution, extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL), the organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to dryness, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether (v/v) = 1/20-1/3) cartridge and concentrated to dryness to give 1- (3-methoxythiophen-2-yl) -N- ((9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methyl) methylamine (53A) (0.20 g, 94% yield) as a brown oil.
LCMS m/z=373.2[M+H + ];
The second step is that: 1- (3-Methoxythiophene-2-yl) -N- ((9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methyl) methanamine hydrochloride (Compound 53)
1-(3-methoxythiophen-2-yl)-N-((9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)methyl)methanamine hydrochloride
Figure BDA0001714822470001842
1- (3-Methoxythien-2-yl) -N- ((9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methyl) methylamine (53A) (0.18g, 0.48mmol) was dissolved in ethyl acetate (10 mL), and a solution of hydrochloric acid in ethyl acetate (1L, 1.7 mol/L) was added dropwise with solid precipitated, stirred for half an hour and concentrated to dryness to give 1- (3-Methoxythien-2-yl) -N- ((9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) methyl) methylamine hydrochloride (Compound 53) (0.12 g, 61% yield) as a brown solid.
LCMS m/z=373.2[M+H + ];
1 H NMR(400MHz,CD 3 OD)8.87-8.69(dd,1H),8.14(dt,1H),7.80-7.78(d,1H),7.63-7.60(dt,1H),7.48-7.46(d,1H),7.02-7.00(d,1H),4.29-4.19(q,2H),3.90(s,3H),3.79-3.74(m,2H),2.42-2.39(d,2H),2.02-1.74(m,4H),1.66-1.17(m,8H).
Example 54
N- ((3-Methoxythien-2-yl) methyl) -2- (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) ethylamine hydrochloride (Compound 54)
N-((3-methoxythiophen-2-yl)methyl)-2-(5-(pyridin-2-yl)hexahydrospiro[cyclopenta[c]furan-1,1'-cyclopentan]-5-yl)ethanamine hydrochloride
Figure BDA0001714822470001851
The first step is as follows: 1- ((trimethylsilyl) ethynyl) cyclopentanol (54B)
1-((trimethylsilyl)ethynyl)cyclopentanol
Figure BDA0001714822470001861
Trimethylsilylacetylene (7g, 71.3 mmol) was dissolved in tetrahydrofuran (80 mL) under nitrogen, the temperature was reduced to-78 deg.C, n-butyllithium (26.2mL, 65.4 mmol) was added dropwise to the reaction, the reaction was allowed to warm to room temperature for 1 hour, the temperature was reduced to-78 deg.C, cyclopentanone (1 a) (5g, 59.4 mmol) was added dropwise to the reaction, and the reaction was continued at room temperature for 2 hours. The reaction solution was quenched with a saturated ammonium chloride solution (80 mL), the aqueous phase was extracted with methyl t-butyl ether (50 mL. Times.2), the organic phases were combined, washed with a saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 1- ((trimethylsilyl) ethynyl) cyclopentanol (54B) (10 g, yield: 92%) as an oily liquid.
1 H NMR(400MHz,CDCl 3 )δ1.96-1.88(m,4H),1.84-1.65(m,4H),0.16(s,9H).
The second step: 1-acetylenyl cyclopentanol (54C)
1-ethynylcyclopentanol
Figure BDA0001714822470001862
1- ((trimethylsilyl) ethynyl) cyclopentanol (54B) (10g, 54.8mmol) was dissolved in methanol (100 mL), and potassium carbonate (15g, 109.6mmol) was further added to conduct a reaction at room temperature for 2 hours. Most of the solvent was removed from the reaction solution, the reaction was quenched with water (60 mL), the aqueous phase was extracted with methyl t-butyl ether (30 mL. Times.3), the organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 1-ethynylcyclopentanol (54C) (5.5 g, yield: 91%) as an oily liquid.
The third step: 1- (allyloxy) -1-ethynylcyclopentane (54D)
1-(allyloxy)-1-ethynylcyclopentane
Figure BDA0001714822470001863
Sodium hydrogen (5.4 g, 136mmol) was dissolved in tetrahydrofuran (100 mL) under ice-bath, 1-ethynylcyclopentanol (54C) (10g, 90.8mmol) was added dropwise to the reaction, reacted at room temperature for 1 hour, and allyl bromide (22g, 181.6mmol) was added dropwise to the reaction, and stirred at room temperature overnight. The reaction was quenched with saturated ammonium chloride solution (300 mL), the aqueous phase was extracted with methyl tert-butyl ether (80 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (50 mL × 3), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 100) to give 1- (allyloxy) -1-ethynylcyclopentane (54D) as an oily liquid (12.5 g, yield: 91.7%).
1 H NMR(400MHz,CDCl 3 )δ6.04-5.87(m,1H),5.35-5.22(m,1H),5.14(ddd,1H),4.08(dt,2H),2.47(s,1H),2.10-1.86(m,4H),1.84-1.67(m,4H).
The fourth step: 3a, 4-dihydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentane ] -5 (3H) -one (54E)
3a,4-dihydrospiro[cyclopenta[c]furan-1,1'-cyclopentan]-5(3H)-one
Figure BDA0001714822470001871
1- (allyloxy) -1-ethynylcyclopentane (54D) (0.4 g, 2.66mmol) was dissolved in n-hexane (20 mL), octacarbonyldicobalt (1g, 2.93mmol) was added to the reaction and reacted at room temperature for 0.5 hour, silica gel (10 g) was added to the reaction and stirred for 0.5 hour. The solvent was then spun dry and the mixture was heated to 50 ℃ for 1 hour under oxygen. The reaction was extracted with methyl tert-butyl ether (20 mL × 3), and after the organic phase was concentrated, the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 50.
Ms m/z(ESI):179.1[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ5.95(d,1H),4.26(t,1H),3.47-3.18(m,2H),2.62(dd,1H),2.18(dd,1H),2.03-1.69(m,8H).
The fifth step: tetrahydropiro [ cyclopenta [ c ] furan-1, 1' -cyclopentane ] -5 (3H) -one (54F)
tetrahydrospiro[cyclopenta[c]furan-1,1'-cyclopentan]-5(3H)-one
Figure BDA0001714822470001872
3a, 4-dihydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentane ] -5 (3H) -one (54E) (1.6 g, 8.97mmol) was dissolved in methanol (30 mL), palladium on carbon (0.4 g, wt= 10%) was added, the reaction system was evacuated and replaced with hydrogen gas three times, and the reaction was carried out at room temperature for 5 hours under hydrogen gas (40 psi). The pad was filtered with suction and the filter cake was washed with methanol (20 mL. Times.2) and the filtrate was concentrated to give tetrahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5 (3H) -one (54F) as a yellow oil (1.5 g, 93% yield).
Ms m/z(ESI):181.1[M+H + ];
And a sixth step: hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentane ] -5-carbonitrile (54G)
hexahydrospiro[cyclopenta[c]furan-1,1'-cyclopentane]-5-carbonitrile
Figure BDA0001714822470001881
Tetrahydrotiro [ cyclopenta [ c ] furan-1, 1' -cyclopentane ] -5 (3H) -one (54F) (2.3 g, 12.8mmol) and p-toluenesulfonylmethylisonitrile (5.7 g, 29mmol) were dissolved in ethylene glycol dimethyl ether (50 mL) under a nitrogen blanket, ethanol (1.4 g, 29mmol) and potassium tert-butoxide (5g, 45mmol) were added to the reaction, and the reaction was allowed to warm to 60 ℃ for 3 hours. After cooling, a saturated ammonium chloride solution (50 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 5).
Ms m/z(ESI):191.6[M+H + ];
The seventh step: 5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentane ] -5-carbonitrile (54H)
5-(pyridin-2-yl)hexahydrospiro[cyclopenta[c]furan-1,1'-cyclopentane]-5-carbonitrile
Figure BDA0001714822470001882
Hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentane ] -5-carbonitrile (54G) (0.6G, 3.14mmol) and 2-fluoropyridine (0.37g, 3.76mmol) were dissolved in toluene (20 mL) under nitrogen, cooled to 0 deg.C, and bis (trimethylsilyl) potassium amide (3.8mL, 3.76mmol) was added dropwise to the reaction and allowed to react overnight at room temperature. To the reaction solution was added a saturated ammonium chloride solution (20 mL), the separated aqueous phase was extracted with ethyl acetate (20 mL × 2), the combined organic phases were washed with a saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 5).
Ms m/z(ESI):269.2[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.62(d,1H),7.85-7.73(m,1H),7.69-7.59(m,1H),7.40-7.28(m,1H),3.87-3.80(m,1H),3.77-3.61(m,1H),3.10-2.88(m,2H),2.79-2.53(m,2H),2.42-2.19(m,2H),1.96-1.44(m,7H),1.39-1.23(m,1H).
The eighth step: 5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1,1' -cyclopentane ] -5-carboxylic acid (54I)
5-(pyridin-2-yl)hexahydrospiro[cyclopenta[c]furan-1,1'-cyclopentane]-5-carboxylic acid
Figure BDA0001714822470001891
5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1,1' -cyclopentane ] -5-carbonitrile (54H) (0.55g, 2.0 mmol) was dissolved in sodium hydroxide solution (25% aq.,6 mL) and methanol (6 mL), and the reaction was carried out by heating to 100 ℃ for 16 hours. Cooling, regulating the pH of the reaction liquid to be approximately equal to 7 by using concentrated hydrochloric acid, decompressing and concentrating the direct reaction liquid to obtain a crude product of 5- (pyridine-2-yl) hexahydrospiro [ cyclopent [ c ] furan-1,1' -cyclopentane ] -5-carboxylic acid (54I), and directly putting the crude product into the next step for reaction.
Ms m/z(ESI):288.2[M+H + ];
The ninth step: 5- (pyridin-2-yl) hexahydrospiro [ cyclopent [ c ] furan-1,1'-cyclopentane ] -5-carboxylic acid methyl ester (54J) methyl5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1,1' -cyclopentane ] -5-carboxylate
Figure BDA0001714822470001892
5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1,1' -cyclopentane ] -5-carboxylic acid (54I) (0.57g, 2.0 mmol) was dissolved in N, N-dimethylformamide (20 mL), and potassium carbonate (0.55g, 4.0 mmol) and iodomethane (0.42g, 3.0 mmol) were added to the reaction, followed by reaction at room temperature for 2 hours. To the reaction solution was added water (50 mL), the aqueous phase was extracted with ethyl acetate (20 mL × 3), the combined organic phases were washed with a saturated sodium chloride solution (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 4).
Ms m/z(ESI):302.2[M+H + ];
The tenth step: (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) methanol (54K)
(5-(pyridin-2-yl)hexahydrospiro[cyclopenta[c]furan-1,1'-cyclopentan]-5-yl)methanol
Figure BDA0001714822470001901
Lithium aluminum hydride (0.1g, 2.65mmol) was dissolved in tetrahydrofuran (10 mL), and cooled to 0 ℃ to add 5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentane ] -5-carboxylic acid methyl ester (54J) (0.4 g, 1.33mmol) in tetrahydrofuran (5 mL) to the reaction and allowed to react at room temperature for 2 hours. The reaction was cooled to 0 ℃, quenched with water (0.1 mL), sodium hydroxide solution (10%, 0.2 mL) and water (0.3 mL) in that order, dried by adding anhydrous sodium sulfate, stirred for 20 minutes, the solid was filtered and washed with tetrahydrofuran (10 mL × 3). The combined organic phases were concentrated to give (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) methanol (54K) (0.36 g, yield: 99%).
The eleventh step: (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) methanesulfonic acid methyl ester (54L)
(5-(pyridin-2-yl)hexahydrospiro[cyclopenta[c]furan-1,1'-cyclopentan]-5-yl)methyl methanesulfonate
Figure BDA0001714822470001902
(5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) methanol (54K) (0.36g, 1.3mmol) and triethylamine (0.20g, 2.0mmol) were dissolved in dichloromethane (15 mL), cooled to 0 ℃ and methanesulfonyl chloride (0.18g, 1.6mmol) was added dropwise to the reaction, and the reaction was allowed to proceed at room temperature for 4 hours. The reaction solution was quenched with water (20 mL), the aqueous phase of the separated liquid was extracted with dichloromethane (20 mL. Times.2), the organic phases were combined, washed with a saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give methyl 5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) methanesulfonate (54L) (0.45 g, yield: 97%) as a yellow oily liquid.
The twelfth step: 2- (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) acetonitrile (54M)
2-(5-(pyridin-2-yl)hexahydrospiro[cyclopenta[c]furan-1,1'-cyclopentan]-5-yl)acetonitrile
Figure BDA0001714822470001911
Methyl (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) methanesulfonate (54L) (0.45g, 1.3mmol) was dissolved in N, N-dimethylformamide (10 mL), and potassium cyanide (0.17g, 2.6 mmol) was added, after which the reaction was carried out at 140 ℃ for 4 hours. To the reaction solution was added water (30 mL), the aqueous phase was extracted with ethyl acetate (20 mL × 3), the combined organic phases were washed with a saturated sodium chloride solution (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =10: 1-3) to give 2- (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) acetonitrile (54M) (0.19 g, yield: 53%) as an oily liquid.
Ms m/z(ESI):283.1[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.62(d,1H),7.70(d,1H),7.42(d,1H),7.20(d,1H),3.75(dd,1H),3.61(dd,1H),2.97-2.77(m,3H),2.75-2.53(m,2H),2.31(dd,1H),1.88-1.53(m,9H),1.29-1.25(m,1H).
The thirteenth step: 2- (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) ethanamine (54N)
2-(5-(pyridin-2-yl)hexahydrospiro[cyclopenta[c]furan-1,1'-cyclopentan]-5-yl)ethanamine
Figure BDA0001714822470001912
Lithium aluminum hydride (0.05g, 1.3 mmol) was dissolved in tetrahydrofuran (10 mL), cooled to 0 deg.C, and 2- ((3aR, 5R,6 aS) -5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) acetonitrile (54M) (0.19g, 0.67mmol) in tetrahydrofuran (5 mL) was added to the reaction and allowed to react overnight at room temperature. The reaction was cooled to 0 ℃, quenched with water (0.05 mL), sodium hydroxide solution (10% aq.,0.1 mL) and water (0.15 mL) in that order, dried by adding anhydrous sodium sulfate, stirred for 20 minutes, and the solid was filtered and washed with tetrahydrofuran (10 mL × 3). The combined organic phases were concentrated to give 2- (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) ethanamine (54N) (0.19 g, yield: 99%).
Ms m/z(ESI):287.2[M+H + ];
A fourteenth step of: n- ((3-Methoxythiophen-2-yl) methyl) -2- (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan ] -5-yl) ethanamine (54O)
N-((3-methoxythiophen-2-yl)methyl)-2-(5-(pyridin-2-yl)hexahydrospiro[cyclopenta[c]furan-1,1'-cyclopentan]-5-yl)ethanamine
Figure BDA0001714822470001921
2- ((3aR, 5R, 6aS) -5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) ethylamine (54N) (0.19g, 0.66mmol) was dissolved in dichloromethane (10 mL), and sodium sulfate (0.47g, 3.3mmol) and 3-methoxythiophene-2-carbaldehyde (0.14g, 1.0mmol) were added to the reaction and reacted at room temperature overnight. Sodium borohydride (0.038g, 1.0mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (10 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):413.2[M+H + ];
The fifteenth step: n- ((3-Methoxythien-2-yl) methyl) -2- (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan ] -5-yl) ethylamine hydrochloride (Compound 54)
N-((3-methoxythiophen-2-yl)methyl)-2-(5-(pyridin-2-yl)hexahydrospiro[cyclopenta[c]furan-1,1'-cyclopentan]-5-yl)ethanamine hydrochloride
Figure BDA0001714822470001922
N- ((3-Methoxythiophen-2-yl) methyl) -2- (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan ] -5-yl) ethylamine (54N) (0.12g, 0.291mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added, and the reaction was stirred at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give N- ((3-methoxythiophen-2-yl) methyl) -2- (5- (pyridin-2-yl) hexahydrospiro [ cyclopenta [ c ] furan-1, 1' -cyclopentan-5-yl) ethylamine hydrochloride (compound 54) as a white solid (0.13 g, yield: 100%).
Ms m/z(ESI):413.3[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.85(dd,1H),8.59(td,1H),8.15(d,1H),8.03-7.97(m,1H),7.47(d,1H),7.01(d,1H),4.20(s,2H),3.90(d,3H),3.76(dd,1H),3.60(dd,1H),2.96-2.88(m,1H),2.81-2.62(m,4H),2.42-2.27(m,3H),1.79-1.58(m,9H),1.36-1.27(m,1H).
Resolution of Compound 54
Compound 54 (0.12 g) was isolated to give two optical isomers, compound 54O-1 (retention time: 4.56min,43.23mg, oily liquid, ee% =100%, configuration), compound 54O-2 (retention time: 4.89min,44.64mg, oily liquid, ee% = 97.2%).
SFC preparation conditions:
the apparatus is a THar80 preparatory SFC (SFC-16);
a column, chiralPak AD,250 × 30mm I.D.,5 μm;
mobile phase A: carbon dioxide, B: isopropyl alcohol;
gradient B30%;
the flow rate is 60mL/min;
back pressure is 100bar;
the column temperature is 38 ℃; the wavelength is 220nm;
the period is about 8min;
sample preparation, compound is dissolved in methanol to 6mg/ml; injection 2 ml/needle.
The two compounds 54O-1 and 54O-2 are salified according to the method for 54 to obtain 54-1 and 54-2:
Compound 54-1:
Ms m/z(ESI):413.3[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.85(dd,1H),8.58(td,1H),8.14(d,1H),8.04-7.91(m,1H),7.47(d,1H),7.01(d,1H),4.20(s,2H),3.89(s,3H),3.77(dd,1H),3.59(dd,1H),2.94-2.88(m,1H),2.84-2.58(m,4H),2.39-2.28(m,3H),1.88-1.51(m,9H),1.34-1.26(m,1H).
compound 54-2:
Ms m/z(ESI):413.3[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.84(dd,1H),8.54(t,1H),8.11(d,1H),7.99-7.92(m,1H),7.47(d,1H),7.01(d,1H),4.20(s,2H),3.89(s,3H),3.76(dd,1H),3.64-3.56(m,1H),2.95-2.88(m,1H),2.81-2.61(m,4H),2.40-2.26(m,3H),1.85-1.51(m,9H),1.35-1.28(m,1H).
example 55
N- ((3-Methylthioen-2-yl) methyl) -2- ((1r, 1aR,1a1r, 5aS) -1- (pyridin-2-yloctahydro 1H-cyclobutyl [ cd ] pent-1-yl) ethylamine hydrochloride (Compound 55)
N-((3-methoxythiophen-2-yl)methyl)-2-((1r,1aR,1a1r,5aS)-1-(pyridin-2-yl)octahydro-1H-cyclobuta[cd]pentalen-1-yl)ethanamine hydrochloride
Figure BDA0001714822470001941
The first step is as follows: (E/Z) -methyl 2-cyano-2- ((1aR, 1a1S, 5aS) -octahydro-1H-cyclobutyl [ cd ] pentan-1-ylidene) carboxylate (55B)
(E/Z)-methyl2-cyano-2-((1aR,1a1S,5aS)-octahydro-1H-cyclobuta[cd]pentalen-1-ylidene)acetate
Figure BDA0001714822470001942
(1aR, 1a1r, 5aS) -octahydro-1H-cyclobutylpentan-1-one (55A) (0.6 g,4.0 mmol), methyl cyanoacetate (0.4 g,4.0 mmol), ammonium acetate (0.3 g,4.0 mmol), acetic acid (0.3 g, 5.1mmol) and toluene (50 mL) were added to a reaction flask, and the reaction was warmed to reflux for 16 hours. After cooling, a sodium hydrogencarbonate solution (50 mL) was added to the reaction solution, aqueous ethyl acetate (30 mL × 3) was extracted, the organic phases were combined, washed with a saturated saline solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 100.
Ms m/z(ESI):218.2[M+H + ];
The second step is that: (2R) -methyl 2-cyano-2- ((1r, 1aR,1a1R, 5aS) -1- (pyridin-2-yl) octahydro-1H-cyclobutyl [ cd ] pentanyl-1-yl) carboxylate (55C)
(2R)-methyl2-cyano-2-((1r,1aR,1a1R,5aS)-1-(pyridin-2-yl)octahydro-1H-cyclobuta[cd]pentalen-1-yl)acetate
Figure BDA0001714822470001951
Isopropyl magnesium chloride (3.0mL, 6.0mmol) was added into a reaction flask under the protection of nitrogen, the temperature was reduced to 0 ℃, a tetrahydrofuran (10 mL) solution of 2-bromopyridine (0.71g, 6.0mmol) was added dropwise to the reaction, after reaction at room temperature for 3 hours, cuprous iodide (0.05g, 0.05mmol) was added to the reaction, and the reaction was stirred for 0.5 hours, and then a tetrahydrofuran (10 mL) solution of (E/Z) -methyl 2-cyano-2- ((1aR, 1a1S, 5aS) -octahydro-1H-cyclobutyl [ cd ] pentylene-1-ylidene) carboxylate (55B) (0.65g, 3.0mmol) was added to the reaction solution, and reacted at 50 ℃ to 55 ℃ for 8 hours. The reaction mixture was added with ice water (20 mL) and 1N hydrochloric acid (10 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated aqueous solution of brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 80.
Ms m/z(ESI):297.1[M+H + ];
The third step: 2- ((1r, 1aR,1a1r, 5aS) -1- (pyridin-2-yloctahydro-1H-cyclobutyl [ cd ] pentanyl-1-yl) acetonitrile (55D)
2-((1r,1aR,1a1r,5aS)-1-(pyridin-2-yl)octahydro-1H-cyclobuta[cd]pentalen-1-yl)acetonitrile
Figure BDA0001714822470001952
Ethylene glycol (10 mL) was added to (2R) -methyl 2-cyano-2- ((1r, 1aR,1a1R, 5aS) -1- (pyridin-2-yl) octahydro-1H-cyclobutyl [ cd ] pentanyl-1-yl) carboxylic acid ester (55C) (0.4g, 1.35mmol), potassium hydroxide (0.2g, 0.27mmol) was further added thereto, and the mixture was heated to 120 ℃ for reaction at 3 hours. The reaction solution was cooled, water (30 mL) was added, the aqueous phase was extracted with ethyl acetate (20 mL × 4), the organic phases were combined, washed with sodium chloride (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 1) to give 2- ((1r, 1ar,1a1r, 5as) -1- (pyridin-2-yl octahydro 1H-cyclobutyl [ cd ] pentyl-1-yl) acetonitrile (55D) as a yellow oily liquid (0.2 g, yield: 62.2%).
Ms m/z(ESI):239.1[M+H + ];
The fourth step: 2- ((1r, 1aR,1a1r, 5aS) -1- (pyridin-2-yloctahydro-1H-cyclobutyl [ cd ] pentanyl-1-yl) ethylamine (55E)
2-((1r,1aR,1a1r,5aS)-1-(pyridin-2-yl)octahydro-1H-cyclobuta[cd]pentalen-1-yl)ethanamine
Figure BDA0001714822470001961
Lithium aluminum hydride (0.1g, 3.0mmol) was dissolved in tetrahydrofuran (20 mL), cooled to 0 ℃ and 2- ((1r, 1aR,1a1r, 5aS) -1- (pyridin-2-yloctahydro 1H-cyclobutyl [ cd ] pentyl-1-yl) acetonitrile (55D) (0.2 g, 0.8mmol) in tetrahydrofuran (5 mL) was added to the reaction, and the reaction was allowed to complete overnight at room temperature, cooled to 0 ℃, quenched with water (0.2 mL), sodium hydroxide solution (10%, 0.6 mL) and water (0.4 mL), dried by adding anhydrous sodium sulfate, stirred for 20 minutes, the solid was filtered and washed with tetrahydrofuran (20 mL. Times.3). The combined organic phases were concentrated to give 2- ((1r, 1aR, 1a1a1aR, 5aS) -1- (pyridin-2-yloctahydro 1H-cyclobutyl [ cd ] pentyl-1-yl) ethylamine (55 g, 100: 242%) as an oil.
Ms m/z(ESI):243.2[M+H + ];
The fifth step: n- ((3-Methylthioen-2-yl) methyl) -2- ((1r, 1aR,1a1r, 5aS) -1- (pyridin-2-yloctahydro-1H-cyclobutyl [ cd ] pent-anyl-1-yl) ethanamine (55F)
N-((3-methoxythiophen-2-yl)methyl)-2-((1r,1aR,1a1r,5aS)-1-(pyridin-2-yl)octahydro-1H-cyclobuta[cd]pentalen-1-yl)ethanamine
Figure BDA0001714822470001962
2- (9- (pyridin-2-yl) -2, 6-dioxaspiro [4.5] decan-9-yl) ethylamine (55E) (0.22g, 0.91mmol) was dissolved in methylene chloride (15 mL), and sodium sulfate 0.5 g) and 3-methoxythiophene-2-carboxaldehyde (0.13g, 0.91mmol) were added to the reaction, and reacted at room temperature overnight. Sodium borohydride (0.045g, 1.3 mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (5 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and after column chromatography of the crude product with column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):369.2[M+H + ];
And a sixth step: n- ((3-Methylthioen-2-yl) methyl) -2- ((1r, 1aR,1a1r, 5aS) -1- (pyridin-2-yloctahydro 1H-cyclobutyl [ cd ] pent-1-yl) ethylamine hydrochloride (Compound 55)
N-((3-methoxythiophen-2-yl)methyl)-2-((1r,1aR,1a1r,5aS)-1-(pyridin-2-yl)octahydro-1H-cyclobuta[cd]pentalen-1-yl)ethanamine hydrochloride
Figure BDA0001714822470001971
N- ((3-Methylthioen-2-yl) methyl) -2- ((1r, 1aR,1a1r, 5aS) -1- (pyridin-2-yloctahydro 1H-cyclobutyl [ cd ] pent-1-yl) ethylamine (55F) (0.10g, 0.3mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir at room temperature for 0.5 hour, and the reaction mixture was directly spin-dried to obtain N- ((3-Methylthion-2-yl) methyl) -2- ((1r, 1a1r, 5aS) -1- (pyridin-2-yloctahydro 1H-cyclobutyl [ cd ] pent-1-yl) ethylamine hydrochloride (compound 55) (0.10 g, yield 90%).
Ms m/z(ESI):369.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.83-8.82(d,1H),8.59(m,1H),8.21-8.19(d,1H),7.98-7.96(m,1H),7.47-7.46(d,1H),7.09-6.96(d,1H),4.18(s,2H),3.88(s,3H),3.12(m,2H),2.98-2.96(m,1H),2.60-2.55(m,1H),2.54-2.53(m,2H),2.20-1.96(m,2H),1.92-1.87(m,6H),1.69-1.66(m,2H).
Example 57
(R) -N- ((2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl) acetamide hydrochloride (Compound 57)
(R)-N-((2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)methyl)acetamide hydrochloride
Figure BDA0001714822470001981
The first step is as follows: 3- (bromomethyl) thiophene (57B)
3-(bromomethyl)thiophene
Figure BDA0001714822470001982
Thiophen-3-ylcarbinol (28A) (3g, 43mmol) was dissolved in hydrobromic acid (40ml, 48%), reacted for 3h, cooled, added with water (50 mL), extracted with dichloromethane (50 mL × 4), washed with saturated saline solution (150 mL × 3), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and subjected to column chromatography for purification (n-hexane/ethyl acetate =10: 1) to give 3- (bromomethyl) thiophene 57B (3 g, yield 70%
1 H NMR(400MHz,CDCl 3 ):δ7.32–7.28(m,2H),7.12–7.11(m,1H),4.61(s,2H).
The second step is that: 3- (Azidomethyl) thiophene (57C)
3-(azidomethyl)thiophene
Figure BDA0001714822470001983
3- (bromomethyl) thiophene 57B (3 g, 22.63mmol) was dissolved in DMF (20 mL), sodium azide (2.2 g,33.9 mmol) was added, and the reaction was continued at 60 ℃ for 5h after the addition was complete. Water (100 mL) was added, extraction was performed with ethyl acetate (20 mL. Times.3), the organic phases were combined, washed with a saturated saline solution (30 mL. Times.1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 3- (azidomethyl) thiophene 57C (3 g, 96% yield) as a yellow oil, which was directly charged to the next step.
1 H NMR(400MHz,CDCl 3 ):δ7.32–7.28(m,2H),7.12–7.11(m,1H),4.34(s,2H)
The third step: thiophene-3-ylmethylamines (57D)
thiophen-3-ylmethanamine
Figure BDA0001714822470001991
3- (azidomethyl) thiophene 57C (3g, 21.55mmol) was dissolved in methanol (40 ml), pd/C (10%) was added, reacted for 2h under an atmosphere of hydrogen balloon, filtered, the filtrate was concentrated, and purified by column chromatography (CH 2Cl2/MeOH = 10).
1 H NMR(400MHz,CDCl 3 ):δ7.32–7.25(m,2H),7.12–7.10(m,1H),3.89(s,2H)
The fourth step: n- (thien-3-ylmethyl) acetamide (57E)
N-(thiophen-3-ylmethyl)acetamide
Figure BDA0001714822470001992
Thiophene-3-ylmethylamine 57D (1.3 g, 11mmol) was dissolved in dichloromethane (20 mL) at room temperature, triethylamine (2.3 g, 23mmol) and acetyl chloride (1.4g, 17mmol) were sequentially added at 0 ℃, the reaction was continued for 2h, 20mL of water was added to the reaction solution, dichloromethane (20 mL × 3) was extracted, the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, the filtrate was concentrated, and purified by column chromatography (CH 2Cl2/MeOH = 10) to give N- (thiophene-3-ylmethyl) acetamide 57E (1.4g, 80%
1 H NMR(400MHz,CDCl 3 ):δ7.30–7.28(m,1H),7.15(s,1H),7.02(d,1H),5.96(br,1H),4.44(d,2H),2.01(s,3H)
The fifth step: n- ((2-Formylthiophen-3-yl) methyl) acetamide (57F)
N-((2-formylthiophen-3-yl)methyl)acetamide
Figure BDA0001714822470002001
N- (thien-3-ylmethyl) acetamide 57E (0.4g, 2.2mmol) was dissolved in tetrahydrofuran (10 mL), the reaction was cooled to-78 ℃ and N-butyllithium (1.3mL, 3.1mmol) was added, after completion of addition, the reaction was raised to zero for 0.5h, and DMF (0.21g, 3mmol) was added and the reaction was continued for 2h. Ammonium chloride water (20 mL) was added, extraction was performed with ethyl acetate (20 mL × 3), the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and subjected to column chromatography for purification (N-hexane/ethyl acetate =5: 1) to obtain N- ((2-formylthiophen-3-yl) methyl) acetamide 57F as a yellow oil (0.2 g, yield 73%).
1 H NMR(400MHz,CDCl 3 ):δ9.97(s,1H),7.70–7.69(d,1H),7.21-7.20(d,1H),6.43(br,1H),4.67(d,2H),2.01(s,3H)
And a sixth step: (R) -N- ((2- (((2- (9- (pyridin-2-yl) -6-Oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl) acetamide (57G)
(R)-N-((2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)methyl)acetamide
Figure BDA0001714822470002002
N- ((2-formylthiophen-3-yl) methyl) acetamide 57F (0.2g, 1mmol) was dissolved in methylene chloride (10 ml), and (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine intermediate 1 (0.39g, 1.5 mmol), anhydrous sodium sulfate (1.31 g) were successively added thereto. After an overnight reaction at room temperature, sodium borohydride (0.065g, 1.73mmol) was added, stirring was continued for 2h, water (20 mL) was added, extraction was performed with ethyl acetate (20 mL × 3), the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography purification (dichloromethane/methanol =5 1) was performed to obtain (R) -N- ((2- (((2- (9- (pyridin-2-yl) -6-oxospiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl) acetamide 57G (0.2g, 40%) as a yellow oil.
Ms m/z(ESI):428.2[M+H + ]。
The seventh step: (R) -N- ((2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl) acetamide hydrochloride (Compound 57)
(R)-N-((2-(((2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amino)methyl)thiophen-3-yl)methyl)acetamide hydrochloride
Figure BDA0001714822470002011
(R) -N- ((2- (((2- (9- (pyridin-2-yl) -6-Oxospiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl) acetamide 57G (0.16g, 0.37mmol) was dissolved in ethyl acetate (5 mL) at room temperature, ethyl hydrogen chloride in ethyl acetate (2mL, 4N) at 0 deg.C, after completion of the addition, the reaction was continued for 0.5h, and the solvent was removed under reduced pressure to give N- ((2- (((2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethyl) amino) methyl) thiophen-3-yl) methyl) acetamide hydrochloride (Compound 57) (0.16g, 96%)
Ms m/z(ESI):428.2[M+H + ]
1 H NMR(400MHz,CD 3 OD):δ8.88(dd,1H),8.66(s,1H),8.22(d,1H),8.06(s,1H),7.49(d,1H),7.03(d,1H),4.41(s,2H),4.24(s,2H),3.85(m,1H),3.74(m,1H),3.09(td,1H),2.64(td,1H),2.47(d,2H),2.23(m,2H),2.20(d,1H),1.91(s,3H),1.61(m,5H),1.24(t,2H)。
Example 58
(R) -N- ((3- (Cyclopropyloxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 58)
(R)-N-((3-(cyclopropoxymethyl)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002012
Figure BDA0001714822470002021
The first step is as follows: 3- (bromomethyl) thiophene (58B)
3-(bromomethyl)thiophene
Figure BDA0001714822470002022
Thiophen-3-ylcarbinol (3g, 43mmol) was dissolved in hydrobromic acid (40ml, 48%) and reacted for 3h, cooled, water (50 mL) was added, extracted with dichloromethane (50 mL × 4), washed with saturated aqueous sodium chloride solution (150 mL × 3), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated and purified by column chromatography (n-hexane/ethyl acetate =10: 1) to give 3- (bromomethyl) thiophene (58B) as a colorless liquid (3 g, yield 70%).
1 H NMR(400MHz,CDCl 3 ):δ7.32–7.28(m,2H),7.12–7.11(m,1H),4.61(s,2H).
The second step is that: 2- (Thien-3-ylmethoxy) ethanol (58C)
2-(thiophen-3-ylmethoxy)ethanol
Figure BDA0001714822470002023
3- (bromomethyl) thiophene 58B (3g, 22.63mmol) was dissolved in DMF (20 mL), and sodium hydride (0.6 g, 25mmol), ethylene glycol (1.58g, 25mmol), tetrabutylammonium bromide (0.06g, 0.17mmol) were added in that order, and after the addition, the reaction was continued at room temperature for 15 hours. Water (100 mL) was added, extracted with ethyl acetate (20 mL × 3), and the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (petroleum ether/ethyl acetate (V/V) = 3) was performed to obtain 2- (thiophen-3-ylmethoxy) ethanol 58C (2 g, yield 40%) as a colorless liquid.
1 H NMR(400MHz,CDCl 3 ):δ7.32–7.26(m,1H),7.23–7.22(m,1H),7.09–7.07(m,1H),4.57(s,2H),3.76–3.74(q,2H),3.60–3.58(q,2H).
The third step: 3- ((2-Bromoethoxy) methyl) thiophene (58D)
3-((2-bromoethoxy)methyl)thiophene
Figure BDA0001714822470002031
Dissolving 2- (thiophen-3-ylmethoxy) ethanol 58C (3.4g, 21mmol) in tetrahydrofuran (40 mL), adding carbon tetrabromide (14g, 43mmol), adding triphenylphosphine (11g, 43mmol) dropwise at zero degrees, reacting at room temperature for 2h, filtering, washing the filter cake with petroleum ether (20 mL), concentrating the organic solvent, and performing column chromatography petroleum ether/ethyl acetate (V/V) =50: 1) Yellow liquid 3- ((2-bromoethoxy) methyl) thiophene 58D (4.7 g, 100% yield) was obtained.
1 H NMR(400MHz,CDCl 3 ):δ7.32–7.26(m,1H),7.24–7.23(m,1H),7.10–7.08(m,1H),4.60(s,2H),3.79–3.76(t,2H),3.49–3.46(t,2H).
The fourth step: 3- ((vinyloxy) methyl) thiophene (58E)
3-((vinyloxy)methyl)thiophene
Figure BDA0001714822470002032
Dissolving 3- ((2-bromoethoxy) methyl) thiophene 58D (4.7g, 21mmol) in tetrahydrofuran (20 mL) at room temperature, adding potassium tert-butoxide (4.8g, 43mmol) at 0 ℃, continuing to react for 2h at room temperature after the addition is finished, adding water (40 mL) into the reaction liquid, extracting with ethyl acetate (20 mL x 3), combining organic phases, washing with saturated saline solution (30 mL x 1), drying with anhydrous sodium sulfate, concentrating the filtrate, and separating and purifying by column chromatography (100% petroleum ether) to obtain a light yellow liquid product, namely 3- ((vinyloxy) methyl) thiophene (58E) (2.2g, 60%).
1 H NMR(400MHz,CDCl 3 ):δ7.33–7.31(m,1H),7.09(t,1H),6.55(q,1H),4.77(s,2H),4.31–4.28(t,1H),4.09–4.07(q,1H).
The fifth step: 3- (Cyclopropyloxymethyl) thiophene (58F)
3-(cyclopropoxymethyl)thiophene
Figure BDA0001714822470002041
3- ((vinyloxy) methyl) thiophene (58E) (1.6 g, 13mmol) was dissolved in dichloromethane (30 mL), diiodomethane (7g, 26mmol) was added, diethyl zinc (3.2g, 26mmol) was added dropwise at zero degrees, and after completion of addition, the reaction was carried out at room temperature for 5 hours. Ammonium chloride solution (15 mL) was added, and extraction was performed with ethyl acetate (20 mL × 3), and the organic phases were combined, washed with saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and subjected to column chromatography for purification (n-hexane/ethyl acetate =20 = 1) to obtain 3- (cyclopropyloxymethyl) thiophene (58F) (0.9 g, yield 73%) as a pale yellow liquid product.
1 H NMR(400MHz,CDCl 3 ):δ9.97(s,1H),7.30–7.26(m,1H),7.22(q,1H),7.08-7.07(m,1H),4.65(s,2H),3.36–3.32(m,1H),0.65–0.61(m,2H),0.50–0.45(m,2H).
And a sixth step: 3- (Cyclopropyloxymethyl) thiophene-2-aldehyde (58G)
3-(cyclopropoxymethyl)thiophene-2-carbaldehyde
Figure BDA0001714822470002042
3- (Cyclopropyloxymethyl) thiophene (58F) (0.4g, 3mmol) was dissolved in tetrahydrofuran (15 mL), added and the reaction was cooled to-78 deg.C, n-butyllithium (1.2mL, 3mmol) was added, the reaction was raised to zero for 0.5h, dimethylformamide (0.3g, 4mmol) was added and the reaction was continued for 2h. Ammonium chloride water (20 mL) was added, extracted with ethyl acetate (20 mL × 3), and the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and subjected to column chromatography separation and purification (n-hexane/ethyl acetate =30: 1) to obtain a pale yellow liquid product, 3- (cyclopropyloxymethyl) thiophene-2-aldehyde (58G) (0.2G, 50% yield).
1 H NMR(400MHz,CDCl 3 ):δ10.10(d,1H),7.67(d,1H),7.26(t,1H),4.87(s,2H),3.41-3.38(m,1H),0.66-0.55(m,1H),0.54-0.52(m,1H).
The seventh step: (R) -N- ((3- (Cyclopropyloxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (58H)
(R)-N-((3-(cyclopropoxymethyl)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470002051
3- (Cyclopropoxymethyl) thiophene-2-aldehyde 58G (0.2g, 1mmol) was dissolved in dichloromethane (10 ml), and (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.3g, 1mmol), anhydrous sodium sulfate (1.31G) was added thereto in this order. After reacting overnight at room temperature, sodium borohydride (0.060g, 2mmol) was added, stirring was continued for 2H, water (20 mL) was added, extraction was performed with ethyl acetate (20 mL × 3), the organic phases were combined, washed with a saturated saline solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and purified by column chromatography (dichloromethane/methanol =15: 1) to obtain (R) -N- ((3- (cyclopropyloxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine (58H) (0.18g, 46%)
Ms m/z(ESI):427.2[M+H + ]
The eighth step: (R) -N- ((3- (Cyclopropyloxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine hydrochloride (Compound 58)
(R)-N-((3-(cyclopropoxymethyl)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002052
(R) -N- ((3- (Cyclopropoxymethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine (58H) (0.18g, 0.42mmol) was dissolved in ethyl acetate (5 mL) and after addition of ethyl hydrogen chloride solution (2mL, 4N) at 0 ℃ for 0.5H, the solvent was removed under reduced pressure to give (R) -N- ((3- (cyclopropylmethyl) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] sunflower-9-yl) ethylamine hydrochloride (compound 58) (0.1g, 96%) as a white solid.
Ms m/z(ESI):427.2[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.86(d,1H),8.57(m,2H),8.14(d,1H),7.49(d,1H),7.04(d,1H),4.63(s,2H),4.36(s,2H),3.84(m,1H),3.73(ddd,1H),3.43(m,1H),3.07(m,1H),2.53(m,2H),2.31(m,1H),2.18(m,2H),1.60(m,5H),1.23(m,1H),0.60(m,2H),0.53(m,2H).
Example 59
N- ((3-Methoxythien-2-yl) methyl) -2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] N-hexane-2, 1' -cyclopentan-6-yl) ethylamine hydrochloride (Compound 59)
N-((3-methoxythiophen-2-yl)methyl)-2-(6-(pyridin-2-yl)-3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentan]-6-yl)ethanamine hydrochloride
Figure BDA0001714822470002061
The first step is as follows: 1- (3- ((tetrahydro-2H-pyran-2-yl) oxy) prop-1-yn-1-yl) cyclopentanol (59B)
1-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-yn-1-yl)cyclopentanol
Figure BDA0001714822470002062
Under the protection of nitrogen, 2- (2-propargyloxy) tetrahydropyran (1 a) (30g, 214mmol) is dissolved in tetrahydrofuran (150 mL), the temperature is reduced to-78 ℃, n-butyl lithium (103mL, 257mmol) is added into the reaction dropwise, after the addition is finished, the reaction is carried out for 0.5 hour, cyclopentanone (19g, 225mmol) is added into the reaction dropwise, and the reaction is continued for 2 hours after the temperature is raised to room temperature. The reaction solution was quenched with a saturated ammonium chloride solution (80 mL), separated, the aqueous phase was extracted with ethyl acetate (80 mL × 2), the organic phases were combined, washed with a saturated sodium chloride solution (80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 1- (3- ((tetrahydro-2H-pyran-2-yl) oxy) prop-1-yn-1-yl) cyclopentanol (59B) (50 g, yield: 95%) as an oily liquid.
The second step is that: 1- (3-hydroxypropan-1-yn-1-yl) cyclopentanol (59C)
1-(3-hydroxyprop-1-yn-1-yl)cyclopentanol
Figure BDA0001714822470002071
1- (3- ((tetrahydro-2H-pyran-2-yl) oxy) prop-1-yn-1-yl) cyclopentanol (59B) (50g, 223mmol) was dissolved in methanol (150 mL), cooled to 0 deg.C, and concentrated hydrochloric acid (1.9 mL, 23mmol) was added dropwise and reacted at room temperature for 2 hours. To the reaction was added saturated sodium bicarbonate solution to adjust PH ≈ 7, most of methanol was removed, water (80 mL) was added, the aqueous phase was extracted with ethyl acetate (80 mL × 4), the organic phases were combined, washed with saturated sodium chloride solution (80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 10) to obtain 1- (3-hydroxypropan-1-yn-1-yl) cyclopentanol (59C) as an oily liquid (30 g, yield: 96%).
1 H NMR(400MHz,CDCl 3 )δ4.31(s,2H),2.18(s,2H),2.03-1.87(m,4H),1.88-1.66(m,4H).
The third step: 1- (3-hydroxypropan-1-en-1-yl) cyclopentanol (59D)
1-(3-hydroxyprop-1-en-1-yl)cyclopentanol
Figure BDA0001714822470002072
1- (3-hydroxyprop-1-yn-1-yl) cyclopentanol (59C) (30g, 214mmol) was dissolved in ethyl acetate (120 mL) and quinoline (120 mL), and lindlar palladium (3g, 5% by weight) was added, and the mixture was replaced with hydrogen three times, and stirred under a hydrogen balloon at room temperature overnight for reaction. Suction filtering the reaction pad with diatomite, washing the filter cake with ethyl acetate (30 mL multiplied by 2), concentrating the filtrate to remove the ethyl acetate, and dissolving the product 1- (3-hydroxypropane-1-en-1-yl) cyclopentanol (59D) in quinoline to directly carry out the next reaction.
1 H NMR(400MHz,CDCl 3 )δ5.73-5.61(m,2H),4.34(d,2H),1.97-1.79(m,6H),1.77-1.63(m,4H).
The fourth step: 1-oxaspiro [4.4] non-3-ene (59E)
1-oxaspiro[4.4]non-3-ene
Figure BDA0001714822470002081
1- (3-hydroxyprop-1-en-1-yl) cyclopentanol (59D) (20g, 140.6 mmol) was dissolved in quinoline (160 mL), and cooled to 0 ℃ to add p-toluenesulfonyl chloride (35g, 183mmol) to the reaction in portions, and reacted at room temperature overnight. The reaction solution was directly distilled under reduced pressure, heated to 100-110 ℃ in an oil bath, and the collected fraction was subjected to oil-bath heating to give 1-oxaspiro [4.4] non-3-ene (59E) (10.0 g, yield: 57%) as a colorless liquid product.
1 H NMR(400MHz,CDCl 3 )δ5.86-5.76(m,1H),5.73(dt,1H),4.59(dd,2H),1.84-1.74(m,4H),1.69-1.60(m,4H).
The fifth step: ethyl 3-oxaspiro [ bicyclo [3.1.0] hexane-2, 1' -cyclopentane ] -6-carboxylic acid ethyl ester (59F)
ethyl 3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentane]-6-carboxylate
Figure BDA0001714822470002082
1-oxaspiro [4.4] non-3-ene (59E) (5g, 40.3 mmol) was dissolved in toluene (40 mL) under nitrogen protection, copper sulfate (0.64g, 4.03mmol) was added thereto, the temperature was raised to 100 ℃ and ethyl diazoacetate (9.2g, 80.6 mmol) was dissolved in toluene (20 mL) and slowly dropped (about 7 hours) into the reaction with a syringe pump, and the reaction was continued at 100 ℃ for 1 hour. After cooling, the reaction solution was filtered and the organic phase was concentrated under reduced pressure, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 30.
Ms m/z(ESI):211.1[M+H + ];
And a sixth step: 3-oxaspiro [ bicyclo [3.1.0] hexane-2, 1' -cyclopentane ] -6-carboxamide (59G)
3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentane]-6-carboxamide
Figure BDA0001714822470002083
Ethyl 3-oxaspiro [ bicyclo [3.1.0] hexane-2, 1' -cyclopentane ] -6-carboxylate (59F) (3.6 g, 17.1mmol) was dissolved in formamide (40 mL), and sodium methoxide (2.3 g,42.8 mmol) was added to the reaction, and the temperature was raised to 60 ℃ for reaction for 3 hours. After cooling, a saturated ammonium chloride solution (80 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (40 mL. Times.5), the organic phases were combined, washed with a saturated sodium chloride solution (40 mL. Times.3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give yellow 3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentane ] -6-carboxamide (59G) (2.0G, yield: 64.5%).
Ms m/z(ESI):182.1[M+H + ];
The seventh step: 3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentane ] -6-carbonitrile (59H)
3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentane]-6-carbonitrile
Figure BDA0001714822470002091
3-Oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentane ] -6-carboxamide (59G) (2.0G, 11.0 mmol) was dissolved in dichloromethane (40 mL), triethylamine (2.8g, 27.6 mmol) was added to the reaction, it was cooled to 0 ℃ and the compound trifluoroacetic anhydride (3.0G, 14.3 mmol) was added dropwise to the reaction and reacted at room temperature for 3 hours. Water (50 mL) was added to the reaction solution, the aqueous phase was extracted with dichloromethane (30 mL × 3), the organic phases were combined, washed with a saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 10).
Ms m/z(ESI):164.1[M+H + ];
Eighth step: 6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] hexane-2,1' -cyclopentane ] -6-carbonitrile (59I)
6-(pyridin-2-yl)-3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentane]-6-carbonitrile
Figure BDA0001714822470002092
Under nitrogen protection, 3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentane ] -6-carbonitrile (59H) (1.50g, 9.19mmol) and 2-fluoropyridine (1.07g, 11.0mmol) were dissolved in toluene (20 mL), cooled to 0 ℃ and bis (trimethylsilyl) amino potassium (11.0mL, 11.0mmol) was added dropwise to the reaction, and the reaction was allowed to proceed overnight at room temperature. To the reaction solution was added a saturated ammonium chloride solution (30 mL), the separated aqueous phase was extracted with ethyl acetate (30 mL × 2), the combined organic phases were washed with a saturated saline solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 5).
Ms m/z(ESI):241.1[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.47(ddd,1H),7.80(dt,1H),7.71(td,1H),7.18(ddd,1H),4.26(d,1H),4.13-4.01(m,1H),2.67(d,2H),2.30-2.20(m,1H),2.04-1.95(m,1H),1.89-1.57(m,6H).
The ninth step: 6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] hexane-2,1'-cyclopentane ] -6-carboxamide (59J) 6- (pyridin-2-yl) -3-oxapiro [ bicyclo [3.1.0] hexane-2,1' -cyclopentane ] -6-carboxamide
Figure BDA0001714822470002101
6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentane ] -6-carbonitrile (59I) (0.50g, 2.08mmol) was dissolved in sodium hydroxide solution (25% aq.,10 mL) and ethylene glycol (10 mL), and reacted for 12 hours with warming to 150 ℃. Cooling, water (50 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (30 mL × 3), the combined organic phases were washed with a saturated saline solution (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 1 to 20) to give 6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentane ] -6-carboxamide (59J) (0.45 g, yield: 84%) as a white solid.
Ms m/z(ESI):259.1[M+H + ];
The tenth step: 6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] hexane-2,1'-cyclopentane ] -6-carboxylic acid (59K) 6- (pyridin-2-yl) -3-oxapiro [ bicyclo [3.1.0] hexane-2,1' -cyclopentane ] -6-carboxylic acid
Figure BDA0001714822470002102
6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentane ] -6-carboxamide (59J) (0.35g, 1.36mmol) was dissolved in acetic acid (3 mL) and acetic anhydride (6 mL) under nitrogen protection, and sodium nitrite (0.94g, 13.6 mmol) was added to the reaction, followed by stirring at room temperature overnight. Water (20 mL) and a 1M hydrochloric acid solution (10 mL) were added to the reaction solution, the aqueous phase was extracted with ethyl acetate (20 mL. Times.3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] hexane-2,1' -cyclopentane ] -6-carboxylic acid (59K) (0.30 g, yield: 85.4%) as an oily liquid.
Ms m/z(ESI):260.1[M+H + ];
The eleventh step: 6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] hexane-2,1' -cyclopentane ] -6-carboxylic acid methyl ester (59L)
Methyl6-(pyridin-2-yl)-3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentane]-6-carboxylate
Figure BDA0001714822470002111
6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] N-hexane-2, 1' -cyclopentane ] -6-carboxylic acid (59K) (0.30g, 1.16mmol) was dissolved in N, N-dimethylformamide (10 mL), and potassium carbonate (0.32g, 2.31mmol) and iodomethane (0.25g, 1.74mmol) were added to the reaction solution and reacted at room temperature for 2 hours. Water (50 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (20 mL × 3), the organic phases were combined, washed with a saturated saline solution (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 5) to give methyl 6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentane ] -6-carboxylate (59L) (0.30 g, yield: 95%) as an oily liquid.
1 H NMR(400MHz,CDCl 3 )δ8.49(ddd,1H),7.59(td,1H),7.19(d,1H),7.11(ddd,1H),4.23(d,1H),3.87-3.69(m,4H),2.39(d,1H),2.26(dd,1H),2.19-2.12(m,1H),1.91-1.69(m,3H),1.70-1.54(m,4H).
The twelfth step: (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] hexane-2, 1' -cyclopentan-6-yl) methanol (59M)
(6-(pyridin-2-yl)-3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentan]-6-yl)methanol
Figure BDA0001714822470002112
Lithium aluminum hydride (0.11g, 2.93mmol) was dissolved in tetrahydrofuran (10 mL), and cooled to 0 ℃ to add 6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentane ] -6-carboxylic acid methyl ester (59L) (0.4g, 1.46mmol) in tetrahydrofuran (5 mL) for reaction overnight at room temperature. The reaction solution was quenched with water (0.11 mL), sodium hydroxide solution (10% aq.,0.22 mL) and water (0.33 mL) in this order, dried by adding anhydrous sodium sulfate, stirred for 20 minutes, filtered, and the filter cake was washed with tetrahydrofuran (10 mL × 3). The organic phase was concentrated to give (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentan-6-yl) methanol (59M) (0.30 g, yield: 83.6%).
Ms m/z(ESI):246.2[M+H + ];
The thirteenth step: (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] N-hexane-2, 1' -cyclopentan-6-yl) methanesulfonic acid methyl ester (59N)
(6-(pyridin-2-yl)-3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentan]-6-yl)methylmethanesulfonate
Figure BDA0001714822470002121
(6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentan-6-yl) methanol (59M) (0.30g, 1.22mmol) and triethylamine (0.18g, 1.83mmol) were dissolved in dichloromethane (15 mL), cooled to 0 ℃ and methanesulfonyl chloride (0.17g, 1.47mmol) was added dropwise to the reaction and reacted at room temperature for 4 hours. The reaction solution was quenched with water (20 mL), separated, the aqueous phase was extracted with dichloromethane (20 mL. Times.2), the organic phases were combined, washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give methyl (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] N-hexane-2, 1' -cyclopentan-6-yl) methanesulfonate (59N) (0.39 g, yield: 99%) as a yellow oily liquid.
The fourteenth step is that: 2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentan-6-yl) acetonitrile (59O)
2-(6-(pyridin-2-yl)-3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentan]-6-yl)acetonitrile
Figure BDA0001714822470002122
Methyl (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] N-hexane-2, 1' -cyclopentan-6-yl) methanesulfonate (59N) (0.39g, 1.2mmol) was dissolved in N, N-dimethylformamide (10 mL), and potassium cyanide (0.16g, 2.4mmol) was added thereto, followed by reaction at 140 ℃ for 6 hours. To the reaction solution was added water (50 mL), the aqueous phase was extracted with ethyl acetate (20 mL × 3), the combined organic phases were washed with a saturated saline solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =1 to 3) to obtain 2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentan-6-yl) acetonitrile (59O) (0.07 g, yield: 20%) as an oily liquid.
Ms m/z(ESI):255.1[M+H + ];
The fifteenth step: 2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] hexane-2, 1' -cyclopentan-6-yl) ethylamine (59P)
2-(6-(pyridin-2-yl)-3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentan]-6-yl)ethanamine
Figure BDA0001714822470002131
Lithium aluminum hydride (0.021g, 0.55mmol) was dissolved in tetrahydrofuran (6 mL), and the temperature was lowered to 0 ℃ to add 2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentan-6-yl) acetonitrile (59O) (0.07g, 0.28mmol) in tetrahydrofuran (2 mL) to react overnight at room temperature. The reaction solution was cooled to 0 ℃, quenched with water (0.02 mL), sodium hydroxide solution (10% aq.,0.04 mL) and water (0.06 mL) in this order, dried by adding anhydrous sodium sulfate, stirred for 20 minutes, filtered, and the filter cake was washed with tetrahydrofuran (10 mL × 2). The combined organic phases were concentrated to give 2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentan-6-yl) ethylamine (59P) (0.07 g, yield: 100%).
Ms m/z(ESI):259.1[M+H + ];
Sixteenth, step: n- ((3-Methoxythiophen-2-yl) methyl) -2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] hexane-2, 1' -cyclopentan-6-yl) ethylamine (59R)
N-((3-methoxythiophen-2-yl)methyl)-2-(6-(pyridin-2-yl)-3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentan]-6-yl)ethanamine
Figure BDA0001714822470002132
2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] n-hexane-2, 1' -cyclopentan-6-yl) ethanamine (59P) (0.07g, 0.27mmol) was dissolved in dichloromethane (10 mL), and sodium sulfate (0.19g, 1.4mmol) and 3-methoxythiophene-2-carbaldehyde (0.077g, 0.54mmol) were added to the reaction and allowed to react at room temperature overnight. Sodium borohydride (0.015g, 0.41mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (5 mL) and stirring for 1 hour. The reaction was quenched with water (20 mL), the aqueous phase was extracted with dichloromethane (10 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give crude N- ((3-methoxythiophen-2-yl) methyl) -2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] N-hexane-2, 1' -cyclopentan-6-yl) ethylamine (59R) (0.023 g, yield: 22%) as a yellow oily liquid by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):385.2[M+H + ];
Seventeenth step: n- ((3-Methoxythien-2-yl) methyl) -2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] hexane-2, 1' -cyclopentan-6-yl) ethylamine hydrochloride (Compound 59)
N-((3-methoxythiophen-2-yl)methyl)-2-(6-(pyridin-2-yl)-3-oxaspiro[bicyclo[3.1.0]hexane-2,1'-cyclopentan]-6-yl)ethanamine hydrochloride
Figure BDA0001714822470002141
N- ((3-Methoxythien-2-yl) methyl) -2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] N-hexane-2, 1' -cyclopentan-6-yl) ethylamine (59R) (0.023g, 0.06mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to obtain N- ((3-methoxythiophen-2-yl) methyl) -2- (6- (pyridin-2-yl) -3-oxaspiro [ bicyclo [3.1.0] N-hexane-2, 1' -cyclopentan-6-yl) ethylamine hydrochloride (compound 59) (0.025 g, yield: 99%) as a gray solid.
Ms m/z(ESI):385.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.79(dd,1H),8.57(td,1H),8.05-7.97(m,2H),7.47(d,1H),7.01(d,1H),4.23(s,2H),4.11(d,1H),4.05(dd,1H),3.88(s,3H),3.04-2.86(m,2H),2.66-2.40(m,3H),2.23-2.10(m,2H),1.93-1.72(m,4H),1.71-1.60(m,3H).
Example 60
(R) -N- ((4-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine 4-methylbenzenesulfonate (Compound 60)
(R)-N-((4-ethynyl-3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine 4-methylbenzenesulfonate
Figure BDA0001714822470002151
The first step is as follows: 4-bromo-3-hydroxythiophene-2-carboxylic acid methyl ester (60B)
methyl 4-bromo-3-hydroxythiophene-2-carboxylate
Figure BDA0001714822470002152
Methyl 3-hydroxythiophene-2-carboxylate (60A) (5 g,31.6 mmol) was dissolved in acetic acid (30 mL) under nitrogen, and bromine (10.1g, 63.2mmol) was added dropwise to the reaction, after which the reaction was allowed to proceed overnight at room temperature. To the reaction solution was added a saturated sodium hydrogen sulfite solution (50 mL), the aqueous phase was extracted with methyl t-butyl ether (30 mL. Times.3), the combined organic phases were washed with a saturated sodium hydrogen carbonate solution (30 mL. Times.2) and a saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and after the crude product was recrystallized from methanol, a white solid methyl 4-bromo-3-hydroxythiophene-2-carboxylate (60B) (3.0 g, yield: 40%) was obtained.
1 H NMR(400MHz,CDCl 3 )δ9.73(s,1H),7.37(s,1H),3.92(s,3H).
The second step is that: 4-bromo-3-methoxythiophene-2-carboxylic acid methyl ester (60C)
methyl 4-bromo-3-methoxythiophene-2-carboxylate
Figure BDA0001714822470002161
Methyl 4-bromo-3-hydroxythiophene-2-carboxylate (60B) (3.0g, 12.7mmol) was dissolved in N, N-dimethylformamide (30 mL), and potassium carbonate (3.55g, 25.3mmol) and iodomethane (2.69g, 19.0mmol) were added thereto, and the reaction was completed at 60 ℃ for 2 hours. After cooling, water (60 mL) was added to the reaction mixture, and the solid product was washed out, filtered, and the filter cake was washed with water (20 mL. Times.3) to obtain methyl 4-bromo-3-methoxythiophene-2-carboxylate (60C) (2.85 g, yield: 89.7%) as a white solid after drying.
1 H NMR(400MHz,CDCl 3 )δ7.38(s,1H),4.02(s,3H),3.88(s,3H).
The third step: 3-methoxy-4- ((trimethylsilyl) ethynyl) thiophene-2-carboxylic acid methyl ester (60D)
methyl 3-methoxy-4-((trimethylsilyl)ethynyl)thiophene-2-carboxylate
Figure BDA0001714822470002162
Methyl 4-bromo-3-methoxythiophene-2-carboxylate (60℃) (2.85g, 11.4 mmol) and trimethylsilyne (2.23g, 22.7 mmol) were dissolved in tetrahydrofuran (15 mL) and triethylamine (15 mL), and bis (triphenylphosphine) palladium (II) dichloride (0.398g, 0.57mmol) and cuprous iodide (0.216g, 1.14mmol) were added to the reaction under nitrogen and the temperature was raised to 60 ℃ for 12 hours. The reaction solution was filtered, and the organic phase was directly concentrated, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 50.
Ms m/z(ESI):269.1[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ7.50(s,1H),4.13(s,3H),3.85(s,3H),0.24(m,9H).
The fourth step: (3-methoxy-4- ((trimethylsilyl) ethynyl) thiophen-2-yl) methanol (60E) (3-methoxy-4- ((trimethylsilyl) ethyl) thiophen-2-yl) methanol
Figure BDA0001714822470002163
Lithium aluminum hydride (0.66g, 17.47mmol) was dissolved in tetrahydrofuran (30 mL), cooled to 0 deg.C, and a solution of methyl 3-methoxy-4- ((trimethylsilyl) ethynyl) thiophene-2-carboxylate (60D) (2.8g, 11.65mmol) in tetrahydrofuran (10 mL) was added dropwise to the reaction and allowed to react at room temperature for 2 hours. The reaction was cooled to 0 ℃, and the reaction was quenched with water (0.66 mL), sodium hydroxide solution (10% aq.,1.3 mL) and water (1.3 mL) in this order, and then dried over anhydrous sodium sulfate, filtered, the solid was washed with tetrahydrofuran (20 mL × 2), and the combined organic phases were concentrated to give (3-methoxy-4- ((trimethylsilyl) ethynyl) thiophen-2-yl) methanol (60E) (2.4 g, yield: 85.7%) as an oily liquid.
Ms m/z(ESI):263.1[M+Na + ];
The fifth step: 3-methoxy-4- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (60F) 3-methoxy-4- ((trimethylsilyl) ethyl) thiophene-2-carbaldehyde
Figure BDA0001714822470002171
(3-methoxy-4- ((trimethylsilyl) ethynyl) thiophen-2-yl) methanol (60E) (2.4 g, 9.98mmol) was dissolved in dichloromethane (50 mL), cooled to 0 ℃ and manganese dioxide (8.68g, 99.8mmol) was added to the reaction and reacted at room temperature for 12 hours. The reaction was filtered, the filter cake was washed with dichloromethane (20 mL × 2), and the combined organic phases were concentrated to give 3-methoxy-4- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (60F) as an oily liquid (1.8 g, yield: 75.6%).
And a sixth step: 4-ethynyl-3-methoxythiophene-2-carbaldehyde (60G)
4-ethynyl-3-methoxythiophene-2-carbaldehyde
Figure BDA0001714822470002172
3-methoxy-4- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (60F) (1.8g, 7.55mmol) was dissolved in methanol (20 mL), and potassium carbonate (1.6 g, 11.3mmol) was added to the reaction, followed by reaction at room temperature for 1 hour. The reaction solution was quenched with water (50 mL), the aqueous phase was extracted with ethyl acetate (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 10) to obtain 4-ethynyl-3-methoxythiophene-2-carbaldehyde (60G) as a yellow solid (1.0G, yield: 79.7%).
1 H NMR(400MHz,CDCl 3 )δ10.01(d,1H),7.76(d,1H),4.26(s,3H),3.26(s,1H).
The seventh step: (R) -N- ((4-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (60H)
(R)-N-((4-ethynyl-3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470002181
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.3g, 1.15mmol) was dissolved in methylene chloride (10 mL), and sodium sulfate (0.818g, 5.76mmol) and 4-ethynylthiophene-2-carbaldehyde (60G) (0.287g, 1.73mmol) were added to the reaction at room temperature overnight. Sodium borohydride (0.07g, 1.73mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (30 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):411.2[M+H + ];
The eighth step: (R) -N- ((4-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine 4-methylbenzenesulfonate (Compound 60) (R) -N- ((4-ethyl-3-methoxythiopen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxapiro [4.5] can-9-yl) ethanamine 4-methylbenezene sulfonate
Figure BDA0001714822470002182
(R) -N- ((4-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (60H) (0.08g, 0.2mmol) was dissolved in ethyl acetate (4 mL), and p-toluenesulfonic acid monohydrate (0.04g, 0.2mmol) was dissolved in ethyl acetate (2 mL) and added dropwise to the reaction mixture, followed by stirring at room temperature for 1 hour. The reaction solution was directly spin-dried and dried to give (R) -N- ((4-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine 4-methylbenzenesulfonate (compound 60) as a white solid (0.12 g, yield: 100%).
Ms m/z(ESI):411.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.58(d,1H),7.86(t,1H),7.70(d,2H),7.66(s,1H),7.55(d,1H),7.33(t,1H),7.23(d,2H),4.16(s,2H),4.00(s,3H),3.77-3.73(m,3H),2.94(td,1H),2.50-2.38(m,3H),2.37(s,3H),2.11(td,1H),1.92-1.83(m,2H),1.76-1.64(m,3H),1.58-1.41(m,4H),1.14-1.07(m,1H),0.75-0.67(m,1H).
Example 61
3- (3-Isopropoxyphenyl) -N- ((3-methoxythiophen-2-yl) methyl) -3- (pyridin-2-yl) propyl-1-amine hydrochloride (Compound 61)
3-(3-isopropoxyphenyl)-N-((3-methoxythiophen-2-yl)methyl)-3-(pyridin-2-yl)propan-1-amine hydrochloride
Figure BDA0001714822470002191
The first step is as follows: 3-Isopropoxybenzaldehyde (61B)
3-isopropoxybenzaldehyde
Figure BDA0001714822470002192
3-hydroxybenzaldehyde (61A) (3.05g, 25.0 mmol) was dissolved in N, N-dimethylformamide (30 mL), and potassium carbonate (6.9g, 50.0 mmol) and iodoisopropane (5.09g, 30.0 mmol) were added to the reaction, followed by reaction at 50 ℃ for 6 hours. The reaction was cooled to 0 ℃ and water (90 mL) was added, the aqueous phase was extracted with methyl t-butyl ether (30 mL. Times.3), the organic phases were combined, washed with saturated sodium chloride (30 mL. Times.1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 3-isopropoxybenzaldehyde (61B) (3.9 g, yield: 95%).
1 H NMR(400MHz,CDCl 3 )δ9.96(s,1H),7.43-7.41(m,2H),7.38-7.37(m,1H),7.15-7.13(m,1H),4.66–4.60(m,1H),1.37-1.35(d,2H).
The second step: (3-Isopropoxyphenyl) (pyridin-2-yl) methanol (61C)
(3-isopropoxyphenyl)(pyridin-2-yl)methanol
Figure BDA0001714822470002201
A solution of 2-bromopyridine (1.74g, 11mmol) in tetrahydrofuran (15 mL) was added dropwise to a solution of isopropyl magnesium chloride (5.5 mL, 2M in tetrahydrofuran) at 0 deg.C under nitrogen, then the mixture was stirred at room temperature for 3 hours, then a solution of 3-isopropoxybenzaldehyde (61B) (1.64g, 10mmol) in tetrahydrofuran (20 mL) was added over 30 minutes. The mixture was then stirred at room temperature for 12 hours. The reaction mixture was poured into a mixture of 50g ice/1N HCl (20 mL). The product was extracted with ethyl acetate (30 mL. Times.3), the combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give (3-isopropoxyphenyl) (pyridin-2-yl) methanol (61C) (1.5 g, yield: 62%) as a yellow oily liquid
Ms m/z(ESI):244.1[M+H + ];
The third step: (3-Isopropoxyphenyl) (pyridin-2-yl) methanone (61D)
(3-isopropoxyphenyl)(pyridin-2-yl)methanone
Figure BDA0001714822470002202
(3-Isopropoxyphenyl) (pyridin-2-yl) methanol (61C) (1.2 g,4.9 mmol) was dissolved in dichloromethane (20 mL) at room temperature, pyridinium chlorochromate (2.1g, 9.9 mmol) was added, and the reaction was stirred at room temperature for 3 hours. The reaction was filtered, and the filtrate was concentrated and directly spin-dried to give (3-isopropoxyphenyl) (pyridin-2-yl) methanone (61D) (0.8 g, 70% yield) as a brown liquid.
Ms m/z(ESI):242.1[M+H + ].
The fourth step: (Z/E) -3- (3-Isopropoxyphenyl) -3- (pyridin-2-yl) acrylonitrile (61E)
(Z/E)-3-(3-isopropoxyphenyl)-3-(pyridin-2-yl)acrylonitrile
Figure BDA0001714822470002211
Sodium hydride (0.09g, 4 mmol) was added to tetrahydrofuran (20 mL), the temperature was reduced to 0 ℃ and diethyl cyanomethylphosphonate (0.6g, 3 mmol) was added and, after the addition, the reaction was carried out at 0 ℃ for 1 hour. (pyridin-2-yl) methanone (61D) (0.8g, 3 mmol) was dissolved in tetrahydrofuran (5 mL) and added dropwise to the reaction mixture, and then the mixture was allowed to naturally warm to room temperature for 4 hours. The reaction was cooled to 0 ℃, ammonium chloride solution (30 mL) was added, the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with saturated sodium chloride (30 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give (Z/E) -3- (3-isopropoxyphenyl) -3- (pyridin-2-yl) acrylonitrile (61E) (0.75 g, 90% yield).
Ms m/z(ESI):265.1[M+H + ];
The fifth step: 3- (3-Isopropoxyphenyl) -3- (pyridin-2-yl) propyl-1-amine (61F)
3-(3-isopropoxyphenyl)-3-(pyridin-2-yl)propan-1-amine
Figure BDA0001714822470002212
(Z/E) -3- (3-isopropoxyphenyl) -3- (pyridin-2-yl) acrylonitrile (61E) (0.88g, 3.31mmol) was dissolved in anhydrous methanol (30 mL), cobalt dichloride hexahydrate (0.86g, 6.6 mmol) was added, and sodium borohydride (1.26g, 33.1mmol) was added in portions. The reaction was stirred at room temperature for 12 hours. Water (30 mL) was added, the aqueous phase was extracted with ethyl acetate (30 mL. Times.3), the organic phases were combined, washed with saturated sodium chloride (30 mL. Times.1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 3- (3-isopropoxyphenyl) -3- (pyridin-2-yl) propyl-1-amine (61F) (0.42 g, 47% yield).
Ms m/z(ESI):271.2[M+H + ].
And a sixth step: 3- (3-Isopropoxyphenyl) -N- ((3-methoxythiophen-2-yl) methyl) -3- (pyridin-2-yl) propyl-1-amine (61G)
3-(3-isopropoxyphenyl)-N-((3-methoxythiophen-2-yl)methyl)-3-(pyridin-2-yl)propan-1-amine
Figure BDA0001714822470002213
3- (3-Isopropoxyphenyl) -3- (pyridin-2-yl) propyl-1-amine (61F) (0.41g, 1.5 mmol) was dissolved in methylene chloride (20 mL), and sodium sulfate (1.3 g,7.5 mmol) and 3-methoxythiophene-2-carboxaldehyde (0.23g, 1.6 mmol) were added to the reaction, followed by reaction overnight at room temperature. Sodium borohydride (0.09g, 2.0 mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) =50
Ms m/z(ESI):397.1[M+H + ];
The seventh step: 3- (3-Isopropoxyphenyl) -N- ((3-methoxythiophen-2-yl) methyl) -3- (pyridin-2-yl) propyl-1-amine hydrochloride (Compound 61)
3-(3-isopropoxyphenyl)-N-((3-methoxythiophen-2-yl)methyl)-3-(pyridin-2-yl)propan-1-amine hydrochloride
Figure BDA0001714822470002221
3- (3-Isopropoxyphenyl) -N- ((3-methoxythiophen-2-yl) methyl) -3- (pyridin-2-yl) propyl-1-amine (61G) (50mg, 0.12mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction was directly spun dry to give 3- (3-isopropoxyphenyl) -N- ((3-methoxythiophen-2-yl) methyl) -3- (pyridin-2-yl) propyl-1-amine hydrochloride (compound 61) as a brown solid (50 mg, 100% yield).
Ms m/z(ESI):397.1[M+H + ];
1 H NMR(400MHz,CD 3 OD)δ8.73-8.71(d,1H),8.56-8.52(m,1H),8.09-7.92(d,1H),7.90-7.89(m,1H),7.87(d,1H),7.31-7.29(m,1H),7.02-7.01(d,1H),6.90-6.88(m,1H),4.48(m,1H),4.29(m,1H),4.28(s,1H),3.87(s,3H),3.05(m,1H),2.91(m,1H),2.63-2.59(m,1H),1.30-1.17(d,6H).
Example 62
1-cyclopentyl-5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 62)
1-cyclopentyl-5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-5(pyridin-2-yl)piperidin-2-onehydrochloride
Figure BDA0001714822470002231
The first step is as follows: 5- ((1, 3-Dioxolan-2-yl) methyl) -1-cyclopentyl-5- (pyridin-2-yl) piperidin-2-one (62A)
5-((1,3-dioxolan-2-yl)methyl)-1-cyclopentyl-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470002232
At room temperature, 5- ((1, 3-dioxolan-2-yl) methyl) -5- (pyridin-2-yl) piperidin-2-one (36D) (0.3 g, 1mmol) was dissolved in ethylene glycol dimethyl ether (5 mL), and potassium tert-butoxide (0.12g, 1.14mmol), bromocyclopentane (0.21g, 1.14mmol) and added thereto, the reaction was continued for 0.5h while warming to 60 ℃, bromocyclopentane (0.12g, 1.14mmol) was added to the reaction solution every 1h, potassium tert-butoxide (0.12g, 1.14mmol) was added repeatedly for 8 times, water (20 mL) was added to the reaction solution, ethyl acetate was extracted (20 mL × 2) and anhydrous sodium sulfate was added thereto and dried, the filtrate was filtered, the solvent was removed by concentration under reduced pressure, column chromatography (dichloromethane/methanol = 30) gave 5- ((3-dioxolan-2-yl) methyl) -1-cyclopentyl-5- (pyridin-2-yl) piperidin-2-one (62 g,92 g) piperidine-2-one (a) as a yellow oily product.
Ms m/z(ESI):263.1[M+H + ]。
The second step is that: 2- (1-cyclopentyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde (62B)
2-(1-cyclopentyl-6-oxo-3-(pyridin-2-yl)piperidin-3-yl)acetaldehyde
Figure BDA0001714822470002241
5- ((1, 3-Dioxolan-2-yl) methyl) -1-methyl-5- (pyridin-2-yl) piperidin-2-one 62A (0.5g, 1mmol) was dissolved in tetrahydrofuran (15 mL) and concentrated hydrochloric acid (1 mL) at room temperature, stirred overnight at room temperature, and the reaction was concentrated to give 2- (1-cyclopentyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde (62B) (0.4g, 100% crude) as a black oily product, which was directly used in the next step.
Ms m/z(ESI):287.2[M+H + ]。
The third step: 1-cyclopentyl-5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -5- (pyridin-2-yl) piperidin-2-one (62C)
1-cyclopentyl-5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470002242
2- (1-cyclopentyl-6-oxo-3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde (62B) (0.50g, 1.7 mmol) was dissolved in methylene chloride (15 mL), and (3-methoxythiophen-2-yl) methylamine (0.3g, 2.1mmol), triethylamine (0.23g, 1.3mmol), and anhydrous sodium sulfate (1.7 g) were added thereto in this order. The reaction was allowed to react overnight at room temperature, sodium borohydride (0.1g, 2.6 mmol) was added, stirring was continued for 2h, water (20 mL) was added, extraction was performed with dichloromethane (30 mL × 2), the organic phases were combined, washed with saturated brine solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (dichloromethane/methanol = 30).
Ms m/z(ESI):414.2[M+H + ]。
The fourth step: 1-cyclopentyl-5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 62)
1-cyclopentyl-5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-5(pyridin-2-yl)piperidin-2-onehydrochloride
Figure BDA0001714822470002251
1-cyclopentyl-5- (2- (((3-methoxythiophen-2-yl) methyl) amino) ethyl) -5- (pyridin-2-yl) piperidin-2-one (62C) (0.15g, 0.36mmol) was dissolved in ethyl acetate (5 mL) and the solution of ethyl hydrogen chloride acetate (2mL, 4N) was added at 0 ℃ and the reaction was continued for 0.5h after completion of addition and the solvent was removed under reduced pressure to give 5- (2- ((3-chlorobenzyl) amino) ethyl) -1-isopropyl-5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 62) (0.16g, 95%) as a white solid at room temperature.
Ms m/z(ESI):414.2[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.84(d,1H),8.44(s,1H),7.94(m,2H),7.47(d,1H),7.01(d,1H),4.21(s,2H),3.88(s,3H),3.70(d,2H),2.90(td,1H),2.74(td,1H),2.59-2.24(m,6H),1.80-1.61(m,7H)。
Example 63
5- (2- (((3-methoxythiophen-2-yl) amino) ethyl) -1- (pent-3-yl) -5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 63)
5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-1-(pentan-3-yl)-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470002252
Figure BDA0001714822470002261
The first step is as follows: 5- ((1, 3-Dioxolan-2-yl) methyl) -1- (pentane-3-yl) -5- (pyridin-2-yl) piperidin-2-one (63A)
5-((1,3-dioxolan-2-yl)methyl)-1-(pentan-3-yl)-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470002262
At room temperature, 5- ((1, 3-dioxolan-2-yl) methyl) -5- (pyridin-2-yl) piperidin-2-one (36D) (0.7g, 2.7mmol) was dissolved in ethylene glycol dimethyl ether (5 mL), potassium tert-butoxide (0.3g, 2.7mmol), bromocyclopentane (0.4g, 2.7mmol) were added at room temperature, the reaction was continued for 0.5h by heating to 60 ℃, 3-bromopentane (0.4g, 2.7mmol) and potassium tert-butoxide (0.3g, 2.7mmol) were added to the reaction solution every 1h, 8 times were repeated, 20mL of water was added to the reaction solution, ethyl acetate was extracted (20 mL × 2), anhydrous sodium sulfate was added and dried, the filtrate was filtered, the solvent was removed by concentration under reduced pressure, and column chromatography (dichloromethane/methanol = 30) gave 5- ((1, 3-dioxolan-2-yl) methyl) -1- (piperidin-2-yl) piperidin-2-one (a) as a yellow oily product (63 g,86 g, b).
Ms m/z(ESI):333.2[M+H + ]。
The second step is that: 2- (6-oxo-1- (pent-3-yl) -3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde (63B)
2-(6-oxo-1-(pentan-3-yl)-3-(pyridin-2-yl)piperidin-3-yl)acetaldehyde
Figure BDA0001714822470002263
5- ((1, 3-Dioxolan-2-yl) methyl) -1- (pentan-3-yl) -5- (pyridin-2-yl) piperidin-2-one 63A (0.5g, 2mmol) was dissolved in tetrahydrofuran (15 mL) and concentrated hydrochloric acid (1 mL) at room temperature, stirred overnight at room temperature, and the reaction was concentrated to give 2- (6-oxo-1- (pentan-3-yl) -3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde 63B (0.4g, 100% crude) as a black oil, which was directly used in the next step.
Ms m/z(ESI):289.2[M+H + ]。
The third step: 5- (2- (((3-methoxythiophen-2-yl) amino) ethyl) -1- (pent-3-yl) -5- (pyridin-2-yl) piperidin-2-one (63C)
5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-1-(pentan-3-yl)-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470002271
2- (6-oxo-1- (pent-3-yl) -3- (pyridin-2-yl) piperidin-3-yl) acetaldehyde (63B) (0.50g, 1.7mmol) was dissolved in methylene chloride (15 ml), and (3-methoxythiophen-2-yl) methylamine (0.3g, 2.1mmol), triethylamine (0.23g, 1.3mmol), anhydrous sodium sulfate (1.7 g) were added thereto in this order. The reaction was allowed to react overnight at room temperature, sodium borohydride (0.1g, 2.6 mmol) was added, stirring was continued for 2h, water (20 mL) was added, extraction was performed with dichloromethane (30 mL × 2), the organic phases were combined, washed with saturated brine solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (dichloromethane/methanol = 30).
Ms m/z(ESI):416.2[M+H + ]。
The fourth step: 5- (2- (((3-methoxythiophen-2-yl) amino) ethyl) -1- (pent-3-yl) -5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 63)
5-(2-(((3-methoxythiophen-2-yl)methyl)amino)ethyl)-1-(pentan-3-yl)-5-(pyridin-2-yl)piperidin-2-one
Figure BDA0001714822470002272
5- (2- (((3-methoxythiophen-2-yl) amino) ethyl) -1- (pent-3-yl) -5- (pyridin-2-yl) piperidin-2-one 63C (0.15g, 0.36mmol) was dissolved in ethyl acetate (5 mL) at room temperature, and an ethyl hydrogen chloride solution (2mL, 4N) was added thereto at 0 ℃ and the reaction was continued for 0.5h, and the solvent was removed under reduced pressure to give 5- (2- (((3-methoxythiophen-2-yl) amino) ethyl) -1- (pent-3-yl) -5- (pyridin-2-yl) piperidin-2-one hydrochloride (Compound 63) (0.16g, 95%) as a white solid.
Ms m/z(ESI):416.2[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.89(dd,1H),8.54(td,1H),8.11(d,1H),7.98(m,1H),7.47(d,1H),7.01(d,1H),4.38(td,1H),4.21(s,2H),3.88(s,3H),3.83(d,1H),3.64(d,1H),2.99(td,1H),2.61(m,3H),2.4(m,3H),1.52(m,3H),0.90(t,3H),0.58(t,3H)。
Example 64
(R) -N- ((5-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine 4-methylbenzenesulfonate (Compound 64)
(R)-N-((5-ethynyl-3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine 4-methylbenzenesulfonate
Figure BDA0001714822470002281
The first step is as follows: 2, 5-bromo-3-methoxythiophene (64B)
2,5-dibromo-3-methoxythiophene
Figure BDA0001714822470002282
3-Methoxythiophene (64A) (11.4g, 99.851mmol) was dissolved in dichloromethane (200 mL) and N-bromosuccinimide (39.63g, 222.67mmol) was added in small portions with stirring and stirring was completed at room temperature for 2 hours. To the reaction mixture was added saturated brine (180 mL), and liquid separation was performed, and the organic phase was washed with a saturated sodium thiosulfate solution (180 mL × 1), and the organic phase was dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography (petroleum ether/ethyl acetate (V/V) = 10/1) to give 2, 5-bromo-3-methoxythiophene (64B) as a brown oil (11 g, yield: 40.5%).
1 H NMR(400MHz,CDCl 3 )δ6.79(s,1H),3.86(s,3H).
The second step: 5-bromo-3-methoxythiophene-2-carbaldehyde (64C)
5-bromo-3-methoxythiophene-2-carbaldehyde
Figure BDA0001714822470002291
The compound 2, 5-bromo-3-methoxythiophene (64B) (5.0g, 18.39mmol) was dissolved in tetrahydrofuran (50 mL) and n-butyllithium (7.4mL, 18.39mmol) was added dropwise at-78 ℃ and stirred at-78 ℃ for 0.5 hour, and then a solution of DMF (2.016g, 27.58mmol) in tetrahydrofuran (5 mL) was added dropwise and the reaction was completed at-78 ℃ for 1 hour. To the reaction solution was added a saturated ammonium chloride solution (80 mL), liquid separation was performed, the organic phase was washed with a saturated sodium chloride solution (80 mL × 1), the organic phase was dried over anhydrous sodium sulfate, filtered, evaporated to dryness, and silica gel column chromatography (petroleum ether/ethyl acetate (V/V) = 10/1) was performed to obtain 5-bromo-3-methoxythiophene-2-carbaldehyde (64C) as a yellow solid (1.5 g, yield: 37%).
1 H NMR(400MHz,CDCl 3 )δ9.99(d,J=1.3Hz,1H),6.73(d,J=1.2Hz,1H),3.92(s,3H).
The third step: 3-methoxy-5- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (64D)
3-methoxy-5-((trimethylsilyl)ethynyl)thiophene-2-carbaldehyde
Figure BDA0001714822470002292
The compound 5-bromo-3-methoxythiophene-2-carbaldehyde (64C) (1.3g, 5.88mmol) was dissolved in tetrahydrofuran (15 mL), trimethylsilylacetylene (1.155g, 11.76mmol), cuprous iodide (0.112g, 0.588mmol), palladium (0.206g, 0.294mmol) ditriphenylphosphine dichloride triethylamine (15 mL) were added, and the reaction was completed at 60 ℃ for 6 hours. Filtration and evaporation to dryness gave a yellow solid as crude 3-methoxy-5- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (64D) (0.9 g, yield: 60%) which was used directly in the next step.
The fourth step: 5-ethynyl-3-methoxythiophene-2-carbaldehyde (64E)
5-ethynyl-3-methoxythiophene-2-carbaldehyde
Figure BDA0001714822470002293
Crude compound 3-methoxy-5- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (64D) (0.90g, 3.78mmol) was dissolved in methanol (10 mL), potassium carbonate (1.04g, 7.55mmol) was added, and the mixture was stirred at room temperature for 1 hour. Filtration, washing of the cake with ether (50 mL × 1) and the organic phase with saturated brine (50 mL × 1), drying over anhydrous sodium sulfate, filtration, and evaporation of the silica gel column chromatography petroleum ether/ethyl acetate (V/V) =30/1 gave 5-ethynyl-3-methoxythiophene-2-carbaldehyde (64E) as a yellow solid product (500 mg, yield: 79.7%).
The fifth step (R) -N- ((5-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (64F)
(R)-N-((5-ethynyl-3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470002301
The compound 5-ethynyl-3-methoxythiophene-2-carbaldehyde (64E) (0.300g, 1.81mmol), (R) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.423g, 1.62mmol) was dissolved in dichloromethane (20 mL), and anhydrous sodium sulfate (1.36g, 9.60mmol) was added and stirred at room temperature overnight. Sodium borohydride (0.039g, 2.44mmol) was added thereto, and the mixture was stirred at room temperature for 1 hour, and then 3 ml of anhydrous methanol was added thereto, and the mixture was stirred for 2 hours. Water (20 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (10 mL × 3), the organic phases were combined and washed with saturated brine (30 mL × 1), the organic phase was dried over colorless sodium sulfate, filtered, evaporated to dryness, and subjected to silica gel column chromatography, EA/PE =2/1-3/1 to give (R) -N- ((5-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (64F) as a yellow solid product (300 mg, yield: 45%).
Ms.m/z(ESI):411.2[M+H + ]。
Sixth step (R) -N- ((5-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine 4-methylbenzenesulfonate (Compound 64)
(R)-N-((5-ethynyl-3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine4-methylbenzenesulfonate
Figure BDA0001714822470002302
The compound (R) -N- ((5-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (64F) (0.165g, 0.402mmol) was dissolved in methylene chloride (20 mL), and p-toluenesulfonic acid (0.069g, 0.402mmol) was added and stirred at room temperature for 1 hour. The reaction solution was evaporated to dryness to give a yellow solid product, N- ((5-ethynyl-3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine p-toluenesulfonate (compound 64) (220 mg, yield: 93.9%). (Note: nuclear magnetism is 1.5 p-toluene sulfonate)
Ms.m/z(ESI):411.2[M+H + -172];
1 H NMR(400MHz,CD3OD)δ8.83(dd,1H),8.52(td,1H),8.09(d,1H),7.96–7.89(m,1H),7.70(d,3H),7.24(d,3H),6.61(s,1H),4.32(s,2H),3.94(s,1H),3.83(s,3H),3.81–3.76(m,1H),3.73–3.64(m,1H),3.04(td,1H),2.55(td,1H),2.43(d,2H),2.37(s,4.5H),2.28(td,1H),2.18–2.08(m,2H),1.94–1.40(m,9H).
Example 65
N- ((3-Methoxythien-2-yl) methyl) -2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) ethylamine hydrochloride (Compound 65)
N-((3-methoxythiophen-2-yl)methyl)-2-(2-(pyridin-2-yl)bicyclo[2.2.2]octan-2-yl)ethanaminehydrochloride
Figure BDA0001714822470002311
The first step is as follows: bicyclo [2.2.2] octane-2-carbonitrile (65B)
bicyclo[2.2.2]octane-2-carbonitrile
Figure BDA0001714822470002321
At room temperature, bicyclo [2.2.2] octan-2-one 65A (0.5g, 4.0mmol) was dissolved in ethylene glycol dimethyl ether (5 mL), p-toluenesulfonylmethylisonitrile (1.8g, 9.3mmol), ethanol (0.42g, 9.1mmol), potassium tert-butoxide (1.6 g, 14mmol) were added in this order under zero-temperature conditions, the reaction was continued for 18 hours while heating to 60 ℃,50 mL of water was added to the reaction solution, ethyl acetate was extracted (30 mL × 2), anhydrous sodium sulfate was added for drying, filtration was performed, the filtrate was concentrated under reduced pressure to remove the solvent, and column chromatography (petroleum ether/ethyl acetate = 5) was performed to obtain a yellow oily product bicyclo [2.2.2] octane-2-carbonitrile 65B (0.3g, 50%).
1 H NMR(400MHz,CD 3 OD):δ2.71(m,1H),1.79-1.68(m,2H),1.62(m,1H),1.58(m,8H)。
The second step is that: 2- (pyridin-2-yl) bicyclo [2.2.2] octan-2-carbonitrile (65C)
2-(pyridin-2-yl)bicyclo[2.2.2]octane-2-carbonitrile
Figure BDA0001714822470002322
At room temperature, (65B) (0.5g, 2.59mmol) and 2-fluoropyridine (0.3g, 3.1mmol) were dissolved in toluene (5 mL), the system temperature was controlled to 20 ℃ below zero, potassium hexamethyldisilazane (0.5g, 2.59mmol) was added dropwise, after completion of addition, reaction was carried out at room temperature for 5 hours, 50mL of water was added to the reaction solution, ethyl acetate was extracted (30 mL × 2), anhydrous sodium sulfate was added thereto, drying was carried out, filtration was carried out, the filtrate was concentrated under reduced pressure to remove the solvent, and column chromatography (petroleum ether/ethyl acetate = 10.
Ms m/z(ESI):213.1[M+H + ]。
The third step: methyl 2- (pyridin-2-yl) bicyclo [2.2.2] octan-2-carboxylate (65D)
methyl 2-(pyridin-2-yl)bicyclo[2.2.2]octane-2-carboxylate
Figure BDA0001714822470002323
2- (pyridin-2-yl) bicyclo [2.2.2] octan-2-carbonitrile (65C) (1.9g, 8.9mmol) was dissolved in methanol (20 mL), sulfuric acid (13g, 132mmol) was added thereto at zero degrees, after addition, the reaction was heated to 130 degrees and reacted for 12 hours, the reaction solution was slowly added to 250mL of a sodium hydrogencarbonate solution (cooled), stirred for 15 minutes, extracted with ethyl acetate (40 mL. Times.3), washed with a saturated aqueous salt solution (50 mL. Times.1), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and column chromatography (petroleum ether/ethyl acetate (V/V) = 1) was performed to obtain methyl 2- (pyridin-2-yl) bicyclo [2.2.2] octan-2-carboxylate (65D) (1g, 50%) as a yellow oily product.
Ms m/z(ESI):246.1[M+H + ]。
The fourth step: (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) methanol (65E)
(2-(pyridin-2-yl)bicyclo[2.2.2]octan-2-yl)methanol
Figure BDA0001714822470002331
Methyl 2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-carboxylate 65D (0.9g, 3.7mmol) was dissolved in tetrahydrofuran (5 mL) at room temperature, lithium aluminum hydride (0.21g, 5.5mmol) was added at 0 deg.C, and after completion, the reaction was continued at room temperature for 2 hours, and water (0.21 mL), a sodium hydroxide solution (0.42mL, 10 wt), water (0.21 mL) and stirring were added to the system in this order, followed by stirring for ten minutes, sodium sulfate (0.5 g) and stirring for 10 minutes, followed by filtration, and removal of the solvent under reduced pressure to give 2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) methanol 65E (0.45g, 57%) as a white solid.
Ms m/z(ESI):218.2[M+H + ]。
The fifth step: (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) methyl methanesulfonate (65F) (2- (pyridin-2-yl) bicyclo [2.2.2] ]octan-2-yl) methyl methansulfonate
Figure BDA0001714822470002332
2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) methanol 65E (0.45g, 2.1mmol) was dissolved in dichloromethane (10 mL) at room temperature, triethylamine (0.31g, 3.1mmol) and methanesulfonyl chloride (0.28g, 2.5 mmol) were added in this order at 0 ℃, and after completion of addition, reaction was continued at room temperature for 1 hour, water (20 mL) was added to the system, ethyl acetate was extracted (40 mL. Times.3), the mixture was washed with a saturated aqueous salt solution (50 mL. Times.1), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the solvent was removed under reduced pressure to give a yellow oily substance (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) methylmethanesulfonate 65F (0.59 g), which was directly used in the next step.
Ms m/z(ESI):296.2[M+H + ]。
And a sixth step: 2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) acetonitrile (65G)
2-(2-(pyridin-2-yl)bicyclo[2.2.2]octan-2-yl)acetonitrile
Figure BDA0001714822470002341
At room temperature, (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) methyl methanesulfonate 65F (0.59g, 2.0mmol) was dissolved in N, N-dimethylformamide (6 mL), potassium cyanide (0.33g, 5.0mmol) was added, and after completion, the reaction was continued at 140 degrees for 3 hours, and water (10 mL) was added to the system, followed by extraction with ethyl acetate (20 mL × 2), washing with a saturated aqueous salt solution (20 mL × 1), drying over anhydrous sodium sulfate, concentration under reduced pressure, column chromatography (petroleum ether/ethyl acetate (V/V) = 1), to obtain 2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) acetonitrile 65G (0.35g, 70%) as a yellow oily substance.
Ms m/z(ESI):226.2[M+H + ]。
The seventh step: 2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) ethylamine (65H)
2-(2-(pyridin-2-yl)bicyclo[2.2.2]octan-2-yl)ethanamine
Figure BDA0001714822470002342
2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) acetonitrile 65G (0.35g, 1.55mmol) was dissolved in tetrahydrofuran (8 mL) at room temperature, lithium aluminum hydride (0.12g, 3.09mmol) was added at zero degrees, and after completion of the addition, the reaction was carried out at room temperature for 10 hours, and water (0.12 mL), a sodium hydroxide solution (0.24mL, 10 wt), water (0.12 mL) and the like were added to the system in this order, followed by stirring for ten minutes, addition of sodium sulfate 0.5G and the like, followed by stirring for 10 minutes, filtration, and removal of the solvent under reduced pressure to obtain 2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) ethylamine 65H (0.30g, 85%) as a yellow oily substance.
Ms m/z(ESI):231.2[M+H + ]。
The eighth step: n- ((3-Methoxythiophen-2-yl) methyl) -2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) ethylamine (65I)
N-((3-methoxythiophen-2-yl)methyl)-2-(2-(pyridin-2-yl)bicyclo[2.2.2]octan-2-yl)ethanamine
Figure BDA0001714822470002343
2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) ethylamine 65H (0.20g, 0.90mmol) was dissolved in methylene chloride (10 mL), and 3-methoxythiophene-2-aldehyde (0.15g, 1mmol) and anhydrous sodium sulfate (0.5 g) were added thereto in this order. After an overnight reaction at room temperature, 3mL of methanol and sodium borohydride (0.05g, 1.35mmol) were added, stirring was continued for 2h, water (20 mL) was added, extraction was performed with dichloromethane (20 mL × 2), the organic phases were combined, washed with saturated aqueous sodium chloride solution (30 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography (dichloromethane/methanol = 30) was performed to give the product N- ((3-methoxythiophen-2-yl) methyl) -2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) ethylamine 65I (0.14g, 50%) as a yellow oil.
Ms m/z(ESI):357.2[M+H + ]。
The ninth step: n- ((3-Methoxythien-2-yl) methyl) -2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) ethylamine hydrochloride (Compound 65)
N-((3-methoxythiophen-2-yl)methyl)-2-(2-(pyridin-2-yl)bicyclo[2.2.2]octan-2-yl)ethanaminehydrochloride
Figure BDA0001714822470002351
N- ((3-Methoxythien-2-yl) methyl) -2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) ethylamine 65I (0.14g, 0.39mmol) was dissolved in ethyl acetate (5 mL) and the ethyl hydrogen chloride acetate solution (2mL, 4N) was added at 0 ℃ and the reaction was continued for 0.5h, and the solvent was removed under reduced pressure to give N- ((3-Methoxythien-2-yl) methyl) -2- (2- (pyridin-2-yl) bicyclo [2.2.2] oct-2-yl) ethylamine hydrochloride (Compound 65) (0.16g, 97%) as a white solid.
Ms m/z(ESI):357.2[M+H + ];
1 H NMR(400MHz,CD 3 OD):δ8.85(q,1H),8.63(d,1H),8.19(d,1H),8.02(t,1H),7.47(d,1H),7.00(d,1H),4.19(s,2H),3.88(s,3H),2.65(m,2H),2.39(m,1H),2.18(m,3H),2.02(m,4H),1.75-1.38(m,7H).
Example 66
N- ((3-Methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-2-en-9-yl) ethylamine hydrochloride (Compound 66)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002361
The first step is as follows: 1, 4-dioxaspiro [4.4] cyclo-7-ene (66B)
1,4-dioxaspiro[4.4]non-7-ene
Figure BDA0001714822470002362
Trimethylsilyltriflate (2.21g, 12.2mmol) was added to dichloromethane (100 mL) at-70 ℃ under nitrogen. 1, 2-bis (trimethylsiloxy) ethane (25.1g, 122mmol) and 3-cyclopenten-1-one (66A) (10g, 122mmol) were added dropwise to the reaction mixture at-70 ℃ to complete the reaction at-70 ℃ for 5 hours. Triethylamine (20 mL) and a sodium hydrogencarbonate solution (20 mL) were added dropwise to the reaction solution successively at-70 ℃ and the aqueous phase was extracted with methylene chloride (50 mL. Times.3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 1, 4-dioxaspiro [4.4] cyclo-7-ene (66B) (10 g, yield: 65%) as an oily liquid.
1 H NMR(400MHz,CDCl 3 )δ5.64(s,2H),3.88(s,4H),2.51(s,1H)。
The second step is that: 1- (2-hydroxyethoxy) cyclopentyl-3-enemethyl cyanide (66C)
1-(2-hydroxyethoxy)cyclopent-3-enecarbonitrile
Figure BDA0001714822470002371
1, 4-dioxaspiro [4.4] cyclo-7-ene (66B) (6.4g, 51mmol) and cyanotrimethylsilane (5g, 51mmol) were charged into a reaction flask, and cooled to 0 ℃ and zinc diiodide (0.065g, 0.2mmol) was added to the reaction solution, after which the reaction was allowed to proceed overnight at room temperature. Methanol (30 mL) and 1N hydrochloric acid (30 mL) were added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. The aqueous phase was extracted with dichloromethane (50 mL. Times.3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 1- (2-hydroxyethoxy) cyclopentyl-3-enemethyl cyanide (66C) as a yellow oily liquid (7 g, yield: 90%).
1 H NMR(400MHz,CDCl 3 )δ5.70(s,2H),3.79-3.74(m,4H),2.97-2.96(m,2H),2.88-2.83(m,2H)。
The third step: 1- (2-hydroxyethoxy) cyclopentyl-3-enecarboxylic acid (66D)
1-(2-hydroxyethoxy)cyclopent-3-enecarboxylic acid
Figure BDA0001714822470002372
After 1- (2-hydroxyethoxy) cyclopentyl-3-enecarbonitrile (66C) (3g, 20mmol) was dissolved in ethanol (50 mL), sodium hydroxide (3.9g, 9.8mmol) and water (50 mL) were sequentially added, and the mixture was heated to reflux for 4 hours. After cooling and concentration to remove ethanol, the reaction mixture was adjusted to PH =3-4 by adding 3N hydrochloric acid (50 mL), aqueous phase was extracted with ethyl acetate (30 mL × 5), organic phases were combined, washed with saturated saline solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 1- (2-hydroxyethoxy) cyclopentyl-3-enecarboxylic acid (66D) (2.4 g, yield: 71%).
Ms m/z(ESI):171.1[M-H + ];
The fourth step: 2- ((1- (hydroxymethyl) cyclopentyl-3-en-1-yl) oxy) ethanol (66E) 2- ((1- (hydroxymethyl) cyclic-3-en-1-yl) oxy) ethanol
Figure BDA0001714822470002373
Lithium aluminum hydride (1.5 g, 39mmol) was dissolved in tetrahydrofuran (40 mL), the temperature was reduced to 0 ℃ and 1- (2-hydroxyethoxy) cyclopentyl-3-enecarboxylic acid (66D) (3.4 g, 20mmol) in tetrahydrofuran (10 mL) was added dropwise to the reaction mixture, and the reaction was carried out overnight at room temperature. The reaction was cooled to 0 ℃, quenched with water (0.6 mL), sodium hydroxide solution (10%, 1.2 mL) and water (1.2 mL), dried with anhydrous sodium sulfate, stirred for 20 minutes, the solid filtered and washed with tetrahydrofuran (20 mL × 3). The combined organic phases were concentrated to give 2- ((1- (hydroxymethyl) cyclopentyl-3-en-1-yl) oxy) ethanol (66E) (2.2 g, yield: 70%).
Ms m/z(ESI):159.1[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ5.68(s,2H),3.72-3.70(m,2H),3.62(s,2H),3.46-3.45(m,2H),3.13(s,2H),2.47-2.37(q,4H).
The fifth step: (1- (2- ((methylsulfonyl) oxy) ethoxy) cyclopentyl-3-en-1-yl) methyl methanesulfonate (66F)
(1-(2-((methylsulfonyl)oxy)ethoxy)cyclopent-3-en-1-yl)methyl methanesulfonate
Figure BDA0001714822470002381
2- ((1- (hydroxymethyl) cyclopentyl-3-en-1-yl) oxy) ethanol (66E) (2.2g, 14mmol) was dissolved in dichloromethane (50 mL) and then cooled to-20 ℃. Triethylamine (4.5g, 45mmol) and methanesulfonyl chloride (3.8g, 33mmol) were added dropwise to the reaction mixture at-20 ℃ in this order, and the reaction was carried out at-20 ℃ for 2 hours. Water (80 mL) was added, the aqueous phase was extracted with dichloromethane (50 mL. Times.2), the organic phases were combined, washed with sodium chloride (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give (1- (2- ((methylsulfonyl) oxy) ethoxy) cyclopentyl-3-en-1-yl) methyl methanesulfonate (66F) as a yellow oily liquid (4.2 g, yield: 96%).
1 H NMR(400MHz,CDCl 3 )δ5.69(s,2H),4.35-4.34(m,2H),4.32(s,2H),3.65-3.64(m,2H),3.11-3.04(d,6H),2.53-2.50(m,4H).
And a sixth step: ethyl 9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-ene-9-carboxylate (66G)
ethyl 9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-ene-9-carboxylate
Figure BDA0001714822470002382
Sodium hydride (0.83g, 20.0 mmol) was dissolved in toluene (20 mL), the temperature was lowered to 0 ℃ and pyridine-2-acetic acid ethyl ester (1.4g, 8.3 mmol) was added to the reaction, after which the reaction was carried out at room temperature for 1 hour. A toluene solution (20 mL) of (1- (2- ((methylsulfonyl) oxy) ethoxy) cyclopentyl-3-en-1-yl) methyl methanesulfonate (66F) (2.6 g,8.3 mmol) was added dropwise to the reaction mixture at 0 ℃ and the mixture was heated under reflux for 3 hours. The reaction was cooled to 0 ℃, the reaction was quenched with ammonium chloride solution (30 mL), the aqueous phase was extracted with ethyl acetate (50 mL × 2), the organic phases were combined, washed with sodium chloride (30 mL × 1), dried by adding anhydrous sodium sulfate, filtered, concentrated the crude product and purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1-2) to give ethyl 9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-ene-9-carboxylate (66G) (0.92G, yield: 39%).
Ms m/z(ESI):288.1[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.62-8.60(d,1H),7.72-7.68(m,1H),7.52-7.38(d,1H),7.2-7.19(m,1H),5.67(s,2H),4.26-4.14(m,2H),3.98-3.88(m,1H),3.86-3.84(m,1H),2.49-2.31(m,8H),1.37-1.26-(t,3H).
The seventh step: (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) methanol (66H)
(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)methanol
Figure BDA0001714822470002391
Lithium aluminum hydride (0.5g, 7 mmol) was dissolved in tetrahydrofuran (20 mL), the temperature was reduced to 0 ℃ and then tetrahydrofuran (10 mL) of ethyl 9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-ene-9-carboxylate (66G) (1g, 3.5 mmol) was added dropwise to the reaction mixture, and after completion of addition, the reaction was allowed to proceed overnight at room temperature. The reaction was cooled to 0 ℃, quenched with water (0.6 mL), sodium hydroxide solution (10%, 1.2 mL) and water (0.6 mL), dried with anhydrous sodium sulfate, stirred for 20 minutes, the solid filtered and washed with tetrahydrofuran (20 mL × 3). The combined organic phases were concentrated to give (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) methanol (66H) (0.72 g, yield: 84%).
Ms m/z(ESI):246.2[M+H + ]。
Eighth step: (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) methyl methanesulfonate (66I)
(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)methyl methanesulfonate
Figure BDA0001714822470002392
(9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) methanol (66H) (0.72g, 2.9 mmol) was dissolved in dichloromethane (30 mL) and then cooled to 0 ℃. Triethylamine (0.45g, 4.4 mmol) and methylsulfonyl chloride (0.4 g,3.5 mmol) were added dropwise to the reaction mixture in this order at 0 ℃ and reacted at 0 ℃ for 2 hours. Water (20 mL) was added, the aqueous phase was extracted with dichloromethane (30 mL × 2), the organic phases were combined, washed with sodium chloride (20 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 5.
Ms m/z(ESI):324.1[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.63-8.60(d,1H),7.71-7.69(m,1H),7.39-7.38(d,1H),7.22-7.19(m,1H),5.63(s,1H),5.46(s,1H),4.41-4.39(d,1H),4.27-4.25(d,1H),3.90-3.87(m,2H),2.84(s,3H),2.49-2.38(m,4H),1.96-1.81(m,4H).
The ninth step: 2-9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) acetonitrile (66J)
2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)acetonitrile
Figure BDA0001714822470002401
(9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) methyl methanesulfonate (66I) (0.97g, 3 mmol) was dissolved in dimethyl sulfoxide (40 mL), and sodium cyanide (0.6 g,9 mmol) and sodium iodide (50mg, 0.08mmol) were added thereto, and the reaction was completed at 150 ℃ for 8 hours. Water (50 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 6-1 to 3) to give 2-9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) acetonitrile (66J) as a yellow solid (0.65 g, yield: 85%).
Ms m/z(ESI):255.1[M+H + ]。
The tenth step: 2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-2-en-9-yl) ethylamine (66K)
2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)ethanamine
Figure BDA0001714822470002402
Lithium aluminum hydride (0.19g, 5.1mmol) was dissolved in tetrahydrofuran (20 mL), cooled to 0 deg.C, and then 2-9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) acetonitrile (66J) (0.65g, 2.6 mmol) in tetrahydrofuran (10 mL) was added to the reaction mixture, and the reaction was allowed to proceed overnight at room temperature. The reaction was cooled to 0 ℃, quenched with water (0.6 mL), sodium hydroxide solution (10%, 1.2 mL) and water (0.8 mL), dried by addition of anhydrous sodium sulfate, stirred for 20 minutes, the solid filtered and washed with tetrahydrofuran (20 mL × 3). The combined organic phases were concentrated to give 2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethylamine (66K) (0.6 g, yield: 98%).
Ms m/z(ESI):259.2[M+H + ]。
The eleventh step: n- ((3-Methoxythien-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethanamine (66L)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)ethanamine
Figure BDA0001714822470002411
2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethylamine (66K) (0.34g, 1.3 mmol) was dissolved in methylene chloride (15 mL), and sodium sulfate (1.3 g,10.5 mmol) and 3-methoxythiophene-2-carboxaldehyde (0.22g, 1.6 mmol) were added to the reaction solution, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.074g, 2.0 mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) =50
Ms m/z(ESI):385.2[M+H + ]。
A twelfth step: n- ((3-Methoxythien-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethylamine hydrochloride (Compound 66)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002412
N- ((3-Methylthioen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethanamine (66L) (0.05g, 0.13mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give N- ((3-methoxythiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethylamine hydrochloride (Compound 66) (0.05 g, yield 92.6%) as a yellow solid.
Ms m/z(ESI):385.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.78-8.77(d,1H),8.36-8.35(m,1H),7.96-7.81(d,1H),7.78(m,1H),7.46(d,1H),7.04-7.01(d,1H),5.61(s,1H),5.46(s,1H),4.07(s,2H),3.88-3.84(m,5H),2.99-2.95(m,1H),2.45-2.31(m,2H),2.31-2.25(m,3H),2.04(m,1H),2.03-1.95(m,3H),1.88-1.64(m,2H).
Example 67
N- ((3- (difluoromethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-2-en-9-yl) ethanamine (Compound 67)
N-((3-(difluoromethoxy)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002421
The first step is as follows: n- ((3- (difluoromethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-2-en-9-yl) ethanamine (67A)
N-((3-(difluoromethoxy)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)ethanamine
Figure BDA0001714822470002431
2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethylamine (66K) (0.34g, 1.3 mmol) was dissolved in methylene chloride (15 mL), and sodium sulfate (1.3 g,10.5 mmol) and 3-methoxythiophene-2-carboxaldehyde (0.22g, 1.6 mmol) were added to the reaction solution, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.074g, 2.0 mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give crude N- ((3-methylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethylamine (67A) (0.05 g, yield: 10%) as a yellow oily liquid by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):421.2[M+H + ]。
The second step: n- ((3- (Difluoromethoxy) thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethanamine (Compound 67)
N-((3-(difluoromethoxy)thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002432
N- ((3-Methylthioen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethanamine (67A) (0.05g, 0.13mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction was directly spin-dried to give N- ((3-methylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-en-9-yl) ethylamine hydrochloride (compound 67) as a yellow solid (0.05 g, yield 92.6%).
Ms m/z(ESI):421.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.81-8.80(d,1H),8.65-8.63(m,1H),7.97(d,1H),7.82-7.79(m,1H),7.63-7.60(m,1H),7.05-7.04(d,1H),6.90-6.88(m,1H),6.72-6.69(m,1H),5.61(s,1H),5.46(s,1H),4.31-4.27(d,2H),3.86-3.84(m,2H),3.13-2.99(m,2H),2.58-2.32(m,4H),2.19-2.04(m,2H),2.03-1.95(m,2H),1.94-1.64(m,2H).
Example 68
N- ((3-Methoxythiophen-2-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (Compound 68)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002441
The first step is as follows: ethyl 4' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -carboxylate (68A)
ethyl 4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-carboxylate
Figure BDA0001714822470002442
Ethyl 9- (pyridin-2-yl) -6-oxaspiro [4.5] dec-2-ene-9-carboxylate (66G) (0.86g, 3.0mmol) was dissolved in methylene chloride (40 mL), and the solution was cooled to 0 ℃ to add diethyl zinc n-hexane solution (1.0M, 15mL) and diiodomethane (30.0mmol, 3.5mL) to the reaction solution in this order, and reacted at room temperature for 12 hours. The reaction was cooled to 0 ℃, the reaction was quenched with ammonium chloride solution (30 mL), the aqueous phase was extracted with ethyl acetate (50 mL × 2), the organic phases were combined, washed with sodium chloride (30 mL × 1), dried by adding anhydrous sodium sulfate, filtered and concentrated to give a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1-2).
Ms m/z(ESI):302.2[M+H + ];
The second step is that: (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) methanol (68B)
(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)methanol
Figure BDA0001714822470002451
Lithium aluminum hydride (0.2g, 5.32mmol) was dissolved in tetrahydrofuran (20 mL), the temperature was reduced to 0 ℃ and then tetrahydrofuran (10 mL) of 4' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -carboxylate (68A) (0.8g, 2.66mmol) was added dropwise to the reaction mixture, and the reaction was carried out at room temperature for 4 hours. The reaction was cooled to 0 ℃, quenched with water (0.6 mL), sodium hydroxide solution (10%, 1.2 mL) and water (0.6 mL), dried by addition of anhydrous sodium sulfate, stirred for 20 minutes, the solid filtered and washed with tetrahydrofuran (20 mL × 3). The combined organic phases were concentrated to give (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) methanol (68B) (0.6 g, yield: 87.1%).
Ms m/z(ESI):260.2[M+H + ]。
The third step: (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) methyl methanesulfonate (68C)
(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)methyl methanesulfonate
Figure BDA0001714822470002452
(4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran-4 ' -yl) methanol (68B) (0.6 g, 2.9.31mmol) was dissolved in dichloromethane (30 mL) and then cooled to 0 ℃. Triethylamine (0.35g, 3.47mmol) and methanesulfonyl chloride (0.34g, 3.0mmol) were added dropwise to the reaction mixture in this order at 0 ℃ and reacted at 0 ℃ for 2 hours. Water (20 mL) was added, the aqueous phase was extracted with dichloromethane (30 mL × 2), the organic phases were combined, washed with sodium chloride (20 mL × 1), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 5.
Ms m/z(ESI):338.2[M+H + ]。
The fourth step: 2- (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) acetonitrile (68D)
2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)acetonitrile
Figure BDA0001714822470002461
(4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran-4 ' -yl) methyl methanesulfonate (68C) (0.5 g,1.5 mmol) was dissolved in dimethyl sulfoxide (20 mL), and sodium cyanide (0.44g, 6.0 mmol) and sodium iodide (50mg, 0.08mmol) were added thereto, and the reaction was completed at 150 ℃ for 8 hours. Water (50 mL) was added to the reaction solution, the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 6.
Ms m/z(ESI):269.2[M+H + ]。
The fifth step: 2- (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine (68E)
2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine
Figure BDA0001714822470002462
Lithium aluminum hydride (0.1g, 2.6 mmol) was dissolved in tetrahydrofuran (20 mL), cooled to 0 deg.C, and 2- (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran-4 ' -yl) acetonitrile (68D) (0.35g, 1.3 mmol) in tetrahydrofuran (10 mL) was added to the reaction mixture, and the reaction was allowed to proceed overnight at room temperature. The reaction was cooled to 0 ℃, quenched with water (0.6 mL), sodium hydroxide solution (10%, 1.2 mL) and water (0.8 mL), dried by addition of anhydrous sodium sulfate, stirred for 20 minutes, the solid filtered and washed with tetrahydrofuran (20 mL × 3). The combined organic phases were concentrated to give 2- (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine (68E) (0.3 g, yield: 84.8%).
Ms m/z(ESI):273.3[M+H + ]。
And a sixth step: n- ((3-Methoxythiophen-2-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine (68F)
N-((3-methoxythiophen-2-yl)methyl)-2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine
Figure BDA0001714822470002471
2- (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine (68E) (0.30g, 1.3 mmol) was dissolved in dichloromethane (15 mL), and sodium sulfate (1.3g, 10.5 mmol) and 3-methoxythiophene-2-carboxaldehyde (0.22g, 1.6 mmol) were added to the reaction solution, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.074g, 2.0 mmol) was added to the reaction, and the reaction was stirred for 20 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (30 mL × 4), the organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):399.1[M+H + ]。
The seventh step: n- ((3-Methoxythiophen-2-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (Compound 68)
N-((3-methoxythiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]dec-2-en-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002472
N- ((3-Methoxythien-2-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine (68F) (0.15g, 0.37mmol) was dissolved in ethyl acetate (5 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction was directly spin dried to give N- ((3-methoxythiophen-2-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrooxaspiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (compound 68) as a yellow solid (0.15 g, 93.4% yield).
Ms m/z(ESI):399.1[M+H + ];
1 H NMR(400MHz,CD 3 OD)δ8.79(s,1H),8.40(s,1H),7.97-7.84(d,2H),7.51-7.49(m,1H),7.01-6.99(d,1H),4.17(s,2H),3.88(s,3H),3.61-3.48(m,2H),2.94-2.91(m,2H),2.35-1.84(m,10H),1.22-1.16(m,4H).
Resolution of the compound N- ((3-methoxythiophen-2-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran-4 ' -yl) ethylamine hydrochloride (compound 68)
(compound 68) (420 mg) was taken for resolution, and after separation, two optical isomers, compound 68-1 (retention time: 5.107min,191.76mg, oily liquid, ee% = 99.3%), compound 68-2 (retention time: 6.236min,187.59mg, oily liquid, ee% = 99.7%) were obtained.
Splitting conditions are as follows: apparatus is THar 80 preparatory SFC (SFC-16); a column, chiralPak AD,220 × 80mm i.d.,10 μm; mobile phase A: carbon dioxide, B: ethanol (0.1% ammonia); gradient B40%; the flow rate is 80mL/min; back pressure is 100bar; the column temperature is 38 ℃; the wavelength is 220nm; the period is 5min; sample preparation, compound is dissolved in methanol to make 42mg/ml; injection 2 ml/needle.
The salifying method of the compound 68 is adopted to obtain a compound 68-1 and a compound 68-2:
compound 68-1:
Ms m/z(ESI):399.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.85(dd,1H),8.58(td,1H),8.10(d,1H),8.00(t,1H),7.47(d,1H),7.00(d,1H),4.18(s,2H),3.88(s,3H),3.84-3.75(m,2H),2.93(dd,1H),2.47-2.41(m,1H),2.36-2.26(m,3H),2.18(dd,1H),2.03(dd,2H),1.94-1.84(m,2H),1.43(d,1H),1.26-1.21(m,2H),1.15-1.11(m,1H),0.56(q,1H),0.34-0.23(m,1H).
compound 68-2:
Ms m/z(ESI):399.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.84(dd,1H),8.57(td,1H),8.09(d,1H),7.99(t,1H),7.47(d,1H),7.00(d,1H),4.18(s,2H),3.85(d,3H),3.81-3.72(m,2H),2.95(td,1H),2.44(td,1H),2.36-2.25(m,3H),2.16(td,1H),2.11-1.99(m,2H),1.96-1.84(m,2H),1.43(d,1H),1.29-1.21(m,2H),1.15-1.10(m,1H),0.56(q,1H),0.29(td,1H).
example 69
(R) -N- ((2, 3-dihydrothieno [3,4-b ] furan-6-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 69)
(R)-N-((2,3-dihydrothieno[3,4-b]furan-6-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002491
The first step is as follows: 4-bromo-3- (2-bromoethoxy) thiophene-2-carboxylic acid methyl ester (69A)
methyl 4-bromo-3-(2-bromoethoxy)thiophene-2-carboxylate
Figure BDA0001714822470002492
Methyl 4-bromo-3-hydroxythiophene-2-carboxylate (60B) (5 g, 21.1mmol) was dissolved in N, N-dimethylformamide (50 mL) at room temperature, and potassium carbonate (11.6 g,84.4 mmol) and dibromoethane (31.7 g,168.7 mmol) were added thereto, and the reaction was completed at 80 ℃ for 2 hours. To the reaction solution was added water (100 mL), the aqueous phase was extracted with methyl tert-butyl ether (50 mL × 3), the combined organic phases were washed with a saturated sodium chloride solution (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 20.
1 H NMR(400MHz,CDCl 3 )δ7.40(s,1H),4.48(t,2H),3.88(s,3H),3.69(t,2H).
The second step: 2, 3-Dihydrothieno [3,4-B ] furan-6-carboxylic acid methyl ester (69B)
methyl 2,3-dihydrothieno[3,4-b]furan-6-carboxylate
Figure BDA0001714822470002501
Methyl 4-bromo-3- (2-bromoethoxy) thiophene-2-carboxylate (69A) (5.0g, 14.5 mmol) was dissolved in tetrahydrofuran (50 mL), and the temperature was reduced to-78 ℃ to add n-butyllithium (6.4mL, 16.0mmol) dropwise to the reaction, and the reaction was completed at-78 ℃ for 1.5 hours. The reaction solution was quenched with a saturated ammonium chloride solution (50 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated sodium chloride solution (80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and after the crude product was subjected to column chromatography (petroleum ether/ethyl acetate (v/v) = 20.
1 H NMR(400MHz,CDCl 3 )δ6.94(t,1H),5.08(t,2H),3.85(s,3H),3.03(td,2H).
The third step: (2, 3-Dihydrothieno [3,4-b ] furan-6-yl) methanol (69C) (2, 3-dihydrothieno [3,4-b ] furan-6-yl) methanol
Figure BDA0001714822470002502
Lithium aluminum hydride (0.155g, 4.07mmol) was dissolved in tetrahydrofuran (15 mL), cooled to 0 deg.C, and a solution of methyl 2,3-dihydrothieno [3,4-B ] furan-6-carboxylate (69B) (0.5g, 2.71mmol) in tetrahydrofuran (5 mL) was added dropwise to the reaction, followed by reaction at room temperature for 2 hours. The reaction was cooled to 0 ℃, and the reaction was quenched with water (0.16 mL), sodium hydroxide solution (10%, 0.32 mL) and water (0.32 mL) in this order, followed by addition of anhydrous sodium sulfate, drying, filtering the solid and washing with tetrahydrofuran (20 mL. Times.2), and concentrating the combined organic phases to give an oily liquid (2, 3-dihydrothieno [3,4-b ] furan-6-yl) methanol (69C) (0.41 g, yield: 96.7%).
The fourth step: 2,3-Dihydrothieno [3,4-b ] furan-6-carbaldehyde (69D)
2,3-dihydrothieno[3,4-b]furan-6-carbaldehyde
Figure BDA0001714822470002503
(2, 3-Dihydrothieno [3,4-b ] furan-6-yl) methanol (69C) (0.40g, 2.56mmol) was dissolved in dichloromethane (10 mL), manganese dioxide (2.23g, 2.56mmol) was added to the reaction, and the reaction was completed at room temperature for 12 hours. The reaction solution was filtered to remove a solid and washed with dichloromethane (10 mL. Times.2), and the combined organic phases were concentrated to give 2,3-dihydrothieno [3,4-b ] furan-6-carbaldehyde (69D) as a yellow solid (0.38 g, yield: 96%).
Ms m/z(ESI):155.0[M+H + ]。
The fifth step: (R) -N- ((2, 3-dihydrothieno [3,4-b ] furan-6-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (69E)
(R)-N-((2,3-dihydrothieno[3,4-b]furan-6-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470002511
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.30g, 1.15mmol) was dissolved in dichloromethane (10 mL), and sodium sulfate (0.82g, 5.76mmol) and 2, 3-dihydrothieno [3,4-b ] furan-6-carbaldehyde (69D) (0.266g, 1.73mmol) were added to the reaction mixture at room temperature overnight. Sodium borohydride (0.065g, 1.73mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):399.2[M+H + ]。
And a sixth step: (R) -N- ((2, 3-dihydrothieno [3,4-b ] furan-6-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 69)
(R)-N-((2,3-dihydrothieno[3,4-b]furan-6-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002521
(R) -N- ((2, 3-dihydrothieno [3,4-b ] furan-6-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (69E) (0.15g, 0.376 mmol) was dissolved in ethyl acetate (4 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -N- ((2, 3-dihydrothieno [3,4-b ] furan-6-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (compound 69) (0.16 g, yield: 98%) as a white solid.
Ms m/z(ESI):399.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.87(d,1H),8.61(t,1H),8.18(t,1H),8.03(dd,1H),6.96(t,1H),4.92(t,2H),4.11(s,2H),3.89-3.69(m,2H),3.03-2.96(m,3H),2.53-2.46(m,3H),2.37-2.25(m,1H),2.24-2.11(m,2H),1.99-1.83(m,2H),1.74-1.46(m,5H),1.24-1.17(m,1H),0.88-0.81(m,1H).
Example 70
N- ((3-Methoxythiophen-2-yl) methyl) -2- (2- (pyridin-2-yl) -11-oxadispiro [ 3.1.4) 6 .3 4 ]Tridecan-2-yl) ethan-1-amine hydrochloride (Compound 70)
N-((3-methoxythiophen-2-yl)methyl)-2-(2-(pyridin-2-yl)-11-oxadispiro[3.1.4 6 .3 4 ]tridecan-2-yl)ethan-1-amine hydrochloride
Figure BDA0001714822470002522
Figure BDA0001714822470002531
The first step is as follows: 9-Methenyl6-oxaspiro [4.5] decane (70B)
9-methylene-6-oxaspiro[4.5]decane
Figure BDA0001714822470002532
Potassium tert-butoxide (10.92g, 97.27mmol) and methyltriphenylphosphonium bromide (34.74g, 97.27mmol) were dissolved in diethyl ether (100 mL), added to a reaction flask, heated to reflux for 1 hour, and 6-oxaspiro [4.5] decan-9-one (70A) (10.00g, 64.85mmol) was dissolved in diethyl ether (10 mL) and added dropwise to the reaction and refluxed for 1.5 hours. After cooling, water (100 mL) was added to the reaction solution, and aqueous phase ether (50 mL × 3) was extracted, the organic phases were combined, washed with a saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 20) to give 9-methylalnyl-6-oxaspiro [4.5] decane (70B) as an oily liquid (8.0 g, yield: 80%).
The second step is that: 11-oxadispiro [3.1.4 ] 6 .3 4 ]Tridecan-2-one (70C)
11-oxadispiro[3.1.4 6 .3 4 ]tridecan-2-one
Figure BDA0001714822470002541
Reacting 9-methyl alkenyl-6-oxaspiro [4.5 ]]Decane (70B) (7g, 46.05mmol), dissolved in diethyl ether (100 mL), zn-Cu (40.4g, 621.68mmol) added, stirred and cooled to 0 ℃ and a solution of trichloroacetyl chloride (45.2g, 248.68mmol) in ethylene glycol dimethyl ether (50 mL) added dropwise, after reaction at room temperature for 3 hours, filtered, the filter cake washed with diethyl ether (50 mL. Times.1), the filtrate evaporated to dryness and dissolved in glacial acetic acid (150 mL), zinc dust (31.31g, 478.7 mmol) added in small portions and reacted at 60 ℃ for 3 hours. Cooling, filtration, washing of the filter cake with ether (50 mL × 1), addition of water (300 mL × 3) to the reaction solution, extraction with aqueous ether (100 mL × 3), combination of the organic phases, washing with water (300 mL × 1), drying over anhydrous sodium sulfate, filtration, concentration of the filtrate under reduced pressure, and purification of the crude product by column chromatography (petroleum ether/ethyl acetate (v/v) =10 6 .3 4 ]Tridecan-2-one (70C) (6.0 g, yield: 67.8%).
1 H NMR(400MHz,CDCl 3 )δ3.70-3.63(m,2H),2.87(q,2H),2.84-2.74(m,2H),1.90-1.81(m,4H),1.72(ddd,4H),1.59(tdd,2H),1.46-1.36(m,2H).
The third step: 2-cyano-2- (11-oxadispiro [3.1.4 ] 6 .3 4 ]Tridecan-2-ylidene) acetic acid methyl ester (70D)
methyl 2-cyano-2-(2,6-dioxaspiro[4.5]decan-9-ylidene)acetate
Figure BDA0001714822470002542
Reacting 11-oxadispiro [3.1.4 ] 6 .3 4 ]Tridecan-2-one (70C) (1.8g, 9.26mmol), methyl cyanoacetate (1.84g, 18.53mmol), ammonium acetate (0.72g, 9.26mmol), acetic acid (0.56g, 9.26mmol) and toluene (25 mL) were charged to a reaction flask and the temperature was raised to reflux for 12 hours. After cooling, a sodium hydrogencarbonate solution (50 mL) was added to the reaction mixture, and aqueous ethyl acetate (30 mL × 3) was extracted, the organic phases were combined, washed with a saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and then the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =1 to 5) 6 .3 4 ]Tridecan-2-ylidene) acetic acid methyl ester (70D) (2.0 g, yield: 78.4%).
Ms m/z(ESI):276.2[M+H + ]。
The fourth step: 2-cyano-2- [2- (2-pyridyl) -11-oxadispiro [3.1.4 6 .3 4 ]Tridecan-2-yl radical]Acetic acid methyl ester (70E)
methyl 2-cyano-2-[2-(2-pyridyl)-11-oxadispiro[3.1.4 6 .3 4 ]tridecan-2-yl]acetate
Figure BDA0001714822470002551
Adding isopropyl magnesium chloride (5.7mL, 11.4mmol) into a reaction flask under the protection of nitrogen, cooling to 0 ℃, adding a tetrahydrofuran (15 mL) solution of 2-bromopyridine (1.8g, 11.4mmol) dropwise into the reaction, reacting at room temperature for 2 hours, adding cuprous iodide (0.14g, 0.76mmol) into the reaction, stirring the reaction for 0.5 hours, and adding 2-cyano-2- (11-oxadispiro [3.1.4 ] spiro [3.1.4 ] 6 .3 4 ]A solution of methyl tridecan-2-ylidene) acetate (70D) (2.1g, 7.6 mmol) in tetrahydrofuran (10 mL) was added dropwise to the reaction mixture, and the temperature was raised to 50 ℃ for 5 hours. The reaction was quenched by adding ice water (20 mL) and 1N hydrochloric acid (20 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated saline solution (50 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =10Oily liquid 2-cyano-2- [2- (2-pyridyl) -11-oxadispiro [3.1.4 ] 6 .3 4 ]Tridecan-2-yl radical]Methyl acetate (70E) (1 g, yield: 37%).
Ms m/z(ESI):355.2[M+H + ]。
The fifth step: 2- [2- (2-pyridinyl) -11-oxadispiro [3.1.4 ] 6 .3 4 ]Tridecan-2-yl radical]Acetonitrile (70F)
2-[2-(2-pyridyl)-11-oxadispiro[3.1.4 6 .3 4 ]tridecan-2-yl]acetonitrile
Figure BDA0001714822470002552
Ethylene glycol (20 mL) was added to 2-cyano-2- [2- (2-pyridyl) -11-oxadispiro [3.1.4 ] 6 .3 4 ]Tridecan-2-yl radical]To methyl acetate (70E) (1.0 g, 2.82mmol) was added potassium hydroxide (0.32g, 5.64mmol), and the mixture was heated at 120 ℃ for reaction for 3 hours. The reaction solution was cooled, water (80 mL) was added, the aqueous phase was extracted with methyl t-butyl ether (30 mL × 3), the organic phases were combined, washed with a saturated sodium chloride solution (30 mL × 2), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) =1 to 2) 6 .3 4 ]Tridecan-2-yl radical]Acetonitrile (70F) (0.48 g, yield: 57.4%).
Ms m/z(ESI):297.2[M+H + ];
1 H NMR(400MHz,CDCl 3 )δ8.60(d,1H),7.73(d,1H),7.40(d,1H),7.21(dd,1H),3.64(t,2H),2.87(s,2H),2.61(d,2H),2.32(d,2H),1.82-1.63(m,6H),1.57-1.50(m,3H),1.37-1.26(m,3H).
And a sixth step: 2- [2- (2-pyridinyl) -11-oxadispiro [3.1.4 ] 6 .3 4 ]Tridecan-2-yl radical]Ethylamine (70G)
2-[2-(2-pyridyl)-11-oxadispiro[3.1.4 6 .3 4 ]tridecan-2-yl]ethanamine
Figure BDA0001714822470002561
Lithium aluminum hydride (0.123g, 3.24mmol) was dissolved in tetrahydrofuran (10 mL), and 2- [2- (2-pyridyl) -11-oxadispiro [3.1.4 ] 6 .3 4 ]Tridecan-2-yl]Acetonitrile (70F) (0.48g, 1.62mmol) in tetrahydrofuran (5 mL) was added dropwise to the reaction, and the reaction was allowed to proceed overnight at room temperature. The reaction solution was quenched with water (0.12 mL), sodium hydroxide solution (10%, 0.24 mL) and water (0.24 mL) in this order, dried by adding anhydrous sodium sulfate, stirred for 20 minutes, filtered, and the solid was washed with tetrahydrofuran (20 mL. Times.2). The combined organic phases were concentrated to give 2- [2- (2-pyridyl) -11-oxadispiro [3.1.4 ] as an oily liquid 6 .3 4 ]Tridecan-2-yl radical]Ethylamine (70G) (0.48G, yield: 98.7%).
Ms m/z(ESI):301.2[M+H + ]。
The seventh step: n- ((3-Methoxythiophen-2-yl) methyl) -2- (2- (pyridin-2-yl) -11-oxadispiro [ 3.1.4) 6 .3 4 ]Tridecan-2-yl) ethan-1-amine (70H)
N-((3-methoxythiophen-2-yl)methyl)-2-(2-(pyridin-2-yl)-11-oxadispiro[3.1.4 6 .3 4 ]tridecan-2-yl)ethan-1-amine
Figure BDA0001714822470002562
2- [2- (2-pyridyl) -11-oxadispiro [3.1.4 ] 6 .3 4 ]Tridecan-2-yl radical]Ethylamine (70G) (0.30g, 0.99mmol) was dissolved in dichloromethane (10 mL), and sodium sulfate (0.71g, 4.9mmol) and 3-methoxythiophene-2-carboxaldehyde (0.21g, 1.5mmol) were added to react at room temperature overnight. Sodium borohydride (0.056 g,1.5 mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water (30 mL), the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) =50Dispiro [3.1.4 ] 6 .3 4 ]Tridecan-2-yl) ethan-1-amine (70H) (0.15 g, yield: 35.2%).
Ms m/z(ESI):427.2[M+H + ]。
Eighth step: n- ((3-Methoxythiophen-2-yl) methyl) -2- (2- (pyridin-2-yl) -11-oxadispiro [ 3.1.4) 6 .3 4 ]Tridecan-2-yl) ethan-1-amine hydrochloride (Compound 70)
N-((3-methoxythiophen-2-yl)methyl)-2-(2-(pyridin-2-yl)-11-oxadispiro[3.1.4 6 .3 4 ]tridecan-2-yl)ethan-1-amine hydrochloride
Figure BDA0001714822470002571
Reacting N- ((3-methoxythiophen-2-yl) methyl) -2- (2- (pyridin-2-yl) -11-oxadispiro [ 3.1.4) 6 .3 4 ]Tridecan-2-yl) ethan-1-amine (70H) (0.15g, 0.35mmol) was dissolved in ethyl acetate (5 mL), and an ethyl acetate solution of hydrogen chloride (1 mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. Directly spin-drying the reaction solution to obtain white solid N- ((3-methoxythiophene-2-yl) methyl) -2- (2- (pyridine-2-yl) -11-oxadispiro [ 3.1.4) 6 .3 4 ]Tridecan-2-yl) ethan-1-amine hydrochloride (Compound 70) (0.16 g, 98.3% yield).
Ms m/z(ESI):427.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.81(dd,1H),8.61(td,1H),8.05-7.94(m,2H),7.47(d,1H),7.00(d,1H),4.22(s,2H),3.88(s,3H),3.68-3.64(m,2H),2.81-2.70(m,2H),2.61-2.35(m,6H),1.82-1.78(m,4H),1.72-1.51(m,6H),1.41-1.36(m,2H).
Example 71
(R) -N- ((3- (difluoromethoxy) -4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine 4-methylbenzenesulfonate (Compound 71)
(R)-N-((3-(difluoromethoxy)-4-ethynylthiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine 4-methylbenzenesulfonate
Figure BDA0001714822470002581
The first step is as follows: 4-bromo-3- (difluoromethoxy) thiophene-2-carboxylic acid methyl ester (71A)
methyl 4-bromo-3-(difluoromethoxy)thiophene-2-carboxylate
Figure BDA0001714822470002582
Methyl 4-bromo-3-hydroxythiophene-2-carboxylate (60B) (2.0 g, 8.44mmol) was dissolved in acetonitrile (20 mL) at room temperature, the temperature was reduced to-10 deg.C, a solution of potassium hydroxide (9.5 g, 1699 mmol) in water (20 mL) was added to the reaction, diethyl bromofluoromethylphosphonate (4.5 g,16.9 mmol) was added dropwise to the reaction, and the reaction was stirred at-10 deg.C for 1 hour. The reaction solution was extracted with methyl tert-butyl ether (20 mL × 3), the combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was evaporated to dryness, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 20.
Ms m/z(ESI):310.9[M+Na + ];
The second step: (4-bromo-3- (difluoromethoxy) thiophen-2-yl) methanol (71B)
(4-bromo-3-(difluoromethoxy)thiophen-2-yl)methanol
Figure BDA0001714822470002591
Lithium aluminum hydride (0.18g, 4.7mmol) was dissolved in tetrahydrofuran (10 mL), the temperature was lowered to 0 ℃ and a solution of methyl 4-bromo-3- (difluoromethoxy) thiophene-2-carboxylate (71A) (0.90g, 3.14mmol) in tetrahydrofuran (10 mL) was added dropwise to the reaction and the reaction was carried out at room temperature for 2 hours. The reaction solution was cooled to 0 ℃, and the reaction was quenched with water (0.18 mL), sodium hydroxide solution (10% aq.,0.36 mL) and water (0.36 mL) in this order, and then anhydrous sodium sulfate was added to dry, filter, wash the solid with tetrahydrofuran (20 mL × 2), and concentrate the combined organic phases to give (4-bromo-3- (difluoromethoxy) thiophen-2-yl) methanol (71B) (0.70 g, yield: 86.2%) as an oily liquid.
The third step: 4-bromo-3- (difluoromethoxy) thiophene-2-carbaldehyde (71C)
4-bromo-3-(difluoromethoxy)thiophene-2-carbaldehyde
Figure BDA0001714822470002592
(4-bromo-3- (difluoromethoxy) thiophen-2-yl) methanol (71B) (0.70g, 2.70mmol) was dissolved in dichloromethane (10 mL), and manganese dioxide (2.35g, 27.0 mmol) was added to the reaction, and the reaction was allowed to proceed at room temperature for 12 hours. The reaction was filtered, the filter cake was washed with dichloromethane (20 mL. Times.2), and the combined organic phases were concentrated to give 4-bromo-3- (difluoromethoxy) thiophene-2-carbaldehyde (71C) (0.30 g, yield: 43.2%) as an oily liquid.
1 H NMR(400MHz,CDCl 3 )δ9.96(d,1H),7.68(d,1H),6.68(t,1H).
The fourth step: 3- (Difluoromethoxy) -4- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (71D)
3-(difluoromethoxy)-4-((trimethylsilyl)ethynyl)thiophene-2-carbaldehyde
Figure BDA0001714822470002593
4-bromo-3- (difluoromethoxy) thiophene-2-carbaldehyde (71C) (0.30g, 1.17mmol) and trimethylsilyne (0.46g, 4.67mmol) were dissolved in tetrahydrofuran (5 mL) and triethylamine (5 mL), and trans-bis (triphenylphosphine) palladium (II) dichloride (0.164g, 0.233mmol) and cuprous iodide (0.045g, 0.233mmol) were added to the reaction under nitrogen protection, and the temperature was raised to 100 ℃ for 12 hours. The reaction solution was filtered, and the organic phase was directly concentrated, and the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 50.
1 H NMR(400MHz,CDCl 3 )δ9.98(d,1H),7.77(d,1H),6.90(t,2H),0.26(s,9H).
The fifth step: 3- (Difluoromethoxy) -4-ethynylthiophene-2-carbaldehyde (71E)
3-(difluoromethoxy)-4-ethynylthiophene-2-carbaldehyde
Figure BDA0001714822470002601
3- (difluoromethoxy) -4- ((trimethylsilyl) ethynyl) thiophene-2-carbaldehyde (71D) (0.08g, 0.29mmol) was dissolved in methanol (5 mL), and potassium carbonate (0.06g, 0.43mmol) was added to the reaction, after which the reaction was allowed to proceed at room temperature for 1 hour. The reaction solution was quenched with water (20 mL), the aqueous phase was extracted with ethyl acetate (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 10) to give 3- (difluoromethoxy) -4-ethynylthiophene-2-carbaldehyde (71E) as a yellow solid (0.045 g, yield: 68%).
1 H NMR(400MHz,CDCl 3 )δ9.98(s,1H),7.84(d,1H),6.85(t,2H),3.28(s,1H).
And a sixth step: (R) -N- ((3- (difluoromethoxy) -4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (71F)
(R)-N-((3-(difluoromethoxy)-4-ethynylthiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470002602
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.058g, 0.223mmol) was dissolved in dichloromethane (10 mL), and sodium sulfate (0.116g, 1.11mmol) and 3- (difluoromethoxy) -4-ethynylthiophene-2-carbaldehyde (71E) (0.045g, 0.223mmol) were added to the reaction at room temperature overnight. Sodium borohydride (0.013g, 0.334mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (2 mL) and stirring for 1 hour. The reaction was quenched with water (20 mL), the aqueous phase was extracted with dichloromethane (10 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and the crude product was purified with preparative plate (dichloromethane/methanol (v/v) = 10.
Ms m/z(ESI):447.2[M+H + ];
Eighth step: (R) -N- ((3- (difluoromethoxy) -4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine 4-methylbenzenesulfonate (Compound 71)
(R)-N-((3-(difluoromethoxy)-4-ethynylthiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine 4-methylbenzenesulfonate
Figure BDA0001714822470002611
(R) -N- ((3- (difluoromethoxy) -4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (71F) (0.035g, 0.078mmol) was dissolved in ethyl acetate (4 mL), and p-toluenesulfonic acid monohydrate (0.015g, 0.078mmol) was dissolved in ethyl acetate (2 mL) and added dropwise to the reaction mixture, followed by stirring at room temperature for 1 hour. The reaction solution was directly spin-dried and dried to obtain (R) -N- ((3- (difluoromethoxy) -4-ethynylthiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine 4-methylbenzenesulfonate (compound 71) as a white solid (0.050 g, yield: 100%).
Ms m/z(ESI):447.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.76(d,1H),8.32(t,1H),7.93(d,1H),7.82(s,1H),7.75(t,1H),7.70(d,2H),7.24(d,2H),6.89(t,1H),4.27(s,2H),3.80-3.68(m,3H),3.07-2.99(m,1H),2.57-2.40(m,3H),2.37(s,3H),2.28-2.18(m,1H),2.11-2.01(m,2H),1.88-1.78(m,2H),1.69-1.62(m,1H),1.59-1.47(m,4H),1.20-1.15(s,1H),0.81-0.73(m,1H).
Example 72
(R) -N- ((3-methoxybenzo [ b ] thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 72)
(R)-N-((3-methoxybenzo[b]thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002621
The first step is as follows: 3-methoxybenzo [ B ] thiophene (72B)
3-methoxybenzo[b]thiophene
Figure BDA0001714822470002622
3-bromobenzo [ b ] thiophene (72A) (4.45g, 20.8 mmol) was dissolved in N, N-dimethylformamide (40 mL) and sodium methoxide solution (30 wt%,40 mL) under nitrogen, and cuprous iodide (0.08g, 0.42mmol), cupric oxide (0.84g, 10.5 mmol) and potassium iodide (0.05g, 0.3 mmol) were added to the reaction, and the reaction was allowed to warm to 120 ℃ for 6 hours. The reaction solution was cooled to 0 ℃, the reaction was quenched with water (50 mL), filtered with celite, the filtrate was extracted with dichloromethane (30 mL × 2), the organic phases were combined, washed with saturated ammonium chloride (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and after the crude product was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 100) to give 3-methoxybenzo [ B ] thiophene (72B) (2.6 g, yield: 75.8%) as an oily liquid.
1 H NMR(400MHz,CDCl 3 )δ7.79-7.73(m,2H),7.38-7.32(m,2H),6.29(s,1H),3.97(s,3H).
The second step: 3-Methoxybenzo [ b ] thiophene-2-carbaldehyde (72C)
3-methoxybenzo[b]thiophene-2-carbaldehyde
Figure BDA0001714822470002631
3-methoxybenzo [ B ] thiophene (72B) (1.64g, 10.0 mmol) was dissolved in tetrahydrofuran (20 mL) under nitrogen, the temperature was reduced to-78 deg.C, N-butyllithium (4.4 mL,11.0 mmol) was added dropwise to the reaction, the reaction was stirred for 0.5 hour, N-dimethylformamide (0.88g, 12.0 mmol) was added dropwise to the reaction, and the reaction was continued for 1 hour. The reaction solution was quenched with a saturated ammonium chloride solution (30 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product which was purified by column chromatography (petroleum ether/ethyl acetate (v/v) = 1 to 10) to obtain 3-methoxybenzo [ b ] thiophene-2-carbaldehyde (72C) as an oily liquid (1.6 g, yield: 83.3%).
1 H NMR(400MHz,CDCl 3 )δ10.37(s,1H),7.90(d,1H),7.75(d,1H),7.52-7.48(m,1H),7.45-7.37(m,1H),4.33(s,3H).
The third step: (R) -N- ((3-methoxybenzo [ b ] thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (72D)
(R)-N-((3-methoxybenzo[b]thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470002632
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.30g, 1.15mmol) was dissolved in dichloromethane (10 mL), and sodium sulfate (0.818g, 5.76mmol) and 3-methoxybenzo [ b ] thiophene-2-carbaldehyde (72C) (0.276 g, 1.38mmol) were added to the reaction and reacted overnight at room temperature. Sodium borohydride (0.065g, 1.73mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (30 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):437.2[M+H + ];
The fourth step: (R) -N- ((3-methoxybenzo [ b ] thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 72)
(R)-N-((3-methoxybenzo[b]thiophen-2-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002641
(R) -N- ((3-methoxybenzo [ b ] thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (72D) (0.19g, 0.44mmol) was dissolved in ethyl acetate (4 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -N- ((3-methoxybenzo [ b ] thiophen-2-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (compound 72) as a white solid (0.32 g, yield: 100%).
Ms m/z(ESI):437.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.83(dd,1H),8.57-8.48(m,1H),8.14(dd,1H),7.96(dd,1H),7.86-7.82(m,2H),7.51-7.39(m,2H),4.40(s,2H),4.03(s,3H),3.84-3.79(m,1H),3.75-3.65(m,1H),3.08-3.01(m,1H),2.60-2.40(m,3H),2.40-2.12(m,3H),1.98-1.90(m,1H),1.87-1.83(m,1H),1.68-1.43(m,5H),1.25-1.15(m,1H),0.87-0.82(m,1H).
Example 74
(R) -N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 74)
(R)-N-((2,3-dihydrobenzofuran-7-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002651
The first step is as follows: 2, 3-dihydrobenzofuran-7-carbaldehyde (74B)
2,3-dihydrobenzofuran-7-carbaldehyde
Figure BDA0001714822470002652
Under the protection of nitrogen, 7-bromo-2, 3-dihydrobenzofuran (74A) (2.0g, 10.05mmol) is dissolved in tetrahydrofuran (20 mL), the temperature is reduced to-78 ℃, N-butyllithium (4.5mL, 11.05mmol) is dropwise added into the reaction, the reaction is stirred for 0.5 hour, then N, N-dimethylformamide (1.1g, 15.07mmol) is dropwise added into the reaction, and the reaction is continued for 1 hour. The reaction solution was quenched with a saturated ammonium chloride solution (50 mL), the aqueous phase was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with a saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and after the crude product was subjected to column chromatography (petroleum ether/ethyl acetate (v/v) =10: 1-4) to give 2, 3-dihydrobenzofuran-7-carbaldehyde (74B) as an oily liquid (1.4 g, yield: 94%).
1 H NMR(400MHz,CDCl 3 )δ10.20(s,1H),7.58(d,1H),7.40(dd,1H),6.93(t,1H),4.74(t,2H),3.24(t,2H).
The second step is that: (R) -N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethanamine (74C)
(R)-N-((2,3-dihydrobenzofuran-7-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine
Figure BDA0001714822470002661
(R) -2- (9- (pyridin-2-yl) -6-dioxaspiro [4.5] decan-9-yl) ethylamine (intermediate 1) (0.260g, 1.0 mmol) was dissolved in methylene chloride (10 mL), and sodium sulfate (0.71g, 5.0 mmol) and 2, 3-dihydrobenzofuran-7-carbaldehyde (74B) (0.8g, 1.2mmol) were added to the reaction mixture, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.06g, 1.2mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):393.3[M+H + ];
The third step: (R) -N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (Compound 74)
(R)-N-((2,3-dihydrobenzofuran-7-yl)methyl)-2-(9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethanamine hydrochloride
Figure BDA0001714822470002662
(R) -N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine (74C) (0.18g, 0.46mmol) was dissolved in ethyl acetate (4 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give (R) -N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (9- (pyridin-2-yl) -6-oxaspiro [4.5] decan-9-yl) ethylamine hydrochloride (compound 74) as a white solid (0.195 g, yield: 99.1%).
Ms m/z(ESI):393.4[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.82(d,1H),8.53(d,1H),8.14-7.90(dd,2H),7.27(d,1H),7.10(d,1H),6.87(t,1H),4.61(t,2H),4.07(s,2H),3.83-3.64(m,2H),3.24(t,2H),3.04-2.98(m,1H),2.50-2.44(m,3H),2.31-2.28(m,1H),2.18-2.10(m,2H),1.95-1.83(m,2H),1.70-1.54(m,5H),1.23-1.17(m,1H),0.85-0.83(m,1H).
Example 75
N- ((2, 3-Dihydrothieno [3,4-b ] furan-6-yl) methyl) -2- (4 '- (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] pyran ] -4' -yl) ethylamine hydrochloride (Compound 75)
N-((2,3-dihydrothieno[3,4-b]furan-6-yl)methyl)-2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine hydrochloride
Figure BDA0001714822470002671
The first step is as follows: n- ((2, 3-dihydrothieno [3,4-B ] furan-6-yl) methyl) -2- (4 '- (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] pyran ] -4' -yl) ethylamine (75B)
N-((2,3-dihydrothieno[3,4-b]furan-6-yl)methyl)-2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine
Figure BDA0001714822470002672
(4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran-4 ' -yl) ethylamine (68E) (0.20g, 0.734mmol) was dissolved in methylene chloride (10 mL), and sodium sulfate (0.52g, 3.67mmol) and 2, 3-dihydrothieno [3,4-b ] furan-6-carbaldehyde (0.14g, 0.88mmol) were added to the reaction solution, and the reaction was allowed to proceed overnight at room temperature. Sodium borohydride (0.04g, 1.10 mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):411.2[M+H + ]。
The second step is that: n- ((2, 3-Dihydrothieno [3,4-b ] furan-6-yl) methyl) -2- (4 '- (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] pyran ] -4' -yl) ethylamine hydrochloride (Compound 75)
N-((2,3-dihydrothieno[3,4-b]furan-6-yl)methyl)-2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine hydrochloride
Figure BDA0001714822470002681
N- ((2, 3-dihydrothieno [3,4-B ] furan-6-yl) methyl) -2- (4 '- (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] pyran ] -4' -yl) ethylamine (75B) (0.10g, 0.24mmol) was dissolved in ethyl acetate (4 mL), and an ethyl acetate solution of hydrogen chloride (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give N- ((2, 3-dihydrothieno [3,4-b ] furan-6-yl) methyl) -2- (4 '- (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] pyran-4' -yl) ethylamine hydrochloride (compound 75) as a white solid (0.11 g, yield: 100%).
Ms m/z(ESI):411.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.87(dd,1H),8.62(td,1H),8.15(d,1H),8.06-8.12(m,1H),6.96(t,1H),4.92(td,2H),4.10(s,2H),3.84-3.72(m,2H),3.02-2.92(m,3H),2.46(td,1H),2.38-2.31(m,3H),2.24-2.15(m,1H),2.13-2.03(m,1H),1.99(s,2H),1.95-1.85(m,2H),1.31-1.21(m,2H),1.17-1.09(m,1H),0.56(q,1H),0.32-0.26(td,1H).
Resolution of the compound N- ((2, 3-dihydrothieno [3,4-b ] furan-6-yl) methyl) -2- (4 '- (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] pyran ] -4' -yl) ethylamine hydrochloride (Compound 75)
N- ((2, 3-dihydrothieno [3,4-B ] furan-6-yl) methyl) -2- (4 '- (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] pyran ] -4' -yl) ethylamine hydrochloride (100 mg) was taken for resolution, and after separation, two free base compound optical isomers were obtained, compound 75B-1 (retention time: 3.27min,24.46mg, oily liquid, ee% = 100%), compound 75B-2 (retention time: 5.55min,37.3mg, oily liquid, ee% = 100%).
Splitting conditions are as follows: the instrument is Waters 80 preparatory SFC (SFC-6); column ChiralPak AD,300 × 50mm i.d.,10 μm mobile phase a: carbon dioxide, B: ethanol (0.1% ammonia); gradient B40%; the flow rate is 80mL/min; back pressure is 100bar; the column temperature is 38 ℃; the wavelength is 220nm; the period is 8min; sample preparation, compound is dissolved in methanol to prepare 5mg/mL; injection of 4 mL/needle.
Compound 75B-1 and Compound 75B-2 following the salt formation procedure for Compound 75, two optical isomers Compound 75-1 and Compound 75-2, can be obtained:
compound 75-1:
Ms m/z(ESI):411.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.83(dd,1H),8.53(td,1H),8.12-7.87(m,2H),6.96(t,1H),4.92(td,2H),4.09(s,2H),3.81-3.73(m,2H),3.02-2.91(m,3H),2.45(td,1H),2.36-2.24(m,3H),2.19-1.99(m,3H),1.94-1.84(m,2H),1.43(d,1H),1.26-1.09(m,3H),0.56(q,1H),0.29(td,1H).
compound 75-2:
Ms m/z(ESI):411.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.85(dd,1H),8.57(td,1H),8.14-7.97(m,2H),6.96(d,1H),4.92(t,2H),4.09(s,2H),3.82-3.75(m,2H),3.02-2.92(m,3H),2.45(td,1H),2.36-2.26(m,3H),2.16(td,1H),2.11-1.97(m,2H),1.94-1.85(m,2H),1.43(d,1H),1.24(dt,2H),1.18-1.12(m,1H),0.56(q,1H),0.29(td,1H).
example 76
N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (compound 76)
N-((2,3-dihydrobenzofuran-7-yl)methyl)-2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine hydrochloride
Figure BDA0001714822470002701
The first step is as follows: n- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine (76B)
N-((2,3-dihydrobenzofuran-7-yl)methyl)-2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine
Figure BDA0001714822470002702
(4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine (68E) (0.22g, 0.8mmol) was dissolved in methylene chloride (10 mL), and sodium sulfate (0.57g, 4.04mmol) and 2, 3-dihydrobenzofuran-7-carbaldehyde (0.144g, 0.97mmol) were added to the reaction mixture to react at room temperature overnight. Sodium borohydride (0.046 g, 1.10mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):405.3[M+H + ]。
The second step is that: n- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran-4 ' -yl) ethylamine hydrochloride (compound 76)
N-((2,3-dihydrobenzofuran-7-yl)methyl)-2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine hydrochloride
Figure BDA0001714822470002711
N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran-4 ' -yl) ethylamine (76B) (0.22g, 0.54mmol) was dissolved in ethyl acetate (4 mL), and an ethyl acetate solution of hydrogen chloride (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction was directly spin-dried to give N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (compound 76) as a white solid (0.24 g, yield: 100%).
Ms m/z(ESI):405.3[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.84(d,1H),8.56(t,1H),8.10-7.96(m,2H),7.27(dd,1H),7.11(d,1H),6.87(t,1H),4.61(t,2H),4.07(s,2H),3.81-3.72(m,2H),3.24(t,2H),2.98(td,1H),2.47(td,1H),2.31(dd,3H),2.22-2.16(m,1H),2.03(dd,2H),1.94-1.85(m,2H),1.43(d,1H),1.27-1.19(m,2H),1.15-1.10(m,1H),0.56(q,1H),0.29(td,1H).
Resolution of the compound N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran-4 ' -yl) ethylamine hydrochloride (compound 76)
N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (compound 76) (240 mg) was taken for resolution, and after separation, two optical isomers, compound 76B-1 (retention time: 5.566min,126.78mg, oily liquid, ee% = 100%), compound 76B-2 (retention time: 7.202min,95.87mg, oily liquid, ee% = 100%) were obtained.
Splitting conditions are as follows: apparatus is THar 80 preparatory SFC (SFC-16); column Phenomenex Lux Cellulose-2,250 × 30mm i.d.,5 μm. Mobile phase a: carbon dioxide, B: ethanol (0.1% ammonia); gradient B40%; the flow rate is 50mL/min; back pressure is 100bar; the column temperature is 38 ℃; the wavelength is 220nm; the period is 15min; sample preparation, compound is dissolved in methanol to make 8mg/ml; injection 2 ml/needle.
By the salt-forming method of the compound 76, N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- ((4S) -4'- (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4 '-yl) ethylamine (the compound 76-1) and N- ((2, 3-dihydrobenzofuran-7-yl) methyl) -2- ((4' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2 '-pyran ] -4' -yl) ethylamine (the compound 76-2) can be obtained:
compound 76-1:
Ms m/z(ESI):405.3[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.84(dd,1H),8.58(t,1H),8.11(d,1H),8.00(t,1H),7.27(dd,1H),7.11(d,1H),6.87(t,1H),4.61(t,2H),4.07(s,2H),3.82-3.72(m,2H),3.24(t,2H),2.98(td,1H),2.47(td,1H),2.36-2.29(m,3H),2.19(td,1H),2.03(dd,2H),1.94-1.86(m,2H),1.43(d,1H),1.26-1.21(m,2H),1.17-1.10(m,1H),0.56(q,1H),0.29(td,1H).
compound 76-2:
Ms m/z(ESI):405.3[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.84(dd,1H),8.58(t,1H),8.11(d,1H),8.00(t,1H),7.27(dd,1H),7.12(d,1H),6.87(t,1H),4.61(t,2H),4.07(s,2H),3.82-3.75(m,2H),3.24(t,2H),2.98(td,1H),2.47(td,1H),2.32(dd,3H),2.21(dd,1H),2.10–1.99(m,2H),1.94-1.86(m,2H),1.43(d,1H),1.26-1.21(m,2H),1.16-1.07(m,1H),0.56(q,1H),0.29(td,1H).
example 77
N- ((5-Fluoropyridin-3-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (Compound 77)
N-((5-fluoropyridin-3-yl)methyl)-2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine hydrochloride
Figure BDA0001714822470002721
Figure BDA0001714822470002731
The first step is as follows: n- ((5-Fluoropyridin-3-yl) methyl) -2- (4 ' - (pyridin-2-yl) Tetrahydropiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine (77B)
N-((5-fluoropyridin-3-yl)methyl)-2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine
Figure BDA0001714822470002732
(4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran-4 ' -yl) ethylamine (68E) (0.25g, 0.918mmol) was dissolved in dichloromethane (10 mL), and sodium sulfate (0.65g, 4.59mmol) and 5-fluoropyridine-3-carbaldehyde (0.14g, 1.10mmol) were added to the reaction and reacted at room temperature overnight. Sodium borohydride (0.052g, 1.38mmol) was added to the reaction, and the reaction was stirred for 10 minutes, followed by addition of methanol (10 mL) and stirring for 1 hour. The reaction was quenched with water, the aqueous phase was extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was purified by column chromatography (dichloromethane/methanol (v/v) = 50.
Ms m/z(ESI):382.2[M+H + ].
The second step is that: n- ((5-Fluoropyridin-3-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (Compound 77)
N-((5-fluoropyridin-3-yl)methyl)-2-(4'-(pyridin-2-yl)tetrahydrospiro[bicyclo[3.1.0]hexane-3,2'-pyran]-4'-yl)ethanamine hydrochloride
Figure BDA0001714822470002741
N- ((5-Fluoropyridin-3-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine (77B) (0.25g, 0.655 mmol) was dissolved in ethyl acetate (4 mL), and a solution of hydrogen chloride in ethyl acetate (1mL, 2.0M) was added to stir the reaction at room temperature for 0.5 hour. The reaction solution was directly spin-dried to give N- ((5-fluoropyridin-3-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (compound 77) as a white solid (0.27 g, yield: 98.6%).
Ms m/z(ESI):382.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.80-8.66(m,4H),8.24(dd,2H),8.11-8.07(m,1H),4.33-4.27(m,2H),3.88-3.73(m,2H),3.13(td,1H),2.64(td,1H),2.44-2.30(m,4H),2.12(dd,2H),2.01-1.91(m,2H),1.48(d,1H),1.26-1.22(m,2H),1.20-1.11(m,1H),0.58(q,1H),0.30(td,1H).
Resolution of the Compound N- ((5-Fluoropyridin-3-yl) methyl) -2- (4 ' - (pyridin-2-yl) Tetrahydropiro [ bicyclo [3.1.0] Hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (Compound 77)
N- ((5-fluoropyridin-3-yl) methyl) -2- (4 ' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2' -pyran ] -4' -yl) ethylamine hydrochloride (compound 77) (265 mg) was taken for resolution to give, after separation, two optical isomers compound 77B-1) (retention time: 5.46min,115.09mg, oily liquid, ee% = 99.1%), compound 77B-2 retention time: 5.97min,84.81mg, oily liquid, ee% = 99.4%).
Splitting conditions are as follows: the apparatus is a THar 80 preparatory SFC (SFC-16); column Phenomenex Lux Cellulose-2,250 × 30mm i.d.,5 μm. Mobile phase a: carbon dioxide, B: ethanol (0.1% ammonia); gradient B35%; the flow rate is 60mL/min; back pressure is 100bar; the column temperature is 38 ℃; the wavelength is 220nm; the period is 8min; sample preparation, compound is dissolved in methanol to 8.8mg/ml; injection 2 ml/needle.
By the salt-forming method using the compound 77, N- ((5-fluoropyridin-3-yl) methyl) -2- ((4's) -4' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2 '-pyran ] -4' -yl) ethylamine (the compound 77-1) and N- ((5-fluoropyridin-3-yl) methyl) -2- ((4 'r) -4' - (pyridin-2-yl) tetrahydrospiro [ bicyclo [3.1.0] hexane-3, 2 '-pyran ] -4' -yl) ethylamine (the compound 77-2) can be obtained:
compound 77-1:
Ms m/z(ESI):382.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.88(dd,1H),8.73(dt,3H),8.21(d,2H),8.08(t,1H),4.31(s,2H),3.87-3.73(m,2H),3.15-3.10(m,1H),2.67-2.61(m,1H),2.41-2.30(m,4H),2.12(dd,J=20.3,14.0Hz,2H),2.00-1.92(m,2H),1.47(d,1H),1.30-1.22(m,2H),1.17-1.11(m,1H),0.57(q,1H),0.30(td,1H).
compound 77-2:
Ms m/z(ESI):382.2[M+H + ];
1 H NMR(400MHz,CD3OD)δ8.88(dd,1H),8.77-8.66(m,3H),8.21(d,2H),8.08(t,1H),4.29(s,2H),3.87-3.73(m,2H),3.12(td,1H),2.63(td,1H),2.42-2.30(m,4H),2.11(dd,2H),2.00-1.91(m,2H),1.47(d,1H),1.29-1.22(m,2H),1.17-1.11(m,1H),0.58(q,1H),0.30(td,1H).
biological testing
1. In vitro mu receptor Activity assay
Forskolin stimulates cAMP release from OPRM1 cells (available from DiscoveviRx) which are a cell line with high expression of human mu-opioid receptor, and mu-opioid receptor agonist inhibits Forskolin-stimulated cAMP release. The agonistic activity of a compound at the human mu-opioid receptor can be determined by assaying the inhibitory effect of the compound on forskolin stimulated cAMP release. Firstly, forskolin with a certain concentration and a test compound with different concentrations are incubated with a human mu-opioid receptor high-expression cell strain. Then, use
Figure BDA0001714822470002751
The Ultra cAMP kit (purchased from PerkinElmer's cat # TRF 0263) detects cAMP levels in cells based on the principle of time-resolved fluorescence resonance energy transfer (TR-FRET). The specific method comprises the following steps:
CHO-K1OPRM1 cells were cultured in DMEM-F12 medium containing diabody (100U/ml penicillin, 100g/ml streptomycin) and 10% FBS. On the day of the experiment, cells were detached with PBS/5mM EDTA and harvested by centrifugation. Then, the cells were resuspended with a StULATION Buffer (14.5 ml 1X HBSS, 75. Mu.l 1M HEPES, 30. Mu.l 250mM IBMX, 200. Mu.l 7.5% BSAstabilizer, PH7.4) and the cell concentration was adjusted to 1X 105cells/ml. Forskolin (final concentration of 1.5. Mu.M) and various concentrations of compounds (final concentration of 1000,200,40,8,1.6,0.32,0.064,0 nM) were added to the Ststimulation Buffer and 5. Mu.l per well were added to 384 well plates. A further 5. Mu.l of cell suspension (cell mass 500 cells/well) was added to each well and incubated at room temperature for 30min. Then, 5. Mu.l of 4X Eu-cAMP tracer working solution (Eu-cAMP stock solution diluted 50-fold with cAMP Detection Buffer) was added to each well. Then 5. Mu.l of 4 × Ulight-anti-cAMP working solution (dilution of the ULight-anti-cAMP stock solution 150 times with cAMP Detection Buffer) was added to each well. And incubated at room temperature for 1h. The 384 well plates were tested for cAMP levels using a microplate reader (Perkin Elmer, envision) TR-FRET method. The data obtained were processed and fitted with origin7.5 software to EC50 and the maximum pharmacodynamic activity (Efficacy (%)) of the compound was calculated. Efficacy (%) = maximum pharmacodynamic activity of compound/maximum pharmacodynamic activity of positive compound 100%, positive compound is TRV-130. The test results are shown in Table 1.
TABLE 1 in vitro assay of mu receptor Activity
Figure BDA0001714822470002761
The TRV-130 structure is as follows:
Figure BDA0001714822470002771
and (4) conclusion: the compound can activate opioid mu receptor and has obvious activity in vitro.
2. In vitro detection of beta-arrestin activity
OPRM1 cells (purchased from Discovex Rx company) are cell lines with high expression of human mu-opioid receptor, meanwhile, the cell lines also highly express beta-arrestin 2 fused with beta galactosidase fragments, and the highly expressed human mu-opioid receptor genes are fused with complementary fragments of the beta-galactosidase. If the compound is capable of acting on the beta-arrestin pathway, it will promote the binding of the mu-receptor to beta-arrestin 2, when the two fragments of beta galactosidase are fused together, exhibiting intact beta-galactosidase activity. Thus, by using a beta galactosidase activity detection kit (purchased from Applied Biosystems) to detect beta galactosidase activity, it is possible to detect whether a compound acts on the beta-arrestin pathway. The specific method comprises the following steps:
CHO-K1OPRM1 cells were cultured in DMEM-F12 medium containing diabody (100U/ml penicillin, 100g/ml streptomycin) and 10% FBS. The day before the experiment, cells were digested with trypsin, collected by centrifugation, counted, and plated in 96-well cell culture plates (20000) cells/well), and cultured for 24h. On the day of the experiment, the medium was aspirated and 90. Mu.l of fresh medium was added. Dilution of the Positive or test Compounds with medium gradient (final concentration 1X 10- 3 ,10- 4 ,10- 5 ,10- 6 ,10- 7 ,10- 8 ,10- 9 M), add 10. Mu.l to 96-well plates and incubate for 90min in an incubator. Then, the cells were washed once with PBS, PBS was removed, and 20. Mu.l of lysine Solution (containing 0.5mM DTT) was added to each well and incubated for 10min. Add 4 μ l of lysed cells per well to 384 well plates. Galacton-
Figure BDA0001714822470002773
And diluting the substrate by 50 times by using Reaction Buffer, balancing to room temperature, adding a 384-well plate into 20 mu l of each well, mixing uniformly, incubating at 25 ℃ for 30min in a dark place, and detecting a chemiluminescent signal. The origin7.5 assay was used to fit the EC50 and calculate the maximum pharmacodynamic activity (Efficacy (%)) of the compound. Efficacy (%) = maximum pharmacodynamic activity of compound/maximum pharmacodynamic activity of positive compound × 100%. The positive compound was TRV-130. The test results are shown in Table 2.
TABLE 2 in vitro beta-arrestin Activity assay results
Figure BDA0001714822470002772
Figure BDA0001714822470002781
"-" indicates no activity.
And (4) conclusion: the compound of the invention has no obvious activity on beta-arrestin and has good preference.
3. Mouse hot plate experiment
Female C57 mice 18-22g were purchased from Duoduosho laboratory animals, inc. The temperature of the hot plate apparatus was set to 56 ℃ and the experiment was started after 30min of stabilization after temperature rise. Sequentially placing the animals into a hot plate instrument for testing, and observing the foot reaction of the animals after licking, wherein the foot reaction is used as an index of pain reaction; recording the time from the animal entering the hot plate to the time of the animal licking the hindpaw caused by the thermal stimulus, and according with Animals with group entry criteria (paw response time below 25s after licking) were group-numbered. Grouped by baseline threshold, 10 per group. Compounds at different concentrations were given subcutaneously at 10ml/kg for 15min and the reaction time was recorded with 30 seconds as the cut-off time. And (3) carrying out statistical analysis on the result, and calculating the% MPE value according to a formula: % MPE = (Tn-T0)/(30-T0), (Tn is the animal's time to lick the foot after administration, T0 is the animal's time to lick the foot before administration). And the ED was fitted by analyzing the data with origin7.5 software 50 The value is obtained. The results are shown in Table 3.
TABLE 3 results of the experiment
Figure BDA0001714822470002782
Figure BDA0001714822470002791
And (4) conclusion: the compound has obvious analgesic effect in a hot plate pain model.
4. Colon motility experiment of mice
Male C57 mice, 18-22g, were purchased from Duoduoshu laboratory animals, inc. Fasting was not prohibited overnight. On the day of the experiment, 10 animals were randomized into groups. The compound was formulated in terms of 5% DMSO,95% physiological saline to 0.03mg/ml,0.1mg/ml,0.3mg/ml,1mg/ml,3mg/ml,5mg/ml (free base concentration), and the amount of compound administered was 10ml/kg. Animals were weighed and administered subcutaneously. After 30min, the mice were anesthetized with a small animal anesthetic (Matrx, VME 2), 5% isoflurane (rewarded life technologies ltd.) for 0.5-1min, the mice were taken out of the anesthesia machine and glass beads (2 mm in diameter) were inserted into the anus of the mice, advancing by 2cm. The time for which the mice expelled the glass beads from the body was observed and recorded. Maximum observation time 240min. Maximum effect (MPE (%)) was calculated using Office Excel software. And the ED was fitted using origin7.5 software analysis 50 The value is obtained. MPE = (test group time-blank group time)/(240-blank group time) × 100%. The results are shown in Table 4.
TABLE 4 mouse Colon motility test results
Example numbering ED 50 (mg/kg)
Compound 28 22.3
TRV-130 32.6
Morphine (morphine) 4.1
And (4) conclusion: the compounds of the present invention, particularly compound 28, had less effect on colonic motility.
While the examples have described the compounds described herein, those skilled in the art will recognize that various modifications may be made without departing from the spirit and scope thereof.

Claims (7)

1. A compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof,
Figure FDA0003904913390000011
wherein
A is selected from
Figure FDA0003904913390000012
B is pyridyl;
R 1 is selected from H;
R 21 selected from-OCHF 2 、-CH 2 OCH 3 An ethynyl group;
n is selected from 2; m is selected from 1;
or when n =2,m =2, a is selected from
Figure FDA0003904913390000013
B is pyridyl, R 21 Ethynyl and methoxy, respectively.
2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
A is
Figure FDA0003904913390000014
B is
Figure FDA0003904913390000015
R 1 Is selected from H;
n is selected from 2.
3. A compound, or a pharmaceutically acceptable salt thereof,
Figure FDA0003904913390000016
Figure FDA0003904913390000021
4. a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the salt is selected from the hydrochloride, sulfate, acetate, benzenesulfonate or p-toluenesulfonate salt.
5. A pharmaceutical composition, said composition comprising: an effective dose of a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or further comprising one or more other therapeutic agents and a pharmaceutically acceptable carrier or excipient.
6. The composition of claim 5, further comprising at least one additional analgesic, anti-constipation agent.
7. Use of a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, or a composition according to claim 5, in the manufacture of a medicament for the prevention or treatment of pain.
CN201810702595.3A 2017-07-04 2018-07-02 Opioid receptor agonists and uses thereof Active CN109206417B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210889662.3A CN115124520A (en) 2017-07-04 2018-07-02 Opioid receptor agonists and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710535396 2017-07-04
CN2017105353963 2017-07-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210889662.3A Division CN115124520A (en) 2017-07-04 2018-07-02 Opioid receptor agonists and uses thereof

Publications (2)

Publication Number Publication Date
CN109206417A CN109206417A (en) 2019-01-15
CN109206417B true CN109206417B (en) 2023-01-03

Family

ID=64989805

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810702595.3A Active CN109206417B (en) 2017-07-04 2018-07-02 Opioid receptor agonists and uses thereof
CN202210889662.3A Pending CN115124520A (en) 2017-07-04 2018-07-02 Opioid receptor agonists and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210889662.3A Pending CN115124520A (en) 2017-07-04 2018-07-02 Opioid receptor agonists and uses thereof

Country Status (1)

Country Link
CN (2) CN109206417B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7019035B2 (en) * 2017-09-18 2022-02-14 上海華匯拓医薬科技有限公司 μ-opioid receptor agonists and their preparation methods and their use in the medical field
CN113214264B (en) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 Dihydropyrrolo five-membered heteroaryl substituted oxaspiro derivatives, preparation method and medical application thereof
CN114269738B (en) * 2020-08-10 2023-09-29 成都苑东生物制药股份有限公司 MOR receptor agonist compound, preparation method and application thereof
CN112694485B (en) * 2020-09-10 2023-04-07 四川海品信医药科技有限公司 Opioid receptor agonist thiophene compound and preparation method thereof
US20240109895A1 (en) * 2020-12-29 2024-04-04 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Oxaspiro substituted pyrrolopyrazole derivative, intermediate thereof, and preparation method therefor
CN117751126A (en) * 2021-08-02 2024-03-22 上海枢境生物科技有限公司 Oxaspiro derivative, preparation method and application thereof
WO2023030319A1 (en) * 2021-08-31 2023-03-09 天地恒一制药股份有限公司 Opioid receptor agonist, and preparation method therefor and use thereof
CN117263956A (en) * 2022-01-19 2023-12-22 天地恒一制药股份有限公司 Opioid receptor agonist, preparation method and application thereof
CN116041336A (en) * 2022-01-21 2023-05-02 成都苑东生物制药股份有限公司 New crystal form, application and preparation method of 6-oxaspiro [4,5] decane compound
CN116589451A (en) * 2022-02-11 2023-08-15 成都苑东生物制药股份有限公司 New crystal form, application and preparation method of 6-oxaspiro [4,5] decane compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702561A (en) * 2011-03-23 2014-04-02 特维娜有限公司 Opioid receptor ligands and methods of using and making same
WO2017063509A1 (en) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 Oxa spiro derivative, preparation method therefor, and applications thereof in medicines
CN106588899A (en) * 2015-10-15 2017-04-26 江苏恒瑞医药股份有限公司 Pyridyl-substituted 6-oxaspiro[4.5]decane derivative and preparation method thereof, and applications of pyridyl-substituted 6-oxaspiro[4.5]decane derivative in medicines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702561A (en) * 2011-03-23 2014-04-02 特维娜有限公司 Opioid receptor ligands and methods of using and making same
WO2017063509A1 (en) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 Oxa spiro derivative, preparation method therefor, and applications thereof in medicines
CN106588899A (en) * 2015-10-15 2017-04-26 江苏恒瑞医药股份有限公司 Pyridyl-substituted 6-oxaspiro[4.5]decane derivative and preparation method thereof, and applications of pyridyl-substituted 6-oxaspiro[4.5]decane derivative in medicines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A G Protein-Biased Ligand at the m-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine;Scott M. DeWire等;《J Pharmacol Exp Ther》;20130331;第344卷;第708-717页 *
Structure-Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine(TRV130), for the Treatment of Acute Severe Pain;Xiao-Tao Chen等;《J. Med. Chem.》;20130924;第56卷;第8019-8031页 *

Also Published As

Publication number Publication date
CN109206417A (en) 2019-01-15
CN115124520A (en) 2022-09-30

Similar Documents

Publication Publication Date Title
CN109206417B (en) Opioid receptor agonists and uses thereof
ES2451024T3 (en) Furo and thieno [3,2-c] pyridines
CN107847765B (en) 1, 4-substituted piperidine derivatives
JP6373973B2 (en) ZESTE homolog 2 enhancer inhibitor
TWI730937B (en) Tetrahydropyridopyrazines modulators of gpr6
CN103664973B (en) Spiro-oxindole compounds and their use as therapeutic agents
ES2673279T3 (en) Pyrazol Amide Derivative
CN114630832A (en) Pyrimido-cyclic derivative and application thereof in medicine
EA014956B1 (en) Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
TW201605866A (en) Furo- and thieno-pyridine carboxamide compounds useful as PIM kinase inhibitors
JPWO2007040166A1 (en) Novel condensed pyrrole derivatives
CN112313234B (en) Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists
DK2725908T3 (en) PERIPHERALLY EFFECTIVE OPIOID COMPOUNDS
CN111712499A (en) ATR inhibitor and application thereof
CN111989327A (en) Compounds for the treatment of pain
KR20220140710A (en) Triazolopyridazine derivatives, methods for their preparation, drug compositions and uses
CN112469722A (en) Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists
KR102351782B1 (en) Pyrido 5-membered aromatic ring compound, preparation method and use thereof
CN115968288A (en) Heteroaromatic ring compounds as RET kinase inhibitors, their preparation and use
KR20200118008A (en) Tetrahydropyrrole compound, its preparation method, pharmaceutical composition and use
EP2516445A2 (en) Tricyclic derivatives and their pharmaceutical use and compositions
CN112574183B (en) PD-1 inhibitor and preparation method and application thereof
WO2023030319A1 (en) Opioid receptor agonist, and preparation method therefor and use thereof
TW202313608A (en) 2,8-diazaspiro[4.5]decane compounds
CN114437096A (en) Spiro-heterocyclic compound, and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240108

Address after: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region

Patentee after: Tibet Haisike Pharmaceutical Co.,Ltd.

Address before: 611130 No.136 Baili Road, Wenjiang cross strait science and Technology Park, Chengdu, Sichuan

Patentee before: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd.